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1. INTRODUCTION 
1.1. MOLECULAR CONTROL OF CELL CYCLE 
1.1.1. Overview of cell cycle 
The cell cycle is the process by which a eukaryotic cell duplicates exactly its genetic 
content and then divided into two daughter cells genetically identical to the parent cell. To achieve 
this, the cell also need to double the cell mass and duplicate all the organelles. Therefore, the cell 
cycle is therefore a complex set of nuclear and cytoplasmic processes that must be coordinated. 
The eukaryotic cell cycle commonly consists of four well-defined and sequential phases (Figure 
1.1): G1, S (for DNA Synthesis), G2 and M (for Mitosis). Arguably, the two major cell cycle events 
required for cell division are S and M-phase. During S-phase the cell replicates the entire genome 
and the centrosome to produce copies for both daughter cells whereas during mitosis the cell 
divides the duplicated genetic content into two identical cells. Mitosis constitutes the shortest 
phase of the cycle and, in cells growing in culture, occupies only about 10% of the entire process 
which takes about 24 hours on average. The M and S-phases are separated by two “Gap” stages, 
the G1 and G2 phases. G1 follows on from mitosis and is a time when the cell is sensitive to 
negative or positive cues from growth signalling networks. During G2, the cell assesses that the 
genome and other cellular organelles are correctly duplicated; the cell doubles its size and 
prepares to undergo mitosis (Morgan, 2007).  
 
 
 
 
 
 
 
 
 
 
 
After passing through mitosis and into a new G1-phase, the new cell either continues 
through another division cycle or ceases to divide, entering a resting state (G0) that may last 
hours, days, or the whole lifetime of the cell (Figure 1.1). In most cultured cell lines, G0 represents 
a state when cells have reversibly withdrawn from the cell cycle in response to high cell density or 
growth factors deprivation. Stimulation by mitogens causes these quiescent cells to re-enter the 
cell cycle through G1 phase and undergo a new cell division cycle. Alternatively, cells may 
irreversibly withdraw from the cell cycle into terminally differentiated or senescent out-of-cycle 
state. Most functional cells in the human body reside in this differentiated state. They have 
Figure 1.1. The eukaryotic cell cycle 
phases. The eukaryotic cell cycle consists of four 
sequential phases: G1, S, G2 and M. During S-
phase the cell replicates its DNA and the 
centrosome. Mitosis is accompanied by 
breakdown of the nuclear envelope, chromosome 
condensation, segregation of the sister 
chromatids into two new nuclei (karyokinesis) and 
cell division into two genetically identical daughter 
cells (cytokinesis). After mitosis the new cells 
either continue through another division cycle or 
enter in a resting state (G0).  
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acquired their specialized form and function and are not cycling. Only minorities of cells are 
actively proliferating and these are located mainly in the stem-transit amplifying compartments of 
self-renewing tissues such as epithelia and bone marrow (Morgan, 2007).  
In addition, the transition from one phase to the next are monitored by sensor mechanisms, 
called checkpoints, which exist to ensure the correct order of events (Hartwell and Weinert, 1989). 
Initiation of each phase is dependent on the proper progression and completion of the previous 
one. The primary checkpoint acts late in G1 and is known as the “restriction point” (Figure 1.2). 
Once cells have passed this point, they normally are committed to a round of cell division. Apart 
from the restriction point, other checkpoints exist at S-phase and G2/M transition to ensure that 
cells have fully and correctly replicated their DNA or during mitosis to ensure that conditions 
remain suitable to complete cell division (Morgan, 2007).  
1.1.2. The cell cycle machinery. CDKs and cyclins 
Eukaryotic cell division represents an evolutionarily conserved process involving temporally 
ordered and discrete steps. This implied a tightly controlled series of molecular events and 
different rate-limiting proteins to regulate specific cell cycle phase transitions (Hartwell, et al., 
1974; Nurse, 1975; Evans, et al., 1983). These concepts gave birth to the idea of the cell cycle 
machinery that both drives and controls progression through the division cycle (Murray and Hunt, 
1993). For the discoveries that led to the identification of the key elements in cell cycle 
researchers Leland Hartwell, Paul Nurse, and Tim Hunt received the Nobel Prize for Physiology 
and Medicine in 2001.  
Progression through the cell cycle is under the strict control of a family of serine/threonine 
protein kinases, which act at precisely timed intervals, phosphorylating proteins involved in cell 
cycle progression and modulating their activities (Murray, 2004). Some of these substrates 
include for example nuclear lamins, histone H1 or myosin whose phosphorylation respectively 
promotes breakdown of the nuclear envelope, mitotic chromosome condensation or inactivation of 
the contractile machinery after cytokinesis (Morgan, 2007). These kinases are heterodimers 
consisting of a regulatory subunit, the cyclin, and a catalytic subunit, the cyclin-dependent protein 
kinase (CDK). As its name indicates, the catalytic activity of the CDK depends on the binding of 
the regulatory cyclin subunit (Figure 1.3). The number of CDKs has increased considerably during 
evolution. According to the latest versions of the human and mouse genomes, there are 21 genes 
encoding CDKs and 5 other genes encoding CDK-like proteins with conserved primary structure 
(Malumbres, et al., 2009). Of these 21 CDKs, CDK1-11 are the best-characterized members. 
CDK1, 2, 3, 4 and 6 are thought to be the major regulators of “the core cell cycle”, CDK5 functions 
in neuronal development and CDK7-11 function mainly as transcriptional regulators, although 
CDK7 and 11 have additional cell cycle functions (Satyanarayana and Kaldis, 2009). The 
physiological role of the rest of CDKs remains essentially unknown (Malumbres, et al., 2009).  
The expression of the majority of core cell-cycle CDKs remains relatively constant 
throughout the cell cycle. In contrast, the activating partners are synthesized and destroyed in a 
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cyclical fashion during each phase of cell cycle and thus they were originally designated “cyclins” 
(Evans, et al., 1983). Nowadays, the analysis of the human genome has revealed up to 29 genes 
sharing a conserved domain of approximately 150-amino acids involved in the binding to CDKs 
and termed the “cyclin box” (Malumbres and Barbacid, 2005). Similarly to CDKs, of all cyclins 
identified, only a few have been reported to regulate the core cell cycle, such as D, E, A and B-
type cyclins. Cyclins C, H and T are involved in regulation of the RNA polymerase II transcription 
(Loyer, et al., 2005). Moreover, as we will see below, every cyclin determines the substrate 
specificity of selected CDKs and generally confers them of spatial and temporal activity at defined 
points in the cell cycle (Morgan, 1997; Miller and Cross, 2001).  
1.1.3. Cell cycle regulation 
The basic regulation of the cell cycle was established by pioneering studies in yeasts. In 
these organisms, cell cycle progression is controlled by a single CDK (Cdc28 in S. cerevisiae and 
Cdc2 in S. pombe) that binds to specific cyclins at different stages of the cycle. In contrast, in 
mammalian cells, cell cycle progression is regulated by specific cyclin/CDK complexes at defined 
phases in a sequential and orderly fashion (Morgan, 1997).  
According to the “classical” cell cycle model (Figure 1.2), at early G1 phase, mitogenic 
signals such as growth factors and cytokines are first sensed and integrated by expression of the 
D-type cyclins (D1, D2 and D3) (Matsushime, et al., 1991; Won, et al., 1992; Sherr, 1995) that 
preferentially bind  to and activate CDK4 and CDK6 (Matsushime, et al., 1992). These complexes 
initiate phosphorylation of retinoblastoma (RB) protein family members (RB, p107 and p130) 
whose phosphorylation status plays a major role in controlling E2F transcriptional activity 
(Harbour, et al., 1999). Unphosphorylated RB binds to and inhibits the transcription factor E2F. 
Thus, activation of CDK4/6 leads to the partial inactivation of RB and the release of active E2F 
transcription factors which results in the transcriptional activation of E2F responsive genes 
(Weinberg, 1995; Dyson, 1998). These genes include E-type (E1 and E2) cyclins (Botz, et al., 
1996; Geng, et al., 1996) as well as genes necessary for DNA synthesis such as the DNA 
polymerase-α, among others (DeGregori, et al., 1995). This allows the activation of CDK2 by 
binding to E-type cyclins in the late G1 phase (Sherr and Roberts, 1999,2004). Cyclin E/CDK2 
complexes complete the phosphorylation and inactivation of pocket proteins (Lundberg and 
Weinberg, 1998; Harbour, et al., 1999) leading to passage through the restriction point at the 
boundary of the G1/S phase (Figure 1.2), which commits the cell to S-phase entry and to 
complete a round of cell division (Planas-Silva and Weinberg, 1997). Later CDK2 plays an 
important role in S-phase progression by complexing with A-type (A1 and A2) cyclins (Pines and 
Hunter, 1990; Tsai, et al., 1991), which are expressed throughout the S and G2 phases and are 
required for DNA replication (Girard, et al., 1991; Geley, et al., 2001). A-type cyclins also activate 
CDK1 at G2/M transition (Tsai, et al., 1991; Murphy, et al., 1997) to facilitate the onset of mitosis 
(Furuno, et al., 1999) and they are rapidly degraded upon entry into mitosis by the anaphase 
promoting complex (APC) (Geley, et al., 2001). Finally, B-type cyclins synthesis that begins at the 
Introduction 
6 
 
end of S-phase (Pines and Hunter, 1989), facilitates the formation of the cyclin B/CDK1 
complexes responsible for driving cells through mitosis (Riabowol, et al., 1989). Degradation of B 
cyclins also by the APC complex is required to the output of mitosis (Geley, et al., 2001; Harper, 
et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, the basic concept put forward in which each phase of the cycle is driven by 
specific cyclin/CDK complexes, has recently challenged by genetic studies in mice. Systematic 
knockout of CDK loci in the mouse germline has shown that CDK2 (Berthet, et al., 2003; Ortega, 
et al., 2003), CDK4 (Rane, et al., 1999; Tsutsui, et al., 1999) and CDK6 (Malumbres, et al., 2004) 
are not essential for cell cycle progression of most cell types, although loss of each of these 
CDKs results in particular developmental defects. Furthermore, concomitant loss of multiple 
interphase CDKs (CDK2,4,6) enhances the scope of these developmental defects but does not 
result in a general disturbance of the cell cycle in most cell types (Malumbres, et al., 2004; 
Berthet, et al., 2006; Barriere, et al., 2007). This may be due to compensatory activities among 
mitotic kinase CDK1 and these CDKs (Aleem, et al., 2005). Altogether, the mouse knockout 
studies have shown that CDK1 alone is sufficient to drive cell cycle progression, compensating for 
the loss of CDK2, 3, 4 and 6. In this sense, triple knockout (TKO) mouse embryos lacking all 
interphase CDKs develop normally until mid-gestation (Santamaria, et al., 2007). 
Interestingly, there are no compensatory activities between interphase CDKs and CDK1. 
The ablation of Cdk1 leads to embryonic development arrest, preventing embryos from 
developing beyond the blastocyst stage (Diril, et al., 2012) or even the two-cell stage 
(Santamaria, et al., 2007) in spite of carrying all interphase CDKs. Cdk1 replacement by Cdk2 
using homologous recombination also results in early embryonic lethality, indicating that CDK1 
cannot be compensated by CDK2, despite being expressed from the Cdk1 locus (Satyanarayana, 
et al., 2008). The conditional in vivo ablation of Cdk1 in MEFs results in DNA re-replication 
because of an increase in cyclin A2/CDK2 activity (Diril, et al., 2012). The fact that CDK1 alone 
Figure 1.2. Regulation of the cell cycle progression through the different phases by cyclin/CDK 
complexes. Cyclin D/CDK4-6 first and then cyclin E/CDK2 trigger the transition from G1 to S phase (Restriction 
point) by phosphorylating RB protein family members among other proteins and activating E2F transcription 
factors. Progression into S and G2 phases requires the activity of cyclin A bound to CDK2 and CDK1 respectively. 
Finally, the activity of cyclin B/CDK1 is required for mitosis (“M”).    
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can drive the cell cycle in most mammalian cells suggests that animal cells and yeasts share the 
basic control mechanism of the cell cycle. 
There are also compensatory activities among cyclins. Ablation of the genes encoding 
individual D-type cyclins only leads to specific developmental defects in mice (Ciemerych and 
Sicinski, 2005). However, concomitant ablation of the three D-type cyclins results in embryonic 
lethality owing to haematopoietic defects. Nevertheless, D1-/-/D2-/-/D3-/- mouse fibroblasts 
proliferate normally although they require increased mitogenic stimulation for cell cycle re-entry 
(Kozar, et al., 2004).  
Ablation of the genes encoding cyclin E1 and cyclin E2 also results in embryonic lethality 
owing to placental defects. However, E-type cyclins are largely dispensable for embryonic 
development when the placental defects are rescued and therefore for cell cycle progression of 
most embryonic cells (Geng, et al., 2003; Parisi, et al., 2003). Interestingly, expression of cyclin 
E1 within the cyclin D1 locus rescues most phenotypes observed in cyclin D1-/- mice, revealing a 
functional overlap between different classes of cyclins (Geng, et al., 1999).  
Cyclin A1 is expressed almost exclusively during meiosis of male germline cells in the 
testes (Sweeney, et al., 1996; Yang, et al., 1997). Accordingly, male cyclin A1-/- mice are 
completely viable but sterile because of a meiotic arrest during spermatogenesis (Liu, et al., 1998; 
van der Meer, et al., 2004). In contrast, cyclin A2-/- mouse embryos die shortly after implantation 
(Murphy, et al., 1997; Kalaszczynska, et al., 2009). Conditional ablation of both cyclin A1 and A2 
in mouse fibroblasts leads to prolonged expression of cyclin E1 across the cell cycle without 
affecting cell cycle progression. Nevertheless, they are essential for cell-cycle progression of 
hematopoietic and embryonic stem cells. Only when all A- and E-type cyclins are deleted, the cell 
division is arrested, suggesting that cyclins A and E play redundant roles in cell cycle progression 
(Kalaszczynska, et al., 2009).  
Finally, studies in cyclin B1- and cyclin B2-null mice have confirmed that cyclin B2 is non-
essential for normal growth and development. Cyclin B1 appears to compensate for the loss of 
cyclin B2 in B2-/- mice. In contrast, loss of cyclin B1 results in early embryonic lethality (Brandeis, 
et al., 1998). It is unclear whether cyclin B1-/- MEFs do proliferate or not.  
In summary, from all the different cyclin members that regulate the canonical cell cycle, 
cyclin A2 and B1 appear to be the most non redundant cyclins, as their deletion led to early 
embryonic lethality. Altogether, the information available to date leads to the current model where 
cyclins A and B and CDK1 represent absolutely the basic ‘‘core’’ elements of the cell-cycle 
machinery (Murphy, et al., 1997; Hochegger, et al., 2008).  
1.2. MOLECULAR REGULATION OF CDKs ACTIVITY 
As indicated above, CDKs play pivotal roles in cell cycle control. Their regulation ensures 
the correct timing of kinase activity during cell cycle. Apart from binding to cyclins, CDKs activity is 
regulated by two others mechanisms including phosphorylation of critical residues in the CDKs 
and binding of cyclin dependent kinase inhibitors (CKIs). CDK activity can also be modulated by 
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its subcellular localization and/or its accessibility to substrates, although these regulatory 
mechanisms are less well characterized (Morgan, 1995; Murray, 2004).  
1.2.1. Cyclin binding to CDKs 
Most of the current information on the structure and activity of CDKs is based on crystal 
structures of human CDK2 (De Bondt, et al., 1993) and cyclin A/CDK2 complex (Jeffrey, et al., 
1995; Russo, et al., 1996b). Essentially, it can be translated to others CDKs although each cyclin 
induces specific conformation changes on its bound CDK. Roughly, the structure of monomeric 
CDK2 consists of a small N-terminal lobe (N-lobe) rich in β-sheets and a larger C-terminal lobe 
(C-lobe) rich in α-helices (Figure 1.3). The ATP-binding site lies in a deep cleft between the two 
lobes of the kinase. Monomeric CDK2 differs from the cyclin-bound structure basically in two 
regulatory regions: an α-helix which contains a conserved PSTAIRE amino acid sequence 
exclusive of CDKs and a flexible loop called the activation loop or “T-loop” which contains a 
phosphorylatable residue (Thr160). The PSTAIRE helix also contains a conserved catalytic 
residue (Glu51) which is involved in ATP binding. In absence of the cyclin, the PSTAIRE helix is 
outwards and the T-loop is positioned in front of the catalytic cleft entrance, blocking the access of 
the ATP. CDK2 association with cyclin A causes significant conformational changes in the kinase 
that serves to configure the catalytic site for ATP binding (Figure 1.3). The PSTAIRE helix domain 
moves inwards, bringing the Glu51 inside the catalytic cleft, where together with others conserved 
residues (Lys33 and Asp145) and a magnesium ion (Mg2+) coordinates the ATP phosphate atoms 
and correctly orients them for catalysis. Meanwhile, the T-loop moves away from the catalytic cleft 
entrance and exposes the phosphorylatable Thr160, setting the stage for the full activation of the 
kinase (Pavletich, 1999).  
1.2.2. CDKs regulation by phosphorylation 
Apart from cyclin binding, the complete activation of cyclin A/CDK2 complex requires 
several phosphorylation and dephosphorylation events at different residues in the protein.  
First, Thr160 phosphorylation on the T-loop promotes an additional conformational change 
in CDK2 and completes the reorganization of the substrate binding site that was started by the 
cyclin (Figure 1.3) (Russo, et al., 1996b). The phosphate group at Thr160 acts as an organizing 
center in the substrate binding site and allows the CDK to interact more effectively with 
substrates, optimizing the phosphoryl transfer and increasing the catalytic activity of cyclin/CDK 
complex (Jeffrey, et al., 1995; Russo, et al., 1996b; Brown, et al., 1999). This Thr160 
phosphorylation event is catalyzed by the CDK activating kinase (CAK), which is composed of 
three subunits: CDK7, cyclin H and MAT1 (ménage a trois) (Fesquet, et al., 1993; Fisher and 
Morgan, 1994; Makela, et al., 1994; Devault, et al., 1995). The CAK is also responsible for the 
activating phosphorylation of Thr161 in CDK1, Thr172 in CDK4 and Thr177 in CDK6 which are 
structurally equivalent to Thr160 in CDK2 (Lolli and Johnson, 2005).  
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CDK phosphorylation by CAK is antagonized by a specific phosphatase called KAP (CDK-
associated phosphatase). KAP dephosphorylates Thr160 in human CDK2 when the cyclin subunit 
is degraded or dissociates, and prevents CDK2 kinase activity upon subsequent association with 
cyclin A (Hannon, et al., 1994; Poon and Hunter, 1995). 
Second, cyclin/CDK complexes can also be inactivated via inhibitory phosphorylation of two 
conserved residues near the N-terminus (Thr14 and Tyr15 in human CDK1 and 2; Tyr17 and 
Thr19 in CDK4 and Tyr13 in CDK6) located within the ATP-binding site of the kinase. The 
negatively charged phosphate group on Thr14 prevents ATP binding, while that on Tyr15 
interferes with phosphate transfer to the substrate (Gould and Nurse, 1989; Atherton-Fessler, et 
al., 1993; Morgan, 1995). These inhibitory phosphorylation events are carried out by Wee1, a 
kinase conserved in all eukaryotes and Myt1. Nuclear Wee1 specifically phosphorylates Tyr15, 
whereas cytoplasmic Myt1 phosphorylates both Tyr15 and Thr14, with a stronger affinity for Thr14 
(Featherstone and Russell, 1991; Parker and Piwnica-Worms, 1992; Mueller, et al., 1995). Unlike 
activating phosphorylation, CDK inhibitory phosphorylations are essential for cell cycle regulation 
and particularly at mitosis for the control of CDK1 activation (Solomon, et al., 1990; Krek and 
Nigg, 1991). Dephosphorylation of both residues accompanies entry into mitosis and this is 
carried out by dual specific phosphatases of the CDC25 family (Dunphy and Kumagai, 1991; 
Strausfeld, et al., 1991). In vertebrates, CDC25 family has three isoforms: CDC25A, CDC25B and 
CDC25C. Inhibition of CDC25 phosphatases in response to DNA damage or other stress 
conditions, decreases CDK activity and leads to cell cycle arrest (Boutros, et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3. Cell cycle inhibitors: INK and CIP/KIP protein families 
The interaction of cyclin/CDK complexes with CDK inhibitors or CKIs is one of the most 
important mechanisms regulating CDK activity and therefore the cell cycle progression (Morgan, 
1997). Negative CDK regulation by CKIs is an important step linking anti-mitogenic signals to cell 
cycle arrest in response to normal as well as extreme conditions, such as stress or DNA damage 
Figure 1.3. CDK activation by cyclin binding and CAK phosphorylation at Thr160. CDK structures 
corresponding to non-activated (monomeric CDK2), partially active (cyclin A/CDK2 complex) and fully active 
(phosphorylated cyclin A/CDK2 complex) states. In CDK2, the PSTAIRE helix is highlighted in red, the T-loop in 
yellow and the Thr160 is indicated by yellow spheres. The phosphate groups of ATP and phosphorylated Thr160 
are indicated by red spheres. Adapted from (Pavletich, 1999). 
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(Satyanarayana and Kaldis, 2009). Based on their sequence homology, structure and CDKs 
specificities, CKIs are divided into two distinct families: The INK4 (Inhibitors of CDK4) and the 
CIP/KIP (CDK Interacting Protein/Kinase Inhibitory Protein) protein families (Pavletich, 1999; 
Sherr and Roberts, 1999).  
The INK4 family comprises p16INK4A, p15INK4B, p18INK4C and p19INK4D. These inhibitors bind 
to free CDK4/6 and inhibit their kinase activity interfering with their association to D-type cyclins 
and distorting the ATP binding site that leads to reduced affinity for ATP. Its ectopic expression 
arrests the cell cycle in G1-phase (Pavletich, 1999; Sherr and Roberts, 1999) and functional Rb 
seems to be required for this process (Bruce, et al., 2000).  
The CIP/KIP family consists of three members, p21CIP1/Waf1 (CDK Interacting Protein 1), 
p27KIP1 (Kinase Inhibitory Protein 1) and p57KIP2 (Kinase Inhibitory Protein 2). This family is 
characterized to contain a conserved N-terminal domain that mediates binding to a broader 
spectrum of cyclin/CDK complexes already formed, inhibiting their activities. These complexes 
include cyclin A-E/CDK2, cyclin D/CDK4-6 and cyclin A-B/CDK1 heterodimers and therefore they 
are able to inhibit progression at every cell cycle phase (Sherr and Roberts, 1999). Among these 
CKIs, p27KIP1 is specifically relevant because reduced p27KIP1 levels are frequently observed in 
human cancers in association with tumor aggressiveness and poor patient outcome as described 
below.  
1.2.4. The CDK inhibitor p27KIP1 
p27KIP1 (p27 hereafter) was first identified by affinity chromatography as a 27 kDa protein 
(hence its name) that bound to cyclin E/CDK2 complexes and inhibited their activity in response 
to the proliferation arrest induced by TGF-β and cell-cell contact in lung epithelial cells (Polyak, et 
al., 1994a; Slingerland, et al., 1994). Soon after, the p27 cDNA was cloned from mink, mouse, 
and human cDNA libraries by two different screening approaches: identifying proteins that 
interacted with mouse cyclin D1 and CDK4 in a yeast "two-hybrid" interaction assay (Toyoshima 
and Hunter, 1994) and by peptide micro-sequencing of purified p27 protein isolated from Mv1Lu 
cells arrested in G1 by contact inhibition (Polyak, et al., 1994b).  
1.2.4.1. Structure of p27 gene and protein 
In humans, p27 is encoded by the CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B) gene 
(Figure 1.4) and maps to the locus 12p13.1-p12 (Pietenpol, et al., 1995; Ponce-Castaneda, et al., 
1995). It contains two coding and one non-coding exons. In agreement with the NCBI RNA 
reference sequence collection (RefSeq), this gene is transcribed into a single mRNA of 2413 base 
pairs which encodes a protein of 198 amino acids. As we previously mentioned, it contains a 
conserved N-terminal kinase inhibitory domain (KID) (aa 25-93) which is homologous to the KID 
domains of p21CIP1 and p57KIP2 (38% and 44% identity respectively) (Russo, et al., 1996a). The 
crystal structure of p27KID domain bound to cyclin A/CDK2 complex has been resolved and 
shows that it binds the complex interacting with both cyclin A and CDK2 in an extended but 
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ordered conformation, comprising two α-helices and a β-structure (Figure 1.5). Binding of p27 to 
CDK2 is accompanied by extensive structural changes in the N-lobe and the catalytic cleft of 
CDK2. This domain also contains a small 310 helix that inserts into the catalytic cleft of CDK2, 
mimicking ATP and inhibiting its kinase activity (Russo, et al., 1996a).  
 
 
 
 
 
 
 
 
 
 
 
In contrast, p27 C-terminal domain is extended and flexible when p27 is bound to cyclin 
A/CDK2 complex (Figure 1.5) according to results obtained from NMR studies (Galea, et al., 
2008a). This flexibility provides a molecular basis for the sequential signal transduction conduit 
that regulates p27 degradation. The C-terminal domain also contains a classical bipartite nuclear 
localization signal (NLS), consisting of two clusters of basic residues separated from each other 
by ten amino acids (aa 152/154-165/169) (Reynisdottir and Massague, 1997) of which Lys153, 
Arg154, Lys165 and especially Arg166, play a critical role in the nuclear localization of p27 (Zeng, 
et al., 2000). In addition, p27 also contains a putative nuclear export signal (NES) identified 
between amino acids 32 and 45 (Muller, et al., 2000; Connor, et al., 2003). 
Moreover, p27 presents several phosphorylatable residues (Ser10, Tyr74, Tyr88, Tyr89, 
Thr157, Thr187 and Thr198) which are involved in regulation of p27 activity, localization and 
stability, that we will be discussed below (Chu, et al., 2008). In addition, it has been shown that 
p27 can be acetylated at Lys100 by the acetyltransferase PCAF (P300/CBP-Associated Factor) 
inducing its degradation via proteasome (Perez-Luna, et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. CDKN1B gene structure and localization in the human genome and major features p27 
protein. Chr (Chromosome); TSS (Transcription start site); KID (Kinase inhibitory domain); NES (Nuclear export 
signal); NLS (Nuclear localization signal); posttraductional modifiable amino acids (*) and bp (base pairs).  
Figure 1.5. Structure of the p27/cyclin A/CDK2 
complex. Schematic view of p27 (25-198 aa) 
illustrated as ribbons, bound to cyclin A/CDK2 complex 
illustrated as solvent accessible surface (magenta and 
cyan, respectively). The KID domain (grey) contains 
two critical phosphorylatable residues, Tyr74 and 
TyrY88 (blue and red spheres, respectively) and the 
310 helix subdomain which is inserted into the ATP 
binding pocket of CDK2. The C-terminal domain of p27 
(yellow tube), which contains Thr187 (green spheres), 
is intrinsically unstructured and highly dynamic. 
Adapted from (Galea, et al., 2008a). 
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Finally, p27 belongs to the growing family of “natively unfolded”, “intrinsically disordered” or 
“unstructured” proteins. The disordered protein regions lack of secondary structure and present a 
large number of possible conformations that, after the substrate binding, converge to a well-
defined structure with high affinity for the substrate. In this sense, p27 binds cyclin/CDK 
complexes through a sequential mechanism involving binding-induced protein folding. The 
absence of a pre-existing folding strongly facilitates p27 interaction with a number of targets 
(Bienkiewicz, et al., 2002; Lacy, et al., 2004). 
1.2.4.2. Regulation of p27 
Expression of p27 is controlled at different levels including transcription, translation and 
ubiquitin mediated degradation. In addition, p27 activity can be modulated at the same time by its 
subcellular localization or by complexing into different cyclin/CDK complexes. Furthermore, p27 
degradation and its subcellular localization are governed in turn by its phosphorylation status 
(Chu, et al., 2008). Therefore, p27 regulation is complex, although it is largely accepted that p27 
is mainly regulated at protein stability level. 
Regulation of p27 gene transcription 
Although p27 levels are largely controlled at the post-transcriptional level, several 
transcription factors have been shown to bind and regulate the CDKN1B promoter. For instance, 
E2F1, which is itself activated by cyclin/CDK complexes (through RB phosphorylation), activates 
the p27 promoter leading to a negative feedback loop (Wang, et al., 2005a). SP1, NF-Y and the 
vitamin D3 receptor (VDR) might also up-regulate p27 expression during cell differentiation in 
response to vitamin D3 stimulation (Inoue, et al., 1999; Huang, et al., 2004). STAT3 also binds to 
murine p27 promoter and induces p27 expression, mediating differentiation of myeloid murine 
cells in response to granulocyte colony-stimulating factor (G-CSF) (de Koning, et al., 2000). 
Menin, the protein encoded by the MEN1 (multiple endocrine neoplasia) tumour suppressor gene, 
recruits MLL histone methyltransferase complex to the first exon of CDKN1B, activating the p27 
expression (Milne, et al., 2005). However, CDKN1B regulation is carried out mainly by 
transcription factors of the Forkhead box class O family, such as FoxO3a (also called FKHR-L1) 
and FoxO4 (also called AFX). These transcription factors integrate signals from cytokines, 
PI3K/AKT(PKB) and RAS signaling pathways to modulate p27 gene transcription (Dijkers, et al., 
2000; Medema, et al., 2000; Trotman, et al., 2006). For example, AKT phosphorylates and 
inactivates FoxO4, suppressing FoxO4-mediated p27 gene transcription in LNCaP human 
prostate carcinoma cell line (Graff, et al., 2000).  
On the other hand, the transcription factor MYC represses the CDKN1B promoter in several 
immune system cell lines through a putative Inr element at the transcription start site (TSS) 
(Yang, et al., 2001; Chandramohan, et al., 2004). 
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Regulation of p27 mRNA translation 
p27 mRNA translation is maximal in quiescence and early G1 and decreases after mitogen 
stimulation as cells progress toward S-phase (Hengst and Reed, 1996; Millard, et al., 1997). Cell 
cycle-dependent translation of p27 is mainly controlled by the 5' untranslated region of p27 mRNA 
(5′ UTR), which contains an internal ribosome entry site (IRES). The IRES is a specialized RNA 
structure that recruits ribosomes to the mRNA in a cap-independent manner and maintains 
efficient p27 mRNA translation during quiescence when most cellular cap-dependent translation is 
reduced (Miskimins, et al., 2001; Kullmann, et al., 2002). Several proteins, such as PTBP1 (also 
known as hnRNP I) or ELAVL1 and ELAVL4 (also known as Hu-R and Hu-D, respectively) have 
been described to bind to the p27 IRES and to modulate p27 mRNA translation (Millard, et al., 
2000; Kullmann, et al., 2002; Cho, et al., 2005). Finally, miR-221 and miR-222 bind to the 3′UTR 
of p27 mRNA and inhibit its translation. Down-regulation of miR-221/222 in different tumour cells 
increased p27 expression and inhibited cell proliferation (le Sage, et al., 2007).  
Regulation of p27 protein stability 
However, the best known mechanism regulating p27 protein levels in the cell is post-
translational and controls the protein degradation through the ubiquitin-proteasome pathway 
(Pagano, et al., 1995). In quiescent cells, p27 accumulates in the nucleus where it binds to 
cyclin/CDK complexes to block cell cycle progression (Sherr and Roberts, 1999). To re-enter the 
cell cycle upon mitogenic stimulation, the cell need to down-regulate p27 levels rapidly. In fact, 
p27 half-life falls five-to eightfold during G1/S transition. For it, p27 undergoes a rapid ubiquitin-
proteasome-mediated proteolysis following two main pathways, dependent or independent of 
p27-Thr187 phosphorylation (Nakayama and Nakayama, 2006; Chu, et al., 2008). 
 
p27 proteolysis dependent on Thr187-phosphorylation  
 
The best characterized degradation pathway takes place in the nucleus at G1/S transition 
and is mediated by the SCFSKP2 (SKP1/CUL1/F-Box protein: SKP2) ubiquitin ligase complex 
(Figure 1.6 and 1.7) (Carrano, et al., 1999; Sutterluty, et al., 1999; Tsvetkov, et al., 1999) which 
will be discussed in more detail below. The SCFSKP2 complex consists of the RING-finger protein 
RBX1, CUL1, SKP1, the F-box protein SKP2 and the accessory protein CKS1 (Nakayama and 
Nakayama, 2006). Efficient p27 ubiquitination by SCFSKP2 complex requires prior p27 
phosphorylation at Thr187 which is mediated by active cyclin E-A/CDK2 complexes (Muller, et al., 
1997; Sheaff, et al., 1997; Vlach, et al., 1997; Montagnoli, et al., 1999). The phosphate group at 
Thr187 is recognized by the phosphate binding pocket of CKS1, and promotes the binding of p27 
to the CKS1/SKP2 interface (Hao, et al., 2005) (Figure 1.11). Thus, CKS1 deficiency prevents 
SKP2 binding to p27, leading to p27 up-regulation (Ganoth, et al., 2001; Spruck, et al., 2001). In 
addition, p27 ubiquitination also requires its stable binding to a cyclinA/CDK2 complex 
(Montagnoli, et al., 1999; Zhu, et al., 2004b) because cyclin A binds SKP2 (Zhang, et al., 1995; Ji, 
et al., 2006) and CDK2 binds CKS1 (Bourne, et al., 1996). Therefore, cyclin A/CDK2 complex 
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phosphorylates and stimulates p27 recruitment to the SCFSKP2 ubiquitin ligase complex which
induces p27 polyubiquitination and subsequent degradation by the proteasome (Nakayama and
Nakayama, 2006).
Nevertheless, p27 binds to and inhibits cyclin A-E/CDK2 catalytic activity at G0/G1 phases
(Pavletich, 1999) preventing p27-Thr187 phosphorylation. Therefore, active trimeric complexes
are required to efficiently phosphorylate p27 at Thr187. To solve this conflict p27 contains several
phosphorylatable tyrosines within its KID domain (Tyr74, Tyr88 and Tyr89). Tyr88 is highly
conserved among CKIs of CIP/KIP family and it is part of the 310-helix that inserts into the catalytic
cleft of CDK2 displacing the ATP (Russo, et al., 1996a). Tyr88 phosphorylation by non-receptor
tyrosine kinases (NRTKs), such as ABL and SRC family members or Janus kinase 2 (JAK2)
(Galea, et al., 2008b; Jakel, et al., 2011), promotes 310-helix ejection from the catalytic cleft,
opening up the ATP binding pocket and allowing p27-Thr187 phosphorylation by the own CDK2 in
the trimeric complex (Figure 1.6). Thus, p27 phosphorylation at Tyr88 initiates the passage from a
cyclin E/CDK2 inhibitor at G0 to a cyclin E-A/CDK2 substrate at the G1/S transition (Chu, et al.,
2007; Grimmler, et al., 2007).
p27 proteolysis independent on Thr187-phosphorylation
Although SCFSKP2 mediates probably the most potent degradation pathway of nuclear p27
at G1/S transition, p27 proteasome-mediated degradation can also occur by SCFSKP2 and Thr187-
independent pathways (Hara, et al., 2001; Malek, et al., 2001). The second main degradation
pathway is carried out by the KIP1 ubiquitination-promoting complex (KPC) and takes place in the
Figure 1.6. Scheme illustrating the phosphorylation mechanism involving Tyr88 and Thr187 which
triggers p27 ubiquitination and 26S proteasomal degradation in both normal and cancer cells.
Phosphorylation of Tyr88 (1), (and possibly Tyr74) by non-receptor tyrosine kinases (NRTKs), ejects subdomain 310
from the ATP binding pocket of CDK2 allowing Thr187 within the flexible C-terminal domain to encounter the CDK2
active site and to be phosphorylated by CDK2 (2). P-Thr187-p27 is recognized by SCFSKP2 ubiquitin ligase which
ubiquinates p27 (3) targeting it for proteasomal degradation and releasing active cyclin A/CDK2 complexes (4).
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cytoplasm in early G1 (Kamura, et al., 2004) (Figure 1.7). The KPC ubiquitin ligase consists of 
two subunits, the RING finger protein KPC1 and KPC2. KPC1 binds to free cytoplasmic p27 
whereas KPC2 interacts with the 26S proteasome (Hara, et al., 2005; Kotoshiba, et al., 2005). 
Recently, a third E3 ubiquitin ligase, Seven in Absentia Homolog 1 (SIAH1) together with its 
adaptor protein SIAH-interacting protein (SIP), has been also shown to ubiquitinate p27 in the 
cytoplasm, in response to glucose depletion (Nagano, et al., 2011). Finally, it has been reported 
other ubiquitin ligases involved in the ubiquitination and proteasomal degradation of p27 such as 
the transcription factor and HECT domain family ubiquitin ligase UBE3A/E6-AP, the p53-inducible 
protein with a RING-H2 domain Pirh2 or CUL4A/B-based E3 ligases, but their mechanisms of 
action are less well characterized (Chu, et al., 2008; Lu and Hunter, 2010).  
Regulation by the subcellular localization of p27 
The subcellular localization of p27 plays an important role by rendering the protein available 
to the different degradation pathways, as mentioned, but also by regulating cell cycle-independent 
functions such as cell motility.  
To perform its function as cell-cycle inhibitor, p27 needs to be imported into the nucleus 
during the G1-phase. For that, the C-terminal region of p27 contains a NLS (aa 152–169) that 
guides p27 into the cell nucleus (Reynisdottir and Massague, 1997; Zeng, et al., 2000). Importins-
α3 and α5 recognize p27-NLS and importin-β mediates p27-importin-α association with the 
nuclear pore complex (Sekimoto, et al., 2004). In this transport also participates the nuclear pore 
complex-associated protein mNPAP60 (Muller, et al., 2000).  
However, in early G1, p27 can also be detected in cytoplasm. p27 phosphorylation on 
Ser10 increases p27 binding to exportin 1 (also known as CRM1) through the NES and promotes 
nuclear export of p27 (Figure 1.7) (Rodier, et al., 2001; Ishida, et al., 2002; Connor, et al., 2003). 
In this process also participates the core component of COP9/signalosoma Jab1/CSN5 which 
functions as an adaptor between p27 and CRM1 (Tomoda, et al., 1999; Tomoda, et al., 2002). 
Ser10 is one of the major phosphorylation sites of p27. It is estimated that 75% of p27 phosphate 
incorporation occurs on this residue (Borriello, et al., 2007). Ser10 can be phosphorylated by 
multiple kinases including MIRK (also known as DYRK 1B), CDK5, KIS, AKT/PKB, TM4SF5 or 
the CaM kinase II (Jakel, et al., 2012). Nevertheless, there are discrepancies about the role of 
Ser10 phosphorylation in the nuclear export of p27 at the G0/G1 transition, because this export 
occurs normally in knock-in p27S10A MEFs, indicating that it is not essential for this process 
(Kotake, et al., 2005).  
In the cytoplasm, p27 phosphorylation on Thr157 and Thr198 delays nuclear import of p27 
(Larrea, et al., 2009b). Thr157 is located within the NLS and phosphorylation of this residue 
promotes p27 association to 14-3-3 protein which suppresses importin α/β-dependent nuclear 
localization, leading to p27 cytoplasmic retention (Figure 1.7) (Sekimoto, et al., 2004). Several 
protein kinases can phosphorylate Thr157 including SGK1 (Hong, et al., 2008), AKT/PKB (Liang, 
et al., 2002; Shin, et al., 2002; Viglietto, et al., 2002) and all Pim family members (Pim1, Pim2, 
and Pim3) (Morishita, et al., 2008). Pim and AKT kinases also phosphorylate p27 on Thr198 
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promoting p27 binding to 14-3-3 proteins and preventing p27 re-entry into cell nucleus (Fujita, et 
al., 2002; Morishita, et al., 2008). In addition, Thr198 phosphorylation by RSK1 which is an 
effector of both Ras/MAPK and PI3K/PDK1 pathways or AMP-activated protein kinase (AMPK), 
also stabilizes p27 at G1-phase, preventing ubiquitin-dependent degradation of free p27 (Kossatz, 
et al., 2006; Liang, et al., 2007; Larrea, et al., 2009a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulation of p27 by sequestration in complexes with D-cyclins 
As previously mentioned, the cyclin A-E/CDK2 complexes are the main p27 targets at G1/S 
transition. However, p27 also binds to cyclin D/CDK4-6 complexes when cells pass through G1-
phase of cell cycle. This reduces the p27 levels available for inhibition of cyclin A-E/CDK2 
complexes, allowing CDK2 activity and driving cells through G1/S phase transition. However, p27 
Figure 1.7. Role of phosphorylation events in modulating p27 function, activity and stability related to 
its subcellular localization during cell cycle.  In early G1, p27 phosphorylation at Ser10 promotes EXP1-
dependent nuclear export to the cytoplasm where p27 interacts with the KPC ubiquitin ligase complex that 
promotes p27 ubiquitination and degradation by the proteasome. However, phosphorylation at Thr157 and Thr198 
lead to p27 cytoplasmic retention bound to 14-3-3 proteins, stabilizing p27, suppressing importin α/β-dependent 
nuclear localization and promoting increased cell motility via inhibition of RhoA-ROCK activity. While in the nucleus, 
p27 promotes cyclin D/CDK4-6 complexes assembly. In mid-G1, p27 inhibits cyclin E/CDK2 complexes, preventing 
G1/S transition. Upon mitogenic stimulation, p27-Tyr88 phosphorylation contributes to cyclin E/CDK2 activation and 
Thr187 phosphorylation, allowing p27 ubiquitination through SCFSKP2, proteolysis by the proteasome and cell cycle 
progression through S-phase. (Inset at the upper right) Protein kinases involved in p27 phosphorylation. 
Schematic representation of p27 showing the regulatory phosphorylation residues and the protein kinases involved 
in every phosphorylation event. For more details, see the text. 
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is redistributed from cyclin D/CDK4-6 to cyclin A-E/CDK2 complexes when cells are arrested by 
growth factor deprivation, drug treatment or UV irradiation (Poon, et al., 1995). Therefore, it has 
been suggested that cyclin D/CDK4-6 complexes can function as a reservoir for p27, regulating 
p27 activity (Poon, et al., 1995; Soos, et al., 1996). In this line, it has been described that cyclin 
D1 induction by the MEK/ERK pathway regulates the assembly of cyclin D1/CDK4 complexes 
which sequester and reduce the effective inhibitory threshold of p27, preventing p27-mediated cell 
cycle inhibition (Cheng, et al., 1998; Ladha, et al., 1998). In addition, the proto-oncogene MYC 
has been also shown to play an important role in p27 sequestration through modulation of cyclin 
D and E protein levels (Perez-Roger, et al., 1997; Bouchard, et al., 1999; Perez-Roger, et al., 
1999; Obaya, et al., 2002). 
1.2.4.3. p27 functions 
Although most studies focus on p27 function in cell cycle regulation, it has also been 
associated to many other biological processes, such as cell differentiation, apoptosis and cell 
motility, and its subcellular localization appears to play an important role in these functions 
(Borriello, et al., 2007; Chu, et al., 2008). It is also important to mention that recently it has been 
described a new function of p27 as a transcriptional regulator of genes involved in different 
cellular processes as cell cycle, mitochondrial organization and respiration, RNA processing, 
splicing and translation among others. p27 was found bound to the promoters in association with 
p130/E2F4 complexes and co-repressors as mSIN3A and HDACs (Pippa, et al., 2011). This work 
lays the foundation for a new function of p27 unknown to date. 
p27 function in cell cycle regulation 
As previously mentioned, p27 was initially identified associated to cyclin E/CDK2 
complexes in cells that had been growth arrested with TGF-b (Koff, et al., 1993; Polyak, et al., 
1994b). Subsequently, p27 was linked to G1-arrest in response to several other antimitogenic 
signals such as growth factors deprivation, differentiation signals, contact inhibition, loss of cell 
adhesion to the extracellular matrix, cAMP, rapamycin, lovastatin or anti-IgM treatment (Hengst 
and Reed, 1998). Nowadays, it is widely accepted that the effect of p27 in cell proliferation is 
mainly due to the inhibition of cyclin E/CDK2 complexes in G1 and G1/S transition of cell cycle 
(Figure 1.7 and 1.8). In this sense, a p27 mutant (p27CK-) unable to bind cyclin/CDK complexes 
owing to four point mutations in the KID domain (Arg30, Leu32, Phe62 and Phe64 for Ala 
substitutions), cannot arrest cell cycle at G1 (Vlach, et al., 1997). Furthermore, its importance in 
regulating cell proliferation is emphasized by the fact that p27-/- mice are 20-30% larger than wt 
animals and display organomegaly and hyperproliferation of multiple tissues (Fero, et al., 1996; 
Kiyokawa, et al., 1996; Nakayama, et al., 1996). 
On the other hand, p27 binds not only to the cyclin E/CDK2 complex, but also to cyclin 
A/CDK2, cyclin D/CDK4-6 and cyclin B/CDK1 complexes. Early studies indicated that inhibition of 
these complexes occurred at greater stoichiometric amounts of p27 than those needed to inhibit 
cyclin E/CDK2 complexes (Figure 1.8) (Polyak, et al., 1994b; Toyoshima and Hunter, 1994; Blain, 
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et al., 1997; Obaya, et al., 2002). However, structural and biochemical studies suggest that only 
one CIP/KIP molecule should be able to block the activity of a cyclin/CDK complex (Russo, et al., 
1996a; Hengst, et al., 1998). Recently, it has been described that tyrosine phosphorylation in the 
KID domain (Tyr88 and Tyr89 by ABL kinases (James, et al., 2008; Ray, et al., 2009) or Tyr74 by 
SRC kinases (Larrea, et al., 2008)), converts p27 from a cyclin D1/CDK4 bound inhibitor to a 
bound non-inhibitor, in a similar way as occurs in the binding of p27 to cyclin A-E/CDK2 
complexes described above (Chu, et al., 2007; Grimmler, et al., 2007). 
Finally, although the CIP/KIP family of CKIs were originally described as general inhibitors 
of CDK activity (Harper, et al., 1993; Xiong, et al., 1993), several studies suggest an active role 
for both p21 and p27 as assembly factors for the formation of cyclin D/CDK4-6 complexes (Figure 
1.7 and 1.8) (LaBaer, et al., 1997). In fact, p27 and p21 deficient cells show defects in the 
assembly of these complexes (Cheng, et al., 1999a). However, more recent studies show that 
although cyclin D/CDK4-6 complex formation is favored by p21 or p27 (Bagui, et al., 2000; 
Obaya, et al., 2002), their presence is not strictly required (Bagui, et al., 2003). Finally, p27 
phosphorylations at Thr198 and Thr157 have also been involved in p27 assembly function, 
increasing cyclin D1/CDK4 assembly in early G1 (Larrea, et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic model of p27 levels and activity during cell cycle and the relative sensitivity of 
cyclin/CDK complexes to inhibition by p27. The p27 protein levels remains maximal at G0 and early G1 and 
drop rapidly at the G1/S-phase transition. p27 binds to and inhibits a broader spectrum of cyclin/CDK complexes 
already formed. Graphs were taken and adapted from (Polyak, et al., 1994b). They show baculovirally expressed 
human cyclin/CDK combinations assayed for in vitro histone H1 and RB kinase activity in the presence of different 
concentrations of pure recombinant C-terminal hexahistidine tagged p27. Relative phosphorylation levels were 
quantitated and plotted as the percentage of phosphorylation observed in reaction without p27. Cyclin E/CDK2 was 
inhibited half-maximally at 0.5 nM p27 (Polyak, et al., 1994b). Complete inhibition of cyclin A/CDK2, cyclin 
B1/CDK1 or cyclin D2/CDK4 required an 8 to 10-fold higher concentration of p27.  
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Involvement of p27 in cell differentiation processes 
With a few exceptions, terminal differentiation involves an irreversible cell cycle exit into a 
G0 state (Munoz-Alonso and Leon, 2003). This process is usually accompanied by up-regulation 
of CKIs. For instance, p27 is induced during progression to terminal differentiation of human 
hematopoietic progenitors (CD34+ blast cells) (Taniguchi, et al., 1999). p27 is also up-regulated 
during chemically induced differentiation of several hematopoietic cell lines into myeloid, erythroid 
or megakaryocytic lineages (Steinman, 2002; Munoz-Alonso and Leon, 2003; Gomez-Casares, et 
al., 2012). Furthermore, p27 overexpression promotes the differentiation of different 
hematopoietic cell lines toward monocytic (Liu, et al., 1996; Muto, et al., 1999; Rots, et al., 1999), 
erythroid (Munoz-Alonso, et al., 2005; Acosta, et al., 2008) or megakaryocytic lineages 
(Matsumura, et al., 1997). However, despite inducing proliferative arrest, p27 cannot induce 
differentiation in others erythroleukemia cell lines (Matushansky, et al., 2000; Tamir, et al., 2000) 
and, in contrast to its potential requirement in myelopoiesis, p27 down-modulation is a 
prerequisite for normal T-cells development (Tsukiyama, et al., 2001). 
Finally, studies carried out in p27-/- mice shows that p27 controls the development of the 
mouse cerebral cortex by regulating differentiation of cortical progenitor cells into neurons by 
stabilizing the Neurogenin 2 transcription factor (Nguyen, et al., 2006) and that p27 cooperates 
with p57KIP2 regulating the cell cycle exit and differentiation in lens, placenta and pituitary gland 
(Zhang, et al., 1998; Bilodeau, et al., 2009). However, despite exhibit an expansion of 
hematopoietic progenitors, p27-/- mice do not display a defect in the ability to differentiate these 
cells (Fero, et al., 1996).  
The role of p27 in apoptosis 
The role of p27 in programmed cell death remains ambiguous (Drexler and Pebler, 2003). 
In a number of cancer cell lines, overexpression of p27 induces a pro-apoptotic effect (Katayose, 
et al., 1997; Wang, et al., 1997; Dijkers, et al., 2000; Nickeleit, et al., 2008). However, the 
molecular mechanism by which p27 causes apoptosis is largely unknown although it appears to 
require the activation of downstream effectors such as caspase-3 (Nickeleit, et al., 2008). On the 
other hand, p27 protects different carcinoma and leukemic cell lines from chemically-induced 
apoptosis (Philipp-Staheli, et al., 2001; Drexler and Pebler, 2003) and it also plays an 
anti-apoptotic role in normal fibroblasts from p27-/- mice cultured in absence of growth factors 
(Hiromura, et al., 1999).  
Involvement of p27 in cell motility 
p27 also displays a dual behavior in the regulation of cell motility. On the one hand, 
cytoplasmic p27 stimulates cell motility through inhibition of RhoA GTPase. p27 binds through its 
C-terminal domain to RhoA, preventing its activation by Rho–GEFs and disrupting ROCKs 
activation (Figure 1.7). In keeping with this finding, p27-/- MEFs show increased RhoA-ROCK 
activity, increased actin stress fibres and focal adhesions, and decreased cell motility (Besson, et 
al., 2004b). In this manner, p27 controls mouse cerebral cortex development by regulating 
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migration of neurons to the cortical plate (Nguyen, et al., 2006). In addition, cytoplasmic p27 also 
stimulates cell migration through action on GTPase RAC (a positive regulator of cell motility) 
(Nagahara, et al., 1998; McAllister, et al., 2003).  
In contrast, p27 negatively regulates migration in several other cell models (Goukassian, et 
al., 2001; Sun, et al., 2001). In normal MEFs and fibrosarcoma cells, cytoplasmic p27 inhibits 
migration by binding also through its C-terminal domain to stathmin, a microtubule-destabilizing 
protein. p27 impairs the tubulin sequestering activity of stathmin, promoting increased microtubule 
polymerization and inhibition of cell motility (Baldassarre, et al., 2005).  
Altogether, these effects of cytoplasmic p27 in cell migration have been associated with p27 
oncogenic functions as tumor invasiveness and metastasis (Besson, et al., 2004a; Baldassarre, et 
al., 2005; Wu, et al., 2006; Denicourt, et al., 2007). 
1.2.4.4. p27 and cancer 
Given the main key function of p27 as CDK inhibitor and thus as an essential cell cycle 
regulator, disruption of p27 function was promptly associated to cancer development. Actually, 
p27 down-regulation has been observed in almost 50% of all human cancers and it usually 
correlates with their histological aggressiveness and with poor prognosis of the tumor (Slingerland 
and Pagano, 2000; Philipp-Staheli, et al., 2001; Chu, et al., 2008). Moreover, low p27 expression 
has been also correlated with high proliferation rate in lymphomas, prostate and liver cancer 
although not in other cancer types as colon or breast cancer (Slingerland and Pagano, 2000).  
With a very few exceptions such as human patients with MEN1 syndrome-like phenotype 
(Pellegata, et al., 2006; Molatore, et al., 2010), mutations and especially the homozygous deletion 
of CDKN1B gene are extremely rare in cancer (Ponce-Castaneda, et al., 1995; Philipp-Staheli, et 
al., 2001). Therefore, p27 gene cannot be classified as a "classic" tumor suppressor gene 
because it does not fulfil the Knudson's double mutation criterion (Fero, et al., 1998). 
Nevertheless, loss of p27 heterozygosity is frequent in certain human cancers including myeloid 
and lymphoblastic leukemias (Pietenpol, et al., 1995; Takeuchi, et al., 1995) and ovarian cancer 
(Hatta, et al., 1997).  
The reduction of nuclear p27 protein levels in different human cancers (such as breast and 
prostate cancer) without apparent changes in the p27 mRNA expression support the hypothesis 
that p27 down-regulation is mainly due to posttranslational mechanisms (Catzavelos, et al., 1997; 
Cordon-Cardo, et al., 1998). In keeping with this hypothesis, reduced p27 expression has been 
associated to SKP2 overexpression and enhanced proteasome-mediated degradation in breast, 
prostate and colorectal cancer among others (Gstaiger, et al., 2001; Hershko, et al., 2001; 
Signoretti, et al., 2002; Drobnjak, et al., 2003) (Figure 1.14).  
Another mechanism used by the tumor cells to impair the p27-mediated regulation of cell 
cycle progression is the cytoplasmic sequestration of the protein. p27 retention in the cytoplasm 
mediated by AKT-dependent Thr157 phosphorylation has been observed in breast cancer (Liang, 
et al., 2002; Shin, et al., 2002; Viglietto, et al., 2002) and pituitary tumors (Musat, et al., 2005). 
Interestingly, this aberrant cytoplasmic localization of p27 has been associated with higher 
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metastatic potential in carcinomas of the breast, esophagus and uterus, as well as in some 
lymphomas and leukemias (Besson, et al., 2004a) supporting the hypothesis that p27 may also 
act as pro-oncogenic factor in particular circumstances and supporting way p27 is rarely entirely 
lost in human malignancies.   
Several mouse models confirm the role of p27 in suppressing tumorigenesis. All p27-/- mice 
develop intermediate lobe pituitary adenomas over the age of 10 weeks. The loss of only one p27 
allele (p27+/-) reduces the frequency and increases the latency of these tumors at an intermediate 
level when compared with p27-/- mice (Fero, et al., 1996). Molecular analysis of these tumors 
showed that the remaining wild type allele is neither mutated nor silenced. Thus, p27 is a dose-
dependent tumor suppressor in mice (Fero, et al., 1998). Moreover, p27 deficiency cooperates 
with other oncogenic events such activation of the TRK-T1 oncogene; PTEN, RB and APC 
mutation (Min/+) heterozygosity or inhibin-α deletion to promote tumor formation in different 
mouse organs (Figure 1.9) (Blain, et al., 2003). Interestingly, in Eµ-MYC transgenic mice (in which 
MYC is overexpressed in B lymphocytes under the control of the immunoglobulin heavy chain 
promoter), the loss of p27, but not p21, synergizes with MYC in lymphomagenesis, reducing mice 
survival (Martins and Berns, 2002). However, CDK2 is not required for the effect of p27 in both 
cell cycle and tumor formation (Martin, et al., 2005).  
Finally, homozygous p27 CK-/CK- mice and to a lesser extend p27 CK-/+ mice, are prone to a 
higher tumor multiplicity than homozygous p27-/- mice indicating the existence of cyclin/CDK-
independent pro-oncogenic functions of p27 and that p27CK- mutant behaves as a dominant 
oncogene in vivo (Besson, et al., 2007).  
 
 
 
 
 
 
1.3. CONTROLLED DEGRADATION OF CELL CYCLE REGULATORS 
The levels of cyclins, CKIs and many other key regulators oscillate during the cell cycle as a 
result of periodic proteolysis. The ubiquitin-proteasome system (UPS) is a protein-quality control 
system responsible for the degradation of most intracellular misfolded proteins, but also has a 
crucial role in maintaining and regulating cellular homeostasis. This system mediates the 
degradation up to 90% of such short-lived cell cycle regulatory proteins, controlling accurately 
their intracellular concentrations and thus the correct timing of cell cycle. Therefore, aberrant 
activity of UPS is crucial in cancer development (Murray, 2004; Pickart, 2004; Lipkowitz and 
Weissman, 2011) 
Figure 1.9 Mouse models recapitulate the 
role of p27 in human cancers. While p27-/- mice 
only display pituitary tumors, p27 loss enhances 
the malignancy and frequency of tumor formation 
in cooperation with different oncogenic stimuli. 
Adapted from (Blain, et al., 2003).  
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1.3.1. The ubiquitin–proteasome system 
The ubiquitin–proteasome proteolytic pathway comprises two discrete steps: First, the 
covalent attachment of multiple ubiquitin molecules to the target protein or Ubiquitination (Pickart, 
2001) and second, the degradation of the polyubiquitynated protein by the 26S proteasome 
complex, the only ATP and ubiquitin-dependent multicatalytic protease that is responsible for 
most non-lysosomal protein degradation in eukaryotic cells (Finley, 2009) (Figure 1.10). 
Ubiquitin is a small (76 aa) highly conserved protein (Goldstein, et al., 1975; Schlesinger 
and Goldstein, 1975) that has been found ubiquitously in all eukaryotic organisms, hence its 
name. Ubiquitination is the reaction that results in the formation of a covalent isopeptide bond 
between the C-terminal glycine residue (Gly76) in the ubiquitin and the epsilon-amino group of a 
lysine residue in the substrate. This requires the sequential action of at least three enzymes: an 
ubiquitin-activating enzyme (UBA or E1), an ubiquitin-conjugating enzyme (UBC or E2) and an 
ubiquitin ligase (E3). The E1 enzyme activates ubiquitin as a thiolester in an ATP-dependent 
reaction and transfers the activated ubiquitin to the catalytic cysteine residue of an E2. Finally, E3 
ligases act as mediators to transfer ubiquitin from E2 to a lysine residue in the substrate protein 
(Pickart, 2001). Successive conjugation rounds of ubiquitin monomers to lysines of previously 
attached ubiquitins result in the formation of a poly-ubiquitin chain that ultimately can be 
recognized by the proteasome, leading to its processing into small peptides and the recycling of 
ubiquitins (Figure 1.10) (Pickart and Cohen, 2004; Finley, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Overview of the ubiquitin-proteasome pathway. Ubiquitination involves three enzymes: a 
ubiquitin-activating enzyme (UBA or E1), a ubiquitin conjugating enzyme (UBC or E2) and a ubiquitin ligase (E3). 
E3s can themselves form a thiolester bond with ubiquitin (HECT-domain E3s) before substrate attachment, or can 
function as a bridge between an activated E2 and its target (RING E3s). The ubiquitinated substrate is then 
recognized by the 26S proteasome which recycle the ubiquitins and destroys the substrate in an ATP-dependent 
manner. DUB (Deubiquitylating enzyme); PPi (pyrophosphate) and Ub (Ubiquitin). Adapted from (Pickart, 2001; 
Ravid and Hochstrasser, 2008) 
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1.3.2. The ubiquitin ligase enzymes (E3s) 
However, the specificity and adaptability of ubiquitination is provided by ubiquitin ligases 
(E3s), which physically interact with target substrates (Nakayama and Nakayama, 2005). In 
humans, only two E1 enzymes (UBA1 and UBA6) and approximately 40 E2 enzymes have been 
identified. By contrast, it is estimated that there may be as many as 1000 E3 ligases, each of 
which has the potential to recognize multiple substrates (Hicke, et al., 2005; Li, et al., 2008).  
Based on the sequence homology and structural similarities of their E2-binding domains, 
E3s can be classified into two major subfamilies (Figure 1.10): the HECT domain family 
(Homologous to E6-AP C-terminus) and the RING finger domain family (Really Interesting New 
Gene). They differ in the way they transfer ubiquitin to the substrate. The HECT proteins contain a 
conserved catalytic cysteine, which acts as an ubiquitin acceptor from E2 enzymes forming an 
ubiquitin thiolester intermediate. Ubiquitin is then transferred to the substrate from HECT E3 
enzyme. In contrast, RING E3s enzymes act as scaffolds by facilitating interaction between E2s 
and substrates but do not possess catalytic activity per se (Deshaies and Joazeiro, 2009; Rotin 
and Kumar, 2009; Metzger, et al., 2012).  
RING E3s ligases comprise >95% of all predicted E3s and they can function as monomers, 
dimers or multi-subunit complexes. In the case of multi-subunit RING E3 ligases, the RING 
protein functions as part of a multi protein complex and substrates are recruited by a separate 
subunit (Deshaies and Joazeiro, 2009; Metzger, et al., 2012). Multi-subunit RING E3s include the 
Cullin based RING E3 ligase (CRL) superfamily and several CRL-like E3 ligases as the Anaphase 
Promoting Complex/ Cyclosome (APC/C). CRLs are defined by a common catalytic core which 
consists of a RING finger protein (RBX1 or 2) and a Cullin family member (CUL1, 2, 3, 4A, 4B, 5, 
7 and 9 (PARC)). In CRLs, the Cullin protein serves as a scaffold to assemble multiple proteins, 
besides the RING finger protein that recruits the E2 enzyme, an adaptor protein which in turn 
binds to the substrate-recognition proteins often characterized by the presence of F-box, SOCS 
box or BTB protein-protein interaction domains (Petroski and Deshaies, 2005; Li, et al., 2008). 
1.3.3. The SCF ubiquitin ligases and the F-box component 
The archetypal CRLs, which contain CUL1 and the RING finger protein RBX1, are 
commonly known as SCF ubiquitin ligases (from SKP1-CUL1-F-box). Within the SCF complex, 
CUL1 brings the E2 enzyme through the RBX1 (also known as HRT1 or ROC1), and recruit 
substrates through the adaptor protein SKP1 (S-phase kinase associated protein 1) and an F-box 
protein. This latter component confers the SCF complex designation, as SCFSKP2, where SKP2 
(S-phase kinase associated protein 2) is the F-box protein (Figure 1.11) (Cardozo and Pagano, 
2004; Petroski and Deshaies, 2005). In the SCF complex, the interaction of F-box proteins with 
the adaptor protein (SKP1) occurs through the F-box domain, a ~40 aa motif that was first 
identified in human cyclin F, hence its name (Bai, et al., 1996). The F-box proteins are the 
substrate-recognizing subunits which determine the versatility in substrate specificity of SCF E3 
Introduction 
24 
 
ligase complexes (Jia and Sun, 2011). According to the HUGO Gene Nomenclature Committee, 
71 F-box proteins have been identified in humans. They have been classified into three major 
classes, depending on the types of substrate interaction domains identified in addition to the F-
box motif: those with leucine-rich repeats (LRR) known as (FBXLs), those with WD40 domains or 
(FBXWs) and those with “other” types of protein-protein interaction motifs or no recognizable 
domains (FBXOs) (Jin, et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A single F-box protein can target multiple substrates even with opposite biological 
functions, whereas the same substrate can be recognized by different F-box proteins (Skaar, et 
al., 2009). Moreover, most SCF substrates are recognized and bound by the F-box protein only 
when they are post-translationally modified, adding an extra level of regulation. Although the most 
widely reported prior modification is phosphorylation, substrates have also been reported to 
require acetylation (Hwang, et al., 2010) or glycosylation (Guinez, et al., 2008). For instance and 
as mentioned above, degradation of p27 by SCFSKP2 is triggered only following phosphorylation at 
Thr187 (Figure 1.11) (Carrano, et al., 1999; Montagnoli, et al., 1999; Sutterluty, et al., 1999; 
Tsvetkov, et al., 1999). In this thesis, we will focus on FBXL1 (SKP2), the best characterized 
mammalian F-box protein and the one involved in p27 degradation.  
1.3.4. The F-box protein SKP2 
The discovery of SKP2 (S-phase Kinase-associated Protein 2) preceded the identification 
of F-box proteins as components of the SCF ubiquitin ligase complexes. SKP2 belongs to the 
FBXL class of F-box proteins. It was originally discovered because of its ability to interact with 
cyclin A/CDK2 complexes in transformed cells together with SKP1 (p19) and CKS1 (p9), (Zhang, 
et al., 1995). Several important characteristics of SKP2 were described in this early study, 
Figure 1.11. Model of the SCFSKP2 complex 
whit their substrate target. CUL1 forms a rigid, 
bi-lobed structure which acts as a ‘molecular 
scaffold’ on which to assemble the SCFSKP2 
complex. The C-terminal globular domain recruits 
RBX1, which in turn recruits the E2 enzyme (UBC) 
and the ubiquitin. In the other hand, the CUL1 N-
terminal domain recruits SKP1, which then binds to 
the SKP2 protein substrate recognition subunit via 
interactions between its F-box domain and the C-
terminus of SKP1. SKP2 also binds to the adaptor 
protein CKS1 and Cyclin A. For its part, CKS1 
binds to CDK2 and recognizes the p27 
phosphorylated on Thr187. Adapted from 
(Schulman, et al., 2000; Zheng, et al., 2002; Hao, 
et al., 2005). (Protein data bank files: 2AST; 1JSU; 
1LDK and 3A33) 
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including its overexpression in many transformed cell lines and that its regulation along the cell 
cycle. Unlike SKP1 and CUL1, SKP2 protein level is low in early G1 phase, while it increases 
during G1/S transition and is maximal in S and G2 phases of the cell cycle (Zhang, et al., 1995; 
Kurland and Tansey, 2004; Yung, et al., 2007). Nowadays, It is well known that, through 
degradation of its target substrates, SKP2 plays a critical role in regulating many cellular 
processes such as cell cycle progression, inhibition of differentiation, apoptosis or senescence 
and cell motility all of which are closely related to cancer development (Frescas and Pagano, 
2008).  
1.3.4.1. Structure of SKP2 gene and protein 
In humans, SKP2 gene is located in the locus 5p13.2 with a genomic size of 31998 pb 
according to the UCSC database (hg19 assembly) (Figure 1.14). In agreement with the NCBI 
RNA reference sequences collection (RefSeq), alternative splicing of this gene generates three 
transcript variants encoding three different isoforms. The transcript variant 1 represents the 
longest transcript and encodes for the most studied isoform of 424 aa, SKP2A (SKP2 hereafter). 
As prototypical FBXL protein, it contains an N-terminal F-box domain (aa 94-140) through which it 
interacts with SKP1 (Schulman, et al., 2000; Zheng, et al., 2002). Deletion of this domain prevents 
SKP2 to assemble into a SCFSKP2 complex (Schulman, et al., 2000). In addition, the N-terminal 
domain shows a “destruction box” (D-Box) (aa 3-6) that critically controls SKP2 stability (Bashir, et 
al., 2004) and two phosphorylatable serines (Ser64 and Ser72) and two acetylatable lysines 
(Lys68 and Lys71) within a NLS (aa 63-80) which also play an important role in SKP2 stability, 
localization, and activity (Gao, et al., 2009; Lin, et al., 2009; Inuzuka, et al., 2012). In the other 
hand, the C-terminal domain contains 10 tandem leucine-rich repeats (LRR) and an unstructured 
C-tail region responsible for the interaction of SKP2 with CKS1 and their substrates (Figure 1.12) 
(Wang, et al., 2004). 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. SKP2 gene structure, localization in the human genome and major features of SKP2 
protein. Chr (Chromosome); TSS (Transcription start site); D (Destruction box); NLS (Nuclear localization 
signal); LRR (Leucine-rich repeat) posttraductional modifiable amino acids (*) and bp (base pairs).  
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The transcript variant 2 presents a different C-terminal domain that is encoded by an 
alternative tenth exon. The resulting isoform SKP2B is shorter (410 aa). Unlike SKP2A, the 
SKP2B amino acid sequence changes from aa 355 interrupting the ninth and tenth LRRs and the 
remaining C-terminal tail. However, they are practically undistinguishable by size using 
conventional immunoblot and an antibody directed toward the full length of SKP2 (Ganiatsas, et 
al., 2001).   
Finally, the transcript variant 3 lacks the first to five coding exons and presents a new first 
exon which match within the fourth intron of variant 1, while the sixth forward exons are in-frame. 
The resulting isoform is shorter (210 aa) at the N-terminus, lacking of the F-box domain compared 
to SKP2A while maintaining all the LRR and C-terminal domain. According to Schulman et al. it 
could not assemble into SCF complexes (Schulman, et al., 2000).  
1.3.4.2. SKP2 regulation 
SKP2 gene is periodically expressed throughout the cell cycle (Kurland and Tansey, 2004). 
Alteration in SKP2 protein levels during cell cycle progression is partly due to changes in gene 
expression and protein stability. Nevertheless, post-translational modifications such as 
phosphorylation and acetylation also regulate protein localization, stability, and activity.  
Regulation of SKP2 gene expression  
Several transcription factors have been found to bind to the SKP2 promoter (Figure 1.13) 
and to induce SKP2 gene expression such as E2F1 (Zhang and Wang, 2006), the GA-binding 
protein (GABP) which has been found to be dependent on the cell cycle (Imaki, et al., 2003), 
CBF1 (RBPJ) which is a key effector of the Notch signaling pathway (Sarmento, et al., 2005), 
FoxM1 (Wang, et al., 2005b), SP1 and Elk-1 (Appleman, et al., 2006) or the orphan nuclear 
hormone receptor 1 (NOR1) which regulates vascular smooth muscle cells (VSMC) proliferation 
in response to mitogenic stimulation (Gizard, et al., 2011). 
In addition, numerous oncogenic signals such as the overexpression of Janus kinase 2 
mutant (JAK2V617F) or BCR-ABL, both involved in myeloproliferative disorders, are also known to 
induce SKP2 gene expression through the STAT3-5 transcription factors (Furuhata, et al., 2009). 
BCR-ABL has been also shown to induce SKP2 gene expression through the PI3K/AKT signalling 
pathway (Andreu, et al., 2005; Chen, et al., 2009). AKT could trigger SKP2 gene expression by 
regulating E2F protein levels (Reichert, et al., 2007). Finally, NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) signaling, involved in inflammation and cancer, also regulates 
SKP2 gene expression through the binding of p52/RelA or p52/RelB to the SKP2 promoter 
(Schneider, et al., 2006; Barre and Perkins, 2007).  
On the other hand, the transcriptional repressors for SKP2 are less well-known (Figure 
1.13). Nevertheless, it has been described that STAT1 and Foxp3 (Forkhead box p3) can act as 
repressors on the SKP2 promoter. Interestingly, Foxp3 down-regulation has been correlated with 
SKP2 overexpression in human breast cancer samples (Zuo, et al., 2007; Wang, et al., 2010b). 
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Lastly, p53 has been also shown to repress SKP2 gene expression in response to UV-induced 
DNA damage (Barre and Perkins, 2010).  
 
 
 
 
 
 
 
 
 
 
 
Regulation of SKP2 protein stability 
SKP2 levels may also be regulated by post-translational modifications and changes in its 
rate of protein degradation. In early G1, SKP2 is ubiquitinated and degraded by the ubiquitin 
ligase APC/CCdh1 (Bashir, et al., 2004; Wei, et al., 2004). However, after mitogenic stimulation 
SKP2 is highly phosphorylated and up-regulated (Bilodeau, et al., 1999). SKP2 phosphorylation at 
Ser-64 by CDK2 and, to a lesser extent, Ser-72 by AKT1 contributes to the stabilization of SKP2 
by preventing its association with Cdh1 and protecting it from APC/CCdh1-mediated degradation 
(Rodier, et al., 2008; Gao, et al., 2009; Lin, et al., 2009). Ser72 phosphorylation by AKT also 
promotes SKP2 cytosolic relocalization (Gao, et al., 2009; Lin, et al., 2009). Cytosolic SKP2 
neither forms a complex with CUL1 and SKP1 and therefore it may not trigger p27 degradation 
(Lin, et al., 2009). However, SKP2 phosphorylation on Ser64 by CDK2 is dispensable for its 
subcellular localization and for SKP2 assembly into an active SCF complex (Bashir, et al., 2010; 
Boutonnet, et al., 2010).  
In addition, SKP2 can be acetylated by p300 at Lys-68 and Lys-71 within of the NLS 
leading also to increased SKP2 stability through impairment of the Cdh1-mediated proteolysis and 
to its cytoplasmic retention. Moreover, this process can be antagonized by the mitochondrial 
deacetylase SIRT3 (NAD-dependent deacetylase sirtuin-3). Inactivation of this tumor suppressor 
leads to elevated SKP2 acetylation and stability (Inuzuka, et al., 2012).  
1.3.4.3. Biological functions of SKP2 
SKP2 in cell cycle progression and proliferation 
The function of SKP2 in cell cycle progression and proliferation is closely linked to its ability 
to promote degradation of cell cycle regulatory proteins. In fact, a SKP2 mutant (LRRSKP2) lacking 
the N-terminal and F-box domains and thus defective in SCFSKP2 E3 ligase activity (Schulman, et 
al., 2000) is less efficient at promoting cell cycle progression and proliferation, and primary tumor 
Figure 1.13. Regulation of SKP2 gene expression.  Transcription factor binding site position described on 
the literature relative to the SKP2 transcription start site (TSS) from UCSC genome browser. Exon 1 is illustrated 
by a green box. The relative position to the TSS is indicated along the horizontal axis.  
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formation compared to wild-type SKP2 (Chan, et al., 2010). As previously mentioned, the best-
known substrate of SKP2 is p27. This is mainly based on the genetic evidence showing that p27 
accumulates at high levels in Skp2-/- cells, resulting in a reduced cell proliferation. Accordingly, 
Skp2-/- mice are characterized by a reduced organ size and body weight (Nakayama, et al., 2000). 
Combined ablation of p27 (Skp2-/-/p27-/- cells) rescues this phenotype and the cell proliferation 
defect shown in Skp2-/- cells suggesting that p27 is required for their development and that p27 is 
the main substrate for SKP2 functions (Nakayama, et al., 2004).  
However, it has been reported that SKP2 also regulates ubiquitination and degradation of 
many other substrates involved in cell proliferation including the p27-related CKIs p21CIP1 (Yu, et 
al., 1998) and p57KIP2 (Kamura, et al., 2003); and several cell cycle regulators such as p130 
(Tedesco, et al., 2002), cyclin A (Nakayama, et al., 2001), cyclin D1 (Yu, et al., 1998) or cyclin E 
(Nakayama, et al., 2000). Transcription factors such as E2F-1 (Marti, et al., 1999), FOXO1 
(Huang, et al., 2005), and MYC (Kim, et al., 2003; von der Lehr, et al., 2003), have also been 
implicated as potential substrates of SKP2. Some of these proteins such as, cyclin A, cyclin D1 
and E2F-1 do not accumulate in Skp2-/- cells, suggesting that there exists a certain redundancy 
for their ubiquitination in the absence of SKP2 (Nakayama, et al., 2000; Nakayama, et al., 2001). 
Two examples are cyclin E and MYC which can be both targeted by SCFSKP2 or by SCFFBW7 
complexes (Koepp, et al., 2001; Welcker, et al., 2004; Yada, et al., 2004).  
Other biological functions of SKP2 
In addition to its well-known role in cell cycle progression, targeting one of the most 
important cell cycle inhibitors, SKP2 has been also involved in additional biological functions such 
as differentiation, cell survival or cell migration. Generally, SKP2 hinders cell differentiation 
processes, such as differentiation of human embryonic stem cells (hESc) (Egozi, et al., 2007) or 
chemically-induced erythroid differentiation of human leukaemia cells (Gomez-Casares, et al., 
2012) at least in part, through its ability to down-regulate p27.  
In the other hand, SKP2 plays an important role in cell survival through its ability to restraint 
apoptosis and senescence. Skp2-/- MEFs display a higher apoptosis rate compared to wt MEFs 
(Nakayama, et al., 2000). Consistent with this observation, SKP2 silencing induces apoptosis in 
different lung cancer cell lines (Yokoi, et al., 2003) and potentiates cell apoptosis of HCT116 cells 
upon stimulation with DNA damage agents in a p53-dependent manner (Kitagawa, et al., 2008). 
Moreover, human RB1-/- cells also undergo apoptosis after SKP2 knockdown (Wang, et al., 
2010a).  
With regard to its role in senescence, SKP2 deficiency alone does not induce senescence 
per se but sensitizes cancer-prone cells expressing RAS and E1A oncoproteins to cellular 
senescence response. Furthermore, genetic SKP2 inactivation in combination with ARF loss or 
PTEN heterozygosity also triggers senescence response by ARF/p53 and DDR (DNA damage 
response)-independent pathways (Lin, et al., 2010).  
Finally, SKP2 has been also involved in promoting cell motility and migration. SKP2 is 
primarily localized in the nucleus in normal cells. However, acetylation by p300 (Inuzuka, et al., 
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2012) or AKT-mediated phosphorylation (Lin, et al., 2009) in the NLS region promotes its 
cytoplasmic relocalization where SKP2 enhances cellular migration through ubiquitination and 
destruction of E-cadherin (Inuzuka, et al., 2012). In this sense, Skp2-/- cells display a defect in cell 
migration and invasion whereas restoration of a permanent cytosolic SKP2 mutant (SKP2NES) 
rescues these defects (Lin, et al., 2009). Furthermore, the expression of RhoA GTPase has been 
also shown to rescue partially these defects observed in Skp2-/- MEFs, indicating that it is an 
important downstream effector responsible for SKP2-mediated cell migration (Chan, et al., 2010).  
SKP2 as a transcriptional regulator 
Finally, apart from its function as ubiquitin ligase, SKP2 has been also found to function as 
a possible transcriptional regulator. It was known that SKP2 appeared to stimulate the 
transcriptional activity of MYC (Kim, et al., 2003; von der Lehr, et al., 2003) but the underlying 
mechanism remained elusive. Recently, it has been described that SKP2 cooperates with MYC to 
induce RhoA transcription by recruiting MIZ1 and the transcriptional coactivator p300 to the RhoA 
promoter. This interaction seems to be independent of its E3 ligase activity because a SKP2 
mutant (LRRSKP2) which lacks of the N-terminal and F-box domains also interacts with MYC, 
p300, and MIZ1 and cooperates with them in the up-regulation of transcription. Moreover, SKP2 
mutants defective in MYC binding fail to activate transcription suggesting that the function of 
SKP2 in transcriptional regulation is critically dependent on MYC (Chan, et al., 2010).  
1.3.4.4. SKP2 and cancer 
As previously mentioned, SKP2 is a key player in the control of proliferation and 
differentiation targeting several cell cycle regulators for degradation. In addition, SKP2 has been 
involved in many other biological processes such as cell survival, migration, invasion, and 
metastasis all of which are closely related to cancer development (Frescas and Pagano, 2008). 
Consistent with this notion, SKP2 overexpression has been detected in most human cancers 
(Wang, et al., 2012b), frequently associated with reduced p27 levels, high proliferative rates and 
poor outcome, representing an adverse prognostic marker (Figure 1.14) (Hershko, 2008). 
Moreover, in certain human cancers, SKP2 overexpression has been associated to cancer 
progression and metastasis (Wang, et al., 2012a).  
The mechanisms involved in SKP2 up-regulation in human cancers are diverse and include 
gene amplifications and over-activated oncogenic signalling pathways leading to the SKP2 
transcriptional induction or/and the SKP2 protein stabilization. For instance, amplification of the 
region within chromosome 5 that contains the SKP2 gene have been reported in selected human 
tumors such as glioblastoma (Saigusa, et al., 2005) and non-small cell lung cancers (Yokoi, et al., 
2004; Zhu, et al., 2004a). However, gene amplification has been associated with advanced stage 
of tumor progression, but not with early cancers that overexpress SKP2 (Hershko, 2008). On the 
other hand, a correlation between SKP2 over-expression and elevated AKT activity has been 
reported in colon and prostate cancer (Lin, et al., 2009) and also in breast cancer metastasis 
(Chan, et al., 2012). Interestingly, AKT activation has been also correlated with SKP2 cytosolic 
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accumulation during colon cancer metastasis to lymph nodes (Lin, et al., 2009) and cytoplasmic 
SKP2 has been also reported in the more aggressive forms of breast and prostate cancers 
(Inuzuka, et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, several mouse models also confirm the oncogenic role of SKP2 in tumorigenesis. 
Overexpression of SKP2 in the T-cell compartment cooperates with N-Ras to induce T cell 
lymphomas in mice (Latres, et al., 2001), while prostate specific expression of SKP2 leads to 
prostatic intraepithelial neoplasia (PIN) (Shim, et al., 2003). Moreover, in agreement with a critical 
role for SKP2 in tumor progression, Skp2-/- mice are resistant to tumor development induced by 
loss of either p19ARF or the PTEN tumor suppressor proteins (Lin, et al., 2010). Moreover, Skp2 
deficiency delays BCR-ABL–induced leukemogenesis in a bone marrow transplantation model, 
suggesting that SKP2 plays an important role in this process upon BCR-ABL overexpression 
(Agarwal, et al., 2008). In contrast, Skp2 loss has modest effects on MYC-driven 
lymphomagenesis, despite cancelling MYC’s ability to suppress p27 protein levels (Old, et al., 
2010). Finally, using a well-established lung metastasis model generated by tail vein injection of 
breast cancer cells, it has been demonstrated that overexpression of SKP2 or MYC promotes 
lung metastasis whereas its knockdown reduces it (Chan, et al., 2010). Taken together, these 
studies clearly establish that SKP2 behaves as a proto-oncogene and that SKP2 overexpression 
may contribute to the development and progression of human cancers. 
1.4. THE TRANSCRIPTION FACTOR MYC 
MYC (originally known as c-MYC) was the first oncogenic transcription factor discovered. In 
the late seventies, the study of the genome of three retroviruses (MC29, MH2 and OK10) that 
produced a kind of leukemia in birds known as “MYeloCytomatosis”, led to the identification of the 
viral transforming gene v-Myc (Duesberg and Vogt, 1979; Hu, et al., 1979; Sheiness and Bishop, 
1979). Three years later, chicken MYC (c-MYC), the proto-oncogenic version of v-Myc the host 
genome, was identified by homology (Vennstrom, et al., 1982). Subsequently, MYC genes from 
Figure 1.14. Oncogenic role 
and prognostic significance of 
SKP2 overexpression in human 
cancers. SKP2 has been found 
overexpressed in all listed human 
cancers, inversely correlated with 
p27 protein levels. S and P 
denote bad prognosis of disease 
associated to high SKP2 or low 
p27 levels, respectively. Adapted 
from (Malumbres and Barbacid, 
2001; Chu, et al., 2008; Hershko, 
2008).  
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human, mouse and rat were cloned and characterized (Crews, et al., 1982; Dalla-Favera, et al., 
1982b; Hayashi, et al., 1987). The discovery that MYC was consistently altered in Burkitt 
lymphoma by chromosomal translocation marked it as a bona fide human oncogene (Dalla-
Favera, et al., 1982a; Taub, et al., 1982). Nowadays, it is well known that MYC is one of the most 
highly over-activated oncogenes among different human cancers (Beroukhim, et al., 2010). 
MYC belongs to a family of transcription factors that includes N-MYC and L-MYC, which are 
encoded by MYCN and MYCL1 genes respectively (DePinho, et al., 1987). MYCN was identified 
from the discovery of amplified sequences highly homologous to v-Myc oncogene in human 
neuroblastoma cell lines (Kohl, et al., 1983; Schwab, et al., 1983) whereas MYCL1 was identified 
in small cell lung cancer, by homology to MYC (Nau, et al., 1985). All members of MYC family 
have a predominantly nuclear localization and a short half-life, and its expression is generally 
correlated with cell proliferation. However, they have different expression pattern during 
embryonic development, being MYC the most widely expressed in adult tissues. Both MYC and 
N-MYC are crucial for proper functioning of Hematopoietic Stem Cell (HSCs) (Laurenti, et al., 
2008). Myc-/- mice embryos die before E12 due to hematopoietic and placental defects (Dubois, et 
al., 2008), while Mycn-/- embryos die before E11.5 with neuroectodermal and heart defects 
(Charron, et al., 1992). In contrast, Mycl-/- mice show no altered phenotype, making it non-
essential for normal murine development (Murphy, et al., 2005). Finally, it has been shown that 
Mycn can replace Myc in vivo (Malynn, et al., 2000). 
1.4.1. Structure of MYC gene and protein 
In humans, MYC maps in the locus 8q24.21, consisting of 3 exons. Its expression is 
regulated by four potential promoters, called P0, P1, P2 and P3 (Figure 1.15), although mRNA  
transcribed from promoters P1 and P2 accounts for approximately 25% and 75% of total MYC 
mRNAs, respectively (Liu and Levens, 2006; Wierstra and Alves, 2008). Depending on the 
translation start codon, the MYC protein can be translated into three different isoforms, which 
mainly differ at the N-terminal region of the protein. The predominant isoform (MYC-2) is 
translated from the canonical AUG located at the start of second exon and possesses 439 amino 
acids and a molecular weight of 64 kDa (Persson, et al., 1984). A minor MYC protein variant of 
454 amino acids and 67 kDa (MYC-1), initiates at a CUG-leucine codon at the 3´-end of the first 
exon (Hann, et al., 1988). In addition, MYC gene also produces a smaller protein called MYC-S 
(MYC-Short), translated from internal AUG codons and lacking most of the N-terminal region of 
the protein, in which resides the transcriptional regulatory region. Accordingly, it has been 
suggested that it could serve as a dominant negative of MYC protein (Spotts, et al., 1997; Xiao, et 
al., 1998). In most system studied the expression of this protein is much lower than MYC1/2. 
MYC belongs to a small group of transcription factors containing basic (b), helix-loop-helix 
(HLH) leucine zipper (LZ) domains (Figure 1.15) (Landschulz, et al., 1988; Dang, et al., 1989; 
Murre, et al., 1989; Prendergast and Ziff, 1989). These domains are located in the C-terminal 
region of the protein and are highly conserved among MYC family members. The basic domain is 
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responsible for specific sequence recognition and DNA binding whereas the HLH-LZ domains are 
involved in the formation of heterodimers with the protein MAX (Figure 1.16) (Blackwood and 
Eisenman, 1991; Amati, et al., 1992; Kato, et al., 1992, Kretzner, 1992 #270).  
On the other hand, the MYC protein also contains an unstructured N-terminal transcriptional 
regulatory region, which includes several highly conserved regions across species and between 
different MYC family members, termed MYC Boxes (MB). These regions are responsible for most 
of the biological effects exerted by MYC. To date, four different MYC boxes have been identified, 
denoted as MBI, MBII, MBIII and MBIV (Figure 1.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MBI and MBII are located in the region initially described as responsible for the activation of 
transcription, also known as Transcriptional Activation Domain (TAD) (aa 1-143) (Kato, et al., 
1990). MBI contains two major phosphorylation sites of MYC, Thr 58 and Ser 62, and it has been 
associated with its stability and its transforming capacity (Stone, et al., 1987; Sears, et al., 2000). 
MBII is the most important region in relation to the transcription. Mutations in this region inhibit the 
binding of most transcription coactivators recruited by MYC (Freytag, et al., 1990; McMahon, et 
al., 1998; Oster, et al., 2003). Both regions are needed for MYC induced transformation, blocking 
differentiation and apoptosis (Stone, et al., 1987; Freytag, et al., 1990; Evan, et al., 1992). On the 
other hand, MBIII is involved in the repression of transcription (Herbst, et al., 2005; Kurland and 
Tansey, 2008) while MBIV contains a NLS and it is important for the binding of MYC to DNA 
despite being located outside of the basic domain (Dang and Lee, 1988; Cowling, et al., 2006). 
1.4.2. Regulation of MYC expression 
MYC expression is tightly regulated by transcriptional, posttranscriptional and 
posttranslational mechanisms. In the first place MYC expression is controlled by many 
transcriptional regulatory motifs found within its proximal promoter region in which converge 
multiple signaling pathways that are triggered from diverse extracellular signals (Wierstra and 
Figure 1.15. MYC gene structure, localization in the human genome and major features of MYC 
protein. Chr (Chromosome); P (Promoter); UTR (Untranslated region); NLS (Nuclear localization signal); I, II, III 
and IV (MYC Boxes); b (basic)-HLH (helix-loop-helix)-LZ (Leucine zipper) domain; phosphorylatable amino acids 
(*) and bp (base pairs).  
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Alves, 2008; Levens, 2010; Dang, 2012). MYC expression remains almost undetectable when 
cells are at quiescent state and increases rapidly under various mitogenic stimuli. During 
quiescence, complexes formed by E2F (1, 2 and 4); proteins of the pocket family (Rb, p107, 
p130) and histone deacetylases (HDACs) bind to the MYC promoter preventing its transcription 
(Albert, et al., 2001). In contrast, MYC is steadily expressed in cells that are in continuous 
proliferation (Hann, et al., 1985; Rabbitts, et al., 1985; Thompson, et al., 1985). For that, it is very 
important a sequence located 1.5 kb upstream of the P1 promoter called FUSE (The Far Up-
Stream Element), at which constitutively binds the FUSE binding protein (FBP) activating its 
transcription and allowing continuity in the MYC expression (He, et al., 2000). In contrast, the 
binding of the FIR protein (FBP interacting repressor), which forms a ternary complex with FBP 
and FUSE, blocks activator-dependent MYC transcription (Liu, et al., 2000; Chung and Levens, 
2005; Liu, et al., 2006). Moreover, the ability of MYC to negatively regulate their own expression 
through a negative feedback loop, keeps this expression at moderate levels in the absence of 
specific activation (Facchini, et al., 1997; Luo, et al., 2004). 
MYC levels decay rapidly during cellular differentiation, until its disappearance in terminally 
differentiated cells. MYC repression during differentiation is usually regulated, directly or 
indirectly, by transcription factors that control differentiation on each cell type such as GATA-1 
(Acosta, et al., 2008), CTCF (Delgado, et al., 1999; Torrano, et al., 2005), C/EBPα (Freytag and 
Geddes, 1992) or Klf4 and Ovol1 (Nascimento, et al., 2011). In addition, the complexes formed by 
E2F4/pRb (Iakova, et al., 2003); E2F6, HMTs and PcG proteins (Ogawa, et al., 2002); or 
BRG1/BAF subunit of the SWI/SNF chromatin remodeling complex (Nagl, et al., 2006) collaborate 
in the repression of MYC during cell differentiation. 
MYC promoter is also target of multiple oncogenic stimuli. For instance, the loss of the 
tumor suppressor APC results in constitutive nuclear localization of the b-catenin cofactor TCF4, 
downstream of the WNT pathway, which promotes a constitutive oncogenic MYC expression 
(Pomerantz, et al., 2009; Tuupanen, et al., 2009; Sotelo, et al., 2010). Recently, BRD4 
(Bromodomain-containing protein 4) has been shown to bind to the MYC promoter and to play a 
critical role in MYC expression in leukemia and lymphoma cell lines (Delmore, et al., 2011; Mertz, 
et al., 2011).  
Finally, MYC expression is regulated not only by an array of transcription factors, but also 
by non-B DNA structures including single-stranded bubbles, G-quadruplexes or Z-DNA structures 
in the promoter (Hurley, et al., 2006; Brooks and Hurley, 2010; Levens, 2010). Genome-wide 
association studies have also identified common SNPs 1Mb upstream MYC gene associated with 
different cancers (breast, prostate and colorectal cancer) that have been involved in MYC 
overexpression (Pomerantz, et al., 2009; Tuupanen, et al., 2009; Ahmadiyeh, et al., 2010; Sotelo, 
et al., 2010; Wasserman, et al., 2010). 
MYC expression is also controlled by posttranslational mechanisms. MYC mRNA has a 
short half-life of about 30 minutes. This feature is related to A-U rich sequences located in the 3'-
UTR whose deletion greatly increases the stability of MYC mRNA (Jones and Cole, 1987; Brewer 
and Ross, 1988). In addition, MYC mRNA has been also shown to be targeted by several 
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miRNAs such as let-7, miR-34 or miR-145, affecting also its stability (Kim, et al., 2009; Sachdeva, 
et al., 2009; Cannell, et al., 2010; Christoffersen, et al., 2010).  
Finally, posttranslational modifications also affect the stability of MYC protein, helping to 
regulate their levels in the cell (Hann, 2006; Vervoorts, et al., 2006). The MYC protein itself is 
phosphorylated, ubiquitinated, and degraded, with a half-life in the order of 20–30 min (Gregory 
and Hann, 2000). MYC stability is mainly controlled by phosphorylation at two residues, Thr58 
and Ser62 (Figure 1.15). CDK1/2 and/or mitogen-activated kinases activated by RAS, 
phosphorylate MYC at Ser62 leading to its stabilization. By contrast, phosphorylation at Thr58 by 
GSK-3β, facilitates dephosphorylation at Ser62 by a complex formed by the PP2A phosphatase, 
the PIN1 prolyl-isomerase and the scaffold protein Axin1, allowing its recognition by the SCFFBW7 
E3 ligase. SCFFBW7 ubiquitinates MYC and targets it for proteasomal degradation (Sears, 2004; 
Arnold, et al., 2009; Hydbring, et al., 2010). Nevertheless, MYC binding to the ubiquitin-specific 
protease USP28 (Popov, et al., 2007) or MYC ubiquitination at N-terminus by SCFβ-TrCP (Popov, et 
al., 2010) antagonizes SCFFBW7 mediated turnover, leading to MYC stabilization. In addition, it has 
been reported that acetylation of MYC by acetyltransferases such as GCN5, PCAF, TIP60 or 
p300/CBP usually results in an increase in protein stability (Vervoorts, et al., 2003; Patel, et al., 
2004a; Faiola, et al., 2005; Nascimento, et al., 2011), although it has been also described that 
deacetylation by Sirt1 similarly results in increased MYC stability (Menssen, et al., 2012). 
All these mechanisms contribute to the regulation of MYC levels in the cell. Tumor-
associated alterations affecting any of these mechanisms in general deregulate and enhance 
MYC expression. Given that MYC proteins function primarily as transcription factors, the 
consequences of these alterations result in the deregulation of MYC target genes, some of which 
are in turn oncogenes, contributing to tumorigenesis. 
1.4.3. Transcriptional activation by MYC 
Activation of transcription by MYC is 
intimately ligated to the formation of 
heterodimeric complexes with MAX (MYC-
associated factor X) (Figure 1.16) 
(Blackwood and Eisenman, 1991; 
Prendergast, et al., 1991; Wenzel, et al., 
1991). MAX is a small size protein, of 
which up to 6 isoforms resulting from 
alternative splicing processes have been 
identified according to the UCSC database 
(provided by RefSeq, August 2012), being 
MAX(L) with 160 aa (22 kDa) and MAX(S) 
with  151 aa (21 kDa) the two majority 
isoforms (Blackwood, et al., 1992; Kato, et 
Figure 1.16 Two perspectives of heterodimeric 
structure of b-HLH-LZ domains of MYC-MAX bound to and 
E-box sequence of DNA. The colours of the helixes correspond 
to the coloured domains in the figure 1.15. Adapted from PDB 
1NKP deposited by (Nair and Burley, 2003). 
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al., 1992; Makela, et al., 1992; Zhang, et al., 1997). MAX protein, like MYC, is a member of the b-
HLH-LZ family of transcription factors. MYC-MAX heterodimerization through the HLH-LZ domain 
aligns the adjacent basic regions on each molecule to grip onto specific DNA hexanucleotide 
sequences termed E-boxes (Nair and Burley, 2003). The canonical E-box CACGTG is the 
sequence recognized with higher affinity by MYC-MAX heterodimers (Blackwood and Eisenman, 
1991; Seitz, et al., 2011), although there are several non-canonical E-boxes which are also 
recognized with a similar affinity in vivo and whose sequence slightly differs from the canonical 
(Blackwell, et al., 1990; Grandori, et al., 1996).  
Activation of gene transcription by MYC requires the recruitment of a number of cofactors 
which ultimately modify the global chromatin structure (Knoepfler, et al., 2006; Knoepfler, 2007). 
On the one hand, MYC has been reported to interact through the b-HLH region with the 
BAF47/SNF5/INI1 subunit of SWI/SNF ATP-dependent chromatin remodeling complex, being this 
interaction important for its transactivation potential (Cheng, et al., 1999b). This complex provokes 
ATP-dependent nucleosomal remodeling to make the chromatin more accessible to the basal 
transcriptional machinery (Reisman, et al., 2009).  
On the other hand, MYC has been also shown to recruit to the chromatin different Histone 
Acetyl-Transferases (HATs) coactivators, or in the more recently proposed nomenclature, KATs 
[Lysine (K) Acetyl Transferases] (Allis, et al., 2007) (Figure 1.17). They are able to catalyze the 
transfer of an acetyl group (CH3CO) from acetyl-CoA to the terminal amine on the side chain of 
lysine residues on histones but also on many other proteins (Glozak, et al., 2005). Acetylation of 
histones tails reduces the positive charges and promotes a relaxation of chromatin conformation, 
usually known as the passage to an "open chromatin", which allows the recruitment of 
transcription factors and an increase in transcription. 
It has been reported that MYC binds GCN5-related HATs (GNATs) such as TFTC and 
STAGA complexes (McMahon, et al., 2000; Flinn, et al., 2002; Liu, et al., 2003);  the MYST-
related HATs, TIP60 and HBO1 (Frank, et al., 2003; Martinato, et al., 2008); CBP (CREB binding 
protein) and p300 (E1A-associated protein 300 kDa) (Vervoorts, et al., 2003; Adhikary, et al., 
2005) and the general transcription factor TFIID subunit TAF1 (TBP-associated factor-1) 
(Hateboer, et al., 1993).  
In the GNAT complexes, MYC interacts with TRRAP (Transactivation-Transformation 
Associated Protein), the largest subunit of these 2 MDa complexes that functions as scaffold for 
the GCN5 histone acetyltransferase (Figure 1.17). TRRAP is a member of the ATM/PI3K-related 
serine/threonine kinase (PIKK) family that was originally isolated as a cofactor of MYC and 
recruited to most MYC target genes after mitogen-mediated activation in a MBII-dependent 
manner (McMahon, et al., 1998; Frank, et al., 2001). In addition, GNC5 is a MYC target gene and 
GNC5 knockdown interferes with MYC-induced global histone (H3 and H4) acetylation (Knoepfler, 
et al., 2006). 
TIP60-type HAT complex also contain TRRAP as the largest scaffold subunit together with 
P400 (EP400) and the ATP-dependent DNA helicases TIP48 (RUVBL2) and TIP49 (RUVBL1) 
(Figure 1.17) (Frank, et al., 2003). TIP48 and TIP49 have been also found to bind directly to MYC 
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through the MBII independently of TRRAP, and TIP49 has been found to play an essential role in 
MYC-dependent transformation (Wood, et al., 2000). Lastly, p300 recruitment to MYC target 
genes requires MYC polyubiquitination by the E3 ubiquitin ligase HectH9 and this process seems 
to be required for MYC-induced cell proliferation (Adhikary, et al., 2005). The acetyltransferases 
GCN5, TIP60, HBO1, CBP, P300 and TAF1 are now known as KAT2A, KAT5, KAT7, KAT3A, 
KAT3B and KAT4 respectively (Allis, et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistently with its biding to HATs, MYC has been found associated to chromatin regions 
enriched in acetylated lysines on histone H3 (H3K9ac, H3K14ac, H3K18ac and significantly 
H3K27ac), histone H4 (H4K5ac, H4K12ac, H4K8ac and H4K91ac) and H2A (H2AK5ac) 
(Guccione, et al., 2006; Martinato, et al., 2008). For instance, promoter regions of transcriptionally 
active genes are highly enriched in H3K27ac (Wang, et al., 2008) and there is a good correlation 
between MYC and H3K27ac on genome positioning in Hela and K562 cells (Shao, et al., 2012). 
Moreover, it has been shown that MYC interacts with CBP/P300, the only KAT described at the 
moment which is able to acetylate H3 on Lys27 (H3K27ac) (Tie, et al., 2009; Jin, et al., 2011; Tie, 
et al., 2012).  
 
 It has also been described that promoters occupied by MYC show a strong correlation with 
H3K4me3 and H3K79me3 (histone H3 lysine trimethylated on lysine 4 and 79); chromatin marks 
that also have a positive correlation with active genes (Guccione, et al., 2006; Martinato, et al., 
2008; Nascimento, et al., 2011). Furthermore, histone methylation seems to be critical for MYC to 
recognition of its target genes. In this sense, histone methyltransferase SMYD3 (KMT3E) 
knockdown leads to diminished histone H3K4me3 at the hTERT promoter, resulting in a reduction 
in MYC occupancy on this promoter (Liu, et al., 2007). In addition, changes in the histone 
methylation patterns have been also observed upon MYC binding. In Drosophila, dMYC binds 
and inhibits the activity of H3K4me3 demethylases, Rbp2 and Plu1. These proteins are lysine (K) 
DeMethylases (KDMs) of the Jumanji family. The mammalian orthologs of Rbp2 (JARID1A or 
Figure 1.17. MYC is present on the chromatin in association with different Histone acetyltransferase 
complexes (HATs). HATs recruited by MYC principally acetylate multiple lysines on histones H3 and H4 (such as 
H3K9 or H3K27), promoting a locally relaxed chromatin conformation which is associated to transcriptionally active 
genes (Frank, et al., 2003; Vervoorts, et al., 2003; Liu, et al., 2007). 
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KDM5A) and Plu1 (JARID1B or KDM5B), have been also shown to bind to MYC, indicating that 
the MYC function regulating demethylase activity is highly conserved (Secombe and Eisenman, 
2007; Secombe, et al., 2007).  
Moreover, MYC has been also found to directly interact with different components of Mixed 
(Myeloid/Lymphoid) Lineage Leukemia complex (MLL1) (Figure 1.18) such as Menin, ASH2L, 
RBBP5, and the own MLL1 (KMT2A). 
This complex possesses H3K4 
trimethylase activity further supporting a 
role of MYC in controlling H3K4me3 
(Steward, et al., 2006; Luscher-Firzlaff, 
et al., 2008; Bres, et al., 2009). Since 
the abundance of histone modifications 
and their combinations has 
exponentially grown in recent years, the 
role of MYC in chromatin remodelling is 
getting more important. 
 
Finally, MYC also interacts with different subunits of general transcription factors that make 
up the RNA polymerase II preinitiation complex (PIC) (Figure 1.19) such as TBP (TATA binding 
protein), a key component of TFIID (Hateboer, et al., 1993; Maheswaran, et al., 1994; Barrett, et 
al., 2005); the RAP74 subunit of TFIIF (McEwan, et al., 1996) or the CDK7 subunit of TFIIH. 
CDK7 recruitment by MYC in an MBII-dependent manner to TSS, increases CAK (cyclin 
H/CDK7/MAT1) activity and concomitant Ser5 phosphorylation of C-terminal repeat domain (CTD) 
of RNA Pol II, which in turn is associated to initiation of transcription (Bouchard, et al., 2004; 
Cowling and Cole, 2007). Furthermore, MYC can promote the mRNA transcriptional elongation by 
activation of RNA pol II (Figure 1.19) (Price, 2010; Rahl, et al., 2010). Once the RNA pol II has 
been recruited to the promoter of the target gene, MYC binds through the MBI to the cyclin 
T1/CDK9 complex, also known as P-TEBb (positive transcription elongation factor b) (Eberhardy 
and Farnham, 2001,2002; Gargano, et al., 2007). P-TEFb phosphorylates the Ser2 of RNA Pol II 
CTD ultimately activating mRNA transcriptional elongation. In this interaction of MYC with P-TEFb 
also participates SKIP/SNW1 (Ski-interacting protein) and Menin (Marshall, et al., 1996; Bres, et 
al., 2008; Bres, et al., 2009). Recent reports suggest that MYC functions as an amplifier of gene 
expression, i.e., MYC does not activate silent genes but increases the transcription rate of genes 
already actives. The mechanism seems to lie on its ability to promote transcriptional elongation (Lin, 
et al., 2012; Nie, et al., 2012). 
In summary, MYC has a triple activity as a transcriptional regulator. On one side, MYC acts 
as a general chromatin activator. Second, MYC acts as a "classical" transcription factor activating 
the basal transcription machinery of genes which it binds. Third, MYC is an enhancer of 
transcription elongation.  
 
Figure 1.18. MYC interacts with different subunits of 
MLL1 complex. This complex possesses H3K4 trimethylase 
activity and is also associated to transcriptionally active genes 
(Bres, et al., 2009). 
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1.4.4. Transcriptional repression by MYC 
In addition to its known role in the activation of transcription, MYC also plays an important 
role as transcriptional repressor and this activity is also important for its transforming potential 
(Claassen and Hann, 1999). The first evidence supporting a negative role of MYC in transcription 
came from the observation that ectopic MYC or v-MYC overexpression repressed endogenous 
MYC protein, resulting in an auto-repression loop (Cleveland, et al., 1988). This negative 
feedback mechanism is not precisely understood, although it is known the implication of PcG 
(Polycom) proteins and suggests that it could act as a homeostatic regulator of MYC protein 
levels in vivo (Penn, et al., 1990; Goodliffe, et al., 2005). Currently, Genome-wide analyses have 
demonstrated that MYC represses at least as many genes as it activates (Dang, et al., 2006).  
To repress target genes, MYC does not bind DNA directly instead it physically interacts with 
other transcriptional activators such as TFII-I, YY1, NF-Y, SMAD, SP1 or MIZ1 that are bound to 
enhancers or initiator elements (Inr) in the core promoter regions, preventing them from their 
transactivation function. For it, MYC disrupts their interactions with other coactivators such as 
p300 or recruits the corepressor DNMT3A. DNA methylation by DNMT3A has a silencing effect 
on transcription. Examples of genes repressed by MYC through these mechanisms include the 
CDK inhibitors p15INK4B and p21CIP1 (Wanzel, et al., 2003; Kleine-Kohlbrecher, et al., 2006; Herkert 
and Eilers, 2010). 
Finally, another critical but indirect mode for MYC-mediated gene repression is through its 
ability to induce miRNAs expression (Chang, et al., 2008) such as the miR-17-92 cluster which 
targets many components of the TGF-b signaling pathway (Dews, et al., 2010), E2F1 (O'Donnell, 
et al., 2005) or the own MYC (Aguda, et al., 2008).  
1.4.5. MYC target genes 
Direct targets of MYC are defined as those genes whose expression is directly altered by 
direct MYC binding to the genes (Dang, et al., 2006). The identification of these genes is difficult 
because of the abundance of E-boxes and other sequences recognized by MYC in the genome, 
Figure 1.19. MYC interacts with the 
RNA polymerase II preinitiation complex 
(PIC) and stimulates mRNA 
transcriptional elongation.  MYC has 
been found associated to different subunits 
of TFIID (TBP and TAF1), TFIIF (GTF2F1) 
and TFIIH (CDK7). In the other hand, MYC 
functionally cooperates with TFIIH and P-
TEFb to phosphorylate the C-terminal 
domain (CTD) of the RNA polymerase II on 
Ser5 and Ser2 respectively stimulating 
transcriptional elongation.  
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as well as the limited transactivation ability of MYC as demonstrated by reporter assays (Barrett, 
et al., 2005).  
The first strategy developed to identify MYC target genes was based on the design of 
chimeric protein called “MYCER”, fusing the hormone-binding domain of the human estrogen 
receptor (ER) to the C-terminal domain of MYC (Eilers, et al., 1989; Littlewood, et al., 1995). Upon 
exposure to estrogens the chimeric protein changes conformation activating transcription. Genes 
responding to ligand-stimulated MYCER in the presence of a protein synthesis inhibitor such as 
the cycloheximide, and therefore without requiring newly synthesized transcription factors, are 
considered direct MYC target genes. This system allowed the identification of α-prothymosin, the 
first reported MYC target gene (Eilers, et al., 1991). Another strategies used to identify MYC 
target genes and to differentiate them of those induced indirectly by growth factors were the use 
of MYCER in serum deprived cells or the absence of gene regulation in serum-stimulated Myc-/- 
rat fibroblasts (Mateyak, et al., 1997; Watson, et al., 2002). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, promoter-reporter assays have been extensively used as supporting 
evidence for direct target genes and to validate the activity of several transcription factors 
(Kretzner, et al., 1992). However, these artificial constructs are unable to reflect the in vivo 
chromatin context of target genes. Chromatin immunoprecipitation (ChIP) provides direct physical 
evidence of the association of a transcription factor with a specific target gene in vivo. 
Subsequently, the development of genome-scale techniques (SAGE, microarrays, ChIP-on-chip, 
ChIP-PET and ChIP-sequencing) has allowed significantly increasing the amount of information 
available about the genes regulated by MYC. All these techniques have highlighted the global role 
of MYC in the regulation of transcription. Depending on the study, it is estimated that MYC is able 
to regulate the expression of over 15% of all human genes (Dang, et al., 2006). Moreover, as 
discussed above and below, given that MYC controls the three RNA polymerases (I, II and III), 
the target genes encode all forms of RNAs including mRNA, rRNA, tRNA, miRNA as well as other 
Figure 1.20 Distribution of MYC targets by gene ontology (GO). One thousand five hundred and sixty-one 
MYC targets from http://www.myccancergene.org are displayed in concentric rings with functional groups colored 
and labelled. Adapted from (Dang, et al., 2006).  
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non-coding RNAs. Through the regulation of all these genes MYC achieves broad effects on 
many different cell biology processes such as cell cycle regulation; signal transduction; 
transcription and RNA processing; protein biosynthesis, transport and degradation; carbohydrate, 
amino acid and nucleotide metabolism; and cell adhesion and cytoskeleton remodelling among 
others (Figure 1.20) (Menssen and Hermeking, 2002; Fernandez, et al., 2003; Patel, et al., 2004b; 
Dang, et al., 2006; Luscher and Vervoorts, 2012). 
1.4.6. Biological functions of MYC 
In general, the biological functions of MYC depend on its transcriptional activity. The 
widespread influence of MYC in the regulation of transcription and its many target genes make 
him a very important regulator of multiple biological functions, among which it should be noted the 
induction of cell proliferation and cell growth, inhibition of terminal differentiation, induction of 
apoptosis but suppression of senescence, as well as its role in tumorigenesis and cancer 
development (Grandori, et al., 2000). 
1.4.6.1. MYC function in proliferation and cell cycle regulation 
Soon after MYC discovery several studies showed its ability to stimulate cell proliferation 
(Palmieri, et al., 1983; Hann, et al., 1985). MYC is not expressed in quiescent cells, but it is 
rapidly induced by growth factors (Kelly, et al., 1983; Armelin, et al., 1984; Campisi, et al., 1984). 
MYC overexpression or activation produces a shortening of G1 phase and promotes cell cycle 
progression through S-phase (Karn, et al., 1989; Eilers, et al., 1991; Steiner, et al., 1995).  In 
contrast, disruption of both MYC alleles in rat fibroblast (Rat-1 cells) leads to a prolongation of G1 
and G2 phases and a delay of S-phase entry (Mateyak, et al., 1997); and conditional MYC 
ablation in murine fibroblast and/or B lymphocytes reduces their proliferation rate (de Alboran, et 
al., 2001).  
MYC promotes cell proliferation regulating the expression of several genes involved in cell 
cycle progression. On the one hand, MYC promotes the transcription of positive cell cycle 
regulators such as D1 and D2 cyclins (Bouchard, et al., 1999; Perez-Roger, et al., 1999), cyclin 
A2 (Jansen-Durr, et al., 1993; Hoang, et al., 1994; Barrett, et al., 1995), cyclin B1 (Yin, et al., 
2001), cyclin E1 (Jansen-Durr, et al., 1993; Perez-Roger, et al., 1997), CDK4 (Hermeking, et al., 
2000) and CDK6 (Li, et al., 2003); CDC25A and B (Galaktionov, et al., 1996; Li, et al., 2003) and 
E2F1 and E2F2 (Sears, et al., 1997; Baudino, et al., 2003). On the other hand, MYC represses 
the transcription of negative cell cycle regulators as p15INK4B (Seoane, et al., 2001; Staller, et al., 
2001) and p21CIP1 (Claassen and Hann, 2000; Gartel, et al., 2001; Wu, et al., 2003) or genes 
implicated in promoting cell cycle arrest under stress conditions such as GADD45 and GADD153 
(Chen, et al., 1996; Marhin, et al., 1997).  
 However, one of the most important targets of MYC in cell proliferation is the CDK inhibitor 
p27. MYC accelerates cell proliferation rates, at least in part, through its ability to down-regulate 
p27 protein levels (Vlach, et al., 1996; Keller, et al., 2007). First, MYC can suppress p27 
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expression at transcriptional level in lymphoid and breast cancer cells (Yang, et al., 2001; 
Chandramohan, et al., 2004). Second, MYC induces cyclin E transcription directly or through the 
induction of E2F transcription factors, increasing the levels of cyclin E/CDK2 complexes (Ohtani, 
et al., 1995; Steiner, et al., 1995; Vlach, et al., 1996; Perez-Roger, et al., 1997). Third, induction of 
both D cyclins and their catalytic partners CDK4 and 6 by MYC, allows the assembly of cyclin 
D/CDK4-6 complexes, which sequester p27 and relieve the inhibition of cyclin E/CDK2 complexes 
(Soos, et al., 1996; Bouchard, et al., 1999; Obaya, et al., 2002). All these effects stimulate cyclin 
E/CDK2 activity which in turn phosphorylates p27 on Thr-187. P-Thr187-p27 is recognized by the 
SCFSKP2 complex following, ubiquitination and degradation by the proteasome, as previously 
described. Finally, MYC induces the expression of some of the components of the SCFSKP2 
complex, including CUL1 (O'Hagan, et al., 2000) and CKS1 (Keller, et al., 2007).  
The antagonism between MYC and p27 in proliferation and tumor development has been 
evidenced in knockout mouse models. Loss of p27 accelerates lymphoma development in Eµ-
MYC transgenic mice (Martins and Berns, 2002), a mouse model of human Burkitt lymphoma 
(Adams, et al., 1985). In contrast, loss of Cks1 in Eµ-MYC mice suppresses the MYC ability to 
down-regulate p27 protein levels, impairs MYC-induced proliferation and delays lymphoma onset 
tripling the lifespan of these mice (Keller, et al., 2007). Similarly, Skp2 ablation in Eµ-MYC B cells 
abolishes the suppression of p27 protein, showing these cells slower proliferation rates ex vivo. 
Nevertheless, Skp2 loss only has modest effects on MYC-induced lymphomagenesis (Old, et al., 
2010). By contrast, Myc-/- cells usually show increased p27 protein levels (Mateyak, et al., 1999; 
de Alboran, et al., 2001). Altogether, these findings make MYC a key regulator of cell cycle and 
cell proliferation, with particular importance in the G1-S transition, promoting p27 degradation.  
1.4.6.2. Role of MYC in differentiation 
Inhibition of cell differentiation was one of the first biological effects described for MYC; 
concretely, the inhibition of chemically-induced erythroid differentiation of the F-MEL murine 
erythroleukemia cell line (Coppola and Cole, 1986; Dmitrovsky, et al., 1986; Prochownik and 
Kukowska, 1986). Accordingly, MYC expression usually decreases when cells differentiate 
(Gonda and Metcalf, 1984; Lachman and Skoultchi, 1984; Grosso and Pitot, 1985) and inhibition 
of MYC expression has been associated with induction of myeloid differentiation in HL-60 
promyelocytic cells (Holt, et al., 1988). Lately, the role of MYC as inhibitor of differentiation is 
gaining more attention since the discovery that MYC is one of four transcription factors able to 
reprogram differentiated cells into pluripotent cells (Takahashi and Yamanaka, 2006).  
MYC-mediated inhibition of differentiation usually occurs by blocking the up-regulation of 
"master genes" required to trigger the cell specific differentiation process, such as  C/EBP-α 
during adipocyte differentiation of murine 3T3-L1 cells (Freytag and Geddes, 1992; Tao and 
Umek, 1999) or GATA1 during erythroid differentiation of K562 leukemia cells (Acosta, et al., 
2008). On the other hand, MYC is also able to inhibit differentiation through its ability to induce 
proliferation insomuch as cell differentiation usually implies a proliferative arrest and cell cycle exit 
into G0, although not always (Leon, et al., 2009). Finally, it has been described that MYC-Nick, a 
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cytoplasmic cleavage product of MYC which lacks the NLS and DNA-binding domain, promotes 
muscle cell differentiation in a transcription independent manner (Conacci-Sorrell, et al., 2010). 
Nevertheless, there are certain models such as human epidermal and hematopoietic stem 
cells or B lymphocytes in which MYC expression is required for differentiation. In these models, 
MYC promotes differentiation by amplifying the population of precursor or stem cells. (Gandarillas 
and Watt, 1997; Wilson, et al., 2004; Habib, et al., 2007).  
1.4.6.3. MYC functions in cell size 
MYC overexpression has been associated with the accumulation of cell mass and the 
increase in cell size in different models (Langdon, et al., 1986; Iritani and Eisenman, 1999; 
Johnston, et al., 1999). This increase has been related with the effects of MYC in protein 
synthesis (Mateyak, et al., 1997; Iritani and Eisenman, 1999) and cell metabolism (Dang, 1999). 
For instance, MYC stimulates transcription of rRNAs genes involved in ribosome biogenesis 
through RNA polymerase I and regulates the expression of several proteins involved in rRNA 
processing and maturation (van Riggelen, et al., 2010). In addition, MYC stimulates transcription 
of transfer RNAs (tRNAs) and 5S ribosomal RNAs (5S rRNAs), by activating RNA polymerase III 
(Gomez-Roman, et al., 2003; Kenneth, et al., 2007). On the other hand, MYC regulates the 
expression of many genes involved in mitochondrial biogenesis (Li, et al., 2005), and nucleotide 
and glucose metabolism (Shim, et al., 1997; Kim, et al., 2004; Liu, et al., 2008; Wang, et al., 
2011a).  
1.4.6.4. Role of MYC in apoptosis 
High MYC levels induce apoptosis in different cell models in the absence of growth factors 
or when the cells are placed in suboptimal growth conditions (Askew, et al., 1991; Evan, et al., 
1992; Shi, et al., 1992). MYC sensitizes cells to undergo apoptosis by both p53-dependent and 
p53-independent mechanisms (Sakamuro, et al., 1995). On the one hand, MYC overexpression 
can activate p53 indirectly through the ARF–MDM2–p53 pathway (Hermeking and Eick, 1994; 
Wagner, et al., 1994; Zindy, et al., 1998) or through the ATM-p53 pathway in response to DNA-
damage (Lindstrom and Wiman, 2003). On the other hand, MYC can mediate apoptosis by 
altering the balance of pro- and anti-apoptotic factors. In the Eµ–MYC mouse model, MYC 
indirectly suppresses the anti-apoptotic proteins Bcl-2 and Bcl-XL and triggers apoptosis by 
inducing the pro-apoptotic proteins Bax or Bim (Adhikary and Eilers, 2005; Dansen, et al., 2006). 
Finally, loss-of-function mutations interfering with apoptosis are strongly selected for MYC-driven 
tumorigenesis (Eischen, et al., 1999).  
1.4.6.5. Role of MYC in senescence 
In contrast, MYC expression has been associated to the suppression of oncogene-induced 
senescence (OIS). For example, MYC suppresses RAS-induced senescence in primary rat 
embryonic fibroblasts (Hydbring, et al., 2010). For that, MYC represses p21CIP1, involved in 
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promoting senescence (Post, et al., 2010); and stimulates the activity of CDK2 and drives the 
expression of hTERT and WRN target genes, whose inactivation promotes senescence under the 
condition of active MYC (Xu, et al., 2001; Grandori, et al., 2003; Campaner, et al., 2010). Finally, 
conditional MYC inactivation induces senescence even in established tumours including 
lymphoma, being this an important mechanism to induce tumor regression (Wu, et al., 2007).  
1.4.7. Role of MYC in tumorogenesis and cancer 
Deregulation of MYC is strongly associated with the emergence of a variety of human 
cancers and is also able to induce tumorigenesis in several transgenic mice models. MYC 
translocation in Burkitt lymphoma was the first example connecting a specific chromosomal 
alteration with malignant transformation in human cancer. In this type of B-cell lymphoma, the 
MYC gene is translocated from chromosome 8 to 14, 2 or 22, containing  the genes for heavy and 
light immunoglobulin chains (Dalla-Favera, et al., 1982a; Taub, et al., 1982). Thus, MYC 
expression becomes regulated by the promoters of the immunoglobulin chains, resulting in MYC 
overexpression. In addition, MYC has been also found frequently translocated in multiple 
myeloma and in diffuse large B-cell lymphoma (DLBCL) (Boxer and Dang, 2001). With or without 
translocation, MYC levels have been found deregulated in a wide range of human cancers, such 
as melanoma, lymphoma, multiple myeloma, myeloid leukemia, breast, prostate, lung and 
gastrointestinal cancers (Nesbit, et al., 1999). The mechanisms by which MYC appears 
deregulated are very different and they include, in addition to the previously mentioned 
translocations, gene amplifications, transcriptional activation or retroviral transduction, being this 
the first mechanism identified in chicken (Sheiness and Bishop, 1979). All these mechanisms 
result in an increase of the MYC protein in tumor cells. On the other hand, they have also been 
described several point mutations in the MYC coding sequence associated with cancer. These 
alterations prevent MYC binding to proteins that inhibit its activity, such as p107 (Gu, et al., 1994) 
or increase the stability of MYC protein as mutations affecting Thr58 or Ser62 which render MYC 
resistant to degradation by SCFFBW7. These mutations are frequent in Burkitt's lymphoma (Boxer 
and Dang, 2001) and have been shown to perturb transgenic mammary tumorigenesis (Wang, et 
al., 2011b).  
The involvement of MYC in tumorigenesis is clearly related to its role as activator of cell 
proliferation, evading growth suppressors and differentiation, as well as its ability to regulate cell 
metabolism and protein synthesis, all discussed in previous sections. However, there are other 
processes of great significance in cancer development (Hanahan and Weinberg, 2011) in which 
MYC has been also involved (Figure 1.21), such as increased genomic instability, immortalization, 
angiogenesis and changes in morphology and cell adhesion:  
i) MYC overexpression has been linked to increased genomic instability and loss of 
chromosomal organization in tumor cells (Mai, et al., 1996; Felsher and Bishop, 1999; 
Prochownik, 2008) through different mechanisms as the induction of reactive oxygen species 
(ROS) which results from increased mitochondrial biogenesis and metabolism (Vafa, et al., 2002) 
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or by enhancing DNA replication with subsequent DNA damage (Iguchi-Ariga, et al., 1987; 
Gutierrez, et al., 1988; Dominguez-Sola, et al., 2007). In addition, MYC inhibits the repair of 
double-strand DNA breaks provoked by gamma irradiation in normal human cells (Karlsson, et al., 
2003) and possesses the ability to structurally modify chromosomes through induction of 
telomeric fusions (Louis, et al., 2005). Finally, overexpression of MYC cooperates with loss of p53 
to induce genomic instability, evading the G1 and G2/M checkpoints (Yin, et al., 1999). In our 
laboratory, it has been shown that MYC contributes to genomic instability during CML progression 
(Albajar, et al., 2011).  
ii) MYC overexpression promotes immortalization of murine cells (Sedivy, 1998), human 
fibroblasts (Benanti, et al., 2007) or human prostate epithelial cells, at least in part, through its 
ability to induce hTERT, the catalytic subunit of telomerase (Gil, et al., 2005). hTERT is a well-
known MYC target gene and telomerase is critical for cells to avoid senescence and acquire 
immortality (Wu, et al., 1999; Cerni, 2000). 
iii) MYC is essential for 
vasculogenesis during murine embryonic 
development through the induction of 
pro-angiogenic factors such as VEGF 
(Baudino, et al., 2002; He, et al., 2008). 
In addition, MYC overexpression 
stimulates the growth and the expansion 
of blood and lymphatic vessels during 
lymphomagenesis in Eµ-MYC transgenic 
mice (Ruddell, et al., 2003; Mezquita, et 
al., 2005). Finally, MYC possesses the 
ability to induce neovascularization of 
tumors by inducing interleukin-1β 
(Shchors, et al., 2006) or by suppressing 
the angiogenesis inhibitor 
thrombospondin-1 (Ngo, et al., 2000; 
Watnick, et al., 2003) through the 
induction of mir17-92 microRNA cluster 
(Dews, et al., 2006).  
iv) MYC promotes cell motility by repressing many genes involved in cell adhesion, 
cytoskeletal architecture and extracellular matrix such as actin, cdc42, the α3β1 integrin, N-
cadherin or several collagens (Inghirami, et al., 1990; Barr, et al., 1998; Coller, et al., 2000; 
Wilson, et al., 2004) or by inducing the expression of several metalloproteases such as MPP-7, 
11 and 13 (Giambernardi, et al., 1998). On the other hand, MYC has been linked to epithelial-
mesenchymal transition (EMT) and metastasis via its up-regulation of miR-9, which targets E-
cadherin (Ma, et al., 2010), as well as by its ability to transactivate the PcG repressor protein Bmi-
1 (Guney, et al., 2006; Song, et al., 2009).  
Figure 1.21. MYC has been direct- or indirectly 
involved in all and every one of the hallmarks of 
cancer defined in 2011 by Hanahan and Weimberg. 
(Hanahan and Weinberg, 2011).  
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v) Finally, MYC possesses immunosuppressive potential by impairing antigen processing 
and presentation, and thus preventing T-cells from recognizing tumor cells (Staege, et al., 2002; 
God and Haque, 2010). 
1.5. THE K562 AND THE Kp27MER CELL MODELS 
The K562 cell line derives from a patient with chronic myeloid leukemia (CML) in blast crisis 
(Lozzio and Lozzio, 1975). This has led to an extensive use of this cell line as a model for 
studying CML and other hematological malignancies. Among the molecular features of this cell 
line should be noted the expression of BCR-ABL tyrosine kinase resulting from a reciprocal 
translocation between chromosome 9 and 22 which is intimately related to the pathogenesis of 
CML (Collins, et al., 1987; Goldman and Melo, 2003). Moreover, this cell line does not express 
p53 (Law, et al., 1993) and is deficient in the CKIs p15INK4b and p16INK4a (Drexler, 1998). In 
contrast, it shows a high MYC expression although MYC gene is not amplified (Gomez-Casares, 
et al., 1993). Finally, this cell line is multipotent and it can mature along distinct hematopoietic 
lineages (Lerga, et al., 1999) making it an excellent model to study the hematopoietic 
differentiation.  
The stable Kp27MER cell line was developed in our laboratory to study the antagonism 
between MYC and p27 in proliferation and cell differentiation (Acosta, et al., 2008). This cell line 
derives from the original K562 cell line and it contains an additional p27 gene controlled by the 
sheep metallothionein promoter which responds to different concentrations of ZnSO4 in the 
culture medium (ranging between 0-75 µM in non-toxic conditions) and the quimera MYCER 
protein which can be activated in presence of low doses (100-200 nM) of 4-hydroxy-tamoxifen 
(4HT) (Littlewood, et al., 1995). Induction of high levels of p27 with 75 µM of ZnSO4 (the maximum 
allowable dose without affecting their viability) result in a rapid proliferative arrest accompanied by 
cell accumulation in G1-phase and a moderate erythroid differentiation of these cells. The 
activation of MYCER by 4HT in these conditions is not able to reverse this growth arrest but 
inhibits the p27-mediated differentiation repressing several erythroid master genes. However, in 
presence of moderate p27 levels (50 µM ZnSO4), MYC provokes an increase in the fraction of 
cells in S-phase and a consistent increase in cell proliferation. This effect of MYC on cell 
proliferation can be explained, at least in part, by the ability of MYC to induce a reduction in the 
p27 protein levels (Acosta, et al., 2008). 
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2. AIMS
There is a functional antagonism between the CDKs inhibitor p27 and the oncogenic
transcription factor MYC in cell proliferation and tumorigenesis. Besides being a positive regulator
of cyclins and CDKs, MYC has the ability to down-modulate p27 levels. Several mechanisms
have been proposed to explain the inverse relationship between MYC and p27 both at
transcriptional and posttranscriptional level. However some of these mechanisms have not been
reproduced in other experimental models or no correlation was found in the clinical context.
Furthermore, in our laboratory we have observed that this antagonism between MYC and p27
seems to be dependent on p27 expression levels.
In the present study we aim to investigate the molecular mechanisms that may explain the
antagonism between MYC and p27 in different experimental contexts. For this purpose we
propose the following objectives:
1. To establish the molecular mechanism that determines the antagonism between MYC
and p27 in proliferation; to study its functionality in different cell systems, in animal
models and in human cancer.
2. To establish why MYC effect on cell proliferation is dependent on the levels of p27.

 3. MATERIAL AND METHODS
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3. MATERIAL AND METHODS 
3.1. CHRONIC MYELOID LEUKEMIA SAMPLES 
Bone marrow mononuclear cells from 4 healthy controls, 31 CML patients at diagnosis and 
8 patients that achieved the remission of the leukemia after imatinib treatment (Complete 
Molecular Response) were studied. Patients were diagnosed and evaluated for complete 
molecular response as described (Baccarani, et al., 2009). The patients were from the Hospital 
Universitario Marqués de Valdecilla (Santander, Spain) and Hospital Universitario Dr. Negrín (Las 
Palmas, Spain). The study was according to procedures approved by the ethics committees of 
both hospitals.  
Bone marrow mononuclear cells were prepared by Ficoll-Hypaque density gradient 
centrifugation method. For this purpose, bone marrow samples (~3.5 ml) were diluted with one 
volume of PBS (~3.5 ml). Diluted sample was carefully poured over 3 ml of Ficoll-Hypaque 
solution (Histopaque®-1077, Sigma-Aldrich) avoiding mixing both phases. Tube was then 
centrifuged at 2,000 rpm for 15 min in a swinging-bucket rotor with no brake. The mononuclear 
cells  located at the interphase between the plasma (upper layer) and the Ficoll-Hypaque (bottom) 
phases, were transferred to a new tube, washed twice in PBS and pelleted at 1,500 rpm for 5 min. 
Total RNA and protein extracts from bone marrow mononuclear cells were then extracted as 
indicated below (Section 3.4.2 and 3.6.1 respectively). MYC and SKP2 mRNA expression 
correlation was determined with the Pearson´s correlation coefficient. SKP2 and MYC mRNA 
expression between groups (control, diagnosis and CMR) was compared using the non-
parametric Mann–Whitney U test. P-values below 0.05 were considered significant. Statistical 
analysis was carried out with the GraphPad Prism 4.0 software.  
3.2. CELL CULTURE 
3.2.1. Cell lines and maintenance 
K562 cell line was obtained from American Type Culture Collection (ATCC). K562, K562-
derived and non-adherent cell lines were grown in R10F medium, i.e., RPMI 1640 basal medium 
(Lonza) supplemented with 10% (v/v) foetal calf serum (Lonza), 150 µg/ml gentamycin (Lab. 
Normon) and 2 µg/ml ciprofloxacin (Sigma-Aldrich). When indicated, R10F medium was also 
supplemented with specific selective antibiotics [500 µg/ml geneticin (G418), 1 µg/ml puromycin 
or 100 µg/ml hygromycin B (all from Sigma-Aldrich)] to grow each cell line in particular as 
indicated in table 3.1. Cells were maintained in a humidified atmosphere at 37ºC and 5% CO2. 
Non-adherent
 
cells were kept growing in exponential phase (<106 cells/ml) and sub-cultured twice 
a week at a ratio of 1:3 and 1:6 depending on the confluence. 
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Table 3.1. Non-adherent cell lines used in this study. 
 
 
Cell lines Origin 
Culture medium and 
resistence 
References 
K562 Human chronic myeloid leukemia (ATCC) R10F   (Lozzio and Lozzio, 
1975) 
KMYCJ 
K562 cells stably transfected with a MYC 
gene inducible by ZnSO4 
R10F supplemented 
with hygromycin B  
(Delgado, et al., 1995) 
KMER4 
K562 cells stably transfected with a vector 
expressing the MYCER construct  
R10F with puromycin  
(Albajar, et al., 2011) 
(Acosta, et al., 2008) 
Kp27-5 
K562 cells stably transfected with a p27 gene 
inducible by ZnSO4. 
R10F with G418  
(Munoz-Alonso, et al., 
2005) 
Kp27MER 
Kp27-5 cells stably transfected with the 
MYCER gene 
R10F with G418 and 
puromycin  
(Acosta, et al., 2008) 
KMYCBp53 
KMYCB cells expressing a p53 mutant 
(Val135) that is activated at 32 °C  
R10F with hygromycin B 
and puromycin  
(Ceballos, et al., 2000) 
KMERpSR 
KMER4 cells infected with retrovirus 
expressing pSR empty vector 
R10F with puromycin  This Thesis 
KMERshSKP2 
KMER4 cells infected with retrovirus 
expressing pSR-shSKP2 
R10F with puromycin  This Thesis 
P493.6  
Immortalized human B cells (EREB2-5) 
expressing a tetracycline-repressible MYC 
gene 
R10F with hygromycin B  
(Schuhmacher, et al., 
1999)  
 
 
Adherent cell lines were grown in D10F media i.e., Dulbecco’s Modified Eagle Medium 
(DMEM) (Lonza) supplemented with 10% foetal calf serum (Lonza), 150 µg/ml of gentamycin 
(Lab. Normon) and 2 µg/ml of ciprofloxacin (Sigma-Aldrich). When indicated, D10F medium was 
also supplemented with specific selection antibiotics: geneticin/G418, puromycin or hygromycin B 
at the concentrations indicated above. Cells were maintained in a humidified atmosphere at 37ºC 
and 5% CO2. Adherent cell lines were sub-cultured twice a week at a ratio of 1:6 and 1:10 and 
cell densities were kept below 70-80% confluence. For this purpose, cell culture media was 
aspirated, the cells were washed with 15 ml phosphate buffered saline (PBS). Cells were then 
detached using 1-3 ml Trypsin-EDTA solution (Sigma-Aldrich). Finally, trypsin activity was 
neutralized with D10F. Table 3.2 provides a list of the adherent cell lines used in this study and 
their selection antibiotics. 
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 Table 3.2. Adherent cell lines used in this study.  
 
Cell lines Origin 
Culture medium 
and resistance  
References 
TM1 
Mv1Lu lung epithelial cell line with a 
tetracycline-repressible MYC gene  
D10F with G418 and 
hygromycin B  
(Warner, et al., 1999) 
TGR-1 Rat-1 fibroblasts Hprt- D10F (Prouty, et al., 1993) 
HO15.19 
Myc-null rat fibroblasts generated 
from TGR1 cells  by homologous 
recombination 
D10F with G418  
(Mateyak, et al., 
1997) 
MEFs Cdk2-/- 
Mouse embryonic fibroblasts from 
Cdk2-/-  mouse  
D10F with G418  (Ortega, et al., 2003) 
MEFs Cdk2-/- Lv 
MEFs Cdk2-/-  transduced with Lv141-
GFP empty vector 
D10F with G418  This Thesis  
MEFs Cdk2-/- LvMYC 
MEFs Cdk2-/-  transduced with Lv141-
GFP-MYC vector  
D10F with G418  This Thesis  
MEFs cyclin E1-/-/E2-/-  
Mouse embryonic fibroblasts from 
cyclin E1-/-/E2-/- mouse  
D10F with G418 and 
puromycin  
(Geng, et al., 2003) 
MEFs cyclin E1-/-/E2-/- Lv 
MEFs cyclin E1-/-/E2-/-  transduced 
with Lv141-GFP empty vector  
D10F with G418 and 
puromycin  
This Thesis 
MEFs cyclin E1-/-/E2-/- 
Lv-MYC 
MEFs cyclin E1-/-/E2-/- transduced 
with Lv141-GFP-MYC vector  
D10F with G418  and 
puromycin 
This Thesis  
HEK293T 
Human embryonic kidney expressing 
the T antigen 
D10F  (Graham, et al., 1977) 
Phoenix-A 
HEK293T cells expressing gag-pol 
and envelope proteins. 
D10F  (Pear, et al., 1993) 
3.2.2. Cell proliferation analysis  
For proliferation assays, cells were plated at a concentration of 2.5 x 105 cells/ml on day 0 
and cell proliferation was monitored every 24 hours, during 3-4 more days after treatment with the 
corresponding drug. Cell growth was assayed by cell counting in a hemocytometer. Trypan blue 
exclusion test was used for assessment of cell viability.  
3.2.3. Drug treatments 
 When indicated, the exponentially growing cells were treated with 50-75 µM ZnSO4, 200 
nM 4-hydroxytamoxifen (4HT), 10 nM phorbol-12-myristate-13-acetate (TPA), 10 µg/ml 
cycloheximide (CHX), 1-2 µg/ml doxycycline (Doxy) (all reagents from Sigma-Aldrich) or 1 µM 
imatinib mesylate (LC Laboratories, Woburn, MA,USA). 
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 ZnSO4 was used to induce p27 transgene controlled by the metallothionein promoter in 
Kp27-5 and Kp27MER cells or to induce MYC transgene in KMYCJ and KMYCBp53 cells. 4HT 
was used to activate the MYCER protein in KMER4 and Kp27MER cell lines. The tyrosine-kinase 
inhibitor Imatinib and the TPA were used to block cell proliferation and to repress endogenous 
MYC expression in K562 and K562 derived cell lines. Doxycycline was used to repress the 
tetracycline-responsive MYC transgene in P493.6 and TM1 cell lines. CHX was used to inhibit 
protein synthesis in transcriptional experiments in Kp27MER cells. 
75 mM ZnSO4 stock solution was dissolved in distilled water and filtered through 0.22 µm 
pore size sterile syringe filters (Millipore). 200 µM 4HT, 10 mM TPA, 1 mM Imatinib,  1mg/ml 
doxycycline and 10 mg/ml CHX stock solutions were dissolved in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich). All stock solutions were aliquoted and stored at -20ºC, in the absence of light. 
Stock solutions were added directly to the culture medium (1µl per ml of culture medium) to obtain 
the final desired concentration (usually 1:1000 dilutions). An equal volume of drug solvent 
(distilled water or DMSO) was added to the untreated control cells.  
3.2.4. Transfection  
Electroporation or nucleofection methods were mainly used for transient transfection of 
non-adherent cells (K562 or K562 derived cells) whereas methods based in cationic lipids, such 
the JetPEI transfection reagent, were generally used for transient transfection of adherent cells 
(HEK293T or Phoenix A cells).  
3.2.4.1. Electroporation and nucleofection 
Electroporation and nucleofection were used for reporter transfection in luciferase assays or 
for transient silencing of SKP2 or MYC expression in K562 or K562 derived cells (KMYCJ).  
For electroporation, 5 x 106 cells were resuspended in 800 µl of serum-free medium RPMI 
(Lonza) or 800 µl of Mirus Ingenio transfection reagent (Mirus BioLLC) containing 5 µg of total 
DNA (usually 1 µg of total DNA per 106 cells). The mixture was electroporated in a sterile gene 
pulser cuvette with 0.4 cm gap between electrodes (Bio-Rad) using a Gene Pulser apparatus 
(Bio-Rad) with the following voltage and capacitance settings: 260 V and 1 mFa. After 
electroporation, cells were briefly kept on ice for 5 min and then plated in complete medium 
(R10F) and incubated for the indicated time (24-48 hours).  
For nucleofection 1-3 x 106 cells were resuspended in 100 µl of cell line nucleofector 
solution V (Amaxa) or 100 µl of Mirus Ingenio transfection reagent (Mirus BioLLC) containing 1-3 
µg of total DNA (1 µg of total DNA per 106 cells). The mixture was nucleofected in a nucleofector 
cuvette of 0.1 cm gap using an Amaxa nucleofector apparatus (Amaxa) following the 
manufacturer’s instructions (T-16 program). After nucleofection, cells were briefly kept on ice for 5 
min and then plated in complete medium (R10F) and incubated for the indicated time.  
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3.2.4.2. Transfection based on cationic lipids: jetPEI (Polyplus) 
Cationic lipids-based methods were used for transient transfection of adherent cell lines. 
JetPEI transfection reagent (Polyplus) was used for Phoenix-A or HEK293T cells transfection for 
retroviral or lentiviral particles production respectively. For this purpose ~2 x 106 Phoenix-A or 
HEK293T cells were seeded on 100 mm Ø plates one day before transfection to achieve a 70-
80% confluence the day of transfection. For a 100 mm Ø plate, 10 µl of jetPEI were resuspended 
in 240 µl of 150 mM NaCl in a sterile eppendorf tube (usually 2 µl jetPEI per 1 µg DNA). On a 
different tube, 5 µg of total plasmid DNA were resuspended in 250 µl of 150 mM NaCl. Both tubes 
were vortexed and incubated separately for 5 min at room temperature. Then, both tubes were 
mixed, and incubated for 30 min at room temperature. The resultant mixture containing the 
cationic lipids/DNA complexes was directly added in a drop wise manner onto the plates and 
gently homogenized with the culture medium (D10F) by swirling. Cells were incubated for 24-48 h 
after transfection and transfection efficiency was evaluated by GFP expression under a 
fluorescence microscope.  
3.2.5. Retrovirus production and infection 
For stable expression of the shSKP2 into KMER cells, the cells were infected with retroviral 
particles containing a shSKP2 construct under human H1 promoter produced in Phoenix-A 
amphotropic packaging cells. Phoenix-A cells derive from HEK293T cell line and they 
constitutively express the gag-pol and the envelope proteins to produce amphotropic (A) 
retrovirus. Therefore, to produce retroviral particles with this cell line it is only required to transfect 
the retroviral construct to be packaged. Thus, cells at 70-80% confluence in 100 mm Ø plates 
were transfected with pSR-shSKP2 (Andreu, et al., 2005) or the empty retroviral vector pSuper-
Retro, using jetPEI transfection reagent as previously described (Section 3.2.4.2). 
Two days after transfection retrovirus-containing supernatants were harvested, clarified at 
3,000 rpm, mixed with 4 µg/ml polybrene (Sigma-Aldrich) and filtered through a 0.45 µm filter 
(Millipore). Retrovirus-containing filtered supernatants were used for resuspending a KMER cell 
pellet (~2 x 106 cells). 24 hours after infection, supernatants were replaced with fresh medium 
(R10F) and transduced cells were selected with 1 µg/ml puromycin for 2 weeks. 
3.2.6. Lentivirus production and infection 
For stable MYC-FLAG expression into Cdk2-/- and cyclin E1-/-/E2-/- MEFs, the cells were 
infected with lentiviral particles containing a MYC-FLAG gene construct controlled by the CMV 
promoter, packaged in HEK293T cells. To produce these lentiviral particles, HEK293T cells at 70-
80% confluence in 100 mm Ø plates were transfected  with a mix of three constructs composed of 
1µg of pCMV-VSV-G (Addgene), 3µg of psPAX2 (Addgene)  and  6 µg of LV141-CMV-MYCwt-
IRES-GFP (GeneCopoeia) or the corresponding empty vector LV141-CMV-IRES-GFP 
(GeneCopoeia), using jetPEI transfection reagent (Polyplus) as previously described. 
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The three plasmids together provide all the elements required for packaging the expression 
vector into virions. The LV141-CMV-MYCwt-IRES-GFP plasmid provides the packaging signal 
(Ψ) and the gene construct to be packaged (CMV promoter-MYC-FLAG-IRES-GFP) flanked by 
the LTRs (Long terminal repeats); whereas the packaging plasmids (pCMV-VSV-G and psPAX2) 
provide structural and replication proteins in trans required to produce the lentiviral particles (Gag, 
Pol and VsVg proteins).   
Two days after HEK293T transfection lentivirus-containing supernatants were harvested, 
clarified at 3,000 rpm, mixed with 4 µg/ml polybrene (Sigma-Aldrich) and filtered through a 0.45 
µm filter (Millipore). Then, the culture medium of knockout MEFs was replaced by lentivirus-
containing supernatants and infection was carried out for 24 hours. After transduction, 
supernatant was replaced again with complete fresh medium D10F and lentiviral infection 
efficiency was evaluated by GFP expression in a fluorescence microscope. GFP positive colonies 
were selected and expanded. 
3.3. NUDE MICE XENOGRAFTS 
Six-week-old female nude (Hsd: Athymic Nude-Foxn1nu/nu) mice were provided by Harlan 
Laboratories (Italy) and animal maintaining was performed at the animal facilities of the University 
of Cantabria. Mice were housed in sterile filter-capped cages, with a temperature of 22 ± 2°C, 12 
h light/dark cycle and provided with sterilized food and water ad libitum.  
For xenografts, KMERpSR and KMERshSKP2 cells were resuspended in a serum-free 
culture medium (RPMI 1640) / Geltrex (GIBCO) mixture (1:1 v/v) to a final concentration of 5 x 107 
cells per ml. Then, each mouse was injected subcutaneously with 200 µl KMERpSR cell 
suspension (~107 cells per injection) into the left rear flank and 200 µl KMERshSKP2 cell 
suspension (~107 cells per injection) into the right rear flank by using G-27 needles. After 
injections, tumor development was followed by daily monitoring of the mice. Tumor-bearing mice 
were sacrificed after 21–24 days when the larger tumors reached approximately 1 cm diameter. 
Mice were photographed and the tumors were excised, weighed and measured by using a 
caliper. This study was approved by the Cantabria University Institutional Laboratory Animal Care 
and Use Committee and performed in accordance with the Declaration of Helsinki and the 
European Communities Council Directive (86/609/EEC). 
3.4. DNA AND RNA ANALYSIS 
3.4.1. Bacterial transformation and plasmid DNA purification 
Plasmid DNA (Table 3.3) was transformed into E. coli DH5α competent cells (Invitrogen) for 
DNA amplification. For this purpose, 50 µl E. coli DH5α cells were briefly thawed in hand and 
mixed with 100 ng of plasmid DNA. The mixture was kept on ice for 30 min, followed by a heat 
shock for 1 min at 42 °C and then immediately 2 min incubation on ice. Transformed E. coli DH5α 
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cells were then supplemented with 300 µl LB-media containing no antibiotics and incubated in an 
orbital shaking incubator at 160 rpm for 1 h at 37 °C. After this, the E. coli cells were spread on 
LB-Agar 100 mm Ø plates containing the corresponding selective antibiotic (100 µg/ml ampicillin 
or 50 µg/ml kanamycin) and incubated overnight at 37ºC. 
The next day, a single colony was inoculated into 5 ml LB medium containing the 
appropriate antibiotic and grown overnight in an orbital shaking incubator at 37°C and 160 rpm. 
Subsequently, the bacterial culture was harvested by centrifugation at 4,000 rpm for 10 min and 
plasmid DNA was purified with the NucleoSpin Plasmid Miniprep Kit (Macherey-Nagel) following 
the manufacturer’s instructions and analysed by restriction analysis to verify the identity of purified 
vector. Plasmid digestions were carried out with two specific restriction endonucleases 
(Fermentas) following the manufacturer’s instructions. Usually, 1 µg of plasmid DNA was digested 
with 1 µl of every selected restriction endonucleases for 1 h at 37ºC. The restriction DNA-
fragments were analysed by agarose gel electrophoresis. For this purpose, the low melting point 
agarose (Pronadisa) was melted in 1X TAE buffer (90 mM Tris-acetate, 2 mM EDTA) in a 
conventional microwave. The agarose concentration of the gels varied from 0.8 to 2.0 % (w/v) 
depending on the size of DNA-fragments to be analysed. Ethidium bromide (0.5 µg/ml) was 
added before gel casting. Samples were mixed with 1/5 volume of agarose gel loading buffer 
(0.005 % bromophenol blue (w/v) and 30 % glycerol (v/v), before loading on the gel. “1 Kb DNA 
ladder” or “100 bp DNA ladder” (Fermentas) were used as DNA size standards. Electrophoresis 
was carried out in an iMupid Mini gel Electrophoresis system at 50-100V for 60-30 min in 1X TAE 
buffer. Finally, gels were visualized in an UV-transilluminator and recorded using a Gel Doc EZ 
Imager (Bio-Rad).  
Alternatively, to prepare high amounts of plasmid DNA for transfections, a single colony 
was inoculated into 5 ml LB medium containing the appropriate antibiotic (100 µg/ml ampicillin or 
50 µg/ml kanamycin) and incubated for 8 hours in an orbital shaking incubator at 37 °C and 160 
rpm. Then, 200 µl of this starter culture were used to inoculate 200 ml LB medium containing the 
same selection antibiotic and grown overnight in the same culture conditions (37 °C and 160 
rpm). 
The following day, the bacterial culture was harvested by centrifugation at 6,000 rpm for 10 
min and plasmid DNA was purified using the Plasmid Midi Kit (Qiagen) following the 
manufacturer’s instructions. After DNA elution from the Anion-Exchange column, DNA was 
desalted and concentrated by isopropanol precipitation and finally, plasmid DNA was 
resuspended in 200 µl of nuclease free water. 
Plasmid DNA concentration was determined by measuring the A260nm using a NanoDrop 
Spectrophotometer (NanoDrop Technologies, Inc.). For DNA concentration calculations, one 
Absorbance unit was considered as 50 µg/ml of double-stranded DNA. 
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Table 3.3. Plasmids used in this study. 
 
Plasmid Insert Origin  Reference 
pRS Retroviral empty vector 
Jesús Gil and  David 
H. Beach Lab. 
(London) 
- 
pRS-shMYC Short hairpin against human MYC 
Jesús Gil and David 
H. Beach Lab. 
(London) 
(Bernard, et al., 2003) 
pSR Retroviral empty vector 
Commercial 
(Oligoengine) - 
pSR-shSKP2 Short hairpin against human SKP2 
Ignacio Pérez-Roger 
Lab. (Moncada) (Andreu, et al., 2005) 
Lv141-CMV-
IRES-GFP 
Lentiviral empty vector  
Commercial 
(Genecopoeia) - 
Lv-CMV-MYCwt-
IRES-GFP 
Human MYC with FLAG epitope  at  
C-terminal domain 
Commercial 
(Genecopoeia) - 
psPAX2 
Gag-Pro-Pol elements for lentiviral 
particles production 
Commercial 
(Addgene) 
Didier Trono Lab. 
(Lausanne) 
pCMV-VSV-G 
VsVg envelope protein for lentiviral 
particles production 
Commercial 
(Addgene) 
Robert A. Weinberg Lab. 
(Cambridge, USA) 
pET-28a 
Empty vector for His6-recombinant 
proteins generation. 
Ignacio Arechaga Lab. 
(Santander) Commercial (Novagen) 
pGEX-KG-GST-
p27 
Human p27 with GST epitope  at  
N-terminal domain 
Oriol Bachs Lab. 
(Barcelona) (Taules, et al., 1999) 
pET28-His6-p27 
Human p27 with hexahistidine epitope  
at N-terminal domain (His6-p27) 
Javier Leon Lab. 
(Santander) This Thesis. 
pGL3-basic 
firefly reporter with no promoter region 
(empty vector) 
Commercial 
(Promega) - 
-1148-SKP2-Luc 
1148 pb of SKP2 promoter and firefly 
luciferase reporter 
Wen-Chun Hung Lab. 
(Taiwan, China) (Huang and Hung, 2006) 
pGL3-4XEBox-
Luc 
Synthetic promoter bearing 4 E-boxes 
and firefly luciferase reporter 
T. Berg Lab. 
(Martinsried) (Kiessling, et al., 2006) 
pGL3-
4XEBoxMut-Luc 
Synthetic promoter bearing 4 mutated  
E-boxes and firefly luciferase reporter 
T. Berg Lab. 
(Martinsried) (Kiessling, et al., 2006) 
pRL-TK 
Herpes simplex virus thymidine kinase 
promoter (HSV-TK)  and Renilla 
luciferase reporter  
Commercial Promega - 
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3.4.2. DNA subcloning 
For pET28-His6-p27 vector construction, the p27 insert from pGEXKG-p27 vector (Taules, 
et al., 1999) was subcloned into pET-28a vector (Novagen). For this purpose, pGEXKG-p27 and 
pET-28a vectors (1 µg of each) were both double digested with NdeI and XhoI restriction 
endonucleases in 1X buffer Orange (Fermentas) for 1 hour at 37ºC. Digested vectors were run in 
1% agarose gels and visualized with a UV-transilluminator. The linearized pET-28a vector and the 
p27 insert were excised from the agarose gel with a scalpel blade and purified with the Wizard SV 
Gel and PCR Clean-up System Kit (Promega) following the manufacturer’s instructions. Then, 
both fragments were ligated with the T4 DNA ligase (Invitrogen) overnight at 22ºC. The following 
day, ligation was transformed into E.coli DH5α cells (Invitrogen) as previously indicated (Section 
3.4.1), plated in LB-agar plates with kanamycin (50 mg/ml) and growth overnight at 37ºC.   
Next day, transformed bacterial colonies were selected and their plasmidic DNA purified. 
PCR screening with T7 promoter (5’-TAATACGACTCACTATAGGG-3’) and T7 terminator (5’-
GCTAGTTATTGCTCAGCGG-3’) primers was performed to identify whether transformants 
contained the p27 insert (Amplicon with p27 insert = 856 pb; amplicon without insert = 318 pb).  
The PCR was analyzed using agarose gel electrophoresis. Positive colonies for pET28-His6-p27 
were grown; plasmid was purified with the NucleoSpin plasmid Kit (Macherey-Nagel) and 
transformed by electroporation into E.coli C41 (DE3) strain (Miroux and Walker, 1996) to 
subsequent protein expression and purification.  
3.4.3. RNA extraction and purification 
Total mRNA extraction from cell cultures was carried out using the RNeasy® Kit (Qiagen) 
according to manufacturer’s instructions protocol. Briefly, samples (~106 cells per extraction) were 
directly lysed and homogenized by pipetting in the presence of a highly denaturing guanidine-
thiocyanate containing buffer (RLT) and then the RNA was selectively bound to a silica 
membrane contained within the RNeasy mini spin columns in presence of ethanol. After several 
washes with RWI and RPE washing buffers to eliminate contaminants, RNA was eluted in 50 µl 
RNase-free water. All steps were carried out in a micro-centrifuge at 10,000 rpm for 1-2 min at 
room temperature.   
On the other hand, total RNA extraction from CML samples was performed using Trizol 
reagent (Invitrogen). Approximately 5 x 106 bone marrow mononuclear cells were lysed directly 
with 1 ml of Trizol reagent for 5 min at room temperature. Then, 200 µl of chloroform was added 
to the homogenized sample, vortexed vigorously for 15 seconds and centrifuged at 12,000 rpm 
for 15 min at 4ºC. After centrifugation, upper aqueous phase containing total RNA was transferred 
carefully into a fresh tube, mixed with 500 µl of 100% isopropanol and incubated for 10 min at 
room temperature to precipitate RNA. To improve RNA precipitation, the samples were then 
centrifuged at 12,000 rpm for 20 min at 4ºC. The RNA pellet was washed once with 1 ml 75% 
ethanol and re-centrifuged at 7,500 rpm for 5 min at 4ºC.  Finally, RNA pellet was briefly allowed 
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to dry at room temperature to eliminate ethanol residues and resuspended in 50 µl of RNase-free 
water. RNA concentration was determined by measuring the A260nm using a NanoDrop 
spectrophotometer. 1 µl RNA sample was subjected to electrophoresis in 1% agarose gels to 
evaluate RNA integrity and the rest of RNA was stored at -70oC until use.  
3.4.4. Reverse Transcription and Polymerase Chain Reaction  
For gene mRNA expression analysis 2 µg of total RNA were retro-transcribed to cDNA 
using the iScript cDNA Synthesis Kit (Bio-Rad), including the iScript reverse transcriptase 
enzyme, RT buffer, oligo (dT) and random hexamers. The reaction mix (40 µl) was incubated as 
follows: 5 min at 25ºC, 30 min at 42ºC and 5 min at 85ºC. Complementary DNA (cDNA) was 
stored at -20ºC until used.  For Polymerase Chain Reaction (PCR) 2 µ l of cDNA were amplified 
using specific primers pairs for each gene to be analyzed (Table 3.4). Primers pairs were 
designed using the Primer 3 software tool (http://frodo.wi.mit.edu, 18-25 bp length; 40-65% GC 
content; Tm 55-65ºC). For conventional PCR, sample reaction was prepared containing 15 µl of 
2X Premix Taq™ (TaKaRa) [including TaKaRa Taq DNA polymerase, 400 nM dNTPs, and PCR 
buffer 2X (20 mM Tris-HCl pH8.3, 100 mM KCl and 3 mM MgCl2)], 300 nM of specific primers 
(forward and reverse primers), 2 µl of template cDNA and distilled water to a final volume of 30 µl. 
Reactions were run using a Thermal Cycler C1000 (Bio-Rad). 
 For quantitative PCR, sample reaction was prepared containing 15 µl of 2X SYBR® Green 
PCR Reaction Mix (Bio-Rad) (including antibody–mediated hot-star iTaq DNA polymerase, 
dNTPs, MgCl2, SYBR Green I dye, fluorescein and PCR buffer 2X), 300 nM of specific primers 
(forward and reverse), 2 µl of cDNA and distilled water to a final volume of 30 µl. The sample was 
divided into two aliquots and loaded on a 96 well plate for real-time PCR as duplicate (15 µl per 
well). Reactions were run using an iQ5 apparatus (Bio-Rad).  
The general PCR-amplification protocol was performed as follows:  
1) 3 min at 95ºC for cDNA denaturalization and hot-star DNA polymerase activation.  
2) 40 repeats including 3 steps for DNA amplification:  
                 -15 seconds at 95ºC (denaturation).  
                 -15 seconds at 55-60ºC (primer annealing) 
                 -15-30 seconds at 72ºC (primer extension) 
3) 10 min at 72 ºC (Full-extension of amplicons) 
 For real time PCR an additional step was added after PCR amplification to determine the 
amplicon melting curve and consisting of: 
4) 81 steps of 10 seconds each one, increasing 0.5ºC each step from 55ºC to 95ºC. 
 
Real-time PCRs were analyzed with the iQ5 Optical system 2.0 software and threshold 
cycles (Ct) were determined by default at the beginning of the exponential phase of PCR 
amplification. The relative mRNA expression was normalized to a housekeeping gene, such as 
Material and Methods  
63 
 
the ribosomal protein RPS14 for human samples or the β-actin for mouse samples, using the 
comparative Delta Ct (∆Ct) method according to the next expression:   
                       
                                 ∆Ct=2 (Ct RPS14 or β-actin – Ct gene of interest) 
 
 Reactions with distilled water instead of cDNA were used as negative controls to detect 
possible amplification from contaminating DNA or primer dimers. The identities of the PCR 
products were verified by agarose gel electrophoresis. Primers sequences and amplicon sizes 
used in RT-qPCR assays are shown in Table 3.4. 
 
Table 3.4. Primers pairs and amplicons size used for RT-PCR analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.5. Chromatin Immunoprecipitation (ChIP) 
ChIP assays were performed to analyse MYC occupancy along SKP2 promoter in K562 
cells untreated or treated with 1µM imatinib or 10 nM TPA for 12 h (to down-regulate endogenous 
MYC). For this end, K562 cells (~25 x 106 cells per ChIP) were washed once with PBS and cross-
Amplified gene Primers (5´-3´) Amplicon size 
Human B23 
5´-AATATGCACTGGCCCTGAAC-3´ 
5´-TTGTTGAAGCAGAGGCAATG-3´ 
158 bp 
Human MYC 
5´-AAGACTCCAGCGCCTTCTCTC-3´ 
5´-GTTTTCCAACTCCGGGATCTG-3´ 
527 bp 
Human SKP1 
5´-CCTGAAAGTTGACCAAGGAAC-3´ 
5´-GAAGGTCTTGCGAATCTCCTC-3´ 
142 bp 
Human RPS14 
5´-TCACCGCCCTACACATCAAACT-3´ 
5´-CTGCGAGTGCTGTCAGAGG-3´ 
157pb 
Human  SKP2 
5´-AGCCCGACAGTGAGAACATC-3´ 
5´-GAAGGGAGTCCCATGAAACA-3´ 
168 bp 
Mouse Cdk2 
5´-GTTGACGGGAGAAGTTGTGG-3´ 
5´-TCTTGAGGTCCTGGTGCAG-3´ 
194 bp 
Mouse cyclin E1 
5´-GCACAGGACTTCTTTGATCG-3´ 
5´-GCGCCATCTGTAACATAAGC-3´ 
155 bp 
Mouse cyclin E2 
5´-GCATTCTGACCTGGAACCAC-3´ 
5´-GGAAGCAATGAACAATGAGG-3´ 
193 bp 
Mouse β-actin 
5´-AGACTTCGAGCAGGAGATGG-3´ 
5´-AGTTTCATGGATGCCACAGG-3´ 
169 bp 
MYC-FLAG 
5´-GTCCGTCCAAGCAGAGGAG-3´ 
5´-TCGCTAGCCATAACCACTTTG-3´ 
162 bp 
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linked with PBS-1% formaldehyde at room temperature for 10 min with rocking. Then, 2 M 
Glycine was added to a final concentration of 125 mM and incubated for another 10 min to stop 
cross-linking. Fixed cells were washed twice with cold PBS-10 mM EDTA and resuspended in 
250 µl of ChIP lysis buffer [50 mM Tris-HCl pH8, 1% SDS (w/v), 1mM EDTA, supplemented 1:100 
with protease inhibitor cocktail Set I (Calbiochem)]. After this, cells were first roughly 
homogenized with a syringe by extensive passes (4-5 times) through a G27 needle and then 
sonicated 6 times for 20 seconds each using a Hielscher UP50H ultrasonic homogenizer 
(Hielscher Ultrasonics) at the maximum settings (100% amplitude and continuous cycle) in an ice-
water bath, leading to chromatin fragments between 250 and 1000 bp length. Afterwards, lysate 
was cleared of cell debris by centrifugation at 14,000 rpm for 10 min at 10º C and supernatant 
containing sheared chromatin was collected and diluted 10 fold with dilution buffer [20mM Tris-
HCl pH8, 150mM NaCl, 1% Triton X-100 (v/v), 1mM EDTA, supplemented with protease inhibitor 
cocktail Set I (Calbiochem)]. The diluted chromatin was divided in 2 aliquots (1ml per aliquot) and 
100 µl of remaining diluted chromatin were also reserved for input DNA.  
For chromatin immunoprecipitation, 1 µg of primary antibody anti-MYC (N262, sc-764) was 
added directly to one aliquot of diluted chromatin and 1 µg of control rabbit IgGs (as control for 
non-specific immunoprecipitation) was added to another one and both of them were incubated 
overnight at 4ºC with rotation.  
The following day, protein G bound to magnetic beads (Dynabeads®-protein G, Invitrogen) 
was used to collect immunocomplexes. Protein G has a very high affinity for the Fc region of 
immunoglobulins, allowing the specific capture of the protein-antibody complexes. For this 
purpose, Dynabeads-protein G were previously pre-equilibrated with dilution buffer to remove the 
storage buffer and blocked with salmon sperm DNA (Upstate) for 1hour at 4ºC with rotation. 
Equilibrated Dynabeads-protein G (25 µl per immunoprecipitation) were added to the samples 
and incubated for 2 hours at 4ºC with rotation to capture the chromatin-immunocomplexes. After 
this, Dynabeads-protein G-chromatin immunocomplexes were harvested using a magnet 
DynaMag™ (Invitrogen) and sequentially washed with 1 ml of low salt wash buffer [20 mM Tris-
HCl pH8, 150 mM NaCl, 1% Triton X-100 (v/v), 1mM EDTA], 1 ml of high salt wash buffer [20 mM 
Tris-HCl pH8, 500 mM NaCl, 1% Triton X-100 (v/v), 1mM EDTA], 1 ml of LiCl wash buffer [20 mM 
Tris-HCl pH8, 250 mM LiCl, 1% NP-40 (v/v), 0,1% Na-DOC (w/v), 1 mM EDTA] and 1 ml of TE 
buffer (10 mM Tris-HCl pH8, 1 mM EDTA). Between washes, the tube was separated from the 
magnet and beads were resuspended by gently pipetting in the respective new wash buffer. 
Finally protein-DNA complexes where separated from the magnetic beads-protein G with 100 µl 
of elution buffer [20 mM Tris-HCl pH8, 1% SDS (w/v), 150mM NaCl, 1 mM EDTA]. To reverse 
protein-DNA formaldehyde cross-linking, immunoprecipitated DNA and inputs were incubated at 
65ºC overnight.  
The next day, samples (Immunoprecipitated DNA and inputs) were treated with 1 µg 
proteinase K for 3 hours at 45ºC; the magnetic beads were removed using the magnet and DNA 
was purified with the Wizard SV PCR Clean-Up system (Promega) following the manufacturer 
instructions and using 100 µl of nuclease free water for elution.  
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Immunoprecipitated DNA was analyzed by quantitative real time-PCR using an iQ5 Real-
Time PCR Detection System (Bio-Rad) as previously described (Section 3.4.4). All qPCR were 
carried out in duplicate with 2 µl of immunoprecipitated DNA at the same annealing temperature 
(56ºC).  
Human SKP2 gene and promoter genomic DNA sequences (and annotated details) were 
obtained from UCSC genome browser database (http://genome.ucsc.edu) GRCh37/hg19 
assembly (February 2009). The primer pairs were designed with the Primer 3 software tool 
(http://frodo.wi.mit.edu/primer3/). Lactate dehydrogenase A (LDHA) E-box amplicon was used as 
positive control of MYC binding (Kim, et al., 2004). The sequences of primers pairs used in ChIP 
assays are listed in Table 3.4. The results are expressed as relative DNA fold enrichment with 
anti-MYC antibody with respect to the DNA enrichment with anti-rabbit IgG and normalized to the 
signal of the input chromatin for each amplicon. 
 
Table 3.4. Primers pairs and amplicon size used for ChIP analyses. The coordinates are referred to the SKP2 
or LDHA transcription initiation sites respectively (as in UCSC genome browser) and are indicated in brackets. 
 
 
Amplified gene Primers (5´→3´) Amplicon size 
LDHA 
(-85/+19) 
5´-TCCTGACTCAGGCTCATGGC-3´ 
5´-AGACAACCGACCGGCAGA-3´ 
103 bp 
SKP2-A 
(-2522/-2397) 
5´-CAGCAGGATGGAGAAACAAAG-3´ 
5´-AGATGATCCACCCACCTCAG-3´ 
126 bp 
SKP2-B 
(-988/-870) 
5´-CACGCTCCCTACTCTTACTGC-3´ 
5´-ATTTGGTTGCTTGCTGTCG-3´ 
119 bp 
SKP2-C 
(-784/-661) 
5´-AGACCTGTCAAGGCTGCAAG-3´ 
5´-ACGCACAACAGCTAAACACG-3´ 
124pb 
SKP2-D 
(-507/-366) 
5´-ACCACTCAGCAGCCAAGGAC-3´ 
5´-ATCGGACGGTGAGCCTAAG-3´ 
142 bp 
SKP2-E 
(-212/-81) 
5´-CATTTCCCAGTCAGCCGTAG-3´ 
5´-GCCCTTACTTCCTTCCCTTG-3´ 
132 bp 
SKP2-F 
(703/854) 
5´-TCCAGACCTGAGTAGCAACG-3´ 
5´-CCAGGTTTGAGAGCAGTTCC-3´ 
152 bp 
SKP2-G 
(14366/14505) 
5´-ATGTTGTTGAGGGCTTCCAG-3´ 
5´-CAACCGACCAGTCACATCC-3´ 
140 bp 
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3.5. LUCIFERASE REPORTER ASSAYS 
These assays were performed with the Dual-Luciferase Reporter (DLR) System (Promega) 
which uses the firefly luciferase as experimental reporter (pGL3 derived vectors) to evaluate the 
promoter activity and the renilla luciferase (provided by pRL derived vectors such as pRL-TK) as 
“control” reporter for experimental data normalization. In this manner, the variability caused by 
differences in transfection efficiency or cell viability is minimized. Both luciferases (firefly and 
renilla) use different substrates in their luminescent reaction allowing independent luminescence 
measurements. 
To evaluate the MYC ability to induce the SKP2 promoter, KMYCJ cells (4 x 106 cells) were 
transfected with 4 µg of the -1148-SKP2-Luc, containing 1148 pb of SKP2 promoter region cloned 
into the pGL3 vector (Huang and Hung, 2006) or the corresponding empty vector (pGL3 basic). 
Additionally, as positive control to evaluate the trans-activating capacity of MYC in KMYCJ cells 
after Zn2+ addition, KMYCJ cells were transfected with 4 µg of an artificial promoter bearing four 
E-box elements cloned into the pGL3 promoter vector (4xEbox-Luc) or the same artificial 
promoter bearing four mutated E-boxes (4xEboxMut-Luc) (Kiessling, et al., 2006). In addition, to 
monitorize the transfection efficiency, KMYCJ cells were also co-transfected with 400 ng of pRL-
TK reporter vector (Promega) containing the renilla luciferase as reporter. 12 hours after 
transfection, the KMYCJ cells were divided in four small plates and every plate was then treated 
with 75 µM ZnSO4 (to induce exogenous MYC) and/or 10 nM TPA (to down-regulate endogenous 
MYC) for another 24 hours. 
On the other hand, to analyze the SKP2 effect on MYC transactivation activity, K562 cells 
(3 x 106 cells) were transfected with 1.5 µg of pSR-shSKP2 to down-regulate SKP2 expression or 
the corresponding empty vector (pSuper-Retro), together with 1.5 µg of 4xEbox-Luc or the MYC-
unresponsive 4xEboxMut-Luc reporter constructs (Kiessling, et al., 2006) and 300 ng of pRL-TK 
renilla luciferase reporter vector (Promega). All transfections for luciferase assays were carried 
out by electroporation with an Amaxa nucleofector apparatus and Mirus Ingenio transfection 
reagent (Mirus Bio LLC) as previously described (Section 3.2.4.1). 
Luciferase activities were assessed 24 hours (for K562 cells) or 36 hours (for KMYCJ cells) 
after transfections with DLR assay System reagents (Promega) according to the manufacturer’s 
instructions. The luminescence signal was measured in a Turner TD-20/20 luminometer (Turner 
Designs).  
Briefly, the cells were washed once with PBS and centrifuged at 1,500 rpm for 5 min. Cell 
pellets were resuspended in 100 µl of 1X passive lysis buffer (PLB) and frozen at -80ºC to 
improve cell lysis. Then, the lysates were clarified by centrifugation at 10,000 rpm for 5 min and 
supernatants (10 µl) were directly used for bioluminescence reaction. To measure firefly 
luciferase, 50 µl of Luciferase Assay Reagent II (LAR II) containing the luciferin substrate of the 
firefly luciferase were mixed with 10 µl of supernatant in a luminometer tube and luminescence 
was immediately quantified. For renilla luciferase activity, 50 µl of the Stop & Glow reagent were 
added to the sample and luminescence was immediately quantified. The Stop & Glo reagent 
quenches firefly luminescence and provides the coelenterazine substrate for renilla luciferase.  
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Luminescence readings were taken in duplicate with a 3 seconds delay and 10 seconds 
acquisition time at room temperature. The firefly data were normalized to renilla luciferase values 
and results were expressed as relative luciferase light units (RLUs) of reporter constructs (-1148-
SKP2-Luc or 4xEbox-Luc) with respect to empty vectors (pGL3-basic or 4xEboxMut-Luc 
respectively).  
3.6. PROTEIN ANALYSIS 
3.6.1. SDS-PAGE and immunoblot  
For protein analysis by immunoblot, cells (~106 cells per immunoblot) were harvested by 
centrifugation at 1,500 rpm for 5 min; washed once with 1ml of cold PBS; resuspended in 100 µl 
of NP40 lysis buffer [50 mM Tris-HCl pH8, 1 % NP40 (v/v), 150 mM NaCl, 1 mM EDTA, 10 mM 
NaF, supplemented with protease inhibitor cocktail Set I (1:100; Calbiochem)] and incubated on 
ice for 30 min. For CML samples lysis, 0.5% SDS (w/v) was added to the NP40 lysis buffer and 
cell lysate was additionally sonicated for 15 seconds using a Hielscher UP50H ultrasonic 
homogenizer at the maximum settings (100% amplitude and continuous cycle) in an ice-water 
bat. The protein lysate was then clarified by centrifugation at 14,000 rpm for 20 min at 4ºC and 
supernatant containing soluble proteins was stored at -80ºC until used. Protein concentration was 
determined using the colorimetric Bio-Rad protein assay (Bio-Rad) based on the Bradford method 
(Bradford, 1976) and by measuring the A595nm in a micro-plate reader spectrophotometer Bio-Tek 
EL340 (Bio-tek Instruments, Inc. Vermont, USA). The protein concentration of unknown sample 
was estimated from a standard curve performed with known concentrations of BSA (Bovine 
Serum Albumin) by extrapolating the A595nm readings.  
Protein samples (40-60 µg of protein lysate) were mixed with 1/5 volume of 5X SDS-PAGE 
loading buffer [100 mM Tris-HCl pH6.8, 5% β-mercaptoethanol (v/v), 5% SDS (w/v), 0.1% 
bromophenol blue (w/v), 50% glycerol (v/v)] and samples were heated at 95º C for 5 min. Then, 
the protein samples were fractionated according to their molecular weight (MW) by Sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The percentage of acrylamide 
acrylamide/bis-acrylamide solution (Bio-Rad) used in the gel was dependent on the molecular 
weight (MW) of the protein to be analyzed, ranging from 8 to 15%. Electrophoresis was carried 
out in a Mini Protean III cuvette powered by a basic PowerPAC supply (Bio-Rad) at 100-150 V for 
2-3 hours, using electrophoresis running buffer [25 mM Trizma pH8.3, 192 mM glycine and 0.1% 
SDS (w/v)]. Prestained SDS-PAGE standards (Bio-Rad) were used to evaluate protein migration 
and separation during gel electrophoresis. 
Proteins were transferred from acrylamide gel to a nitrocellulose membrane (Schleicher & 
Schuell) in a Mini-Trans Blot cell (Bio-Rad) at 300-350 mA for 2 h at 4ºC, using transfer buffer [25 
mM Tris pH8.3, 192 mM glycine and 10-20% methanol (v/v)]. The membrane containing the 
proteins was then incubated for 30 min with 10 ml of TBS-T [20 mM Tris-HCl pH7.5, 150 mM 
NaCl and 0.05 % Tween 20 (v/v)] supplemented with 5% non-fat dry milk (w/v) or with 5% BSA 
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(w/v) (for phospho-specific antibodies). After blocking, the membrane was briefly washed twice 
with 10 ml TBS-T buffer and incubated overnight at 4ºC or for 2-3 hours at room temperature with 
primary antibody diluted in TBS-T solution as indicated in Table 3.5 and supplemented with 1% 
BSA (w/v). 
After primary antibody incubation, the membrane was washed 3 times for 10 min each one 
with TBS-T solution and incubated for another 45 min with a secondary antibody conjugated to 
IRDye680 or IRDye800 fluorochromes  (Li-Cor Biosciences) diluted  1:10000 in TBS-T 1% BSA 
(w/v). Finally, the membrane was washed 3 times for 10 min with TBS-T and signals were 
visualized and recorded with an Odyssey Infrared Imaging Scanner (Li-COR, Biosciences). In 
some cases, membranes were incubated with secondary antibodies conjugated to horseradish 
peroxidase (HRP) and the protein was detected by chemiluminescence using ECL detection 
reagents system (GE healthcare) and followed by exposition to X-ray films (Konica-Minolta). 
Excluding overnight primary antibody incubation at 4ºC, all washes and membrane incubations 
steps were performed under agitation on a shaker platform at room temperature.   
For protein loading control, the membranes were incubated with anti-Actin or anti-α-tubulin 
primary antibodies. In addition, the poly-acrylamide gels were stained with Coomassie Brilliant 
Blue solution [0.025% Coomassie Brilliant Blue R-250 (w/v), 40% methanol (v/v) and 10% glacial 
acetic acid (v/v)] for 10 min at room temperature and distained overnight with distilled water. 
Immunoblot quantification and densitometry analysis was carried out using the ImageJ software. 
The antibodies used for immunoblot analysis are shown in Table 3.5. 
3.6.2. Immunoprecipitation and kinase assays 
For immunoprecipitation, cells (~107 cells per immunoprecipitation) were harvested at 1,500 
rpm for 5 min; washed once with 1 ml PBS; resuspended in non-denaturing lysis buffer [50 mM 
Tris-HCl pH7.5, 150 mM NaCl, 0.5 % NP40 (v/v), 1 mM EDTA, supplemented (1:100) with 
protease inhibitor cocktail Set I (Calbiochem)] and incubated on ice for 30 min. The cell lysate 
was then clarified by centrifugation at 14,000 rpm for 20 min. Protein concentration of the 
supernatant was determined by the Bio-Rad protein assay (Bio-Rad). 500 µg of total protein 
extract were mixed with 1 µg of the appropriate antibody and incubated overnight at 4ºC with 
rotation. The next day, Dynabeads®-protein G (Invitrogen) were used to capture the protein-
antibody immunocomplexes. Dynabeads-protein G (25 µl per immunoprecipitation) were pre-
equilibrated with non-denaturing lysis buffer to remove the storage buffer; added to antibody-
protein extract mixture and incubated for 2 hours at 4ºC with rotation. Finally, Dynabeads-protein 
G-immunocomplexes were collected by using a magnet DynaMag™ (Invitrogen), washed four 
times with 1 ml of non-denaturing lysis buffer and resuspended in 30 µl 1X SDS-PAGE loading 
buffer [20 mM Tris-HCl pH6.8, 1% β-mercaptoethanol (v/v), 1% SDS (w/v), 0.02% bromophenol 
blue (w/v), 10% glycerol (v/v)]. Immunocomplexes were heated at 95ºC for 5 min and subjected to 
SDS-PAGE and immunoblot analysis as previously described (Section 3.6.1). 
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Table 3.5. Primary antibodies used in this work. It is indicated the technique (Tech.) in which they have been 
used:  Immunoblot (IB), immunofluorescence (IF), immunoprecipitation (IP) or chromatin immunoprecipitation (ChIP) and 
the use dilution.  
 
Antibody Immunogen 
Specie  
& type 
Tech. & Use 
dilution 
Reference 
Anti-p27 (C-19) C-terminus of the human p27 Rabbit 
polyclonal 
IB→1:1000 
IF→1:100 
IP→2µg 
Santa Cruz Biotech. 
(sc-528) 
Anti-p27 (BD) Full-length of mouse p27 Mouse 
monoclonal 
IB→1:1000 
BD Transduction 
Laboratories. 
(K-25020) 
Anti-p-p27 (Thr-187) 
Threonine187-phosphorylated 
p27 peptide derived from the 
C-terminus of the human p27 
Rabbit 
polyclonal 
IB→1:500 
Invitrogen 
(71-7700) 
Anti-MYC (N262) Full-length of human MYC Rabbit 
polyclonal 
IB→1:1000 
ChIP→2µg 
Santa Cruz Biotech. 
(sc-764) 
Anti-Actin (I-19) C-terminus of the human actin Goat 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-1616) 
Anti-SKP2 p45 (H-435) Full-length of human SKP2 Rabbit 
polyclonal 
IB→1:1000 
IF→1:100 
Santa Cruz Biotech. 
(sc-7164) 
Anti-SKP1 p19 (H-163) Full-length of human SKP1 Rabbit 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-7163) 
Anti-CUL1 (H-213) N-terminus (57-269 aa) of the 
human CUL1 
Rabbit 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-11384) 
Anti-CKS1 (FL-79) Full-length of human CKS1 Rabbit 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-6238) 
Anti-p53 (FL-393) Full-length of human p53 Rabbit 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-6243) 
Anti-p21CIP1 
Amino acids 1-150 of human 
p21CIP1 
Mouse 
monoclonal 
IB→1:1000 
BD transduction 
laboratories. 
(C-24420) 
Anti-CDK2 (M2) C-terminus of the human 
CDK2 
Rabbit 
polyclonal 
IB→1:1000 
IP→2µg 
Santa Cruz Biotech. 
(sc-163) 
Anti-CDK1 (Cdc2 p34 
19) 
Central region (224-230 aa) of 
human CDK1 
Mouse 
monoclonal 
IB→1:500 
IP→2µg 
Santa Cruz Biotech. 
(sc-54) 
Anti-Cyclin A (H-432) Full-length of human cyclin A2 Rabbit 
polyclonal 
IB→1:1000 
IP→2µg 
Santa Cruz Biotech. 
(sc-751) 
Anti-Cyclin E (HE12) Full-length of human cyclin E1 Mouse 
monoclonal 
IB→1:500 
Santa Cruz Biotech. 
(sc-247) 
Anti-His tag (H-15) Hexahistidine (His6) tag 
Rabbit 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-803) 
Anti-α-Tubulin (H-300) Amino acids 149-448 of 
human α-tubulin 
Rabbit 
polyclonal 
IB→1:1000 
Santa Cruz Biotech. 
(sc-5546) 
Anti-γ-Hemoglobin 
(51-7) 
Full-length of human γ-
Hemoglobin 
Mouse 
monoclonal 
IB→1:500 
Santa Cruz Biotech. 
(sc-21756) 
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Alternatively, after washing with non-denaturing lysis buffer, Dynabeads-protein G-
immunocomplexes were additionally washed twice with 1ml of kinase buffer [50 mM Hepes-NaOH 
pH7.2, 150 mM NaCl, 10 mM MgCl2, 2.5 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol (DTT), 10% 
glycerol (v/v), 10 mM β-glycerophosphate and 10 mM NaF] and resuspended in 40 µl of kinase 
buffer supplemented with 50 µM ATP. 1 µg of recombinant His6-p27 purified from bacteria (see 
Section 3.6.5) per immunoprecipitation was used as substrate for kinase assay. The kinase 
reaction was incubated for 30 min at 30ºC and stopped by addition of 10 µl 5X SDS-PAGE 
loading buffer to the reaction mixture. Samples were then heated at 95ºC for 5 min and subjected 
to SDS-PAGE and immunoblot analysis with anti-p-p27(Thr187) (rabbit polyclonal, Invitrogen) first 
and with anti-p27 (mouse monoclonal, BD Transduction Labs.) later. Immunoblots were scanned 
in different channels (680 and 700 nm) in an Odyssey scanner. Relative kinase activity was 
determined by densitometry analysis using the image J software and represented as the 
percentage of p27p-Thr187 signal with respect to total p27 signal. 
3.6.3. Gel filtration chromatography of total protein extracts 
To analyze p27 complexes in Kp27MER cells we used gel filtration chromatography of total 
protein extracts followed by immunoblot analysis of chromatography fractions. For gel filtration 
chromatography, cells (~107 cells per chromatography) were harvested at 1,500 rpm for 5 min; 
washed once with 1ml PBS; resuspended in 200-300 µl of non-denaturing chromatography lysis 
buffer [50 mM Hepes-NaOH pH7.2, 150 mM NaCl, 0.5% Triton X-100 (v/v), 10% glycerol (v/v), 1 
mM EDTA, 2,5 mM EGTA, 1 mM DTT, 1 mM PMSF, supplemented (1:100) with protease inhibitor 
cocktail (Calbiochem)] and incubated on ice for 30 min. Then, the cell lysate was clarified by 
centrifugation at 14,000 rpm for 20 min and protein concentration was determined by the Bradford 
method using the Bio-Rad protein assay (Bio-Rad). Protein concentration was adjusted to 10 
mg/ml with non-denaturing chromatography lysis buffer. 
2 mg of total protein extract (~200 µl) were directly applied onto a Superdex 200 10/300 GL 
column (GE Healthcare) pre-equilibrated with chromatography buffer [50 mM Hepes-NaOH 
pH7.2, 150 mM NaCl, 0.05% Triton X-100 (v/v), 1 mM EDTA, 2,5 mM EGTA, 1 mM DTT, 10% 
glycerol (v/v) and 1 mM PMSF] and subjected to fast-performance liquid chromatography in an 
ÄKTA purifier apparatus (GE Healthcare) with a flow rate of 0.4 ml/min at 4°C. The protein 
complexes eluting from the column with different volume retentions according to their native 
molecular size were fractionated in 500 µl fractions. 40 µl of each collected fraction were mixed 
with 10 µl of 5X SDS-PAGE loading buffer and subjected to SDS-PAGE and immunoblot as 
previously indicated. Ferritin (443 kDa), catalase (232 kDa), BSA (67 kDa), ovalbumin (45 kDa) 
and chymotrypsin (25kDa) were used as molecular mass standards for gel filtration. 
3.6.4. Immunofluorescence analysis and fluorescence microscopy 
For immunofluorescence assays, approximately 5 x 104 Kp27MER cells (treated for 24 h 
with ZnSO4 and/or 4HT) were spun onto slides at 600 rpm for 3 min by using a cytocentrifuge. 
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Cells were then fixed for 15 min with PBS-3.7% paraformaldehyde (w/v), washed once for 5 min 
with PBS-100 mM glycine and permeabilized with PBS-0.5% Triton X-100 (v/v)-1% BSA (w/v)  for 
another 30 min at room temperature. Fixed and permeabilized cells were incubated overnight at 
4°C in a wet chamber with 50 µl of primary antibodies [rabbit polyclonal anti-SKP2 (sc-7164) and 
mouse monoclonal anti-p27 antibody (BD Transduction Labs.)] diluted 1:100 in PBS-0.05% 
Tween 20 (v/v).  
The next day, cells were washed 3 times with PBS-1% BSA (w/v) and incubated for an 
additional hour with 50 µl of 1:100 diluted fluorescent secondary antibodies [rhodamine 
conjugated anti-mouse or fluorescein isothiocyanate (FITC) conjugated anti-rabbit (Jackson 
ImmunoResearch Laboratories)] in a wet dark chamber at room temperature. Finally, the slides 
were washed again with PBS-1% BSA for 3 times and mounted with anti-fading Vectashield 
mounting medium (Vector Laboratories) with 4’,6’-diamidino-2-phenylindole dihydrochloride 
(DAPI) to stain nuclei. Cells were covered with a coverslip and sealed with nail polish. 
The immunostained cell samples were examined using a Zeiss Axio Imager M1 up-right 
microscope equipped with 20X and 40X Plan-Apochromat objectives, an HBO mercury lamp and 
different fluorescent filter Sets for DAPI, FITC and Rhodamine fluorescent dyes (Set 49 for 
DAPI/UV; Set 38 HE for FITC and set 43 for Rhodamine). 20X or 40X images were captured 
using an AxioCam MRm digital CCD camera and edited with the Zeiss Axio Vision 4.7 software. 
3.6.5. Expression and purification of His6-p27 protein from E. coli cells 
For His6-p27 protein purification, E. coli C41 bacteria carrying the pET28-His6-p27 vector 
were grown in 1 liter of LB medium supplemented with 50 µg/ml kanamycin at 37ºC and 160 rpm 
in an orbital shaking incubator. When the culture reached mid-log phase (A600nm=~0.8), protein 
expression was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and cells were 
allowed to grow for another 4 hours following induction. The cells were then harvested by 
centrifugation at 6,000 rpm for 20 min at 4 °C using an Avanti J-30I centrifuge (Beckman-Coulter), 
washed once with ice-cold PBS and cell pellet was frozen in dry ice and stored at -70ºC until cell 
lysis.  
For cell lysis, the bacterial cell pellet was resuspended in 20 ml Lysis buffer [50 mM Hepes-
NaOH pH7.2, 100 mM NaCl, 0.5 % Triton X-100 (v/v), 0.2 mg/ml lysozime, 5 mM benzamidine, 1 
µg/ml pepstatin, 1mM PMSF and protease inhibitor cocktail (Sigma-Aldrich)], incubated on ice for 
20 min and then sonicated with a Hielscher UP50H ultrasonic homogenizer at maximum settings 
(100% amplitude and constant cycle) in an ice-water bath. The cell lysate was cleared of cell 
debris by centrifugation at 40,000 g for 30 min at 4°C using an Optima XL-100K ultracentrifuge 
(Beckman-Coulter) equipped with a 50Ti rotor.  
The His6-p27 protein was then purified from the soluble protein extract using Nickel affinity 
chromatography at room temperature. The cleared lysate was loaded in a Protino® Ni2+-TED 
2000 Packed Column (Macherey-Nagel), pre-equilibrated with Ni2+-whasing buffer (Ni-W) [50 mM 
Hepes-NaOH pH7.2, 100 mM NaCl, 0.05 % Triton X-100 (v/v)], and the column was washed three 
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times with 10 ml of the same buffer (Ni-W). After washing the bound protein was eluted with 8 ml 
of Ni-elution buffer (Ni-E) [50 mM Hepes-NaOH pH7.2, 100 mM NaCl, 5 mM benzamidine, 1 mM 
PMSF, containing an imidazole-gradient (10-250 mM imidazole)] and collected in 8 fractions of 
1ml each one (Figure 3.1A). The fractions containing the majority of the protein (160-250 mM 
imidazole) were pooled and diluted with 5 volumes of elution buffer without imidazole and then the 
protein solution was concentrated using an Amicon Ultra 10K ultrafiltration device (Amicon®, 
Millipore) to a final volume of 500 µl following the manufacturer’s instructions (1hour at 4,000 rpm 
in a swinging-bucket rotor).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Purification process of His6-p27 protein. A) Nickel affinity purification. B) Gel filtration purification.  
V0 = Void Volume (the elution volume of non-retained proteins that are excluded from the gel filtration). C) SDS-PAGE of 
protein containing fractions. Similar results were achieved for the GST-p27 protein. 
  
Finally, the concentrated protein (500 µl) was loaded on a Superdex 200 10/300 GL column 
(GE Healthcare, Piscataway, NJ) equilibrated with chromatography buffer [50 mM Hepes-NaOH 
pH7.2, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF and 10 % glycerol (v/v)] and 
subjected to Size exclusion chromatography (Figure 3.1B) using an ÄKTA purifier apparatus (GE 
A 
B 
C 
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Healthcare). The fractions containing the His6-p27 protein were pooled, supplemented up to 20% 
glycerol (v/v) and stored at -70°C until use. Protein concentration was determined using the Bio-
Rad Protein-Assay (Bio-Rad) as previously described. Every purification step was evaluated by 
SDS-PAGE to assess the purification process as shown in figure 3.1A and C.  
3.6.6. Expression and purification of GST-p27 protein from E. coli cells 
For GST-p27 protein purification, E. coli C41 bacteria containing the pGEXKG-p27 vector 
(Taules, et al., 1999) were grown in 1 liter of LB medium supplemented with 100 µg/ml ampicillin 
at 37ºC and 160 rpm in an orbital shaking incubator. When the culture reached mid-log phase 
(A600nm=~0.8), GST-p27 protein expression was induced with 1 mM IPTG and cells were allowed 
to grow for another 4 hours. The cells were then harvested by centrifugation at 6,000 rpm for 20 
min at 4 °C using an Avanti J-30I centrifuge (Beckman-Coulter), washed once with ice-cold PBS 
and cell pellet was frozen in dry-ice and stored at -70ºC until cell lysis.  
For cell lysis, the cell pellet was resuspended in 20 ml GST Lysis buffer [50 mM Tris-HCl 
pH8, 100 mM NaCl, 0.5 % Triton X-100 (v/v), 0.2 mg/ml lysozime, 5 mM benzamidine, 1µg/ml 
pepstatin, 1mM PMSF and protease inhibitor cocktail (Sigma-Aldrich)], incubated on ice for 20 
min and then sonicated with a Hielscher UP50H ultrasonic homogenizer at maximum settings 
(100% amplitude and constant cycle) in an ice-water bath. The cell lysate was cleared of cell 
debris by centrifugation at 40,000 g for 30 min at 4 °C using an Optima XL-100K ultracentrifuge 
(Beckman-Coulter) equipped with a 50Ti rotor.  
The fusion GST-p27 protein was then purified from the soluble protein extract by 
glutathione-affinity chromatography. For this purpose, the cleared lysate was incubated at 4ºC for 
1 hour with 1 ml of pre-equilibrated Glutathione Sepharose 4B resin (GE Healthcare) with rotation. 
The loaded resin was then packed by gravity force into a Poly-Prep chromatography column (Bio-
Rad) and washed three times with 10 ml of GST-washing buffer [50 mM Tris-HCl pH8, 100 mM 
NaCl, 0.05 % Triton X-100 (v/v)]. After washing step the bound protein was eluted from the 
column with 8 ml of GST elution buffer (50 mM Tris-HCl pH8, 100 mM NaCl, 20 mM reduced 
glutathione, 5 mM DTT and 1 mM PMSF) and collected in 8 fractions of 1ml each one. The 
fractions containing the majority of the protein were pooled and then the protein solution was 
concentrated using an Amicon Ultra 30K ultrafiltration device (Amicon®, Millipore) to a final 
volume of 500 µl following the manufacturer’s instructions (1hour at 4,000 rpm in a swinging-
bucket rotor).  
Finally, the concentrated protein (500 µl) was loaded on a Superdex 200 10/300 GL column 
pre-equilibrated with chromatography buffer and subjected to Size exclusion chromatography 
using an ÄKTA purifier apparatus (GE Healthcare) in the same conditions as for His6-p27 
purification. The peak fractions containing the GST-p27 protein were pooled; glycerol was added 
to 20% (v/v) final concentration and stored at -70°C until use. Protein concentration was 
determined using the Bio-Rad Protein-Assay (Bio-Rad).  
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4. RESULTS 
4.1. THE MYC-SKP2 INTERACTION 
4.1.1. Induction of MYC is associated to induction of SKP2 
We set out to determine the molecular mechanism of p27 down-modulation induced by 
MYC in the Kp27MER model. In this model, the exogenous p27 expression is induced by 
activating the metallothionein promoter with zinc (Zn2+). Therefore the model is mainly suited to 
study the MYC effect on p27 levels by posttranscriptional mechanisms. It had been described that 
MYC could stimulate proteasome-mediated degradation of p27 through the induction of CUL1 
(O'Hagan, et al., 2000) and CKS1 (Keller, et al., 2007), both components of the SCFSKP2 complex 
which targeted p27 for degradation by the ubiquitin-proteasome system. Thus, we decided to 
analyze CUL1 and CKS1 protein expression by immunoblot in Kp27MER cells treated for 24 
hours with 50 µM ZnSO4 and/or 200 nM 4HT. As shown in figure 4.1, we did not found significant 
changes in CUL1 or CKS1 protein expression 24 hours after MYCER activation in presence of 
p27. Therefore, none of the mechanisms reported to date could explain the p27 downregulation 
induced by MYCER activation in the Kp27MER model.  
 
 
 
 
 
 
 
 
 
Previous studies of large-scale gene expression analysis with microarray-based gene 
profiling in Kp27MER cells showed that MYC blocked the up-regulation of several transcription 
factors with a pivotal role in erythropoiesis, such as NFE2, JUNB, and GATA1, induced in 
presence of high levels of p27 (Acosta, et al., 2008). A subsequent analysis of the microarray data 
revealed that one of the genes up-regulated by MYC in proliferative arrest conditions was SKP2. 
SKP2 encodes for the F-box component of the SCFSKP2 ubiquitin ligase complex which, together 
with CUL1 and CKS1, mediated p27 degradation by the proteasome system (see “Introduction”, 
section 1.2.4.2.). Therefore, SKP2 appeared to be a good candidate to explain the p27 down-
modulation induced by MYC in Kp27MER cells. Nevertheless, no functional interaction between 
MYC and SKP2 had been previously reported although they shared the expression pattern during 
cell cycle. Both proteins showed low expression at G1-phase and were up-regulated when 
entered in S-phase. To rule out the possibility that SKP2 up-regulation could be due to cell cycle 
progression induced by MYC, we decided to study anew SKP2 mRNA, but also protein 
Figure 4.1. MYC has no effect on CUL1 and 
CKS1 protein expression in Kp27MER cell line.  
Kp27MER cells were treated for 24 h with 50 µM 
ZnSO4 and/or 200 nM 4HT and then subjected to 
immunoblot analysis against CUL1, SKP1, CKS1 and 
actin (loading control) as indicated.  
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expression in response to MYC in Kp27MER cells in proliferative arrest conditions. To evaluate 
the proliferative arrest we determined the growth curves during 3 days by counting viable cells. 
SKP2 expression was analyzed by RT-qPCR and immunoblot. As shown in figure 4.2, induction 
of high levels of p27 with 75 µM of ZnSO4 resulted in rapid growth arrest of Kp27MER cells 
(Figure 4.2A) and it was accompanied of SKP2 mRNA down-regulation (Figure 4.3B), as 
predicted. Interestingly, MYC activation (by 4HT treatment) in presence of p27, resulted in a two-
fold increase in SKP2 mRNA expression but did not modify the growth arrest mediated by p27, 
confirming previous results (Figure 4.2B, black bar). Nonetheless, the activation of MYC alone in 
Kp27MER cells resulted in a modest SKP2 mRNA up-regulation. It should be noted that 
Kp27MER cells already express high levels of endogenous MYC. In contrast to MYCER-
expressing cells, 4HT did not modify SKP2 expression in Kp27-5 cells (used here as negative 
control), in which p27 is induced by Zn2+ but do not carry the MYCER allele (Figure 4.2B). This 
result was also observed at the protein level. MYC activation resulted in a robust up-regulation of 
SKP2 protein 24 and 48 hours post-induction, as detected by immunoblot (Figure 4.2C, compare 
lanes 1 vs. 2; 3 vs. 4). The immunoblot also showed down-regulation of endogenous MYC 
subsequent to ectopic MYCER activation. This well-known effect of ectopic MYC overexpression 
(Grignani, et al., 1990; Penn, et al., 1990) confirmed MYCER activation by 4HT. These results 
suggested that MYC was playing a direct role in SKP2 up-regulation in Kp27MER cells 
independently of the proliferative state of the cells, suggesting that SKP2 up-regulation was not a 
consequence of MYC-induced proliferation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm that the effect on SKP2 up-regulation was independent of cell proliferation 
induced by MYC, we decided to study the MYC-SKP2 relationship in other cell models in which 
ectopic MYC expression could be also activated or induced in proliferative arrest conditions.  
Figure 4.2. SKP2 induction by MYC in Kp27MER cells growth-arrested by p27. A) The Kp27MER cell model 
is summarized at the top. Proliferation rates of Kp27MER cells treated with 200 nM 4HT and/or 75 µM ZnSO4 were 
measured by counting viable cells in an hemocytometer over 3 days (bottom panel). B) SKP2 mRNA expression in 
Kp27MER and parental Kp27-5 cells. The cells were treated for 12 h with 200 nM 4HT and 50 µM ZnSO4, and mRNA 
expression was determined by RT-qPCR. C) Immunoblot showing SKP2 up-regulation in response to MYCER in 
Kp27MER cells treated for 24 and 48 hours with 200 nM 4HT and 50 µM ZnSO4 as indicated. Immunoblot also shows 
endogenous MYC down-modulation after MYCER activation with 4HT. 
A B C 
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The K562 cell line derived from a chronic myeloid leukemia (CML) patient in blast crisis 
(Lozzio and Lozzio, 1975) and these cells express the BCR-ABL tyrosine kinase fusion protein. 
Our group had previously described that K562 cells treated with low concentrations of imatinib (1 
µM), a selective BCR-ABL inhibitor, underwent a rapid MYC down-regulation and a reversible 
proliferative arrest (Gomez-Casares, et al., 2004). Thus, we decided to treat KMER4 cells, 
another K562 derived cell line carrying only the activatable MYCER protein (Albajar, et al., 2011), 
with 1 µM imatinib and to test the MYC effect on SKP2 expression. As shown in figure 4.3, 
imatinib treatment led to down-regulation of endogenous MYC protein, as detected by immunoblot 
(Figure 4.3C) and resulted in a proliferative arrest of KMER4 cells (Figure 4.3A) as anticipated. In 
addition, this treatment also led to SKP2 mRNA and protein down-regulation (Figure 4.3B and C 
respectively). However, MYC activation with 4HT in presence of imatinib did not rescue the 
proliferation arrest mediated by this drug (Figure 4.3A) but resulted again in a two-fold induction of 
SKP2 mRNA (Figure 4.3B) and protein (Figure 4.3C, compare lanes 1 vs. 2; 3 vs. 4). It is 
interesting to mention that, although BCR-ABL was previously reported to induce SKP2 
expression (Andreu, et al., 2005; Chen, et al., 2009), ectopic MYC up-regulated SKP2 in arrested 
cells with inhibited BCR-ABL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a second model, we used a different MYC-inducible K562 cell line (KMYCJ cells) 
(Delgado, et al., 1995) in presence of 12-0-tetradecanoylphorbol-13-acetate (TPA). The KMYCJ 
cell line bears a ZnSO4-inducible MYC allele controlled by the metallothionein promoter (Grignani, 
et al., 1990), the same as for p27 in Kp27MER cells. On the other hand, just like imatinib, the 
phorbol ester TPA also inhibited proliferation of K562 cells (Lerga, et al., 1999) and this was 
accompanied by MYC downregulation (Delgado, et al., 1995). However, unlike the reversibility of 
imatinib effect, a just 30 min treatment with 10 nM TPA produced an irreversible proliferative 
arrest of K562 cells (Lerga, et al., 1999). 
Figure 4.3. SKP2 induction by MYC in KMER4 cells growth-arrested with imatinib. A) The KMER4 cell 
model is summarized at the top. Proliferation rates of KMER cells treated with 1µM imatinib and 200 nM 4HT over 3 
days (bottom panel). B) KMER4 cells were treated with 1µM imatinib and 200 nM 4HT (24 h), and SKP2 mRNA 
levels were determined by RT-qPCR. C) KMER4 cells were treated with imatinib and 4HT as indicated, and the 
levels of SKP2, MYC, MYCER, and actin (loading control) in total cell lysates were assayed by immunoblot. 
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As anticipated, treatment of KMYCJ cells with 10 nM TPA resulted in growth arrest (Figure 
4.4A) and a patent MYC down-regulation (Figure 4.4C). In addition, TPA also induced a marked 
down-regulation of SKP2 at mRNA (Figure 4.4B) and protein (Figure 4.4C) levels. However, MYC 
induction with 75 µM of ZnSO4 in KMYCJ cells pre-treated for 12 h with 10 nM TPA (when the 
cells contained very low endogenous MYC levels) resulted in a notable increase in SKP2 mRNA, 
as assessed by RT-qPCR (Figure 4.4D), and protein, as determined in immunoblot (Figure 4.4E). 
It should be noted again that MYC induction did not rescue cells from TPA-induced growth arrest 
(Figure 4.4A), confirming previous results (Lerga, et al., 1999). The results were similar when we 
used a different MYC-inducible K562 clonal cell line (KMYCB) (not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, we assayed SKP2 induction by MYC in the KMYCBp53 cell line (Ceballos, et al., 
2000). This cell line had been previously developed in our laboratory to study the functional 
interaction between MYC and p53. KMYCBp53 cells carried a Zn2+-inducible MYC transgene 
similar to KMYCJ cells. In addition, these cells also carried a constitutively expressed p53Val35 
mutant which adopted an active conformation at 32ºC but not at normal cell culture conditions of 
37ºC. As shown in figure 4.5, p53 activation at 32ºC resulted in an irreversible proliferative arrest 
(Figure 4.5A), as expected. This was accompanied of endogenous MYC down-regulation as 
shown by immunoblot (Figure 4.5C). p53 activation also resulted in a down-modulation of SKP2 
mRNA and protein (Figure 4.5B and C respectively). Once again, MYC induction with Zn2+ did not 
Figure 4.4. SKP2 induction by MYC in KMYCJ cells growth-arrested with TPA. A) The KMYCJ cell model is 
summarized at the top. Proliferation rates of KMYCJ cells treated with 10nM TPA and/or 75 µM ZnSO4 were 
measured by counting viable cells in an hemocytometer over 3 days (bottom panel). B) KMYCJ cells were treated 
with 10 nM TPA for the indicated times and SKP2 mRNA levels were determined by RT-qPCR. C) KMYCJ cells were 
treated as in B, and expression of SKP2, endogenous MYC, and actin (loading control) were assayed by immunoblot. 
D) KMYCJ cells were pre-treated with 10 nM TPA for 12 h and then induced with 75 µM ZnSO4 as indicated. SKP2 
mRNA levels were determined by RT-qPCR. E) KMYCJ cells were pre-treated as in D, and expression of SKP2, 
exogenous MYC (induced by 75 µM ZnSO4), and actin (loading control) were assayed by immunoblot. 
A 
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antagonize the p53-mediated proliferative arrest (Figure 4.5A), but it provoked a concomitant 
increase of SKP2 mRNA (Figure 4.5B) and protein (Figure 4.5C). As control of p53 activation, we 
assayed the p21 expression by immunoblot (Figure 4.5C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, in the four models tested, the methods used to inhibit proliferation (p27 
induction, imatinib or TPA treatment and p53 activation) promoted the down-regulation of 
endogenous MYC and SKP2 expression. However, the induction or activation of MYC in these 
proliferative arrest conditions promoted the up-regulation of SKP2 at mRNA and protein levels. 
Therefore, we concluded that the induction of SKP2 in the four models studied was independent 
of the MYC effect on cell proliferation. 
4.1.2. SKP2 is down-regulated in response to MYC silencing or repression 
The above results strongly suggested that SKP2 could be a MYC target gene as it was 
induced by MYC in proliferative arrest conditions. To confirm this possibility, next we asked 
whether SKP2 was down-regulated in response to MYC down-modulation. For this purpose, we 
used three different experimental models. First, we assessed SKP2 expression after direct MYC 
silencing in K562 cells. K562 cells were nucleofected with a vector (pRSshMYC) codifying a short 
hairpin directed to the third exon of MYC mRNA (Bernard, et al., 2003) or the corresponding 
empty vector (pRS). MYC silencing was confirmed by immunoblot (Figure 4.6A). Interestingly, it 
was accompanied by SKP2 down-regulation at mRNA and protein levels (Figure 4.6B and A 
respectively). MYC silencing also resulted in down-regulation of B23/nucleophosmin mRNA, a 
well-known MYC target gene used here as silencing positive control (Zeller, et al., 2001), but not 
of SKP1 mRNA, used as negative control (Figure 4.6B). This result suggest that the SKP2 down-
Figure 4.5. SKP2 induction by MYC in KMYCBp53 cells growth-arrested by p53. A) The KMYCBp53 cell 
model is summarized at the top. Proliferation rates of KMycBp53 cells treated with 75 µM ZnSO4 and incubated at 37 
or 32 °C were measured by counting viable cells in an hemocytometer over 3 days (bottom panel). B) KMYCBp53 
cells were incubated at 37 or 32 °C, with or without ZnSO4 for 24 h. SKP2 mRNA levels were determined by RT-
qPCR. C) KMYCBp53 cells were treated as in B, and the levels of SKP2, MYC, and actin (loading control) in total cell 
lysates were assayed by immunoblot. 
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regulation observed in the previously described K562-derived cell models could be due, at least in 
part, to MYC down-modulation originated by the different treatments.  
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, we had available in the laboratory two different cell lines carrying 
tetracycline-repressible (tet-off) human MYC transgenes: the human lymphoblastoid P493.6 cell 
line (Pajic, et al., 2000) and the mink lung epithelial TM1 cell line (Warner, et al., 1999). Thus we 
decided to analyze the SKP2 expression after MYC repression with doxycycline in both cell lines. 
As shown in figure 4.7, doxycycline treatment led to rapid MYC down-regulation accompanied by 
a simultaneous down-regulation of SKP2 at protein level (Figure 4.7A and C) in both cell lines. In 
P493.6 cells, SKP2 down-regulation was also tested at mRNA level (Figure 4.7B). Based on 
these findings, we suggested that the MYC-SKP2 interaction was not specific of the K562 cell 
model and it could be extended to other human tissues or animal species.  
 
 
 
 
 
 
 
 
 
 
 
 
Finally, we decided to compare the SKP2 expression between a Myc-deficient rat fibroblast 
cell line (HO15.19 cells) and the corresponding parental cell line (TGR-1 cells) (Mateyak, et al., 
1997). As shown in figure 4.8A, SKP2 protein levels were much lower although detectable in Myc-
null cells. In addition, it had been described that MYC (Dean, et al., 1986) and SKP2 protein 
expression decreased quickly in cultured fibroblasts after growth factors deprivation (Wirbelauer, 
A B 
Figure 4.6. SKP2 is down-regulated after MYC repression in K562 cells. A) K562 cells were nucleofected 
with a short hairpin RNA vector for MYC (shMYC) or the empty vector (Vect.), and MYC, SKP2, and actin expression 
were assayed by immunoblot 24 and 36 h after nucleofection. B) K562 cells were transfected as in A; and 24 h after 
nucleofection, the levels of SKP2, B23/nucleophosmin and SKP1 mRNA were determined by RT-qPCR.  
C A B 
Figure 4.7. SKP2 is down-regulated after MYC repression in lymphoid and epithelial cells. A) Human 
lymphoid P493.6 cells were treated with 1 µg/ml doxycycline (Doxy.) for the indicated times, and SKP2, MYC, and 
actin (loading control) expression were assayed by immunoblot. B) P493.6 cells were treated as in A, and SKP2 
mRNA expression was determined by RT-qPCR. C) TM1 cells were treated with 2 µg/ml doxycycline to repress 
MYC for the indicated times, and SKP2, MYC, and actin expression were determined by immunoblot. 
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et al., 2000; Bashir, et al., 2004; Wei, et al., 2004). Thus, we compared SKP2 expression after 
serum starvation in HO15.19 (Myc-null) and TGR-1 cells to determine whether MYC was 
essential for SKP2 regulation in absence of growth factors. As anticipated MYC and SKP2 were 
both down-regulated in response to serum deprivation in parental TGR-1 cells (Figure 4.8B left). 
In contrast there was not a significant down-regulation of SKP2 protein levels in response to 
serum deprivation in HO15.19 cells (Figure 4.8B right). This result suggested that in absence of 
MYC, SKP2 did not respond to growth factors deprivation and therefore that MYC was the main 
mediator of SKP2 induction in serum response. Taken collectively, all these data suggest that 
MYC was the major regulator of SKP2 expression in cells from different tissues and species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3. MYCER induces SKP2 mRNA expression in the absence of protein 
synthesis 
The previous experiments clearly indicated that MYC was an important regulator of SKP2 
expression but they did not confirm that SKP2 gene was a direct MYC target gene. For this 
purpose, then we asked whether SKP2 mRNA was induced by MYC in Kp27MER cells in the 
presence of cycloheximide (CHX), an eukaryotic protein biosynthesis inhibitor which blocked 
Figure 4.8. SKP2 down-regulation in response to serum deprivation in rat fibroblast but not in Myc null 
cells. A) Myc-null HO15.19 and parental TGR-1 rat fibroblasts were analyzed by immunoblot against MYC, SKP2 and 
actin as loading control. B) TGR1 and Myc-null HO15.19 cells were serum-deprived for the indicated times, and 
SKP2, MYC, and actin expression was analyzed by immunoblot. The bar histograms show the densitometric analysis 
of SKP2 and MYC immunoblots normalised to the corresponding actin levels using the Image J software. 
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translational elongation in the ribosome. In this way we could differentiate whether MYC was 
directly activating SKP2 gene transcription or whether SKP2 expression was indirect and it 
needed intermediary transcription factors synthesized de novo, likely induced by MYC (Watson, et 
al., 2002). Thus, Kp27MER cells were pre-treated with 10 nM TPA for 12 hours to down-regulate 
endogenous MYC and then treated with 10 µg/ml CHX together with 75 µM of ZnSO4 (to induce 
p27) and/or 200 nM 4HT for 6 hours (to activate MYC). CHX effectiveness was confirmed by lack 
of p27 protein induction in response to Zn2+ (Figure 4.9A, compare p27 in lanes 1 and 2 versus 
lanes 3 and 4 in the absence of 4HT and lanes 5 and 6 versus lanes 7 and 8 in its presence). As 
predicted, the remaining endogenous MYC protein showed a reduced stability (Figure 4.9A). It 
had been described that the estimated half-life of MYC was about 30 minutes (Hann and 
Eisenman, 1984). MYCER was more stable in presence of 4HT (Figure 4.9A, compare MYCER 
levels in lanes 9 and 10 versus lanes 11 and 12), although the underlying molecular mechanism 
is unclear. SKP2 mRNA levels were determined by RT-qPCR (Figure 4.9B). The results showed 
that activation of MYC with 4HT led to increased SKP2 mRNA levels even in presence of CHX 
and thus in  the absence protein synthesis. These results strongly suggested that SKP2 gene was 
regulated directly by MYC. Both MYC and MYCER protein levels were very low after 6 h of CHX 
treatment, precluding analysis of SKP2 mRNA expression at longer treatment times.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. MYC induces SKP2 in the absence of protein synthesis. A) Kp27MER cells were pre-
treated for 12 h with 10 nM TPA and then treated with 10 µg/ml cycloheximide (CHX), 4HT, and ZnSO4 for 1–6 
h. Expression of p27, MYC, MYCER, and actin were determined by immunoblot. B) SKP2 mRNA expression 
was determined by RT-qPCR after 6 h of exposure to CHX, ZnSO4, and 4HT as indicated. 
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4.1.4. MYC activates and binds to the human SKP2 promoter 
Based on these previous results, it appeared that SKP2 could be a direct MYC target gene. 
To confirm this, we carried out two more approaches. First, we tested the ability of MYC to 
activate the human SKP2 promoter through promoter-luciferase reporter assays. We transfected 
KMYCJ cells with a luciferase reporter containing 1148 bp of SKP2 promoter (Huang and Hung, 
2006) or the corresponding empty vector (pGL3-basic) and then we treated these cells for 24 
hours with 10 nM TPA to down-regulate endogenous MYC and/or 75 µM of ZnSO4 to induce 
exogenous MYC expression. The results showed that SKP2 promoter activity was significantly 
reduced in TPA-treated cells (Figure 4.10 top panel), consistent with endogenous MYC 
repression by TPA (Figure 4.4). However, SKP2 promoter activity was recovered when 
exogenous MYC was induced by Zn2+ (75 µM of ZnSO4) in presence of TPA (Figure 4.10 top 
panel). As control of the experiment, we used a luciferase reporter bearing four canonical E-boxes 
(4XEbox-Luc) (Kiessling, et al., 2006), which was also notably activated by MYC (Figure 4.10 
bottom panel). The empty luciferase construct and the reporter with four mutated E-boxes 
(4XEboxMut-Luc) were used for corresponding normalizations. These results clearly showed that 
the SKP2 promoter responded to MYC over-expression in K562 cells and strongly suggested that 
SKP2 could be a direct MYC target gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a second approach we used chromatin immunoprecipitation (ChIP) to analyze SKP2 
promoter occupancy by MYC in K562 cells. To date, ChIP is the only method that provides direct 
physical evidence of the association of a transcription factor with a specific target gene in the 
cellular context. Sequence analysis of the human SKP2 gene revealed two non-canonical E-
boxes (CATGCG and CACGCG) in the promoter region (-756 and -395 bp up-stream of the 
transcription start site respectively) and a canonical E-box (CACGTG) in the second exon (735 pb 
Figure 4.10. MYC activates to the human SKP2 promoter. KMYCJ cells were electroporated with a luciferase 
construct containing 1148 bp of SKP2 promoter (Huang and Hung, 2006) or a 4XE-Box luciferase reporter (Kiessling, 
et al., 2006) as experimental control. At 12 h post-transfection, the cells were divided into four aliquots and treated 
with 10 nM TPA to repress endogenous MYC and 75 µM ZnSO4 to induce exogenous MYC. At 36 h post-transfection, 
the cell lysates were prepared, and firefly and renilla luciferase activities were determined. SKP2-luciferase data were 
normalized to the value of cells transfected with the empty vector (pGL3basic-Luc). 4XEbox-Luc data were normalized 
to the mutated 4XEboxMut-Luc construct. Transfection efficiency was also normalized to renilla luciferase activity.  
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down-stream of the TSS). It should be noted that both non-canonical E-boxes have been also 
described as high affinity sequences for MYC in vivo (Grandori, et al., 1996; Kim, et al., 2008). In 
addition, we also found a conserved CpG island in the SKP2 promoter. It had been reported an 
overlapping between these hypomethylated conserved regions and MYC binding sites in the 
genome (Zeller, et al., 2006). Therefore, we tested several amplicons along SKP2 gene including 
these E-boxes and the CpG island to analyze MYC occupancy. The localization of the analyzed 
amplicons is shown in figure 4.11A.  
After cell fixation and DNA sonication (see “Material and Methods”, section 3.4.5.) 
chromatin was immunoprecipitated with a polyclonal antibody against full length MYC protein and 
then, MYC binding was assessed by qPCR. ChIP demonstrated MYC binding to the promoter 
region including the two non-canonical E-boxes but not to a canonical E-box located in the 
second exon (Figure 4.11B left, amplicons C, D and E). MYC binding to the E-box on lactate 
dehydrogenase A (LDHA) promoter (Kim, et al., 2004) was used as ChIP positive control (Figure 
4.11B, LDH). As negative controls, we used K562 cells treated with 1 µM imatinib or 10 nM TPA, 
which inhibit MYC expression as previously described. MYC binding was dramatically reduced 
after both treatments (Figure 4.11B right). These results definitively confirm that SKP2 was a new 
direct MYC target gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. MYC binds to the human SKP2 promoter. A) Scheme of the human SKP2 gene. Amplicons 
(boxes A–E) used for ChIP assays are indicated; the E-boxes (ovals) and localization of CpG island are also shown. 
Coordinates and CpG island are as in the UCSC Genome Browser. B) K562 cells untreated or treated for 12 h with 1 
µM imatinib or 10 nM TPA, to down-regulate endogenous MYC, were fixed with 1% formaldehyde and after cell lysis 
and DNA sonication, chromatin was immunoprecipitated with anti-MYC antibody or rabbit IgG (as negative control of 
immunoprecipitation). MYC occupancy between amplicons A–E was determined by quantitative PCR. The results 
are expressed as DNA fold enrichment with anti-MYC antibody with respect to the DNA enrichment with anti-rabbit 
IgG and normalized to the input chromatin signal for each amplicon. Lactate dehydrogenase A (LDH) E-box 
amplicon was used as positive control (Kim, et al., 2004). The values are the means ±S.E. of three determinations 
from two (TPA and imatinib) or three (plus control) independent ChIP experiments. 
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Moreover, while this Thesis was still in progress, the UCSC (The University of California 
Santa Cruz) Genome Browser (http://genome.ucsc.edu) made public data generated by the 
ENCODE project (Encyclopedia of DNA Elements) (Dunham, et al., 2012). The data sets included 
genome-wide ChIP-sequencing data for MYC and several other regulatory elements related to 
MYC in K562 cells but also in other cell lines. Using these data from Human GRCh37/hg19 
assembly and the ChIP-sequencing data sets generated by the Stanford/Yale/USC/Harvard 
ENCODE study, we corroborated the MYC-binding region to the SKP2 promoter detected by 
conventional ChIP in K562 cells but with higher resolution (Figure 4.12). Moreover, the same 
MYC-binding region was also observed in other cell lines such as NB4 (acute promyelocytic 
leukemia cells), A549 (Lung carcinoma), HepG2 (Hepatocellular carcinoma cells) and Hela 
(Cervical carcinoma cells) (not shown). In addition, MAX, the essential dimerization partner of 
MYC for DNA binding, and the histone acetyl-transferase p300 both immunoprecipitated to the 
same MYC-binding region in K562 cells (Figure 4.12). These results were consistent with the 
detection of H3K9ac and H3K27ac (H3 acetylated on Lysine 9 or 27) histone marks on the SKP2 
promoter, both targets of p300 and generally associated with MYC binding regions. These histone 
ChIP-seq data sets were provided by the Broad Institute. In addition we found that RBBP5, a 
subunit of MLL1 histone methyltransferase complex, also immunoprecipitated on the SKP2 
promoter correlating with an increase in H3K4me3 histone mark (Figure 4.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. MYC binds to the 
human SKP2 promoter. ~64 kb 
genomic window encompassing SKP2 
gene and part of the neighbouring gene 
LMBRD2 (chr5:36,136,146-36,200,141) 
together with ENCODE tracks 
annotations displayed as shown in the 
UCSC Genome Browser (Human 
GRCh37/hg19 assembly, February 
2009). The blue density graphs show 
the signal enrichment based on ChIP-
seq processed data for MYC and MAX 
transcription factors; p300 histone 
acetyltransferase; RBBP5 subunit of 
MLL1 histone methyltransferase 
complex; TATA binding protein (TBP) 
and RNA polymerase II (Pol2); H3K9ac, 
H3K27ac and H3K4m3 histone marks 
on K562 cell line. The two peaks 
correspond to sequences encompassed 
by the amplicons C and E of figure 
4.11B. Additional details for these 
annotations are available on 
(http://genome.ucsc.edu).  
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Finally, different components of the basal transcriptional machinery such as the TBP, or the 
RNA polymerase II were also bound SKP2 promoter with different affinities (Figure 4.12). As we 
previously mention in the Introduction (Section 1.4.3), all these proteins have been found to 
interact with MYC in different models and contexts. Taken collectively, these results indicate and 
suggest that MYC could participate in the recruitment of different complexes with histone acetyl-
transferase and histone methyl-transferase activity to the human SKP2 promoter to coordinate the 
recruitment of the basal transcriptional machinery to the SKP2 promoter and to induce its 
expression, at least in human K562 cells. Moreover these results strongly confirm that SKP2 is a 
new direct MYC target gene. 
4.1.5. SKP2 has no effects on MYC stability or transcriptional activity 
In contrast to our results, previous reports described a positive effect of SKP2 on MYC 
stability and transcriptional activity (Kim, et al., 2003; von der Lehr, et al., 2003). To assess this 
possible effect in K562 cell model we decided to analyze MYC protein levels by immunoblot after 
direct SKP2 silencing. K562 cells were transiently transfected with the pSRshSKP2 vector 
(Andreu, et al., 2005) codifying a short hairpin directed to the second exon of SKP2 mRNA or the 
corresponding empty vector (pSR). SKP2 silencing was confirmed by immunoblot (Figure 4.13A). 
Nonetheless, we found no significant changes in MYC protein levels 24 hours after SKP2 
silencing in K562 cells (Figure 4.13A). On the other hand, we also tested MYC transcriptional 
activity after SKP2 silencing by a luciferase reporter assay using the 4XEbox-Luciferase as MYC 
activity reporter (Kiessling, et al., 2006). As shown in figure 4.13B, luciferase assays also failed to 
show a significant SKP2 effect on MYC-dependent transcriptional activity. Thus we ruled out the 
possible effect of SKP2 on MYC activity and stability at least in the K562 cell model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. SKP2 has no effects on MYC stability or transcriptional activity. A) Immunoblot analysis of 
transfected cell lysates to assess downregulation of SKP2 protein in cells expressing the shSKP2 vector (Vect.). B) 
Transactivation of a MYC-responsive reporter in cells with silenced SKP2. K562 cells were cotransfected with the 
shSKP2 vector (Andreu, et al., 2005) or the corresponding empty vector and the 4XEbox-Luc or 4XE-boxMut-Luc 
luciferase reporters (Mut.) (Kiessling, et al., 2006). At 36 h post-transfection, the cell lysates were prepared, and 
luciferase activity was assessed. The data were normalized to renilla luciferase activity for transfection efficiency.  
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4.1.6. MYC and SKP2 expression correlate in different human hematologic 
tumors 
Most of previous results were obtained from K562 or K562-derived cell lines which in turn 
came from a human CML patient in blast crisis. Thus, we decided to evaluate the MYC-SKP2 
correlation in primary tumor samples from real CML patients to see whether this interaction could 
be translated transferred to a real clinic model. 43 human bone marrow samples, including 4 
healthy controls, 31 CML patients at diagnosis and 8 CML patients in complete molecular 
response [no detection of BCR-ABL transcripts by RT-qPCR after imatinib treatment (Baccarani, 
et al., 2009; Albajar, et al., 2011)] were provided by both the Hospital Universitario Marques de 
Valdecilla (Santander) and the Hospital Universitario Dr. Negrín (Las Palmas). MYC and SKP2 
mRNA levels were determined by RT-qPCR (Figure 4.14A). Although the cohort was not very 
large, the correlation between MYC and SKP2 mRNA expression was statistically significant 
(Figure 4.14B). Next, to determine whether this correlation between MYC and SKP2 at the mRNA 
level also occurred at the protein level, we analyzed a small cohort of CML protein samples by 
immunoblot. The results also confirmed the MYC/SKP2 correlation at the protein level in seven of 
eight patients tested (Figure 4.14C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. MYC and SKP2 expression in CML patients.   A) RT-qPCR analysis of MYC and SKP2 mRNA 
expression in 31 samples from CML patients at diagnosis in chronic phase (D), 8 patients in complete molecular 
response under imatinib treatment (T), and 4 healthy donors (H). The data are arranged from low to high MYC 
expression. mRNA values were normalized to the levels of ribosomal protein small 14 in each case. B) Correlation 
between MYC and SKP2 mRNA levels in the 43 bone marrow samples. The solid line indicates the linear prediction. 
The Pearson’s r and p values are indicated. C) Immunoblot showing SKP2 and MYC expression in 8 samples of CML 
patients at diagnosis. A picture of the gel stained with Coomassie (Coom. Blue) is shown to assess protein loading. 
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We also compared independently the mRNA expression of both MYC and SKP2 between 
the four control samples, the 31 CMLs at diagnosis and the eight patients that achieved a 
complete remission under imatinib treatment (essentially cured from their leukemia). The result 
showed that the mRNA expression of both MYC and SKP2 was significantly lower in the 8 
responding patients and similar to healthy controls with respect to CML samples at diagnosis 
(Figure 4.15). In fact, there were no significant differences between the controls and the CMR 
(Complete molecular response) samples (Figure 4.15). It should be noted that the treated (T) and 
healthy controls (H) accumulate in the left part of the graph, as they tend to express less MYC 
and SKP2, but still correlate (Figure 4.14A). These data reinforced the conclusion that the 
expression of MYC and SKP2 correlated in this leukaemia and that imatinib treatment of CML 
patients down-regulates MYC mRNA expression and SKP2 concomitantly, as in the K562 cell 
model. Therefore, these results support the idea that MYC could be responsible for the induction 
of SKP2 in primary human CML samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, we performed an in silico approach using the Oncomine database 
(www.oncomine.org) to examine a possible correlation between MYC and SKP2 mRNA levels in 
other hematological malignancies. We found a similar distribution of MYC and SKP2 mRNA 
expression in three independent gene-expression profiling studies carried out to classify human 
B-cell lymphomas (Figure 4.16) (Basso, et al., 2005; Hummel, et al., 2006; Klapper, et al., 2008). 
In these three studies, Burkitt´s lymphoma subgroup, in which MYC expression is over-expressed 
as a consequence of a chromosomal translocation that juxtaposes the MYC locus to one of the 
three immunoglobulin (IgG) loci (Delgado and Leon, 2010), also expressed the higher SKP2 
mRNA levels. Nevertheless, it should be noted that MYC translocations also occur in other 
lymphomas such as diffuse large-B-cell lymphoma but they are recurrently associated with non-
IgG partner loci (Hummel, et al., 2006). 
Figure 4.15. Comparative study of MYC and SKP2 mRNA expression between control, diagnosis and 
CMR samples of CML. MYC and SKP2 mRNA expression was independently analyzed according to the three 
groups of samples [Control, Diagnosis and patients in Complete Molecular Response (CMR)] and represented by 
scatter plots. Differential mRNA expression between control patients and patients at diagnosis or between these latter 
and patients in CMR was compared using the Mann-Whitney test. Horizontal lines represent medians. P values are 
indicated for every t tests analysis. The number of samples (n) for every group is indicated under the panels. 
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Finally, we also queried the correlation between MYC and SKP2 expression in tumor 
samples with the in silico transcriptomics database of the GeneSapiens system 
(www.genesapiens.org) (Kilpinen, et al., 2008). This database compares the mRNA expression 
levels of most human genes across 9,783 Affymetrix gene expression array experiments including 
normal human tissues, different cancer types and other diseases. We found again a positive 
Figure 4.16. Correlation between MYC and SKP2 expression in three independent studies classifying 
human B-cell lymphomas. Three different microarray-based studies (Affymetrix platform) were collected from the 
Oncomine database (Oncomine™, Compendia Bioscience, Ann Arbor, MI, https://www.oncomine.org/). The box 
plots depict the differential expression of MYC, SKP2 and GAPDH (as a housekeeping control gene) between 
different subgroups of human B-cell lymphomas, as indicated. P values from t tests, the probes used in each 
microarray analysis and the study reference are indicated over the panels. The number of samples (n) for every 
subgroup is indicated under the panels. 
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correlation between MYC and SKP2 mRNA expression in another human B-cell lymphoma study 
including 234 patient samples (Figure 4.17A). Moreover, we also found a good MYC-SKP2 mRNA 
correlation in acute myeloid leukaemia (AML) (Figure 4.17B) in which MYC has been found 
frequently overexpressed (Delgado and Leon, 2010; Delgado, et al., 2013) and elevated SKP2 
levels represented a poor prognostic factor (Min, et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Correlation between MYC and SKP2 expression in human B-cell lymphoma and acute 
myeloid leukemia (AML). Dot plots showing the positive correlation between MYC and SKP2 mRNA expression in 
individual samples of B-cell lymphoma (A) and AML patients (B). The data were collected from the transcriptomics 
database of the GeneSapiens system (www.genesapiens.org). As a control, the correlations between MYC and the 
housekeeping gene GAPDH are also shown. The number of samples (n), the correlation coefficient (r) and the P 
values are indicated in each case over the panels.  
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4.2. THE MYC-SKP2-p27 AXIS 
4.2.1. MYC induces p27 phosphorylation on Thr-187  
In the first part of this Thesis we have demonstrated that SKP2 was a MYC target gene in 
K562 cells, and probably also in other cell models. Moreover, previous reports firmly established 
that SKP2 was the main F-box protein involved in p27 degradation (Carrano, et al., 1999; 
Sutterluty, et al., 1999; Tsvetkov, et al., 1999). However, our studies did not demonstrate yet that 
SKP2 was responsible for p27 down-regulation in our Kp27MER model. Thus we decided to 
evaluate the MYC-SKP2-p27 axis in Kp27MER cells.  
Given that the main target of the SCFSKP2 complex is the p27 phosphorylated in Thr187 (Lu 
and Hunter, 2010), we first studied whether this phosphorylation was taking place in the 
Kp27MER model. For this purpose, we performed a dose-response study to analyze the fraction 
of p27 phosphorylated on Thr187 (p27pT187). Kp27MER cells were treated with 50 or 75 µM 
ZnSO4 and 4HT at two different times (12 and 24 hours post-induction) and the levels of p27 total 
and p27pT187 were analyzed by immunoblot. The results showed that MYC activation resulted in a 
significant increase in the p27pT187 fraction at both Zn2+
 
concentrations and 12 hours post-induction 
(Figure 4.18A). This finding suggests that the kinases involved in this phosphorylation event were 
not fully inhibited by the high Zn2+-induced p27 levels in presence of active MYC. Then, we 
performed a kinetic study to determine peak of maximum phosphorylation provoked by MYC 
activation. We found that it overlapped with the point of maximum p27 overexpression; around 8-
12 hours post-induction (Figure 4.18B). At longer treatment times, the phospho-p27 fraction and 
the total p27 levels were reduced (not shown). Therefore, MYC induced p27 phosphorylation at 
Thr187, allowing its potential recognition by SCFSKP2 complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18. MYC induces p27 
phosphorylation at Thr187. A) Kp27MER 
cells were treated for 12 and 24 h with 200 
nM 4HT and/or 50 or 75 µM ZnSO4, as 
indicated. Total p27, p27 phosphorylated 
on Thr187 (p27pT187) and actin (as loading 
control) were assayed by immunoblot. B) 
Kp27MER cells were treated for 4–24 h 
with 75µM ZnSO4 or 200 nM 4HT plus 75 
µM ZnSO4. Total p27, p27 phosphorylated 
on Thr187 (p27pT187), and actin (as loading 
control) were assayed by immunoblot. The 
yellow signal shows the overlapping 
between total p27 (red) and p27pT187 
(green).  
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4.2.2. MYC induces p27 phosphorylation independently from cyclin E/CDK2 
complexes 
It had been shown that the cyclin E/CDK2 complexes mediated p27 phosphorylation at Thr-
187 at G1/S phase transition (Muller, et al., 1997; Sheaff, et al., 1997; Vlach, et al., 1997). 
Moreover, it had been also described that MYC induces cyclin E expression activating cyclin 
E/CDK2 complexes (Jansen-Durr, et al., 1993; Muller, et al., 1997; Perez-Roger, et al., 1997). 
Thus, to explain the increase in the phosphorylation of p27 in response to MYC we decided to 
examine whether MYC activation was modifying the cyclin E and CDK2 protein levels in 
Kp27MER cells. As shown by immunoblot analysis, no changes on their expression were 
observed after 12 hours of MYC activation (Figure 4.19A, compare -/+ 4HT treatments in cyclin E 
immunoblot). In contrast, the cyclin E protein levels were increased in cells overexpressing p27, 
suggesting that p27 was stabilizing cyclin E. This finding is in agreement with previous results 
showing that p27 inhibited cyclin E ubiquitination and prevented of its degradation by the 
proteasome (Clurman, et al., 1996). 
On the other hand, it has had been described that (i) cyclin A/CDK2 complexes were also 
able to phosphorylate p27 at Thr-187 in vitro (Muller, et al., 1997; Zhu, et al., 2004b) and that (ii) 
cyclin A was induced by MYC in Rat-1-MYCER fibroblasts (Jansen-Durr, et al., 1993; Hoang, et 
al., 1994; Muller, et al., 1997). Thus we analyzed cyclin A expression and we found an increase of 
cyclin A protein levels concomitant to MYC activation in presence of Zn2+-induced p27 (Figure 
4.19A, compare lanes 1 and 2). Cyclin A induction by MYC can be explained because MYC-MAX 
heterodimers also binds to CCNA2 promoter in K562 cells according to the UCSC genome 
browser (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19. MYC induces cyclin A but not cyclin E or CDK2 expression. A) Kp27MER cells were treated 
for 12 h with 200 nM 4HT and 50 and/or 75 µM ZnSO4, as indicated. MYCER and MYC (as control of MYCER 
activation); CDK2; cyclin A and E; total p27, p27 phosphorylated on Thr187 (p27pT187), and actin (as loading control) 
were assayed by immunoblot. B) P493.6 cells were treated for the indicated times with 2 µg/ml doxycycline (Doxy.). 
MYC, cyclin A and E; CDK2, CDK1 and actin were assayed by immunoblot. P493.6 cells do not express p27 (Pajic, 
et al., 2000). 
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This result was consistent with an independent observation in P493.6 cells where 
repression of MYC by doxycycline closely correlated with cyclin A down-regulation (Figure 4.19B). 
In these cells, MYC repression also resulted in cyclin E down-regulation but with a slower kinetics 
than cyclin A (Figure 4.19B). It should be mentioned that P493.6 cells do not express p27 (Pajic, 
et al., 2000) so its phosphorylation status could not be tested in this experiment. 
Therefore, the induction of cyclin A by MYC could explain the increase in p27-Thr187 
phosphorylation in Kp27MER cells. To directly test this, we decided to study the kinase activity 
associated to cyclin A immunocomplexes on recombinant p27. For this end, we conducted in vitro 
kinase assays using recombinant 6 histidine-tagged p27 (His6-p27) as substrate and the 
phosphospecific antibody anti-p27pT187 to detect the kinase activity of these cyclin/CDK 
immunocomplexes by immunoblot, as described in section 3.6.2 of “Material and Methods’’.  
We confirmed the ability of cyclin A immunocomplexes to phosphorylate recombinant p27 
(Figure 4.20A). This kinase activity was strongly inhibited by Zn2+-induced p27 (i.e., endogenous 
p27) in the absence of activated MYC (Figure 4.20A, Zn2+ treatment). However, in presence of 
activated MYC, cyclin A immunocomplexes phosphorylated efficiently recombinant His6-p27 even 
in presence of endogenous p27 (Figure 4.20A, Zn2+ + 4HT treatment). These results suggests 
that the increase in the p27 phosphorylation rate observed in Kp27MER cells in presence of MYC 
(Figure 4.18) could be due, at least in part, to the kinase activity associated to cyclin A 
immunocomplexes.  
Given that both, CDK2 and CDK1 can be associated to cyclin A (see Introduction, section 
1.1.3.), then we decided to analyze the kinase activity of CDK2 and CDK1 immunocomplexes on 
recombinant His6-p27. First, we analyzed the kinase activity of CDK2 immunocomplexes and we 
confirmed the ability of CDK2 to phosphorylate recombinant p27 (Figure 4.20B, no Zn2+ 
treatment). However, the kinase activity of CDK2 was strongly inhibited by Zn2+-induced p27 in 
the absence but also in the presence of activated MYC, i.e., in the presence of 4HT (Figure 
4.20B). Thus, the p27 phosphorylation induced by MYC in the Kp27MER cells (Figure 4.18) is 
likely not mediated by cyclin A/CDK2 or by cyclin E/CDK2 complexes.  Finally, we asked whether 
cyclin A-associated CDK1 could phosphorylate p27. We confirmed the ability of CDK1 to 
phosphorylate p27 on Thr187 in vitro (Figure 4.20C), as previously shown in a different model 
(Zhu, et al., 2004b). Moreover, we observed that the Zn2+-induced p27 inhibited much less 
efficiently the kinase activity associated to CDK1 compared to CDK2 (Figure 4.20, compare Zn2+ 
treatments in  B and C upper graphs) confirming previous results during p27 discovery (Polyak, et 
al., 1994b). Furthermore, we also observed a slightly increase in the levels of p27pThr187 in the 
CDK1 immunoprecipitates in the presence of active MYC (Figure 4.20 C) suggesting that the 
cyclin A-associated kinase activity was due to cyclinA/CDK1 complexes. As a control, we 
confirmed the binding of cyclin A to CDK1 and CDK2 by immunoprecipitating cyclin A from 
Kp27MER lysates and detecting CDK1 and CDK2 in the precipitates (Figure 4.20D). Strikingly, it 
should be noted that the kinase activity associated to cyclin A, CDK1 and CDK2 was inhibited by 
Zn2+-induced p27 (i.e., endogenous p27) but not by recombinant His6-p27. This finding suggests 
that His6-p27 requires an intracellular modification to inhibit these immunocomplexes. The lack of 
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inhibition of CDK1 and CDK2 by recombinant p27 has been previously observed (Zhu, et al., 
2004b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To better assess the ability of MYC to induce p27 phosphorylation independently of cyclin 
E/CDK2 complex activity we carried out a parallel study in mouse embryonic fibroblasts deficient 
for Cdk2 (Ortega, et al., 2003) and/or E-type cyclins (Geng, et al., 2003) (kindly provided by 
Marcos Malumbres and Piotr Sicinski, respectively). Gene knockout were confirmed by RT-PCR 
(Figure 4.21A and B, respectively). MEFs Cdk2-/- and cyclin E1-/-/E2-/- were infected with lentivirus 
containing the MYC gene tagged with FLAG epitope under the control of the CMV promoter. 
Empty vector (Lv141) was also transduced as a control. Infection was confirmed and scored by 
GFP expression (not shown). MYC-Flag overexpression was assayed by RT-PCR and 
Figure 4.20. MYC induces cyclin A-associated kinase activity in presence of p27 in Kp27MER cells. 
Kp27MER cells were treated for 12 h with 75 µM ZnSO4 and/or 200 nM 4HT and, as indicated. Cell extracts were 
immunoprecipitated against A) cyclin A; B) CDK2 and C) CDK1 and immunocomplexes were subjected to in vitro 
p27 phosphorylation assays (see “Material and Methods”). As negative control of phosphorylation assays, beads 
with no antibody were added to mix reaction (no IP). Total p27 and p27 phosphorylated on Thr187 (p27pT187) were 
assayed by immunoblot. The yellow signal shows the overlapping between total p27 (red) and p27pT187 (green). The 
upper panels show the relative kinase activity of immunocomplexes determined by densitometric analysis of 
corresponding immunoblots. D) Lysates from Kp27MER cells treated for 12h with 75 µM ZnSO4 and/or 200 nM 
were immunoprecipitated with anti-cyclin A antibody, and the levels of cyclin A, CDK2 and CDK1 in the 
immunoprecipitates were determined by immunoblotting. 
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immunoblot (Figure 4.21A, B and C). Cells extracts were immunoprecipitated against cyclin A, 
CDK1 and CDK2, and immunocomplexes were subjected to in vitro p27 phosphorylation assays 
(Figure 4.21D, E and F respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 We found that cyclin A and CDK1 immunocomplexes from both cyclin E1-/-/E2-/- and Cdk2-/- 
MEFs were able to phosphorylate recombinant His6-p27 (Figure 4.21D and E). We also observed 
that CDK2 immunocomplexes from cyclin E1-/-/E2-/- MEFs were also able to phosphorylate 
recombinant His6-p27 (Figure 4.21F). Altogether, these results suggest that at least in mouse 
fibroblasts, CDK2 and E-type cyclins are not strictly required for p27-Thr187 phosphorylation and 
that CDK1 and cyclin A can replace CDK2 and E-type cyclins in this function.  
In addition, we found that MYC promoted cyclin A and CDK1 kinase activity on the extracts 
of both Cdk2-/- and cyclin E1-/-/E2-/- MEFs infected with MYC (Figure 4.21E). However, the 
Figure 4.21. MYC induces CDK1 and cyclin A-associated kinase activity in Cdk2-/- and cyclin E1-/-/E2-/- 
MEFs. MEFs Cdk2-/- and cyclin E1-/-/E2-/- were infected with MYC-Flag or the respective empty lentiviral vector Lv141 
(vect.). A) Cdk2 knockdown and MYC-Flag infection were verified by RT-PCR with primers pairs against β-actin 
(loading control), CDK2 and MYC-Flag. MEFs wt were used as control. B) MEFs cyclin E1-/-/E2-/- knockdown and 
infection were verified by RT-PCR primers pairs against β-actin, cyclin E1, cyclin E2 and MYC-Flag. MEFs wt were 
used as control. C) MEFs Cdk2-/- and cyclin E1-/-/E2-/- infected with MYC-Flag or the respective lentiviral empty vector 
were assayed by immunoblot against MYC and tubulin (as loading control) expression. D) cyclin A, E) CDK1, and F) 
CDK2 immunocomplexes from Cdk2-/- and cyclin E1-/-/E2-/- MEFs infected with MYC-Flag or the respective empty 
vector were subjected to in vitro p27 phosphorylation assays (see “Material and Methods”). As negative control of 
phosphorylation assays, beads with no antibody were added to mix reaction (no IP). Total p27 and p27 
phosphorylated on Thr187 (p27pT187) were assayed by immunoblot. The yellow signal shows the overlapping between 
total p27 (red) and p27pT187 (green). The upper panels show the relative kinase activity of immunocomplexes 
determined by densitometric analysis of respective immunoblots.  
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induction of cyclin A kinase activity by MYC in cyclin E1-/-/E2-/- MEFs was moderate compared to 
this one in Cdk2-/- MEFs. This might be due to a compensatory mechanism to induce cyclin A 
associated kinase activity in absence of E-type cyclins. In MEFs cyclin E1-/-/E2-/-, MYC also 
promoted kinase activity of CDK2, suggesting that cyclin A was the cyclin responsible of CDK2 
activation (Figure 4.21E). Thus, we confirm that MYC is able to induce CDK2 and/or CDK1 kinase 
activity on p27 associated to cyclin A expression.  
4.2.3. MYC reduces p27 protein levels through SKP2 induction  
The previous results indicated that MYC promoted p27 phosphorylation at Thr-187 in 
Kp27MER cells, at least in part, through the induction of cyclin A-associated kinase activity; being 
this phosphorylation event a prerequisite for p27 recognition by the SCFSKP2 ubiquitin ligase 
complex. Thus, we next asked whether the SKP2-induction mediated by MYC was really 
responsible for p27 down-regulation. For this purpose, we analyzed the MYC-SKP2-p27 axis by 
three different approaches. 
First, we analyzed the MYC effect on SKP2 and Zn2+-induced p27 protein levels in the 
Kp27MER model by immunoblot. We treated Kp27MER cells with 50 µM ZnSO4 and/or 200nM 
4HT for 24, 36 and 48 hours. Immunoblot analysis showed that MYC activation by 4HT resulted in 
SKP2 induction and a concomitant significant decrease in p27 levels after p27 overexpression 
(Figure 4.22A, compare lanes 1 vs. 2; 3 vs. 4 and 5 vs. 6). As we will see later, p27 degradation 
also occurred at high p27 levels (75 µM ZnSO4) although the p27 accumulation exceeds its 
degradation rate (Figure 4.27, p27 low exposure).  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.22. MYC-induced 
SKP2 correlates with p27 down-
regulation. A) Expression of p27 in 
Kp27MER after MYC activation. The 
cells were treated with 50 µM ZnSO4 
and/or 200 nM 4HT for 24, 36 and 
48h. MYCER, MYC, SKP2, p27 and 
actin (loading control) protein levels 
were determined by immunoblot. B) 
Kp27-5 cells were treated for 48 h 
with ZnSO4 and 4HT, and protein 
levels of MYC, SKP2, p27 and actin 
(loading control) were determined by 
immunoblot. C) KMER4 cells were 
cultured for 76 h to reach quiescence 
caused by cell density, alone or with 
200 nM 4HT to activate MYC. 
MYCER; SKP2 and p27 protein 
levels were determined by 
immunoblot. 
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As a control that this effect was only due to MYC activation, we performed a similar 
experiment in parental Kp27-5 cells, which bear a Zn2+-inducible p27 transgene but not the 
MYCER construct. 4HT addition to the culture medium did not modify SKP2 and did not reduce 
p27 protein levels in these cells (Figure 4.22B). This result partially confirmed that the induction of 
SKP2 by MYC was responsible for p27 down-regulation in myeloid leukemia cells. Moreover, we 
also tested the MYCER effect on the endogenous p27 in the KMER4 model. In these cells, as in 
parental K562 cells, p27 was up-regulated when cells reached quiescence by culture saturation 
(~1.5 x 106 cells/ml after 3 days in culture). Immunoblot analysis showed that SKP2 levels were 
higher and p27 levels were lower in cells with activated MYC after 72 hours in culture (Figure 
4.22C). 
 
As second approach, we tested the SKP2-p27 interaction in Kp27MER cells by 
immunofluorescence. As shown in figure 4.23 all p27 was predominantly nuclear in Kp27MER 
cells treated with 75 µM ZnSO4. As expected, MYCER activation promoted SKP2 expression and 
it was also detected in the cell nucleus. Interestingly, we found no colocalization of p27 and SKP2 
in Kp27MER cells treated with Zn2+ and 4HT. Instead, p27 and SKP2 expression was mutually 
exclusive. Cells with high nuclear SKP2 levels showed low p27 levels (Figure 4.23, yellow arrows) 
and viceversa (Figure 4.23, white arrows). This mutually exclusive distribution of SKP2 and p27 
has been also reported in other cell models (Lu, et al., 2002). This result also reinforced the result 
of SKP2 induction by MYC and subsequent SKP2-dependent degradation of p27. Moreover, this 
result excluded the possibility that the bulk of p27 would be degraded in the cytoplasm by a 
SKP2-independent pathway (e.g., the KPC ubiquitin ligase).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23. SKP2 and p27 localize in the cell nucleus but they are mutually exclusive. 
Immunofluorescence of p27 and SKP2 proteins in Kp27MER cells exposed to 75 µM ZnSO4 and 4HT for 24 h (as 
indicated). White arrows indicate cells with high p27 and low SKP2 levels in the nuclei. Yellow arrows indicate cells 
with high SKP2 and low p27 levels. The nuclei were DAPI-stained. 
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Third and finally, to really confirm that SKP2 was the main intermediary of p27 degradation 
induced by MYC in the K562 models, we decided to analyze endogenous p27 levels after SKP2 
silencing. For this purpose, we infected KMER4 cells with retrovirus expressing a short hairpin 
against SKP2 mRNA (pSR-shSKP2 vector) (Andreu, et al., 2005) or the corresponding empty 
vector (pSR vector) and we generated the KMERshSKP2 and KMERpSR sublines. SKP2 
silencing in KMER4shSKP2 cells was confirmed by immunoblot, as compared to the KMER4pSR 
subline (Figure 4.24A). Then we compared p27 levels after 2 and 4 days growing in normal 
culture conditions by immunoblot. As previously mentioned K562-derived cells reached 
quiescence by culture saturation (~1.5 x 106 cells/ml) after 3-4 days in culture, accumulating p27. 
As shown also in figure 4.24A, the p27 levels accumulated in the KMERshSKP2 cells were higher 
than in the KMERpSR cells owing to the lower levels of SKP2 in these cells. 
In addition, we also analyzed the effect of SKP2 silencing on cell proliferation. In agreement 
with the increased p27 protein levels, shSKP2-expressing cells grew at a reduced rate (Figure 
4.24B) and showed cell accumulation in the G1 phase (not shown). This result confirmed the 
effect of SKP2 on p27 in the K562-derived models and explained, at least in part, the cell cycle 
activation induced by MYC in the Kp27MER model in presence of low p27 levels (as induced by 
50 µM ZnSO4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4. SKP2 silencing reduces tumor formation from K562 cells in a 
xenograft model in nude mice 
Given the importance of MYC-SKP2-p27 axis in proliferation of K562 cells, as evidenced in 
the previous section, and that the capacity of these cells to develop subcutaneous tumors in nude 
mice has been partially attributed to the effects of MYC overexpression (Xie, et al., 2002; Huang, 
et al., 2012) we evaluated the role of MYC-SKP2-p27 axis in tumorigenesis by comparing the 
tumorigenic capacity of KMERpSR and KMERshSKP2 sublines in nude mice. For this end, the 
same amount of KMERpSR and KMERshSKP2 cells (107 cells per injection site) were injected 
Figure 4.24. SKP2 silencing results in increased p27 levels and low proliferation rate of K562 cells. A) 
KMERshSKP2 and KMERpSR cells were cultured for 2 and 4 days, and the protein levels of SKP2, p27, MYC, and 
α-tubulin (loading control) in cell lysates were assessed by immunoblot. B) Proliferation rates of KMERpSR and 
KMERshSKP2 cells were measured by counting viable cells in a hemocytometer.  
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subcutaneously into the left and right flanks respectively of a group of nine female 
immunocompromised mice (nu/nu) and tumor formation and progression was monitored weekly 
after injections. Three weeks post-injection, the animals were killed and tumours from each 
mouse were excised, measured and weighed. Figure 4.25A shows two representative nude mice 
and the respective developed tumors. As shown in figure 4.25B the mean tumor weight produced 
by KMERshSKP2 cells was significantly reduced as compared to not silenced control cells 
(KMERpSR). A similar reduction was observed when the volume of the tumours was compared 
(not shown). Thus we concluded that the SKP2 induction by MYC and the subsequent p27 
degradation may account at least in part the tumorigenic capacity of these cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.5. The MYC-SKP2-p27 axis in other cell models  
Finally, we studied the MYC-SKP2-p27 axis in some of the initially described models. We 
observed that KMYCJ cells pre-treated with 10 nM TPA for 12 hours accumulated p27 
concomitantly to MYC and SKP2 down-regulation (Figure 4.26A). However, the overexpression of 
MYC with 75 µM ZnSO4 in TPA pre-treated cells promoted a SKP2 up-regulation and a 
concomitant p27 down-regulation 24 and 48 hours post-induction (Figure 4.26A). A similar result 
was also observed in KMYCJ treated with 1 µM imatinib. Endogenous MYC and SKP2 were 
down-modulated in presence of imatinib in these cells as previously described in the KMER 
model. This decrease in SKP2 levels was accompanied by a p27 and γ-globin accumulation 24 
Figure 4.25. SKP2 silencing reduces the size of tumors produced by K562 cells in nude mice. 
Approximately 107 KMERpSR and KMERshSKP2 cells were subcutaneously injected into the left and right 
flanks, respectively, of female athymic nude mice as described  in ‘‘Materials and Methods’’. Tumor-bearing mice 
were sacrificed after 3 weeks and the mice photographed before excision and weighing of tumors. A) Image 
showing two representative mice and the respective developed tumors. The scales shown are in centimetres. B) 
The weight of the tumors generated by KMERpSR and KMERshSKP2 cells respectively was compared using the 
Mann-Whitney test and represented by box plots (covering from 25 to 75% percentiles). Horizontal lines 
represent medians. The P value and the number of tumors (n) are indicated. 
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and 48 hours post-treatment (Figure 4.26B) which resulted in a moderate erythroid differentiation 
of these cells (Gomez-Casares, et al., 2012). However, the overexpression of exogenous MYC 
with 75 µM ZnSO4 in presence of imatinib resulted again in SKP2 induction and a concomitant 
p27 degradation and inhibition of differentiation of these cells (Figure 4.26B).  
On the other hand, in the TGR1 cell model in which MYC and SKP2 were down-regulated 
after serum deprivation we observed a concomitant p27 accumulation as shown by immunoblot in 
figure 4.26C. This result was also appreciated in the K562 cell model in which the glutamine and 
the serum starvation also resulted in a progressive MYC and SKP2 down-modulation followed by 
p27 stabilization (Figure 4.26D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26. The MYC-SKP2-p27 axis in other cell models. A) KMYCJ cells were pre-treated with 10 nM 
TPA for 12 hours and then MYC was induced with 75 µM ZnSO4 for 24 and 48 hours as indicated. MYC, SKP2, 
p27 and actin (as loading control) protein levels in total cell lysates were determined by immunoblot. B) KMYCJ 
cells were treated with 1µM imatinib and/or 75 µM ZnSO4 for 24 and 48 hours as indicated, and the levels MYC, 
SKP2, p27, γ-Hemoglobin (as an erythroid differentiation marker) and α-tubulin (as loading control) were assayed 
by immunoblot. C) TGR1 cells were serum-deprived for the indicated times, and MYC, SKP2, p27 and actin were 
analyzed by immunoblot. D) K562 cells were glutamine and serum-deprived for the indicated times, and MYC, 
SKP2, p27 and actin protein expression was analyzed by immunoblot. 
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4.3. MYC EFFECTS ON p27-CONTAINING COMPLEXES AND ITS 
RELATIONSHIP WITH PROLIFERATION  
4.3.1. Characterization of p27-containing complexes in Kp27MER cells by 
gel filtration 
The mechanism previously described of SKP2-induction by MYC explained the p27 down-
modulation and the increase in cell proliferation observed upon MYC activation at low p27 levels 
(with 50 µM ZnSO4) in Kp27MER cells. However, it did not explain the inability of MYC to 
counteract p27-induced proliferative arrest at high p27 levels (i.e., with 75 µM ZnSO4) (Acosta, et 
al., 2008) given that p27 degradation was also occurring in these conditions (Figure 4.27 low 
exposure).   
 
 
 
 
 
 
 
 
 
 
 
 
It is possible that at these Zn2+ doses p27 could be expressing at such high levels that MYC 
cannot antagonize the p27-mediated proliferative arrest, despite promoting its degradation. To 
explore this point we decided to analyze the p27 distribution at macromolecular level by gel 
filtration chromatographic fractionation of protein extracts followed by immunoblot analysis. This 
technique offered a simple and relatively quick method to analyze the macromolecular distribution 
of p27 and CDKs between different complexes in native conditions. We used a Superdex-200 HR 
column which allowed a very high resolution of native protein complexes in a molecular mass 
range lower than 600 kDa.  
We first analyzed protein extracts of Kp27MER cells treated whit 75 µM ZnSO4 to know the 
p27 distribution in these cells expressing the top p27 protein levels. After the chromatographic 
separation, aliquots of each fraction were analyzed by immunoblotting against p27, CDK2 and 
cyclin E content. Figure 4.28A shows a typical result of a chromatographic fractionation. p27 was 
mainly distributed between two types of complexes: one high molecular weight complex which 
eluted in a wide peak around ~200 kDa and another complex with a lower molecular weight of 
about ~50 kDa. It should be mentioned that the resolution of the column at high molecular weights 
is lower. Therefore, the molecular weight estimation of a protein or protein complex using this 
Figure 4.27. MYC-induced degradation of p27 also 
occurred at high p27 levels (Low exposure). Kp27MER 
cells were treated for 24 h with 50 or 75 µM ZnSO4, and/or 
200 nM 4HT, as indicated. MYCER and MYC (as control of 
MYCER activation); SKP2; p27 and actin (as loading control) 
were assayed by immunoblot. A low exposure of p27 was 
taken to reveal p27 down-modulation in presence of active 
MYC (plus 4HT) at 75 µM ZnSO4.  
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technique is better at low molecular weights. The two peaks were completely resolved, and no 
additional signals were evident in other fractions of the chromatographic analysis or in the flow-
through of the column (~600 kDa aprox.). Interestingly and despite its overexpression, no p27 
was observed eluting in the range 20-30 kDa, around the estimated molecular weight of free-
eluting p27 protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the ~200 kDa complex, p27 coeluted with CDK2 and cyclin E (Figure 4.28A). Importantly, 
a part of CDK2 was also found eluting in a peak around 30 kDa corresponding to the molecular 
weight of its free form (~33 kDa). Given that the cyclin E only appeared in the ~200 kDa complex, 
this suggested that CDK2 was in excess and that cyclin E was rate limiting when it was 
complexed with CDK2. In order to confirm the interaction between CDK2, cyclin E and p27 protein 
in these high molecular weight complexes, the relevant fractions were immunoprecipitated with 
Figure 4.28. Distribution of p27 in Kp27MER cell extracts by gel filtration. A) Kp27MER cells treated with 
75 µM ZnSO4 for 24h were lysed softly in nondenaturing conditions and 3 mg of the protein extract was fractionated 
by gel filtration chromatography on Superdex-200 HR column. Equal aliquots of the indicated fractions (on the top 
of the panel), were analysed by immunoblotting against p27, cyclin E and CDK2. B) The indicated fractions were 
immunoprecipitated against p27 and the presence of CDK2, cyclin E and p27 in the immunoprecipitates was 
assessed by immunoblot. C) Fractions 65/66/67 were heated for 5 min at 100°C and insoluble denatured material 
(pellet) was separated by centrifugation at 20000 rpm for 20 min. Pellet and supernatant were subjected to 
immunoblot against p27 and CDK2 to verify p27 release from cyclin/CDK complexes (Hengst, et al., 1994; Polyak, 
et al., 1994a). Fractions 58/59 and 76/77 were used as immunoblot control. D) The supematant (Super.) was then 
subjected to gel filtration column and the fractions were immunoblotted again with anti-p27 antibody. E) His6-p27 
was expressed in bacteria and purified as described in “Materials and Methods” (section 3.6.5). The purified His6-
p27 was loaded onto a gel filtration column and the fractions were immunoblotted with anti-p27 antibody. Fraction 
numbers and the fraction elution of protein standards are shown at the top and the bottom of the figure.  
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anti-p27 antibody and then, the immunocomplexes were analyzed by immunoblot using 
antibodies against CDK2 and cyclin E. The results showed that p27 was effectively bound to 
CDK2 and cyclin E in the ~200 kDa complex (Figure 4.28B). Moreover, it has been also shown in 
our laboratory that in the Kp27MER model, p27 coimmunoprecipitated with D-type cyclins and 
CDK4/6 in the high molecular weight complex (J. C. Acosta personal communication). 
Furthermore, it has been also reported that cyclin A is also present in this high molecular weight 
complex although in other cell models as Swiss 3T3 MEFs (Poon, et al., 1995).  
With regard to the p27 eluting at ~50 kDa, p27 did not coimmunoprecipitated with CDK2 or 
cyclin E (Figure 4.28B). Thus, we decided to study whether p27 eluting at ~50 kDa was 
associated to another unknown protein. It had been previously described that p27 was heat 
resistant (Hengst, et al., 1994; Polyak, et al., 1994a). Thus, we treated for 5 min at 100 ºC the 
fractions containing the low molecular weight p27 to denature the possible associated proteins 
and to release free p27 (Figure 4.28C). As expected, p27 was heat-resistant but not the co-eluting 
CDK2 which was denatured and precipitated after heat treatment (Figure 4.28C). Then we re-
chromatographed the supernatant under the same conditions to see whether the mobility of p27 
was affected. As shown in figure 4.28D, heat-treated p27 was eluting again with the same 
molecular weight of ~50 kDa. This result suggested that the p27 found in the ~50 kDa was in the 
form of free protein. Finally, to confirm it, we decided to compare the mobility in gel filtration with a 
recombinant p27 hexahistidine-tagged (His6-p27) purified from bacteria. We found again that the 
His6-p27 showed the same mobility as the low molecular weight complex (~50 kDa) (Figure 
4.28E). This result confirmed that p27 eluting at ~50 kDa was in free form.  
Given that free p27 eluted as a 50 kDa protein, it was possible that p27 was behaving as a 
dimer in native conditions. To explore this possibility we decided to carry out an in vitro 
experiment which consisted in mixing equimolar amounts of His6-p27 and a bacterially expressed 
p27 fused with the Glutathione S-transferase at its N-terminus (GST-p27) (Taules, et al., 1999) in 
order to observe intermediate molecular weight complexes GSTp27-His6p27. It should be noted 
that GST-p27 fusion protein has a molecular weight of ~50 kDa in denaturing conditions (Figure 
4.29B, SDS-PAGE). Moreover, it had been described that the GST dimerized in vitro (Parker, et 
al., 1990; Maru, et al., 1996). Gel filtration of GST-p27 showed that it eluted as a single peak of 
around ~300 kDa (Figure 4.29). This finding was consistent with the hypothesis of a dimeric 
conformation of p27 and the expected tetrameric conformation of GST-p27.  
Then we performed the mixing experiment. The mixture His6-p27 + GST-p27 was incubated 
for 3 hours at 37ºC in the chromatography buffer and then subjected to gel-filtration 
chromatography followed by SDS-PAGE and coomassie blue staining. The results did not show 
any intermediate molecular weight complex (Figure 4.29A, blue graph and B). This finding 
indicated that the low molecular weight complex of p27 was not properly a dimer but monomeric 
free p27 which migrated anomalously in gel filtration probably owing to its intrinsically 
unstructured nature (Sivakolundu, et al., 2005). Finally, analytical ultracentrifugation studies 
confirmed that His6-p27 presented an elongated shape conformation and it behaved as a 
monomer in native conditions (German Rivas personal communication).  
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4.3.2. p27 accumulation as free form correlates with the complete cell 
proliferation block observed at high Zn2+ doses in presence of active MYC 
The p27 accumulation as free form within Kp27MER cells exposed to high Zn2+ doses (75 
µM ZnSO4) suggested that p27 could be exceeding the requirements to bind and inhibit all 
available cyclin/CDK complexes. This would explain why MYC could not counteract the cell cycle 
arrest of Kp27MER cells upon treatment by high Zn2+ concentration. To investigate this possibility, 
we decided to compare by gel filtration chromatography the p27 distribution over time (6,12 and 
24 hours) at the two Zn2+ concentrations (50 and 75 µM ZnSO4) and in presence or absence of 
active MYC (4HT) in Kp27MER cells. As shown in figure 4.30, we found that at short periods of 
time of p27 induction (6 hours) with 75 µM Zn2+ all p27 was only present in high molecular weight 
complexes (~200 kDa) and thus bound to cyclin/CDKs. However at 12 and 24 hours post-
induction and coinciding with the top of p27 expression, apart from high molecular weight 
complexes, we observed that p27 also eluted as free form, even in presence of active MYC. 
Interestingly, not free form elution was observed at lower Zn2+ doses in presence or absence of 
active MYC (Figure 4.30, 50 µM Zn2+ treatments).  
Figure 4.29. GST-p27 and His6-p27 do not form heterodimers. An equimolar mixture (1:1) of recombinant 
GST-p27 and His6-p27 was incubated for 3hours at 37ºC in chromatography buffer and then subjected to gel 
filtration chromatography on Superdex-200 HR column. A) The exact elution volumes (Vol.) were determined by 
absorbance a 280 nm using an AKTA purifier apparatus and the UNICORN software (blue graph). The exact 
molecular weights of recombinants GST-p27 and His6-p27 in native or non-denaturing conditions were determined 
by comparing their respective elution volumes with those of known protein standards (red graph). B) Equal aliquots 
of the indicated fractions were analyzed by SDS-PAGE and Coomassie staining to verify protein distribution and 
denatured molecular weight of every protein (bottom panel). On the top of the panels, the arrows indicate the 
elution volume and the molecular weight of protein standards.  
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These findings suggested that at high Zn2+ doses (with 75 µM ZnSO4), p27 first bound all 
available cyclin/CDK complexes and then, the excess of p27 overexpressed, accumulated in free 
form. Moreover these results also indicated that p27 bound only to cyclin/CDK complexes and not 
to monomeric CDKs (Figure 4.28A). Based on these findings and the results obtained by J.C 
Acosta et al. (Acosta, et al., 2008) we conclude that the G1-S transition block occurs at this point 
when p27 begin to accumulate as free form.  
4.3.3. MYC promotes free-p27 displacement toward high molecular weight 
complexes where it co-elutes with SKP2  
However, as previously described in this Thesis, p27 degradation also occurs at high p27 
levels. Thus we decided to analyze in more detail the effect of MYC in the p27 distribution. The 
densitometry quantification of chromatograms from cells Kp27MER cells treated whit 75 µM 
ZnSO4 (Zn2+) at 24h post-induction in the presence and absence of active MYC (Figure 4.30) 
revealed that MYC activation promoted a subtle redistribution of p27 free form to high molecular 
weight complexes (Figure 4.31). This redistribution could be explained, at least in part, through 
the induction of cyclin A (Section 4.2.2.), cyclin D2 or CDK4 among others (Acosta, et al., 2008) 
by MYC and thus the generation of new cyclin/CDK complexes which could be sequestering free 
p27.  
 
Figure 4.30. p27 accumulates in free form after 12 hours post-induction with high Zn2+ doses in 
Kp27MER cell extracts. Kp27MER cells treated with 50 or 75 µM ZnSO4 in presence (A) or absence (B) of 200 
nM 4HT for 6, 12 or 24 hours respectively (as indicated) were lysed softly in nondenaturing conditions and 3mg of 
every protein extract was fractionated by gel filtration chromatography on Superdex-200 HR column. Equal 
aliquots of the indicated fractions (on the top of the panel), were analysed by immunoblotting against p27. Fraction 
numbers and the fraction elution of protein standards are shown at the top of the figure. No appreciable p27 signal 
was found at 6 hours post-induction and low Zn2+ doses (50 µM Zn2+) (not shown).  
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Moreover, at lower Zn2+ doses (50 µM ZnSO4) and 24h post-induction the total p27 levels 
decreased from high molecular weight complexes in presence of active MYC (Figure 4.30, 
compare 50 µM Zn2+ treatments +/- 4HT at 24 hours). This decrease from the high molecular 
weight p27 complexes suggested that the cyclin/CDK/p27 complexes were the main targets for 
p27 degradation by de SCFSKP2 complex, as it has been previously reported (Zhu, et al., 2004b). 
Given that the estimated average molecular weight of a cyclin/CDK/p27 complex was about ~100 
kDa and the high molecular weight complexes had a molecular mass of about ~200 kDa, this also 
suggested the possible presence of proteins other than cyclins, CDKs and the CDK inhibitor 
which could participate in its degradation such as proteins of the SCFSKP2 complex. In addition, it 
had been reported that the in vitro reconstituted SCFSKP2 bound to cyclin A/CDK2/p27 complex 
migrated with an apparent molecular weight of ~230 kDa (calculated MW 251.6 kDa) in gel 
filtration chromatography on a Superdex-200 HR column (Hao, et al., 2005).  Thus, we decided to 
study the possible presence of SKP2 in the high molecular weight complex.  In cells treated with 
50 µM Zn2+
 
and 4HT we found that SKP2 coeluted with p27 complex (Figure 4.32, lower panel) 
suggesting furthermore the presence of other components of SCFSKP2 complex and giving an 
explanation for degradation of p27 from this complex. However, further studies are required to 
confirm the presence of SCFSKP2 elements in these high molecular weight complexes.  
 
 
 
 
 
 
 
 
 
Figure 4.31. MYC promotes p27 free 
redistribution to high molecular weight 
complexes. Relative distribution of free and 
cyclin/CDK bound p27 determined by 
immunoblot densitometry analysis of 
Kp27MER cells treated for 24 hours with 75 
µM ZnSO4 in presence (blue) or absence 
(red) of 4HT. The Image J software was used 
to densitometry quantification analysis. p27 
amounts are expressed as % relative to the 
total p27 in all fractions. Fraction numbers 
and the fraction elution of protein standards 
are shown at the bottom of the figure. 
 
Figure 4.32. SKP2 coelutes 
with high molecular weight p27 
complexes. Immunoblotting analysis 
against p27, CDK2, cyclin E and 
SKP2 of protein extracts from 
Kp27MER cells treated for 24 hours 
with 50 µM ZnSO4 in presence (A) or 
absence (B) of 200 nM 4HT, 
fractionated by gel filltration 
chromatography on Superdex-200 HR 
column. Fraction numbers and the 
fraction elution of protein standards 
are shown at the top of the figure. 
 
A 
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It is widely accepted that the function of the oncogenic transcription factor MYC in cell
proliferation is ligated to its effects on the cell cycle inhibitor p27 (see “Introduction”, section
1.4.6.1.). Previously in our laboratory it was engineered a K562 derived cell line with conditional
expression of p27 and MYC (Kp27MER) to study the antagonism between these two proteins in
proliferation and differentiation (Acosta, et al., 2008). The levels of p27 in these cells can be
modulated by increasing the concentration of inducer (Zn2+) in the culture media. The effect of
MYC in proliferation of these cells was clearly dependent on the levels of p27 protein. At high p27
levels, MYC was not able to counteract the inhibitory effect of p27 on proliferation, but at lower
p27 levels MYC was able to promote an increase in cell proliferation of otherwise arrested cells.
This was due, at least in part, to a moderate down-modulation of p27 levels induced by MYC
(Acosta, et al., 2008). In this work we have used this cell model as a tool to study the mechanism
involved in p27 down-modulation mediated by MYC.
5.1. THE MYC-SKP2 INTERACTION
In the first part of this Thesis we have identified SKP2 as a novel MYC target gene in K562
cells. SKP2 is the F-box protein of the SCFSKP2 ubiquitin ligase complex and thus the protein
involved in the recognition of substrates to be ubiquitinated by this E3 complex, having p27 as
main target. Moreover, we have found that SKP2 regulation by MYC is not only specific of K562
cells but can be observed in several others cell models from different origins or even in primary
tumor samples (CML).
5.1.1. MYC regulates SKP2 expression independently of its effects on cell
proliferation
Several mechanisms have been previously proposed to explain the MYC effect on p27
down-modulation, including transcriptional repression (Yang, et al., 2001; Chandramohan, et al.,
2004) or induction of CUL1 (O'Hagan, et al., 2000) and CKS1 (Keller, et al., 2007). CUL1 and
CKS1 are also components of the SCFSKP2 ubiquitin ligase complex. However, none of the
previously mentioned mechanism seems to work in the Kp27MER model. The transcriptional
repression p27 has been directly discarded because, in these cells, the exogenous p27
expression is controlled by the sheep metallothionein promoter which only responded to heavy
metals. On the other hand, we have not found changes in CUL1 or CKS1 protein expression in
Kp27MER cells after MYC activation in presence or absence of p27. This could be due to
differences in the origin of cell models used in every experiment. CUL1 induction was observed in
primary human fibroblast derived from fetal lung tissue (IMR90 cells) transduced with the MYCER
protein (O'Hagan, et al., 2000), whereas CKS1 induction was observed in B cells from Eµ-MYC
transgenic mice and MEFs transduced with the MYCER construct (Keller, et al., 2007). All this
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has led us to look for an alternative mechanism to explain p27 down-modulation after MYC
activation in Kp27MER cells.
Using a large-scale gene expression analysis of Kp27MER cells performed in our
laboratory (Acosta, et al., 2008) we identified SKP2 as a possible transcriptional target of MYC.
The involvement of SKP2 in p27 degradation is widely accepted and has been confirmed in
studies with knockout mice. Indeed, Skp2-/- mice accumulate high p27 protein levels in all tissues
and they are smaller compared to wild type animals (Nakayama, et al., 2000). Nonetheless, the
elimination of p27 gene in Skp2-/- mice is able to rescue this phenotype (Nakayama, et al., 2004),
demonstrating that SKP2 is the major F-box protein involved in p27 degradation. Given that the
induction of SKP2 by MYC could be relevant to explain the p27 degradation observed in
Kp27MER cells, we decided to study whether SKP2 up-regulation was an indirect effect of MYC
activity or it was a direct effect, i.e., whether SKP2 was a MYC target gene. Nevertheless, since
SKP2 is a protein associated to cell cycle progression (actually, SKP2 stands for “S phase kinase-
associated protein 2”) (Zhang, et al., 1995) and MYC stimulates proliferation, it was conceivably
that SKP2 induction could be an indirect effect of MYC-induced cell proliferation. In fact, SKP2
expression had been already used as an independent marker of MYC-induced cell proliferation in
prostate cancer cells (LNcaP) (Bernard, et al., 2003).
To rule out this possibility we have analyzed SKP2 expression in four K562-derived cell
models, in which we could induce or activate MYC in conditions of proliferative arrest. The
proliferative arrest was achieved by different approaches: ectopic p27 overexpression, TPA and
imatinib treatments, and p53 activation. In all cases, we have found that MYC induces SKP2 at
mRNA and protein levels in proliferative arrest conditions. Thus we have concluded that the
induction of SKP2 by MYC was not an indirect consequence of a MYC-mediated induction of
proliferation but it is directly induced by MYC.
It is worthy to mention that some approaches used here to inhibit cell proliferation have
previously been described to affect SKP2 expression in greater or lesser extent. For instance, it
had been described that the transcription factor p53 repressed SKP2 after DNA damage (Barre
and Perkins, 2010). Accordingly, we have observed that SKP2 is down-modulated after p53
activation in KMYCBp53 cells. However, we found that MYC is able to counteract the SKP2 down-
modulation mediated by p53.
On the other side, K562 cells derive from chronic myeloid leukemia and thus express the
tyrosine kinase BCR-ABL. It has been described that BCR-ABL up-regulates MYC expression
(Xie, et al., 2002; Gomez-Casares, et al., 2004; Samanta, et al., 2006), but also that BCR-ABL
induces SKP2 expression (Andreu, et al., 2005; Chen, et al., 2009). Accordingly, we have
observed that inhibition of BCR-ABL by imatinib promotes SKP2 down-regulation in KMER4 cells.
However, we have found that ectopic MYC up-regulates SKP2 in presence of imatinib, i.e., with
inhibited BCR-ABL. This suggests that the effect of MYC is dominant over the effect of BCR-ABL
on SKP2. A likely explanation is that MYC could be acting downstream of BCR-ABL to induce
SKP2. Therefore, we propose that BCR-ABL induces MYC and, in turn, MYC induces SKP2
expression.
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5.1.2. SKP2 is a MYC target gene
However, the concomitant SKP2 expression after MYC induction or activation in arrested
cells, does not demonstrate yet that SKP2 is a direct MYC target gene. The demonstration is
based on four additional observations:
First, we have found that SKP2 was down-modulated after MYC silencing in K562 cells or
after MYC repression in p493.6 and TM1 cells. In agreement with ours findings, SKP2 was one of
the genes down-regulated in a genome-wide transcriptional study upon MYC silencing in human
breast carcinoma cells (Cappellen, et al., 2007). In addition, we have observed that MYC null rat
fibroblast (HO15.19 cells) express lower SKP2 protein levels than parental cells (TGR-1 rat
fibroblast). Furthermore, unlike TGR-1 cells, SKP2 is not down-regulated after serum deprivation
in MYC null cells suggesting that MYC is essential for SKP2 up-regulation in response to growth
factors stimulation. However, the presence of SKP2 in MYC-/- cells although in small amounts,
indicates that MYC is not absolutely required for SKP2 gene transcription. Thus, SKP2 expression
cannot be expected to correlate to MYC in all cell types and tumors. Lastly, it should be noted that
all these experiments have been carried out with cell models from different tissues and species,
suggesting that the SKP2 regulation by MYC is a general feature in animal cells.
Second, there was the possibility that MYC might stimulate SKP2 expression through the
induction of additional transcription factors which in turn would directly bind and activate SKP2
promoter. For instance, It has been described that MYC induces E2F1 (Berns, et al., 2000) and
that SKP2 was transcriptional target of E2F1 in human tumor cell lines (Zhang and Wang, 2006;
Reichert, et al., 2007) and mouse fibroblasts cells (Yung, et al., 2007). Furthermore, it has been
reported that E2F1 was required for MYC-mediated down-modulation of p27 in Eμ-MYC B cells
(Baudino, et al., 2003). However, we have shown that MYC induces SKP2 mRNA expression in
presence of cycloheximide and thus in absence of de novo protein synthesis. This finding strongly
suggests that MYC induces SKP2 directly and that additional intermediary transcription factors
such as E2F1 are not strictly required to induce SKP2. In accordance with this last suggestion, it
has been reported that SKP2 expression is induced by MYC in absence of E2F1 (Old, et al.,
2010). However, in contrast to our results, Keller and collaborators have shown that MYC
regulates SKP2 indirectly because SKP2 is not induced after MYCER activation in presence of
CHX in primary early-passage MEFs (Keller, et al., 2007). The discrepancy with our results could
lie in the time to study SKP2 mRNA expression after cycloheximide treatment. We have analyzed
SKP2 mRNA expression 6 hours after CHX treatment because MYCER half-life was
approximately of 3 hours in Kp27MER (see figure 4.9A). In contrast, Keller et al. studied SKP2
mRNA expression after 24 hours of cycloheximide treatment. Given the short half-life of MYCER,
it is likely that 24 hours could be too long period of treatment to detect MYC effects in the
experimental setting reported by Keller et al.
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Third, we have shown that MYC transactivates a reporter construct containing 1148 pb of
human SKP2 promoter. It should be noted that K562 derived cell lines with conditional expression
of MYC (KMYCJ, KMYCBp53, KMER4 or Kp27MER cells) express already high levels of
endogenous MYC protein in basal conditions. TPA treatment provokes the down-modulation of
endogenous MYC and allows us to independently analyse the effect of the induced MYC protein
in KMYCJ cells treated with Zn2+. Therefore, we have concluded that MYC induces the SKP2
promoter and that the exogenous Zn2+-induced MYC is able to revert the effect of TPA on SKP2
promoter. This result is also in agreement and complements our previous finding showing SKP2
mRNA and protein expression after MYC induction in KMYCJ cells exposed to TPA (Figure 4.5).
Finally, TPA could be replaced by imatinib with similar results given that it has been shown that
SKP2 promoter is also down-regulated after imatinib treatment in K562 cells (Chen, et al., 2009).
Fourth, we have demonstrated by ChIP experiments that MYC binds to the human SKP2
promoter in K562 cells growing in normal conditions but not in cells with depleted Myc (i.e.,
treated with TPA or Imatinib). Specifically, we have found that MYC binds to a ~400 bp long
region containing two non-canonical E-boxes (CACGCG and CATGCG) upstream of transcription
start site but not to the canonical E-box (CACGTG) found in the second exon. Our results are in
agreement with previous findings showing that MYC has more affinity for these two non-canonical
E-boxes than for the canonical E-box (Grandori, et al., 1996). Moreover, recent studies of high-
throughput sequencing of ChIP DNA (ChIP-PET) have demonstrated that a significant fraction of
the loci occupied by MYC lacks obvious DNA element that resemble canonical E-boxes (Zeller, et
al., 2006; McMahon, 2010). In this sense, it is interesting to mention that the absence of canonical
E-boxes (CACGTG or CACATG) in mouse Skp2 promoter was used by Old and coworkers to
argue that MYC regulated SKP2 expression in an indirect fashion (Old, et al., 2010).
Nevertheless, MYC binding to Skp2 promoter has been recently reported in a ChIP-sequencing
study in mouse embryonic stem cells despite the absence of canonical E-boxes (Kim, et al.,
2010).
Finally and in consistency with our ChIP results we have corroborated the MYC binding to
SKP2 promoter using ChIP-sequencing datasets generated by the ENCODE consortium and
available in the UCSC genome browser. It should be noted that the independent ChIP-
sequencing provided by the ENCODE consortium was also developed in K562 cells using the
same antibody that we have used in this Thesis. Moreover, besides reinforcing our results, these
data have given us the confidence to use this database to in silico analyze the SKP2 promoter
looking for additional elements which could be regulating it. In this way, we have found that in
K562 cells growing in normal conditions, the SKP2 promoter presents several histone marks
associated to active chromatin such as H3K9ac, H3K27ac and H3K4me3, indicating that this
promoter is relatively active. In addition, we have found that it concentrates several proteins
including MAX (the MYC dimerization partner); the histone acetyl-transferase p300 and the
RBPP5 subunit of the histone methyltransferase complex MLL1 (involved in the acetylation or
methylation respectively of these histones) or elements of basal transcription machinery such as
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TBP or RNA polymerase II. All these elements have been found to interact with MYC in a greater
or lesser extent in other cell models, on other loci or in different experimental conditions (see
Introduction, section 1.4.3.). Furthermore, this database shows that MYC binding to SKP2
promoter is not exclusive of K562 cells but also occurs in several other human cell lines including
NB4, HepG2, Hela and A549. These results confirmed that SKP2 regulation by MYC also occurs
in other human tissues, although ChIP-seq data from other species are not available yet.
Taken collectively all these findings we conclude that SKP2 is a new MYC target gene.
Moreover, based on our results and the data of UCSC database we hypothesized the next model
by which MYC/MAX heterodimers recognize and bind to both non-canonical E-boxes on SKP2
promoter, recruiting the histone acetyltransferase CBP/p300 and the histone methyltransferase
complex MLL1 and allowing, in turn, the association of the basal transcription machinery (TBP
and RNA polymerase II among other subunits) to activate and maintain SKP2 expression in K562
cells (Figure 5.1).
5.1.3. SKP2 has no effect on MYC expression or transactivation
We have found that SKP2 is a MYC target gene and therefore that SKP2 expression is
dependent on MYC activity. In addition, it has been reported that SKP2 binds to MYC to activate
its transcriptional activity but at the same time to promote its ubiquitination and degradation by the
proteasome, (Kim, et al., 2003; von der Lehr, et al., 2003). This has led us to explore whether
MYC stability and transcriptional capacity was affected in turn by SKP2 in the K562 model.
However, we have not detected any effect of SKP2 on MYC protein stability (as assessed by
immunoblot) or transcriptional activity (as assessed by luciferase assays) at least in this model.
This discrepancy could be due to differences in cell models used in these studies. We have used
Figure 5.1.  MYC binds to the SKP2 promoter and recruits CBP/p300 and MLL1 complex to activate and
maintain its expression in K562 cells. MYC-MAX heterodimers recognize the two non-canonical E-boxes located on
the SKP2 promoter (CATGTG and CACGCG, 756 and 395 pb upstream of transcription start site, respectively) and
recruit the CBP/p300 histone acetyltransferase which acetylates histone H3 at lysine 27 and the MLL1 histone
methyltransferase complex which trimethylates the histone H3 at lysine 4 on SKP2 promoter allowing an environment
of active chromatin. This allows the recruitment of different elements of basal transcription machinery such as TBP
and RNA polymerase II which in turn are responsible of SKP2 transcription.
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K562 cells, which express high basal MYC levels compared with other human cell lines (Delgado,
et al., 1999). Therefore it could be expected exhaustion of the SKP2-dependent degradation
machinery for MYC in K562 cells. Nevertheless, our results are in agreement with those of Old
and co-workers showing that Skp2 loss does not led to increased levels of MYC protein and does
not  affect the expression of MYC targets genes in B-cells from Eμ-MYC mice (Old, et al., 2010).
Also, most of the recent literature suggest that the major complexes responsible of MYC
ubiquitination and degradation are the HECT domain-containing E3 enzyme, HectH9 (Adhikary, et
al., 2005) and the F-box protein FBW7 (Welcker, et al., 2004; Yada, et al., 2004). In fact, a recent
report has showed that MYC degradation in hematopoietic cells is only dependent on FBW7
ubiquitin ligase and not on SKP2 (Reavie, et al., 2010).
5.1.4. MYC and SKP2 expression correlates in hematologic tumors
Given that the K562 cell model derived from a CML patient in blast crisis, we have studied
the interaction between MYC and SKP2 in primary bone marrow samples from CML patients at
diagnosis and in a small cohort of imatinib treated patients. As well as in K562 derived cell
models, we have found a positive correlation between MYC and SKP2 expression at mRNA and
protein level in CML patients. Moreover, we have found that MYC and SKP2 mRNA levels are
generally up-regulated at diagnosis and that they are down-regulated in imatinib-treated patients.
Accordingly, elevated levels of MYC expression in CML patients at diagnosis and its down-
modulation after imatinib treatment have been previously reported (Albajar, et al., 2011), although
its correlation with SKP2 expression had never been studied before. The importance of SKP2
induction by MYC in CML samples is highlighted by previous results showing that SKP2 is a
mediator of BCR-ABL-induced myeloid leukemia in mice (Agarwal, et al., 2008). Based on our
results we suggest that MYC could be responsible for the induction of SKP2 in primary human
CML samples and that the axis BCR-ABL→MYC→SKP2 could play a key role in the
pathogenesis of CML.
On the other hand, using cancer gene expression databases such as Oncomine and
GeneSapiens we have also found a MYC-SKP2 correlation in human B cell lymphomas and in
acute myeloid leukemia (AML). Remarkably, Burkitt lymphomas express high levels of SKP2
mRNA. This lymphoma is characterized by the deregulation of MYC gene due to a translocation.
In addition, SKP2 mRNA and protein levels have been also found to be markedly elevated in
lymphomas that arise in Eμ-MYC mice (Keller, et al., 2007). Meanwhile, the importance of SKP2
correlation with MYC in AML samples is enhanced because MYC has been found overexpressed
in AML (Delgado and Leon, 2010; Delgado, et al., 2013) and elevated SKP2 levels represent a
poor prognostic factor in this malignancy (Min, et al., 2004). Finally, recent results in our
laboratory show a strong correlation between MYC and SKP2 in chronic lymphocytic leukemia
(CLL) (J.M. Caraballo PhD dissertation). Our findings strongly suggest that MYC is the main
regulator of SKP2 expression in all these hematologic malignancies but probably in several others
human cancers overexpressing SKP2.
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5.2. THE MYC-SKP2-p27 AXIS
In the second part of this Thesis we have demonstrated that p27 down-modulation
previously observed in Kp27MER cells was due to the induction of SKP2 by MYC. Moreover, and
conversely to the idea previously established in the literature, we have identified cyclin A/CDK1
complexes instead of cyclin E/CDK2 complexes as principal mediators of p27 phosphorylation at
Thr187 after MYC activation, being this phosphorylation event a prerequisite for p27 targeting by
the SCFSKP2 ubiquitin ligase complex. Finally, we have shown that SKP2 is an important mediator
for MYC mediated tumorigenesis using a xenograft model in nude mice.
5.2.1. MYC promotes p27 phosphorylation by cyclin A induction
Previous studies indicated that p27 needed to be phosphorylated at Thr187 to be
recognized by the SCFSKP2 ubiquitin ligase complex, and thus to be efficiently ubiquitinated and
targeted by the proteasome system (Hao, et al., 2005). We have found that MYC promotes
p27Thr187 phosphorylation 8-12 hours after MYC activation in cells expressing the MYCER chimera
(Figure 4.18B). Moreover we have observed that the phosphorylation was independent of p27
protein level (Figure 4.18A) suggesting that the kinase involved in this event was not inhibited by
p27. Induction of p27pThr187 by MYC had been previously reported by in vitro phosphorylation
assays, using protein extracts from MYC-expressing cells (Muller, et al., 1997) although it was
never demonstrated in vivo in cells with induced expression of MYC.
The induction of p27Thr187 phosphorylation by MYC led us to investigate the kinase
responsible for this effect. It had been described that MYC induced cyclin E expression (Jansen-
Durr, et al., 1993; Perez-Roger, et al., 1997) and that cyclin E/CDK2 complexes mediated p27
phosphorylation at Thr187 at G1/S phase transition (Muller, et al., 1997; Sheaff, et al., 1997;
Vlach, et al., 1997; Montagnoli, et al., 1999). However, our findings suggest that, not only cyclin
E/CDK2 but also cyclin A/CDK1 complexes play an important role in this phosphorylation event
induced by MYC. This conclusion is based on several observations:
First, we have found no correlation between cyclin E protein levels and p27Thr187
phosphorylation. By contrast, we have observed cyclin E protein stabilization in presence of Zn2+-
induced p27 (Figure 4.19). This effect of p27 on cyclin E stability has been previously reported. It
appears that p27 inhibits the ubiquitination and degradation of cyclin E (Clurman, et al., 1996). On
the other hand, we have found cyclin A expression concomitant to MYC activation even in
presence of Zn2+-induced p27, correlating with p27Thr187 phosphorylation. Induction of cyclin A by
MYC has been also previously described in several other cell models (Jansen-Durr, et al., 1993;
Barrett, et al., 1995; Muller, et al., 1997; Qi, et al., 2007).
Second, the kinase activity of CDK2 on recombinant His6-p27 was completely inhibited by
endogenous p27 in presence of active MYC, after p27 induction by Zn2+ (Figure 4.20B).
Accordingly, complete inhibition of CDK2 kinase activity by p27 using recombinant RB as
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substrate has been previously reported by our group (Acosta, et al., 2008). The complete
inhibition of CDK2 by high levels of endogenous p27, in presence of active MYC also rules out a
possible mechanism of CDK2 activation by another NRTK (Chu, et al., 2007; Grimmler, et al.,
2007) likely induced or activated by MYC. In contrast, besides cyclin A induction by MYC, we
have found kinase activity associated to cyclin A immunocomplexes on recombinant His6-p27
when we activated MYC in presence of endogenous Zn2+-induced p27 (Figure 4.20A).
Third, we have shown by co-immunoprecipitation assays that cyclin A not only binds  CDK2
but also binds to CDK1 in Kp27MER cells (Figure 4.20D) and by kinase assays that CDK1
immunocomplexes are also able to phosphorylate recombinant His6-p27, even in the  presence of
Zn2+-induced p27 (Figure 4.20C). The ability of CDK1 to bind cyclin A (Tsai, et al., 1991) and to
phosphorylate p27Thr187 has been previously reported (Montagnoli, et al., 1999; Zhu, et al., 2004b).
Moreover, unlike CDK2 immunocomplexes, we have found that CDK1 immunocomplexes are not
efficiently inhibited by induced p27. Accordingly, it has been reported that p27 has higher
inhibitory potential on CDK2 than on CDK1 complexes (Polyak, et al., 1994b; Toyoshima and
Hunter, 1994).
 And fourth, through in vitro phosphorylation assays using cyclin A and CDK1
immunocomplexes prepared from Cdk2-/- and Cyclin E1-/-/E2-/- MEFs overexpressing MYC, we
have demonstrated that: i) CDK2 is not necessary for MYC-mediated p27Thr187 phosphorylation
(Figure 4.21); ii) MYC induces CDK1 and CDK2 kinase activity in absence of E-type cyclins
suggesting that cyclin A (and probably also cyclin B, in the case of CDK1) is responsible for this
increased kinase activity; and  iii) MYC induces the kinase activity associated to cyclin A in
absence of CDK2, suggesting that CDK1 is the responsible kinase for this activity. In agreement
with ours results, it has been reported the presence of phosphorylated p27Thr187 in different tissues
from Cdk2-/- mice (Berthet, et al., 2003), arguing that CDK1-mediated phosphorylation of p27Thr187
also occurs in vivo.
In summary, based on these results we propose that MYC promotes p27Thr187
phosphorylation through the induction of cyclin A expression and cyclin A-associated kinase
activity (Figure 5.2). Cyclin A can form complexes with CDK2 and CDK1, being the cyclin A/CDK1
the complexes which efficiently phosphorylate p27 at Thr187 when cyclin E-A/CDK2 complexes
remain completely inhibited by the own p27. This function of CDK1 phosphorylating p27Thr187
owing to MYC-induced cyclin A expression might be surprising given that CDK1 activity has been
generally associated to G2-M phases and p27 activity to G0-G1 phases (see Introduction).
However, the ability of CDK1 alone to drive not only G1-S transition (Aleem, et al., 2005) but the
complete mammalian cell cycle has been previously reported (Santamaria, et al., 2007).
Moreover, it should be noted that CDK1 and CDK2 shared a 60-65% of sequence identity with an
84% similarity (McGrath, et al., 2005) and thus it is conceivably that they could also share the
majority of substrates when complexed with the same cyclin. Lastly and independently of cyclin A
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role in p27 phosphorylation, it should be mentioned that the binding of p27 to cyclin A/CDK2
complex but not to cyclin E/CDK2 complex is required for efficient p27 ubiquitination by SCFSKP2
(Zhu, et al., 2004b) highlighting the importance of cyclin A in p27 targeting for degradation.
Finally, it might be interesting to study why the kinase activity associated to CDK2, cyclin A
and to a lesser extend CDK1 was inhibited by the endogenous Zn2+-induced p27 but not by
recombinant His6-p27 added to the experiment in vitro. The inability of bacterially produced p27 to
inhibit CDK1 and CDK2 has been already observed (Zhu, et al., 2004b) but no explanation has
been proposed yet. The biochemical comparison between recombinant and cellular p27 could
shed light on the posttranslational modifications that likely explain this difference.
5.2.2. MYC down-regulates p27 through SKP2 expression and SKP2
mediates tumor growth in nude mice
Apart from inducing p27Thr187 phosphorylation, we have demonstrated that MYC-induced
SKP2 is responsible for p27 down-regulation in K562-derived cell models (Figure 5.2). This
conclusion is based in three findings:
First, we have shown by immunoblot that p27 protein levels inversely correlates with MYC-
induced SKP2 expression in K562-derived cell models, including Kp27MER cells (Figure 4.22A),
KMER cells growth-arrested by high cell density in culture (Figure 4.22C), KMYCJ cells arrested
by TPA or Imatinib (Figure 4.26A and B) and serum deprived K562 cells (Figure 4.26D). We have
observed the same result in serum deprived TGR-1 cell line (Figure 4.26C).
Figure 5.2.  MYC promotes p27 phosphorylation trough cyclin A induction and cyclin A kinase
associated activity. p27 blocks CDK2 kinase activity which is usually associated to cyclin E and A. MYC induces
cyclin A which binds to CDK2 and CDK1. Cyclin A/CDK1 complexes are not inhibited efficiently by p27. In turn,
p27 is phosphorylated at Thr187 by cyclin A/CDK1 complexes, promoting its recognition by the SCFSKP2 ubiquitin
ligase complex and thus its degradation via proteasome.
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Second, we have shown by immunofluorescence assays that p27 and SKP2 localize in the
nuclei of Kp27MER cells but they are mutually exclusive (Figure 4.23). Accordingly, it has been
reported that SKP2-dependent ubiquitination of p27 only takes place in the cell nucleus
(Nakayama and Nakayama, 2006). Moreover, the absence of p27 staining in the cytoplasm
excludes the possibility of p27 degradation by ubiquitin ligases other than SKP2, such as KPC or
SIAH1/SIP which only operate in the cytoplasm (Kamura, et al., 2004; Nagano, et al., 2011).
Finally, we have found that p27 accumulates in K562 cells after shRNA-mediated SKP2
silencing (Figure 4.24A). This finding confirms that SKP2 is the main mediator of p27 down-
modulation in K562 cells but surely also in other K562-derived cell lines as Kp27MER cells.
Moreover, the reduced proliferation rate of the cells with silenced SKP2 compared to
control cells (Figure 4.24B) also confirms that the MYC-SKP2-p27 axis is an important effector of
cell proliferation mediated by MYC in leukemia cells. In this line, it has been recently reported that
SKP2 is critical for in vivo MYC-driven keratinocyte (Sistrunk, et al., 2011) and lymphocyte hyper-
proliferation (Old, et al., 2010).
We have also confirmed the functionality of the MYC-SKP2-p27 axis in vivo comparing the
growth of tumor xenografts induced upon subcutaneous injection of K562 cells with silenced
SKP2 expression versus control cells. We found that the tumors developed by KMERshSKP2
subline are smaller than these ones developed by control cells suggesting that SKP2 is an
important mediator of the tumor growth. The result is consistent with the reduced proliferation rate
of these cells in culture (Figure 4.24B) owing to the accumulation of p27 in absence of SKP2
(Figure 4.24A). However, reportedly SKP2 loss only has a modest effect in MYC-mediated
lymphomagenesis in Eµ-MYC transgenic mice although lymphoid cell proliferation is impaired
(Old, et al., 2010). Similarly, Skp2 deficiency does not affect the development of spontaneous
tumors within the oral cavity in K5-MYC-transgenic mice (Sistrunk, et al., 2011), a result that could
be explained if cell proliferation in this tissue is less dependent on p27 inhibition.
5.3. THE MYC EFFECTS ON CELL CYCLE DEPENDS ON p27 PROTEIN
LEVELS
In the last part of the Thesis we have found that p27 accumulates in free form in Kp27MER
cells when high p27 levels were induced (i.e., with high Zn2+ doses as 75 µM ZnSO4), even in
presence of active MYC. This suggests that the induction rate of p27 is greater than the
degradation rate mediated by the MYC-SKP2 axis and offers a possible explanation for the
incapacity of MYC to promote proliferation of Kp27MER cells at high p27 concentrations.
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5.3.1. p27 accumulation as free form leads to cell proliferation arrest even
in presence of active MYC
In Kp27MER cells MYC counteracts the effect of p27 in cell proliferation at low p27 levels
(i.e., cells treated with 50 µM ZnSO4) but not at high p27 levels (i.e., cells treated with 75 µM
ZnSO4) (Acosta, et al., 2008). However, we have found that p27-Thr187 phosphorylation and p27
down-modulation by the SCFSKP2 ubiquitin ligase complex also occurs at high Zn2+-induced p27
levels (Figure 4.27). All these findings led us to consider the possibility that there was a threshold
concentration of p27 which determined the complete proliferative arrest and which should be
counteracted by MYC-SKP2 axis to result in cell proliferation.
Using gel filtration chromatography of protein extracts followed by immunoblot analysis we
have found that in Kp27MER cells overexpressing high p27 protein levels (i.e. in cells treated with
75 µM ZnSO4), all p27 distributed between two complexes: a high molecular weight complex
(~200 kDa), in which p27 was found associated to cyclin/CDK complexes, including cyclin
E/CDK2 (Figure 4.28B), but also cyclin D/CDK4-6 (J.C. Acosta PhD dissertation) and a low
molecular weight elution form of around ~50 kDa. We have demonstrated that the low molecular
weight elution form was free p27 by comparing the elution volume of p27 after heat treatment of
the corresponding fractions and that of purified recombinant His6-p27 (Figure 4.28C, D and E).
Moreover, the migration of free p27 as a protein of ~50 kDa in gel filtration initially led us to
believe that p27 behaved as a dimer in native conditions. This has been also suggested by
Bouchard and collaborators (Bouchard, et al., 1999). However, using a mixing experiment with
the two recombinant p27 proteins (His6-p27+GSTp27) we demonstrated that these proteins do
not form heterodimers. Thus we conclude that free p27 [His6-p27 or GSTp27, but also GFPp27
(not shown)] migrates anomalously in gel filtration. This anomalous elution of p27 in gel filtration
chromatography has been also mentioned in the literature (Poon, et al., 1995; Borriello, et al.,
2000). It should be noted that p27 is an intrinsically unstructured protein (Bienkiewicz, et al.,
2002) and thus p27 does not folds into a globular structure as the protein standards used in gel
filtration calibration. The monomeric nature of bacterially produced His6-p27 was confirmed by
analytical ultracentrifugation experiments done in collaboration with the laboratory of German
Rivas (Centro de Investigaciones Biológicas, CSIC, Madrid).
In addition, the comparative analysis of p27 distribution in Kp27MER cells treated with
different Zn2+ dosages, in presence or absence of active MYC and at different times by gel
filtration (Figure 4.30) revealed that:
i) The presence of p27 free form depends on Zn2+ concentration used and thus on the
induced p27 protein levels, with p27 free form only appearing after induction with high Zn2+ doses
(75 µM ZnSO4), and independently of MYC activation.
ii) At short periods of time of p27 induction (~6 hours post-induction), not free p27 was
observed (Figure 4.18B). This suggests that newly translated p27 associates immediately to
cyclin/CDK complexes but does not remain as free form. All this suggests that p27 “accumulates”
as free form into the cells when it is in excess over cyclin/CDK complexes. It must be noted that
Discussion
124
the cyclins determine the amount of these complexes given that CDKs can be also found as free
form in Kp27MER extracts and that free p27 does not bind to free CDKs but to CDK-cyclin dimers
(Figure 4.28). Accordingly, not free form was observed at low p27 levels (50 µM ZnSO4) at any
moment.
Therefore, we propose that p27 reaches the threshold concentration which determines the
complete proliferative arrest when p27 saturates all available cyclin/CDK complexes and it begins
to accumulate as free form. It should be noted that the saturation of all cyclin/CDK complexes
does not imply the complete inhibition of all such complexes, as we have previously demonstrated
(Figure 4.18), but at least the complexes involved in G1-S transition and cell cycle progression
such as cyclin D/CDK4-6 (Acosta, et al., 2008) and cyclin A-E/CDK2 complexes (Section 4.2.2).
5.3.2. MYC promotes the p27 displacement from free form into high
molecular weight complexes containing SKP2
The densitometric analysis of gel filtration cromatographies revealed that MYC promoted
the displacement of free p27 into high molecular weight complexes containing cyclin/CDKs
(Figure 4.31). This could be explained, at least in part, because MYC induces the expression of
cyclin A (Section 4.4.2), cyclin D2 or cyclin B1 (Acosta, et al., 2008) and thus MYC induces the
assembly of new cyclin/CDK complexes (as CDKs are in excess) allowing that free p27 would
bind to these new complexes. Furthermore, given that at low p27 levels we only observed high
molecular weight complexes, SKP2-mediated p27 down-modulation only could be taking place
from these complexes, and this led us to look for SKP2 distribution on them. Thereby, we found
that SKP2 was also co-eluting with the high molecular weight complexes in presence of active
MYC (Figure 4.32).
Thus, we hypothesize that SKP2 is bound to cyclin/CDK/p27 complexes. Although we did
not formally demonstrated this through co-immunoprecipitation assays, it must be mentioned that
SKP2 was originally discovered associated to cyclin A/CDK2 complexes (Zhang, et al., 1995).
This might explain the elevated molecular weight of these complexes (~200 kDa) whereas the
estimated average molecular weight of a cyclin/CDK/p27 complex was just about ~100 kDa. In
agreement with this suggestion, it has been described that the recombinant SCFSKP2 complex
bound to cyclin/CDK/p27 complex presents an elution volume of ~230 kDa (Hao, et al., 2005) in a
gel filtration system similar to the one that we have used in this Thesis (Superdex-200). Moreover,
our hypothesis would be also in agreement with previous reports showing that p27 needs the
interaction with cyclin E-A/CDK2 complex to be targeted by the SCFSKP2 ubiquitin ligase complex
(Montagnoli, et al., 1999; Zhu, et al., 2004b)..
In summary, we concluded that the effect of MYC on proliferation of K562 cells (and likely in
many other cell types) depends on the p27 protein levels. At moderate p27 levels, the MYC-SKP2
axis is able to counteract the effect of p27 as cell cycle inhibitor thus resulting in cell proliferation.
In this scenario, no free p27 is found, as all available p27 is bound and inhibiting cyclin/CDK
complexes. However, a fraction of active cyclin/CDK complexes with no p27 bound is still present
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in the cell. In contrast, at high p27 levels, there is a saturation of all cyclin/CDK complexes and
thus an accumulation of p27 as free form. This p27 free acts as a reservoir to inhibit new
cyclin/CDK complexes induced by MYC, but at the same time counteracts the p27 down-
modulation from cyclin/CDK/p27 complexes by the MYC-SKP2 axis. As a result, the proliferation
continues arrested despite SKP2-mediated p27 degradation (Figure 5.3).
Figure 5.3. The effect of MYC on proliferation of Kp27MER cells depends on the balance between the p27
induction rate and the p27 degradation rate by the MYC-SKP2 axis. At low p27 levels (50 µM ZnSO4) the MYC-
SKP2 axis is able to counteract the effect of p27 as cell cycle inhibitor. However at high p27 levels (75 µM ZnSO4),
p27 accumulates as free form and it serves as reservoir to counteract the p27 degradation promoted by the MYC-
SKP2 axis maintaining the complete cell cycle arrest.
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6. CONCLUSIONS
1. MYC up-regulates the expression of SKP2 in several cell lines from different species, and
appears to be the primary mediator of the induction of SKP2 in response to serum. This
SKP2 up-regulation does not depend on MYC-induced cell proliferation.
2. MYC binds to SKP2 promoter region and activates their expression in the absence of
protein synthesis confirming that SKP2 is a new target gene MYC.
3. SKP2 does not affect the stability and the activity of MYC in K562 cells.
4. MYC and SKP2 expression correlate in several hematological malignancies including
acute and chronic myeloid leukemia, and Burkitt's lymphoma.
5. In K562 cells, MYC promotes p27 phosphorylation at threonine 187 through the induction
of cyclin A and the kinase activity associated to this cyclin, a  phosphorylation required for
p27 recognition by the SCFSKP2 ubiquitin ligase complex. In addition, MYC is able to
promoting such phosphorylation in mouse cells independently of CDK2 or E-type cyclins.
6. SKP2 induction by MYC in K562 cells correlates with decreased p27 levels, leads to an
increase in the proliferative rate and, at least in part, it is responsible for their tumorigenic
capacity in xenographs in nude mice.
7. When p27 is expressed at moderate levels in K562 cells, it is found in high molecular
weight complex together with cyclin/CDK and possibly with SCFSKP2. At high levels, p27
can also found in free form, which is associated with a total proliferation block. MYC
promotes free p27 displacement towards high molecular weight complexes by induction
of cyclins and CDKs. The disappearance of p27 as free form correlates with MYC-
mediated proliferative stimulus.
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8. RESUMEN EN CASTELLANO 
8.1 INTRODUCCIÓN 
 
El ciclo celular es el proceso que permite a una célula eucariota duplicar su contenido 
genético y posteriormente dividirse en dos células hijas genéticamente idénticas. Este proceso se 
divide en cuatro fases: G1, S (en la cual la célula replica su genoma), G2 y M (en la cual la célula 
se divide en dos células hijas) (Morgan, 2007). La correcta progresión a través de las diferentes 
fases del ciclo celular está finamente regulada por la acción coordinada de diferentes complejos 
ciclina/CDK (Murray, 2004; Satyanarayana and Kaldis, 2009). Las CDKs o quinasas 
dependientes de ciclina son las subunidades catalíticas del complejo y forman parte de una gran 
familia de quinasas de residuos de serina y treonina, las cuales controlan la fosforilación de 
diferentes sustratos implicados en la progresión de las diferentes fases del ciclo celular 
(Malumbres, et al., 2009). Las ciclinas, como su propio nombre indica, son proteínas que se 
sintetizan y se degradan específicamente durante las diferentes fases del ciclo y activan a las 
CDKs (Malumbres and Barbacid, 2005). La regulación de los complejos ciclina/CDK tiene lugar a 
varios niveles incluyendo, además de la unión de las ciclinas a sus respectivas CDKs, la 
activación o inhibición por fosforilación/defosforilación de determinados residuos en las CDKs, la 
unión a moléculas inhibidoras de CDKs (CKIs) o la degradación de los diferentes elementos 
(ciclinas y CKIs) por el sistema ubiquitina-proteosoma.  
En esta Tesis nos hemos centrado en el inhibidor de CDKs de la familia Cip/Kip p27Kip1 
(p27 en adelante). Este inhibidor de CDKs se caracteriza por ser una proteína intrínsecamente 
desestructurada que interactúa con ambos componentes del complejo ciclina/CDK (Bienkiewicz, 
et al., 2002; Lacy, et al., 2004). p27 presenta en su dominio N-terminal una pequeña hélice 310 
que se inserta en el bolsillo catalítico de la CDK, mimetizando al ATP e inhibiendo su actividad 
quinasa (Russo, et al., 1996; Pavletich, 1999). p27 puede unirse a una amplia variedad de 
complejos ciclina/CDK, siendo los complejos ciclina E-A/CDK2 su principal diana durante la 
transición entre las fases G1-S del ciclo celular (Polyak, et al., 1994; Toyoshima and Hunter, 
1994; Sherr and Roberts, 1999). p27 se regula principalmente a nivel de estabilidad proteica por 
el sistema ubiquitina-proteosoma, es decir, la degradación de p27 por el proteosoma está 
precedida de su ubiquitinación (Pagano, et al., 1995). La ubiquitinación de p27 es mediada 
principalmente por el complejo ligasa de ubiquitinas SCFSKP2, compuesto por la proteína de 
andamiaje CUL1 sobre la cual se ensamblan RBX1, que interacciona con la enzima conjugadora 
de ubiquitinas E2, y la proteína adaptadora SKP1. A la proteína adaptadora se le unen la 
proteína accesoria CKS1 y la proteína F-box SKP2. La función de las proteínas F-box es la de 
permitir el reconocimiento del sustrato de manera específica y por tanto, dentro del complejo 
SCFSKP2, SKP2 se encarga del reconocimiento de p27 (Nakayama and Nakayama, 2005,2006).  
SKP2, junto con SKP1 y CKS1, fue descubierta asociada a complejos ciclina A/CDK2, cuya 
actividad se asocia principalmente a fase S, de aquí su nombre “S-phase kinase associated 
protein” (Zhang, et al., 1995). SKP2 presenta en su dominio N-terminal un motivo F-box que 
participa en la unión a SKP1 (Schulman, et al., 2000; Zheng, et al., 2002). En su dominio C-
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terminal contiene una serie de repeticiones ricas en Leucina (LRR o “Leucine-rich repeats”) que 
participan en su interacción con los sustratos como p27 (Wang, et al., 2004), pero también con 
otros reguladores del ciclo celular como la ciclina E, p21, p57 y E2F1 (Nakayama and Nakayama, 
2006; Frescas and Pagano, 2008). SKP2 se encuentra frecuentemente sobreexpresada en 
cáncer humano, en muchos casos asociada con la progresión tumoral. De hecho, SKP2 se 
comporta como un oncogén en  ensayos de transformación (Frescas and Pagano, 2008; 
Hershko, 2008). La actividad oncogénica de SKP2 se atribuye principalmente a la degradación 
de p27 (Hershko, 2008). No obstante, el reconocimiento de p27 por parte del complejo SCFSKP2 
requiere de la fosforilación previa de p27 en la treonina 187 y de su unión a complejos ciclina E-
A/CDK2 (Carrano, et al., 1999; Sutterluty, et al., 1999; Tsvetkov, et al., 1999). Son precisamente 
los complejos ciclina E/CDK2 los que fosforilan a p27 en la treonina 187 durante la transición 
entre las fases G1 y S, promoviendo su degradación por el sistema ubiquitina-proteosoma 
(Nakayama and Nakayama, 2006; Jakel, et al., 2012). En consecuencia, los niveles de SKP2 y 
p27 correlacionan inversamente en muchos modelos celulares y en diversos tipos de cáncer 
humano, estando asociados los bajos niveles de p27 con un peor pronóstico de la enfermedad 
(Chu, et al., 2008; Frescas and Pagano, 2008; Hershko, 2008). 
c-MYC (MYC en adelante) es un factor de transcripción oncogénico de la familia de los 
factores de transcripción con dominio básico hélice-lazo-hélice cremallera de leucinas (b-HLH-
LZ). A través de su actividad transcripcional, MYC ejerce una gran variedad de funciones 
biológicas en diferentes modelos celulares relacionadas con la proliferación celular, la 
inestabilidad genómica, metabolismo energético, la síntesis de proteínas y ribosomas, la 
comunicación intercelular y el control de la diferenciación celular (Eilers and Eisenman, 2008; 
Meyer and Penn, 2008; Leon, et al., 2009; Luscher and Vervoorts, 2012). Para ello MYC forma 
heterodímeros con la proteína MAX, los cuales se unen a cajas E en las regiones reguladoras de 
los genes diana y recluta a diferentes coactivadores transcripcionales con actividad histona 
acetil-transferasa (como CBP/p300, GCN5, Tip60, etc.) o histona metil-transferasa (como MLL1) 
(Bres, et al., 2009; Luscher and Vervoorts, 2012). A su vez MYC interacciona con diferentes 
elementos de la maquinaria de transcripción basal de la ARN polimerasa II y estimula la 
elongación del ARNm por esta enzima. De esta forma MYC regula cerca de 1000 genes y se une 
a un 15% de locis genómicos. La mayoría de genes diana (~60%) son activados por MYC de 
manera dependiente de cajas E, aunque una fracción importante de los genes diana (el ~40% 
restante) son reprimidos por MYC (Patel, et al., 2004; Dang, et al., 2006; Zeller, et al., 2006). La 
expresión de MYC se encuentra desregulada en una amplia gama de cánceres humanos, en 
muchos casos asociada a la progresión tumoral y peor pronóstico (Nesbit, et al., 1999; Lutz, et 
al., 2002; Meyer and Penn, 2008).  
Existe un antagonismo funcional entre MYC y p27 en la proliferación. Por un lado, MYC y 
la pérdida de p27 cooperan en modelos animales de carcinogénesis (Martins and Berns, 2002). 
Por otro lado, MYC inhibe la función de p27 en  proliferación a través de diferentes mecanismos. 
En primer lugar, MYC reprime la expresión de p27 a nivel transcripcional (Yang, et al., 2001; 
Chandramohan, et al., 2004). En segundo lugar, MYC induce la expresión de ciclina E 
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directamente o a través de la inducción de E2F aumentando el número y la actividad de 
complejos ciclina E/CDK2 que fosforilan a p27 en la treonina 187 promoviendo la transición entre 
la fase G1 y S (Steiner, et al., 1995; Vlach, et al., 1996; Perez-Roger, et al., 1997). Tercero, MYC 
induce la expresión de ciclina D1 y D2, y de sus parejas catalíticas CDK4 y CDK6, aumentando 
la cantidad de complejos ciclina D/CDK4-6 que a su vez secuestran a p27 de otros complejos 
ciclina E/CDK2 aumentando indirectamente la actividad de estos últimos (Soos, et al., 1996; 
Bouchard, et al., 1999; Perez-Roger, et al., 1999; Obaya, et al., 2002). En cuarto lugar, MYC 
induce la expresión de CUL1 (O'Hagan, et al., 2000) y CKS1 (Keller, et al., 2007) dos de las 
subunidades del complejo SCFSKP2. Recientemente se ha observado una correlación entre MYC 
y la expresión de SKP2 en un modelo de linfoma murino, aunque con efectos modestos en 
linfomagénesis (Old, et al., 2010). Sin embargo se desconoce el mecanismo de interacción entre 
MYC y SKP2. 
En este trabajo hemos retomado el estudio de este antagonismo funcional entre MYC y 
p27 en proliferación. Para ello, hemos utilizado como modelo una sublínea celular estable 
derivada de la línea leucémica humana K562 (Lozzio and Lozzio, 1975) que expresa MYC y p27 
de forma condicional (Kp27MER), obtenida en nuestro laboratorio por el Dr. Juan Carlos Acosta 
(Acosta, et al., 2008). Estas células presentan una copia adicional del gen p27 controlado por el 
promotor de la metalotioneína de oveja que responde a diferentes concentraciones de Zinc (Zn2+) 
en el medio de cultivo (entre 0 y 75 µM de ZnSO4 en condiciones no tóxicas). Además las células 
Kp27MER expresan de forma constitutiva la proteína quimérica MYCER que puede ser activada 
en presencia de pequeñas dosis (100-200 nM) de 4-hidroxitamoxifeno (4HT) (Littlewood, et al., 
1995). La inducción ectópica de altos niveles de p27 mediante la adición de 75 µM ZnSO4 al 
medio de cultivo (la dosis máxima permitida sin afectar a la viabilidad celular) se traduce en un 
bloqueo completo de la proliferación y en la acumulación de estas células en fase G1 del ciclo 
celular. Este fenómeno va acompañado de la inhibición de la actividad quinasa tanto de CDK2 
como de CDK4 y CDK6 y de una diferenciación moderada y específica de estas células hacia el 
linaje eritroide (Acosta, et al., 2008). La activación de MYC con 200 nM de 4HT en estas 
condiciones no es capaz de revertir la parada proliferativa mediada por los altos niveles de p27 
(inducidos por 75 µM ZnSO4), pero si es capaz de contrarrestar la diferenciación mediada por 
p27 reprimiendo la expresión de varios genes maestros de diferenciación eritroide (Acosta, et al., 
2008). Sin embargo, en presencia de niveles moderados de p27 (inducidos por la adición de 50 
µM ZnSO4 al medio de cultivo), MYC provoca un aumento en la fracción de células en fase S y 
un aumento consistente en la proliferación celular. Este efecto de MYC en la proliferación celular 
puede ser explicado, en parte, por la capacidad de MYC para inducir una reducción en los 
niveles de p27 a nivel de proteína (Acosta, et al., 2008). En base a estas observaciones, hemos 
decidido utilizar este modelo como punto de partida para profundizar en el mecanismo molecular 
mediante el cual MYC induce dicha reducción en los niveles de p27, y que parece determinar su 
antagonismo en proliferación. 
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8.2 OBJETIVOS  
 
 
Existe un antagonismo funcional entre el inhibidor de CDKs p27 y el factor de transcripción 
oncogénico MYC en proliferación celular y tumorogénesis. Aparte de ser un regulador positivo de 
ciclinas y CDKs, MYC posee la capacidad de contrarrestar los niveles de p27. Se han propuesto 
varios mecanismos para explicar la correlación inversa entre MYC y p27 tanto a nivel 
transcripcional como postranscripcional. Sin embargo algunos de estos mecanismos no han sido 
reproducidos en otros modelos experimentales o no han sido trasladados al contexto clínico. Por 
otro lado, en nuestro laboratorio hemos observado que este antagonismo entre MYC y p27 
parece ser dependiente de los niveles de expresión de  p27. 
En el presente estudio nos hemos propuesto profundizar y en su caso encontrar 
mecanismos moleculares que puedan explicar el antagonismo entre MYC y p27 en diferentes 
contextos experimentales. Por tanto, nos hemos propuesto los siguientes objetivos:  
 
1. Establecer el mecanismo molecular que determina el antagonismo entre MYC y p27 en 
proliferación; estudiar su funcionalidad en distintos sistemas celulares, en modelos 
animales y en cáncer humano. 
 
2. Establecer por qué el efecto de MYC en la proliferación celular es dependiente de los 
niveles de p27. 
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8.3 RESULTADOS Y DISCUSIÓN 
8.3.1. La interacción MYC-SKP2 
Con el fin de determinar el mecanismo molecular que explicara la disminución de los 
niveles de p27 mediada por  MYC en las células Kp27MER y por tanto el antagonismo funcional 
entre MYC y p27 en proliferación celular, en primer lugar decidimos analizar si alguno de los 
mecanismos previamente descritos en la literatura podía ser trasladado a nuestro modelo celular 
Kp27MER. La represión de p27 por MYC fue directamente descartada dado que, en las células 
Kp27MER, p27 estaba controlado por el promotor de la metalotioneína de oveja que respondía 
exclusivamente a metales pesados como el Zn2+. Tampoco se encontraron cambios en los 
niveles proteicos de CUL1 y CKS1 que pudieran explicar la disminución p27. Por lo tanto, estas 
observaciones sugerían que en nuestro modelo estaba actuando un mecanismo alternativo a los 
previamente referidos.  
Utilizando un estudio de expresión global de ARNm mediante microarrays en células 
Kp27MER (con el biochip de Affimetryx HG-U133A) llevado a cabo por el Dr. J.C. Acosta en su 
trabajo de Tesis encontramos que uno de los genes inducidos por MYC en presencia de altos 
niveles de p27 y por tanto en un contexto de parada proliferativa era SKP2, proteína 
estrechamente involucrada en la degradación de p27, generalmente asociada con la progresión a 
través de la fase S y con la proliferación celular. Los resultados fueron confirmados mediante RT-
qPCR y Western Blot.  
Con el fin de verificar que la inducción de SKP2 no se debía a un efecto indirecto de MYC 
sobre la proliferación, se estudiaron otros modelos en los cuales podíamos inducir MYC en un 
contexto de parada proliferativa. Para ello se utilizaron (i) células KMER (células K562 que 
expresan la proteína MYCER) (Albajar, et al., 2011) tratadas con el inhibidor selectivo de BCR-
ABL imatinib; (ii) células KMYCJ (células K562 con una copia adicional de MYC controlado por el 
promotor de la metalotioneína) tratadas con TPA (Delgado, et al., 1995) y (iii), células 
KMYCBp53 (células K562 con una copia adicional de MYC controlado por el promotor de la 
metalotioneína y expresión constitutiva del mutante p53Val35) en las cuales la activación de p53 a 
32ºC detenía el ciclo celular e inducía apoptosis (Ceballos, et al., 2000). En los tres modelos 
utilizados, la sobreexpresión o la activación de MYC fue capaz de inducir la expresión de SKP2 a 
nivel de ARN y de proteína cuando el ciclo celular se encontraba detenido, lo que indicaba que la 
inducción de SKP2 por MYC era independiente de la inducción de la proliferación mediada por 
MYC. Además, en base a los resultados del experimento en las células KMER en presencia y 
ausencia de imatinib, concluimos que la inducción de SKP2 podía considerarse independiente de 
la actividad de BCR-ABL, la cual había sido previamente relacionada con la activación 
transcripcional de SKP2 (Andreu, et al., 2005; Chen, et al., 2009).  
Los resultados anteriores sugerían que SKP2 podía ser un gen diana de MYC. Para 
confirmar esta posibilidad a continuación nos preguntamos si los niveles de SKP2 también 
respondían a la disminución de los niveles de MYC. Para ello utilizamos 3 aproximaciones 
diferentes. i) En primer lugar se silenció la expresión de MYC mediante siRNA en células K562. 
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El silenciamiento de MYC fue acompañado de una disminución en los niveles SKP2 a nivel de 
ARN y proteína. ii) Por otro lado, se analizó la expresión de SKP2 en dos modelos celulares que 
contenían el gen MYC controlado por un sistema Tet-off represible por tetraciclinas (Ej: 
doxiciclina): Las células linfoblastoides humanas P493.6 (Pajic, et al., 2000) y las células 
epiteliales de pulmón de visón TM1 (Warner, et al., 1999). En ambos modelos, la represión de 
MYC mediante doxiciclina fue acompañada por una reducción en los niveles de SKP2 a nivel de 
ARN y proteína. iii) Por último, se comparó la expresión SKP2 entre fibroblastos de rata 
deficientes en Myc (células HO15.19) y células parentales normales (células TGR-1) (Mateyak, et 
al., 1997), observándose una menor expresión de SKP2 en las células Myc-/-. Además en las 
células HO15.19, a diferencia de las células parentales TGR-1, la expresión de SKP2 no se vio 
prácticamente afectada por la ausencia de suero en el medio de cultivo, sugiriendo que MYC es 
el principal mediador de la expresión de SKP2 en respuesta a la estimulación con factores de 
crecimiento en estas células. En conjunto, todos los resultados anteriores sugerían que MYC no 
solo era un importante regulador de SKP2 en células humanas como K562 y P493.6, sino 
también en células de otras especies animales como visón y rata y por tanto que el efecto de 
MYC sobre SKP2 podía extrapolarse a diferentes modelos experimentales.  
Para evaluar si el efecto de MYC sobre SKP2 era directo o indirecto, es decir, a través de 
otros factores de transcripción inducidos por MYC (como por ejemplo E2F1), se llevó a cabo un 
experimento de activación de MYCER en células Kp27MER en presencia de cicloheximida y por 
tanto, en ausencia de síntesis de nuevas proteínas. Los resultados mostraron que MYCER era 
capaz de inducir la expresión de SKP2 directamente sin necesidad de inducir la expresión de 
otros factores de transcripción intermediarios. De este forma concluimos que MYC inducia la 
expresión de SKP2 directamente en las células Kp27MER y por tanto que SKP2 podía ser 
considerado un nuevo gen diana de MYC. 
Para confirmarlo se realizaron ensayos de trans-activación con un vector que contenía el 
promotor de SKP2 y el gen de la luciferasa como reportero (Huang and Hung, 2006). Para ello se 
utilizaron células KMYCJ tratadas con TPA (que como habíamos demostrado anteriormente, 
disminuía completamente los niveles endógenos de MYC) en presencia y ausencia de Zn2+ (para 
inducir el MYC exógeno). MYC no solo fue capaz de activar el promotor de SKP2 sino que a la 
vez fue capaz de revertir el efecto del TPA sobre la actividad de dicho promotor.  
Además, se realizó un análisis del promotor de SKP2 humano para buscar posibles sitios 
de unión de MYC y se encontraron varias cajas E en el promotor y en el segundo exón del gen. 
Estudios de Inmunoprecipitación de cromatina (ChIP) demostraron que MYC se unía a una 
región que contenía dos cajas-E situadas a unas ~750 y ~400 pares de bases corriente arriba del 
inicio de transcripción respectivamente, controlando la expresión de SKP2. Nuestros resultados 
de ChIP fueron corroborados por otros resultados similares generados por el proyecto ENCODE 
(The Enciclopedia of DNA Elements), accesibles mediante la base de datos del UCSC 
(http://genome.ucsc.edu), que incluían diferentes estudios de ChIP-sequencing para varios 
factores de trascripción incluidos MYC y MAX en células K562, pero también otros reguladores o 
coactivadores transcripcionales como la histona acetiltransferasa p300 y la subunidad RBBP5 del 
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complejo histona metil transferasa MLL1 y diversas marcas de histonas asociadas a cromatina 
activa. Hay que destacar que los resultados de ChIP-seq para MYC y MAX también fueron 
observados en otras líneas celulares humanas como células de leucémia promielocítica aguda  
(NB4), células de carcinoma de pulmón (A549), hígado (HepG2) o cervix (HeLa). En base a 
todos estos resultados concluimos que SKP2 puede ser considerado definitivamente un nuevo 
gen diana de MYC no solo en nuestro modelo K562, sino también en otros modelos celulares 
humanos. Además, a partir de los diversos estudios de ChIP-seq contenidos en esta base de 
datos proponemos un nuevo al mecanismo de activación del promotor de SKP2 por MYC a 
través de los coactivadores p300 y MLL1, proteínas que ya se han visto interaccionar con MYC 
en otros modelos experimentales (ver Introducción).  
 
Por otro lado, analizamos el posible efecto de SKP2 sobre la estabilidad de MYC y sobre 
su capacidad transcripcional en nuestro modelo celular, dado que había sido descrito que SKP2 
participaba en la degradación de MYC (Kim, et al., 2003; von der Lehr, et al., 2003). Para ello se 
silenció SKP2 en células K562 y se estudiaron los niveles de MYC a nivel de proteína sin 
encontrar diferencias significativas. Al mismo tiempo se estudió la actividad transcripcional de 
MYC en ausencia de SKP2 utilizando un vector reportero que contenía 4 cajas E canónicas en su 
promotor (Kiessling, et al., 2006). Tampoco se encontraron diferencias significativas en la 
actividad transcripcional de MYC. Por tanto concluimos que SKP2 no afecta a la estabilidad y la 
actividad de MYC al menos en el modelo K562.  
 
Finalmente, dado que la línea celular K562 provenía de un paciente de leucemia mieloide 
crónica (LMC), se estudiaron los niveles de SKP2 y MYC por RT-qPCR en muestras primarias de 
pacientes de LMC del Hospital Universitario Marqués de Valdecilla (Santander) y del Hospital 
Universitario Dr. Negrín (Las Palmas) encontrándose una correlación positiva en la expresión de 
ambos genes. También observamos que un grupo pequeño de pacientes que habían sido 
tratados con imatinib presentaban menores niveles de MYC y SKP2 a nivel de ARN, resultados 
similares a los obtenidos en el modelo celular KMER tratado con imatinib. Por otro lado, se 
utilizaron las bases de datos de Oncomine (www.oncomine.org) y GeneSapiens 
(www.genesapiens.org) para ver si existía correlación en la expresión de ambos genes en alguna 
otra patología neoplásica hematológica y se encontró una correlación positiva en leucemia 
mieloide aguda (LMA) y en linfoma, especialmente en linfoma de Burkitt, en el cual está 
demostrado que en el 98% de los casos MYC se encuentra translocado sobre el promotor de los 
genes que codifican para las cadenas ligera y pesada de las  inmunoglobulinas (Delgado and 
Leon, 2010; Delgado, et al., 2013). Estos resultados sugieren que MYC puede ser un regulador 
importante de SKP2 en todas estas patologías hematológicas pero probablemente también en 
muchos otros cánceres humanos en los que se han encontrado  niveles elevados de SKP2.  
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8.3.2. El eje MYC-SKP2-p27  
En la primera parte de esta Tesis habíamos demostrado convincentemente que la 
sobreexpresión de SKP2 era una consecuencia directa de la inducción de  MYC, sugiriendo que 
MYC podía regular los niveles de p27 a través de la inducción de SKP2. En la segunda parte nos 
propusimos dilucidar si efectivamente la inducción de SKP2 por MYC realmente contribuía a la 
degradación de p27.  
Para ello decidimos estudiar en primer lugar la fosforilación de p27 en la treonina 187 en 
respuesta a la activación de MYC en las células Kp27MER, ya que estaba descrito que esta 
fosforilación era un requisito indispensable para el reconocimiento de p27 por parte del complejo 
SCFSKP2 (Carrano, et al., 1999; Sutterluty, et al., 1999; Tsvetkov, et al., 1999). Observamos que la 
activación de MYC promovía la fosforilación de p27 entre las 8-12 horas post-inducción e 
independientemente de los niveles de p27, sugiriendo que la quinasa involucrada en esta 
fosforilación no era inhibida por p27.  
Estaba descrito que el principal complejo implicado en esta fosforilación era el complejo 
ciclina E/CDK2 (Muller, et al., 1997; Sheaff, et al., 1997; Vlach, et al., 1997), que a su vez era el 
principal sustrato de p27, y que MYC inducía la expresión de ciclina E y la actividad de los 
complejos ciclina E/CDK2 (Jansen-Durr, et al., 1993; Muller, et al., 1997; Perez-Roger, et al., 
1997). Sin embargo, nosotros no observamos la inducción de ciclina E por MYC en las células 
Kp27MER. En cambio, vimos que la activación de MYC promovía un aumento en los niveles de 
ciclina A a nivel de proteína. En este sentido, también había sido descrito que MYC inducía la 
expresión de ciclina A (Jansen-Durr, et al., 1993; Hoang, et al., 1994; Muller, et al., 1997) y que 
los complejos ciclina A/CDK2 también eran capaces de fosforilar a p27 en la treonina 187 (Muller, 
et al., 1997; Zhu, et al., 2004). 
 Mediante ensayos quinasa in vitro utilizando proteína p27 recombinante (His6p27) como 
sustrato, observamos que los inmunocomplejos de ciclina A eran capaces de fosforilar a p27 y 
que, además, MYC era capaz de inducir actividad quinasa asociada a estos inmunocomplejos. 
Dado que CDK1 y CDK2 podían unirse a ciclina A, decidimos analizar la actividad quinasa de 
ambas CDKs para confirmar dicha fosforilación. Curiosamente, observamos que los 
inmunocomplejos de CDK2 estaban completamente inhibidos por el p27 endógeno (inducido por 
Zn2+), incluso en presencia de MYC activo, excluyendo la posibilidad de que los complejos ciclina 
E-A/CDK2 fueran los responsables de la fosforilación de p27 inducida por MYC. Sin embargo 
observamos que los inmunocomplejos de CDK1 eran más refractarios a la inhibición por el p27 
endógeno y además eran ligeramente activados en presencia de MYC activo. La unión de ciclina 
A a CDK1 y CDK2 en las células Kp27MER fue confirmada mediante coinmunoprecipitación. 
Estos datos sugerían que eran los complejos ciclina A/CDK1, y no los complejos ciclina E-
A/CDK2, los responsables de la fosforilación de p27 en la treonina 187 mediada por MYC.  
Para reforzar esta hipótesis, llevamos a cabo ensayos quinasa con inmunocomplejos de 
CDK1 y ciclina A procedentes de fibroblastos embrionarios de ratones deficientes en Cdk2 y 
ciclinas E. De esta forma, demostramos, por un lado, que la ciclina E no era necesaria para 
activar a CDK2 y mediar la fosforilación de p27 en la treonina 187, sino que ciclina A podía 
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cumplir su función, y que, por otro lado, CDK2 tampoco era necesario para fosforilar a p27 y, por 
tanto, que CDK1 era capaz de suplir su función. Además, observamos que MYC era capaz de 
incrementar la actividad quinasa de los inmunocomplejos de ciclina A y CDK1 sobre el p27 
recombinante, sugiriendo que los complejos ciclina A/CDK1 eran parcialmente responsables de 
esta fosforilación en respuesta a la activación de MYC. En base a todos estos resultados, 
proponemos que MYC induce la fosforilación de p27 en la treonina 187 a través de la activación 
de complejos ciclina A/CDK1 mediante la inducción de ciclina A, y no a través de la activación de 
complejos ciclina E/CDK2 como era anteriormente aceptado. Además, cabe destacar que este 
mecanismo es compatible con la inhibición total de complejos ciclina E/CDK2 por p27.  
 
En segundo lugar nos quedaba por demostrar que la inducción de SKP2 por MYC era la 
responsable de la disminución de los niveles de p27 en células K562. Para ello utilizamos 3 
aproximaciones:  
i) Por un lado analizamos los niveles de MYC, SKP2 y p27 a nivel de proteína mediante 
inmunoblot en diferentes modelos celulares derivados de K562: células Kp27MER tratadas con 
Zn2+ y 4HT, células KMER paradas por alta densidad celular, células KMYC tratadas con imatinib 
o TPA y células K562 privadas de suero. En todos los casos observamos que la inducción de 
SKP2 por MYC se correlacionaba con la bajada de los niveles de p27 y viceversa. Estos 
resultados también fueron reproducidos en células TGR1 privadas de suero. 
ii) A continuación decidimos estudiar la interacción entre SKP2 y p27 en células Kp27MER 
mediante inmunofluorescencia. Encontramos que SKP2 y p27 presentaban una localización 
nuclear en estas células, pero curiosamente ambos eran mutuamente excluyentes. Es decir, las 
células con altos niveles de SKP2 (Inducido por MYC, tras su activación con 4HT) no 
presentaban p27 y viceversa, las células con altos niveles de p27 (inducido por Zn2+) no 
presentaban SKP2 en el núcleo. Este resultado reforzaba considerablemente la degradación de 
p27 por parte de SKP2 al menos en el modelo Kp27MER. 
iii) Por último analizamos la expresión de p27 tras el silenciamiento de SKP2 mediante 
siRNA en células K562 y observamos que las células que expresaban bajos niveles de SKP2 
presentaban mayores niveles de p27, lo cual se traducía en una reducción en su tasa 
proliferativa. 
Por lo tanto, basándonos en estas 3 observaciones, proponemos que la inducción de 
SKP2 por MYC es la responsable de la disminución de los niveles de p27 y que el eje MYC-
SKP2-p27 regula la proliferación en células de leucemia (K562) y sus derivadas. Es decir, 
podemos aseverar que la inducción de SKP2 por MYC y la posterior degradación de p27 es el 
mecanismo responsable del incremento de la proliferación observado en células Kp27MER tras 
la activación de MYC en presencia de unos niveles moderados de p27 (inducido con 50 µM de 
ZnSO4).  
Finalmente evaluamos la implicación del eje MYC-SKP2-p27 en tumorogénesis mediante 
ensayos de tumorogenicidad utilizando un modelo de xenotransplante subcutáneo de células 
K562 en ratones desnudos. Encontramos que las células K562 que presentaban bajos niveles de 
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SKP2 (por silenciamiento) desarrollaban tumores de menor tamaño. Estos resultados sugirieren 
que MYC, a través de la inducción de SKP2 y la degradación de p27, es, al menos en parte, 
responsable de la capacidad tumorogénica de estas células.  
8.3.3. El efecto de MYC sobre los complejos proteicos de p27 y su relación 
con la proliferación 
Por último, en la tercera parte de la Tesis, nos propusimos esclarecer porque MYC era 
capaz de contrarrestar la inhibición de ciclo celular en las células Kp27MER a niveles moderados 
de p27 (50 µM ZnSO4) pero no a niveles elevados de p27 (75 µM ZnSO4), a pesar de inducir en 
ambos casos su degradación a través de SKP2.  
Para ello utilizamos la técnica de cromatografía de exclusión molecular, también conocida 
como gel filtración, que permitía separar complejos proteicos en condiciones nativas en función 
de su peso molecular. Mediante esta técnica, observamos que en células Kp27MER expuestas a 
altas dosis de Zn2+ (75 µM de ZnSO4), p27 se distribuía entre dos tipos de complejos proteicos: 
uno de alto peso molecular (~200 kDa) asociado a complejos ciclina/CDK, y otro de bajo peso 
molecular (~50 kDa) en principio de naturaleza desconocida. La capacidad termorresistente de 
este segundo complejo y las características de elución similares a las de un p27 recombinante 
purificado de bacterias (His6p27) nos permitió confirmar posteriormente que se trataba de p27 en 
forma libre (no unido a otras proteínas). Además, dada su movilidad en gel filtración como una 
proteína de ~50 kDa, nos llevó a sugerir en un primer momento que este se comportaba como un 
dímero en condiciones nativas. Sin embargo, mediante experimentos de mezcla entre dos p27 
recombinantes (GST-p27 y His6-p27) con el fin de encontrar heterodímeros, demostramos que el 
p27 libre no se comportaba como un dímero en condiciones nativas, sino que migraba 
anómalamente en gel filtración posiblemente debido a su forma alargada y su naturaleza 
intrínsecamente desestructurada. Esto fue confirmado mediante ultracentrifugación analítica en 
colaboración con el laboratorio de German Rivas, en el Centro de Investigaciones Biológicas 
(CSIC) en  Madrid.  
Por otro lado, los estudios de gel filtración también nos permitieron observar que las CDKs, 
a diferencia de las ciclinas, también eluían en dos picos mayoritariamente: uno asociado a 
ciclinas y p27 (230-150 kDa) y otro en forma libre al igual que p27 (~30 kDa). Esto sugería que 
las CDKs se encontraban en exceso dentro de las células y que, por tanto, las ciclinas eran las 
proteínas limitantes a la hora de formar los complejos ciclina/CDK. Asimismo, estos resultados 
también demostraban que p27 no se unía a CDKs libres, sino a complejos ciclina/CDK. Esta 
última observación y la presencia de p27 en forma libre sugerían que p27 podía estar excediendo 
los requerimientos para unirse a todos los complejos ciclina/CDK disponibles, y que el exceso de 
p27 podía ser a la vez el responsable del bloqueo total del ciclo celular.  
Para estudiar esta posibilidad, decidimos realizar un estudio comparativo mediante gel 
filtración de la distribución de p27 en células Kp27MER a diferentes dosis de Zn2+, en presencia y 
ausencia de MYC activo (+/- 4HT) y a diferentes tiempos (6,12 y 24 h). Este estudio reveló que:  
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i) La presencia de p27 libre era dependiente de los niveles de p27 sobre-expresados 
dentro de la célula, e independiente de la activación o no de MYC (al menos en las condiciones 
estudiadas). Es decir, solo observamos p27 libre cuando utilizamos altas dosis de Zn2+ (75 µM 
ZnSO4) pero no a dosis moderadas (50 µM ZnSO4). 
 ii) Que al inicio de la sobreexpresión de p27 (~6 horas post-inducción) con altas dosis de 
Zn2+ (75 µM ZnSO4) no había acumulación de p27 en forma libre, sugiriendo que el p27 recién 
traducido se unía directamente a complejos ciclina/CDK, pero no se acumulaba inicialmente en 
forma libre. Estos datos apoyaban la observación de que p27 solo se unía a complejos 
ciclina/CDK y sugerían que la formación de nuevos complejos ciclina/CDK podían promover la 
unión de p27 libre.  
iii) Que la activación de MYC promovía el desplazamiento del p27 libre hacia complejos de 
alto peso molecular. Esto podía ser debido, al menos en parte, a la inducción de ciclina A por 
MYC, como habíamos mencionado previamente, pero también a la inducción de ciclinas D2 o B1 
(Acosta, et al., 2008) y por tanto de nuevos complejos ciclina/CDK. 
iv) Que a niveles moderados de p27 (inducidos con 50 µM ZnSO4) no se observaba p27 en 
forma libre y por tanto, que la degradación de p27 solo podía tener lugar a partir de los complejos 
de alto peso molecular. 
Esta última observación nos llevó a analizar la distribución de SKP2 en las cromatografías 
y encontramos que SKP2 coeluía con los complejos de alto peso molecular, sugiriendo la 
presencia de otros elementos del complejo SCFSKP2, aunque experimentos adicionales son 
requeridos para su confirmación. Estos resultados concordaban con estudios previos que 
demostraban que el peso molecular estimado del complejo  SCFSKP2 unido al complejo ciclina 
A/CDK2/p27 en gel filtración era de ~230 kDa (Hao, et al., 2005) 
En resumen, se concluye que el efecto de MYC en la proliferación de las células K562 (y 
probablemente en otros modelos celulares) depende de los niveles de proteína p27. A niveles 
bajos o moderados de p27, el eje MYC-SKP2 es capaz de contrarrestar el efecto de p27 como 
inhibidor del ciclo celular, promoviendo la proliferación celular. En esta situación, todo el p27 
disponible estaría unido a complejos ciclina/CDK pero quedaría una parte de complejos 
ciclina/CDK libres (no inhibidos por p27). Sin embargo a niveles altos de p27, todos los complejos 
ciclina/CDK tendrían p27 unido (estando por tanto inhibidos) y habría una acumulación del 
exceso de p27 en forma libre. Este p27 libre actuaría como un reservorio de p27 capaz de  inhibir 
nuevos complejos ciclina/CDK inducidos por MYC y al mismo tiempo sería capaz de contrarrestar 
la eliminación de p27 desde de los complejos ciclina/CDK/p27 por el eje MYC-SKP2. Esto explica 
por qué la proliferación de estas células permanece detenida a pesar de la degradación de p27 
mediada por SKP2. 
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8.4. CONCLUSIONES  
 
1. MYC regula la expresión de SKP2 en varias líneas celulares procedentes de diferentes 
especies y tejidos, y parece ser el principal mediador de la inducción de SKP2  en 
respuesta a los factores de crecimiento del suero. La inducción de SKP2 es independiente 
de la inducción de proliferación mediada por MYC. 
 
2. MYC se une a la región promotora de SKP2 e induce su expresión en ausencia de síntesis 
de proteínas, confirmando que SKP2 es un nuevo gen diana MYC. 
 
3. SKP2 no afecta ni a la estabilidad ni a la actividad de MYC al menos en células K562. 
 
4. La expresión de MYC y SKP2 correlacionan en diferentes neoplasias hematológicas 
incluyendo leucemia mieloide aguda, crónica y linfoma de Burkitt.  
 
5. En las células K562, MYC promueve la fosforilación de p27 en la treonina 187 mediante 
inducción de la ciclina A y de la actividad quinasa asociada a dicha ciclina; fosforilación 
requerida para el reconocimiento de p27 por el complejo ligasa de ubiquitinas SCFSKP2. 
Además, en células de ratón, MYC es capaz de promover dicha fosforilación 
independientemente de CDK2 o de las ciclinas E.  
 
6. La inducción de SKP2 por MYC en células K562 se correlaciona con la disminución de 
p27; da lugar a un incremento en su tasa proliferativa y es, al menos en parte, responsable 
de su capacidad tumorogénica en xenotransplates en ratones desnudos.  
 
7. Cuando p27 se expresa en niveles bajos o moderados en células K562, este se encuentra 
asociado a complejos de alto peso molecular junto con complejos ciclina/CDK y, 
posiblemente también, SCFSKP2. A niveles altos de p27, este se acumula además en forma 
libre, lo cual se corresponde con un bloqueo total de la proliferación. MYC, mediante la 
inducción de ciclinas y CDKs, promueve el desplazamiento de p27 libre hacia los 
complejos de alto peso molecular. La desaparición de p27 en forma libre se relaciona con 
el estímulo proliferativo mediado por MYC. 
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SKP2 is the ubiquitin ligase subunit that targets p27KIP1
(p27) for degradation. SKP2 is induced in the G1-S transit of
the cell cycle, is frequently overexpressed in human cancer,
and displays transformation activity in experimental models.
Here we show that MYC induces SKP2 expression at the
mRNA and protein levels in human myeloid leukemia K562
cells with conditional MYC expression. Importantly, in these
systems, induction of MYC did not activate cell proliferation,
ruling out SKP2 up-regulation as a consequence of cell cycle
entry. MYC-dependent SKP2 expression was also detected in
other cell types such as lymphoid, fibroblastic, and epithelial
cell lines. MYC induced SKP2 mRNA expression in the
absence of protein synthesis and activated the SKP2 pro-
moter in luciferase reporter assays. With chromatin immu-
noprecipitation assays, MYC was detected bound to a region
of human SKP2 gene promoter that includes E-boxes. The
K562 cell line derives from human chronic myeloid leukemia.
In a cohort of chronic myeloid leukemia bone marrow sam-
ples, we found a correlation between MYC and SKP2 mRNA
levels. Analysis of cancer expression databases also indicated
a correlation between MYC and SKP2 expression in lym-
phoma. Finally, MYC-induced SKP2 expression resulted in a
decrease in p27 protein in K562 cells. Moreover, silencing of
SKP2 abrogated the MYC-mediated down-regulation of p27.
Our data show that SKP2 is a direct MYC target gene and that
MYC-mediated SKP2 induction leads to reduced p27 levels.
The results suggest the induction of SKP2 oncogene as a new
mechanism for MYC-dependent transformation.
c-MYC (hereafterMYC) is an oncogenic transcription factor
of the helix-loop-helix/leucine zipper protein family. MYC
exerts a wide array of biological functions in different cellular
models related to cell cycle control, genomic instability, ener-
getic metabolism, protein synthesis, intercellular communica-
tion, and control of cell differentiation (for reviews see Refs.
1–3). MYC forms heterodimers with the protein MAX that
bind to E-boxes in the regulatory regions of target genes. MYC
regulates ;1000 genes and binds to 15% of genomic loci (4–7).
Most target genes are activated byMYC in an E-box-dependent
manner, although an important fraction of MYC target genes
are repressed by MYC (reviewed in Refs. 8 and 9). Consistent
with the biological activities of MYC, its expression is deregu-
lated in a wide array of human solid tumors and in leukemia,
often associated to tumor progression (10–12).
SKP2 is an oncogenic protein frequently overexpressed in
human cancers. Moreover, SKP2 behaves as an oncogene in
transformation assays (13, 14). SKP2 encodes the F-box protein
of the ubiquitin ligase SCFSKP2 complex; this complex is com-
prised by three core subunits RBX1, CUL1, and SKP1, whereas
the substrate is bound by SKP2 along with the small protein
CKS1 (14, 15). More than 20 SKP2 substrates have been found,
including several proteins involved in cell cycle control (e.g.
cyclin E, p21, p57, and E2F1) (14), and SKP2 can suppress p53-
mediated apoptosis (16). Nonetheless, the main oncogenic
mechanism of SKP2 is attributed to degradation of the cyclin-
dependent kinase (CDK)4 inhibitor p27KIP1 (hereafter p27)
(13).
p27 was originally described as a CDK inhibitor, with cyclin
E-CDK2 complexes as its primary targets (17, 18). Low p27
levels are associated with a poor prognosis in most tumors (19,
20). p27 is regulated mainly at the protein stability level. The
degradation of p27 by proteosomes is preceded by ubiquityla-
tion (21), which is mediated by the SCFSKP2 complex, in which
SKP2 is the p27-recognizing subunit (22–24). To be recognized
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phorbol-12-myristate-13-acetate; qPCR, quantitative PCR; sh, short
hairpin.
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by the SCFSKP2 complex, p27 must be bound to cyclin-CDK
complexes and phosphorylated at Thr-187. p27 bound to cyclin
E-CDK2 is a target for phosphorylation by the bound CDK2 or
a second active cyclin E-CDK2 complex at Thr-187 (reviewed
in Refs. 25 and 26). The oncogenic activity of SKP2 is attrib-
uted mainly to low p27 levels, and consistently, the levels of
SKP2 and p27 inversely correlate in many tumors and cell
models (13, 14).
MYC and p27 show functional antagonism in proliferation:
MYC and the loss of p27 cooperate in animal carcinogenesis
models (27), and MYC abrogates p27 function in proliferation.
The antagonistic effect of MYC is mediated through several
mechanisms (reviewed in Refs. 11). MYC down-regulates
murine p27 at the transcriptional level (28, 29); in addition, it
induces cyclin D2 and CDK4, which sequester p27 in CDK-
cyclin complexes (30, 31); finally, MYC induces expression of
CUL1 (32) and CKS1 (33), both components of the SCFSKP2
complex. A correlation between MYC and SKP2 expression
was recently described in amurine lymphomamodel, with only
modest effects on p27 levels (34). The previous studies are
nonetheless hampered by the fact that SKP2 is induced in cell
cycle stimulation, which is also a well known MYC activity.
This has made it difficult to distinguish whether SKP2 induc-
tion is a direct effect of MYC. Here we studied the MYC-
SKP2-p27 axis in different cell models with conditionalMYC
expression in which MYC is induced in cell cycle-arrested
cells.We show for here that SKP2 is a directMYC target gene
and that MYC-mediated SKP2 up-regulation contributes to
p27 degradation.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Proliferation—K562 and K562-derived
cell lines were cultured in RPMI 1640mediumwith 8% fetal calf
serum and antibiotics. Unless otherwise stated, the cells (2.5 3
105 cells/ml) were treated with 75 mM ZnSO4, 200 nM 4-hy-
droxytamoxifen (4HT) (Sigma), 10 nM phorbol-12-myristate-
13-acetate (TPA), and 1 mM imatinib. Transient transfections
were performed in a nucleofector (Amaxa) following the man-
ufacturer’s instructions. Short hairpin expression vectors used
were shMyc (35) and pSR-shSKP2 (36). KmycJ are K562 cells
with a MYC gene inducible by ZnSO4 (37). KMER4 are K562
cells stably transfected with a vector expressing the MycER
construct.5 MycER is activated by 4HT (38). Kp27-5 cells are
K562 cells stably transfected with a p27 gene inducible by Zn21
(39). Kp27MER are Kp27-5 cells transduced with the MycER
gene (40). KmycBp53 are KmycB cells expressing a p53 mutant
that is activated at 32 °C (41). KMERshSKP2 are KMER4 cells
infected with retrovirus expressing pSR-shSKP2 and selected
with 1 mg/ml puromycin. pSR-shSKP2 was constructed by
inserting the siRNA sequence AAGGGAGTGACAAA-
GACTTTGTTCAAGAGACAAAGTCTTTGTCACTCCCTT
(36) into theBglII andHindIII sites of pSUPER-retro vector (the
sequence of the hairpin loop is underlined). KMERpSR are
KMER4 cells infected with the empty retroviral vector
pSUPER-retro. TM1 are derived from the Mv1Lu lung epithe-
lial cell line with a tetracyclin-repressible MYC gene (42).
HO15.19Myc-null rat fibroblasts were generated fromparental
TGR-1 by homologous recombination (43). TM1, HO15.19,
and TGR1 cells were cultured in DMEM supplemented with
10% fetal calf serum and antibiotics. P493-6 cells are immortal-
ized human B cells expressing a tetracyclin-repressible MYC
gene (44) and were cultured in RPMI 1640 with 10% fetal calf
serum and antibiotics. Cell proliferationwas determined by cell
counting in a hemocytometer.
Nude Mice Xenografts—KMERpSR or KMERshSKP2 cells
(107) were resuspended in 0.2 ml of RPMI/Geltrex (Invitrogen)
(1:1). The cell suspension was injected subcutaneously into the
right and left flanks of 6-week-old female athymic nude mice
(Hsd:Athymic Nude-Foxn1 nu/nu; Harlan Laboratories mod-
els); after 21–24 days, the mice were euthanized, and the
tumors were weighed.
mRNA Analysis—Total RNA from cell lines and bone mar-
row cells was isolated using the RNeasy kit (Qiagen). RT was
performed with i-Script reverse transcriptase (Bio-Rad). Quan-
titative PCR (qPCR) was performed with the SYBRGreen PCR
kit (Bio-Rad). The sequences of primers used and amplicon
sizes are shown in supplemental Table S1. The data were nor-
malized to ribosomal protein S14 mRNA levels.
Immunoblots—Total cell lysates and immunoblots were car-
ried out as described (39). The blots were developed with sec-
ondary antibodies conjugated to IRDye680 and IRDye800 (Li-
Cor Biosciences) and visualized in an Odyssey scanner. The
antibodies used were anti-actin (goat polyclonal, sc-1616),
MYC (sc-764), SKP2 (sc-7164), p27 (sc-528), a-tubulin (sc-
5546) (all rabbit polyclonals from Santa Cruz Biotechnology),
p27 monoclonal antibody (K-25020; Transduction Labs), and
Thr(P)-187-p27 (rabbit polyclonal, 71-7700; Invitrogen).
Chromatin Immunoprecipitation—The cells (5 3 107) were
fixed in 1% formaldehyde, lysedwith SDS, and sonicated, essen-
tially as described (45). ChIP was performed using Dynabeads-
Protein G (Dynal Biotech) coupled to anti-MYC antibody and
rabbit IgG as specificity control. Quantitative PCR of eluted
DNA was performed with the primers of SKP2 and lactate
dehydrogenase genes indicated in supplemental Table S1.
Immunofluorescence Analysis—Kp27MER cells were treated
withZnSO4 and/or 4HT for 24 h and immunostainedwith anti-
SKP2 and -p27 antibodies as described and revealed with fluo-
rescein- or rhodamine-conjugated secondary antibodies as
described (40). The cells were mounted with Vectashield
mounting medium (Vector Laboratories) with DAPI to visual-
ize nuclei.
Luciferase Assays—The cells (3 3 106) were electroporated
with an Amaxa electroporator and Mirus Ingenio (Mirus Bio
LLC) transfection reagent. KmycJ cells were transfected with 3
mg of the 21148-SKP2 promoter (46) or pGL3basic vector
(Promega) as control. K562 or KmycJ cells were nucleofected
with 1.5 mg of 43Ebox-Luc or the MYC-unresponsive
43EboxMut-Luc reporter constructs (47). K562 cells were
nucleofected with 1.5 mg of pSR-shSKP2 or pSUPER-retro vec-
tor. The cells were lysed, and luciferase activitywasmeasured in
duplicate in a dual luciferase reporter gene assay system (Pro-
mega). The data were normalized to Renilla luciferase values
(0.5 mg of pRL-TK vector in each transfection).5 M. Albajar and J. Leon, submitted for publication.
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Chronic Myeloid Leukemia (CML) Samples—Bone marrow
mononuclear cells (prepared by Ficoll-Hypaque) from 4
healthy controls, 31 CML patients at diagnosis, and 8 patients
that achieved the remission of the leukemia after treatment
(Complete Molecular Response) (48) were studied. The
patients were from the Hospital Universitario Marque´s de Val-
decilla (Santander) and Hospital Universitario Dr. Negrín (Las
Palmas). The study was approved by the ethics committees of
both hospitals.
RESULTS
Induction of MYC Is Associated to Induction of SKP2—We
studied the MYC-SKP2 relationship in cell models in which (i)
ectopic MYC expression is activated or induced and (ii) MYC
induction does not stimulate cell proliferation, a critical condi-
tion to avoid SKP2 up-regulation subsequent to cell cycle pro-
gression. In the Kp27MER cell line, p27 can be induced with
ZnSO4, and MYC can be activated with 4HT (Fig. 1A, top
panel). Large scale gene expression profiling in these cells
showed that MYC activation provoked up-regulation of SKP2
mRNA (40).We set out to validate this microarray data. Induc-
tion of p27 resulted in rapid growth arrest (Fig. 1A) and SKP2
expression was down-regulated (Fig. 1C), as predicted. Impor-
tantly, MYC activation did not modify p27-mediated growth
arrest in this model (Fig. 1A), confirming previous results (40).
MYC activation (i.e. 4HT treatment) nonetheless resulted in a
2-fold increase in SKP2 mRNA in proliferation-arrested
Kp27MERcells (Fig. 1B, black bars).Moreover,MYCactivation
induced robust up-regulation of SKP2 protein, as detected by
immunoblot (Fig. 1C, compare lanes 1 and 2 and lanes 3 and 4).
The immunoblot also showed down-regulation of endogenous
MYC following activation of ectopic MYC. This well known
effect of ectopic MYC (49, 50) confirmed MycER activation by
4HT. In contrast toMycER-expressing cells, 4HT did notmod-
ify SKP2 expression in Kp27-5 cells, in which p27 is induced by
Zn21 but which do not carry the MycER allele (Fig. 1B).
We used KMER4 cells treated with 1 mM imatinib, a BCR-
ABL inhibitor that causes rapid down-regulation of endoge-
nous MYC in K562 cells (51). MYC activation with 4HT in
KMER4 cells did not rescue the proliferation arrestmediated by
imatinib (Fig. 1D). Treatment of KMER4 with imatinib led to
down-regulation of SKP2mRNA, as detected by RT-qPCR (Fig.
1E), and protein, as detected by immunoblot (Fig. 1F). Activation
of MYC in the presence of imatinib resulted in a 2-fold induction
of SKP2 mRNA after 24 h (Fig. 1E) and protein (Fig. 1F, compare
lanes 1 and 2 and lanes 3 and 4). Although BCR-ABL was previ-
ously reported to induceSKP2(36,52)andto induceMYC(51,53),
here we show that ectopic MYC up-regulates SKP2 in prolifera-
tion-arrested cells with inhibited BCR-ABL.
The KmycJ cell line is a K562 derivative that bears a ZnSO4-
inducible MYC allele (37). Treatment of K562 and KmycJ cells
with 10 nM TPA resulted in growth arrest (Fig. 2A). TPA also
induced amarked down-regulation ofMYC, and as anticipated,
SKP2 mRNA and protein expression were also repressed by
TPA (supplemental Fig. S1). MYC induction did not rescue
cells from TPA-induced growth arrest (Fig. 2A), confirming
previous reports (54). We induced MYC in KmycJ cells pre-
treated (12 h) with 10 nM TPA, i.e. when the cells had very low
endogenous MYC levels. In these TPA-arrested cells, MYC
induction with Zn21 resulted in a notable increase in SKP2
mRNA, as assessed by RT-qPCR (Fig. 2B), and in protein, as
FIGURE 1. SKP2 induction by MYC in Kp27MER and KMER cell lines. A, the Kp27MER cell model (top panel). Proliferation rates of Kp27MER cells treated with
200 nM 4HT and 75 mM ZnSO4 were measured by counting viable cells in a hemocytometer (bottom panel). B, SKP2 mRNA expression in Kp27MER cells and
parental Kp27-5 cells. The cells were treated for 12 h with 200 nM 4HT and 50 mM ZnSO4, and mRNA expression was determined by RT-qPCR. The values are the
means 6 S.E. of three experiments. C, immunoblot showing SKP2 up-regulation in response to MYC in Kp27MER cells treated with 4HT and ZnSO4 as indicated.
D, the KMER4 cell model (top panel). Proliferation rates of KMER cells treated with 1 mM imatinib and 200 nM 4HT (bottom panel). E, KMER4 cells were treated with
1 mM imatinib and 200 nM 4HT (24 h), and SKP2 mRNA levels were determined by RT-qPCR. The values are the means 6 S.E. of three experiments. F, KMER4 cells
were treated with imatinib and 4HT as indicated, and the levels of SKP2, MYC, MycER, and actin (loading control) in total cell lysates were assayed by
immunoblot.
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determined in immunoblot (Fig. 2C). The results were similar
when we used a different MYC-inducible K562 cell line
(KmycB) (not shown).
Finally, we assayed SKP2 induction by MYC in the
KmycBp53 cell line. This is a K562-derived cell line bearing a
p53 mutant that is activated at 32 °C and a Zn21-inducible
MYC transgene (41). MYC induction did not antagonize the
p53-mediated proliferation arrest at 32 °C (Fig. 2D). We found
thatMYC inductionwith Zn21 resulted in the increase of SKP2
mRNA (Fig. 2E) and SKP2 protein (Fig. 2F), despite the fact that
the cells were growth-arrested by p53 at 32 °C. We conclude
that MYC induction provokes SKP2 induction independently
of cell cycle activation.
Silencing of MYC Is Associated with Repression of SKP2 in
Several Cell Types—To confirm the effects of MYC on SKP2
expression, we silenced MYC in K562 cells using siRNA. K562
cells were nucleofected with a short hairpin MYC vector (pRS-
shMYC) (35). MYC silencing was confirmed by immunoblot
andwas accompanied by down-regulation of SKP2 protein (Fig.
3A) andmRNA (Fig. 3B). MYC silencing also resulted in down-
regulation of B23/nucleophosmin mRNA (a MYC target gene
used as positive control) but not of SKP1 mRNA, which
encodes another component of the SCFSKP2 complex used here
as negative control (Fig. 2B). To confirm the effect of MYC on
SKP2 expression in cell models other than K562, we studied
SKP2 expression in P493-6 cells, a human lymphoblastoid cell
line carrying a tetracycline-repressible MYC transgene (55). In
these cells, doxycycline treatment led to rapidMYC down-reg-
ulation accompanied by down-regulation of SKP2 protein (Fig.
3C) andmRNA (Fig. 3D).We also testedTM1 cells, amink lung
epithelial cell line also carrying a tet-off humanMYCallele (42).
In TM1 cells, doxycycline addition provoked MYC and SKP2
down-regulation (Fig. 3E), although the cells continued to grow
(not shown).
Finally, we used the Myc-null rat cell line HO15.19, which
does not express MYC (43). We analyzed MYC and SKP2
expression after serum deprivation in Myc-null and parental
cells (TGR1). SKP2 levels were much lower but detectable in
Myc-null cells. In contrast to parental cells, however, there was
little decrease in SKP2 levels in response to serum deprivation
(Fig. 3F). We conclude that MYC is a major regulator of SKP2
expression in cells from different tissues and species.
MYCInducesSKP2mRNAin theAbsenceofProteinSynthesis—
To assess whether MYC directly activated transcription of the
SKP2 gene, we performed the induction experiments in the
presence of the protein synthesis inhibitor cycloheximide
(CHX) using Kp27MER cells, in which MYC can be activated
with 4HT and p27 can be induced by ZnSO4. The cells were
pretreated with 10 nM TPA (12 h) to down-regulate endoge-
nous MYC and then treated with 10 mg/ml CHX for different
periods. CHX effectiveness was confirmed by lack of induction
of p27 protein in response to Zn21 (Fig. 4A, compare p27 in
lanes 1 and 2 versus lanes 3 and 4 in the absence of 4HT and
lanes 5 and 6 versus lanes 7 and 8 in its presence). As predicted,
endogenous MYC showed a high degradation rate. MycER was
more stable in presence of 4HT (Fig. 4A, compareMycER levels
in lanes 9 and 10 versus lanes 11 and 12), although the under-
lying molecular mechanism is unclear. In sharp contrast, we
found that SKP2 was a long-lived protein (.6 h). SKP2 mRNA
levels were determined by RT-qPCR. The results showed that
4HT activation of MycER led to increased SKP2 mRNA levels,
even in the absence of synthesis of new proteins; this was prob-
FIGURE 2. SKP2 induction by MYC in KmycJ and KmycBp53 cell lines. A, the KmycJ cell model (top panel). Proliferation rates of KMycJ cells treated with 10
nM TPA and 75 mM ZnSO4 were measured by counting viable cells in a hemocytometer (bottom panel). B, KmycJ cells were treated with 10 nM TPA for 12 h and
then induced with 75 mM ZnSO4 as indicated. SKP2 mRNA levels were measured by RT-qPCR. C, KmycJ cells were treated as in B, and expression of SKP2, MYC,
and actin (loading control) was assayed by immunoblot. D, the KmycBp53 cell model (top panel). Proliferation rates of KMycBp53 cells were treated with 75 mM
ZnSO4 and incubated at 37 or 32 °C (bottom panel). E, KmycBp53 cells were incubated (37 or 32 °C) alone or with ZnSO4 for 24 h. SKP2 mRNA levels were
determined by RT-qPCR. The values are the means 6 S.E. of three experiments. F, KmycBp53 cells were treated as in E, and the levels of SKP2, MYC, and actin
(loading control) in total cell lysates were assayed by immunoblot.
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ably dependent on theMycER activated by 4HT (Fig. 4B). Both
MYC andMycER protein levels were very low after 6 h of CHX
treatment, precluding analysis of SKP2 mRNA expression at
longer treatment times.
MYC Activates and Binds to the Human SKP2 Promoter—
We tested the ability of MYC to activate the human SKP2 pro-
moter through promoter-luciferase assays. We transfected
KmycJ cells with a luciferase reporter containing 1148 bp of
SKP2 promoter (46). The results showed that the SKP2 pro-
moter was activated by MYC (Fig. 5A, top panel). Consistent
with MYC repression by TPA, MYC transactivation activity
was reduced in TPA-treated cells after transfection and was
elevated when MYC was induced by Zn21. As a positive con-
trol, we used a luciferase reporter bearing four E-boxes
(43Ebox-Luc), which was also activated by MYC (Fig. 5A, bot-
tom panel). The empty luciferase construct and the reporter
with four mutated E-boxes (43EboxMut-Luc) were used for
normalization. These results suggested that SKP2 could be a
direct MYC target gene.
Sequence analysis of the human SKP2 gene revealed several
E-boxes in the promoter and in the second exon.We thus used
ChIP to analyze promoter occupancy byMYC. The localization
of E-boxes in the human SKP2 gene and the amplicons analyzed
in the ChIP experiments are shown in Fig. 5B. ChIP demon-
strated MYC binding to a region with two E-boxes (CATGCG
and CACGCG), mapping at 2756 and 2389 upstream of the
transcription start site (Fig. 5C); both sequences are described
as high affinity E-boxes for MYC in vivo (56, 57). As negative
controls, we used K562 cells treated with imatinib and TPA,
which inhibitMYC expression (Fig. 1, E and F, and supplemen-
tal Fig. S1). MYC binding was dramatically reduced after both
treatments (Fig. 5C). This MYC-binding region was also
detected in K562 and HeLa cells in the ENCODE genome-wide
ChIP sequencing project, published by the UCSC genome
browser (assembly NCBI36/hg18, Yale/UC Davis/Harvard
study). MYC binding to the E-box of the lactate dehydrogenase
A (58) was used as positive control (Fig. 5C). Taken collectively,
our results indicate that human SKP2 is a direct MYC target
gene, at least in human cells.
MYC and SKP2 Expression Correlated in Chronic Myeloid
Leukemia Cells—The K562 cell line is derived from a human
CMLpatient in blast crisis. To confirm the correlation between
SKP2 andMYC expression in vivo, we used RT-qPCR to deter-
minemRNA levels of SKP2 andMYC in the bonemarrow of 31
FIGURE 3. SKP2 is down-regulated after MYC repression. A, K562 cells were
nucleofected with a short hairpin RNA vector for MYC (shMYC) or the empty
vector (Vect.), and MYC, SKP2, and actin expression were assayed by immu-
noblot 24 and 36 h after nucleofection. B, K562 cells were transfected as in
A; at 24 h after nucleofection, the levels of SKP2, B23/nucleophosmin (positive
control), and SKP1 (negative control) mRNA were determined by RT-qPCR.
The values are the means 6 S.E. of three independent transfections. C, human
lymphoid P493-6 cells were treated with 1 mg/ml doxycyclin (Dox), and SKP2,
MYC, and actin expression were assayed by immunoblot. D, P493-6 cells were
treated as in C, and SKP2 mRNA expression was determined by RT-qPCR.
E, TM1 cells were treated with 2 mg/ml doxycyclin to repress MYC for the
periods indicated, and SKP2, MYC, and actin expression were determined by
immunoblot. F, Myc-null HO15.19 rat fibroblasts and parental TGR1 were
serum-deprived for the indicated times, and SKP2, MYC, and actin expression
analyzed by immunoblot.
FIGURE 4. MYC induces SKP2 in the absence of protein synthesis.
A, Kp27MER cells were pretreated for 12 h with 10 nM TPA and then treated
with 10 mg/ml CHX, 4HT, and ZnSO4 for 1– 6 h. Expression of p27, SKP2, MYC,
MycER, and actin were determined by immunoblot. B, SKP2 mRNA expression
in Kp27MER was determined by RT-qPCR after 6 h of exposure to cyclohexi-
mide, ZnSO4, and 4HT as indicated. The data show the means 6 S.E. of three
independent experiments. Ctrol, control.
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CML patients at diagnosis, 8 CML patients that responded to
the treatment, and 4 healthy controls (Fig. 6A). Although the
cohort is small, the correlation betweenMYCand SKP2 expres-
sion was statistically significant (Fig. 6B). To determine
whether this correlation betweenMYC and SKP2 at themRNA
level also occurred at the protein level, we analyzed protein
extracts by immunoblot; the results confirmed the MYC/SKP2
correlation in seven of eight patients tested (Fig. 6C). We used
the Oncomine database to examine a possible correlation
between MYC and SKP2 mRNA levels in other hematopoietic
neoplasias. Three expression profiling studies showed that
Burkitt lymphoma cells, in which MYC expression is deregu-
lated as a consequence of a chromosomal translocation, also
expressed higher SKP2 levels (supplemental Fig. S2). We also
queried the correlation between MYC and SKP2 expression in
tumor sampleswith the in silico transcriptomics database of the
GeneSapiens system (59). CML is not included in these databases,
but analyses showed a correlation between MYC and SKP2
expression in human lymphoma (supplemental Figs. S2 and S3).
MYC Induces SKP2 Accumulation in the Cell Nucleus and
p27 Phosphorylation—Previous studies firmly established that
SKP2 participates in p27 degradation, and our results so far
demonstrated that SKP2 is aMYC target gene inK562 cells.We
thus evaluated whether MYC-induced SKP2 also resulted in
p27 down-regulation in our models. p27 can be degraded in
cytoplasm by a SKP2-independent pathway (60, 61), but
SKP2-dependent ubiquitylation of p27 takes place in the cell
nucleus (15). We thus performed immunofluorescence stud-
ies to explore the localization of both proteins in the K562
model. The results in Kp27MER cells showed that MYC acti-
FIGURE 5. MYC activates and binds to the human SKP2 promoter. A, MYC activation of the human SKP2 promoter. KmycJ cells were electroporated with a
luciferase construct of the human SKP2 promoter and a 4xE-Box luciferase reporter. At 12 h post-transfection, the cells were divided into four aliquots and
treated with 10 nM TPA to repress endogenous MYC and 75 mM ZnSO4 to induce exogenous MYC. At 36 h post-transfection, the cell lysates were prepared, and
firefly and Renilla luciferase activities were determined. SKP2-luciferase data were normalized to the value of cells transfected with the empty vector
(pGL3basic-Luc); 43Ebox-Luc data were normalized to the mutated 43EboxMut-Luc construct. The data were normalized to Renilla luciferase activity for
transfection efficiency. The data show the means 6 S.E. of three measurements in two duplicate experiments. B, scheme of the human SKP2 gene. Amplicons
(boxes A–E) used for ChIP assays are indicated; ovals indicate E-boxes. Coordinates and CpG island are as in the UCSC Genome Browser. C, chromatin was
immunoprecipitated with anti-MYC antibody and rabbit IgG and measured in quantitative PCR for amplicons A–E. Kp27MER cells were treated for 12 h with 1
mM imatinib or 10 nM TPA to down-regulate endogenous MYC. Lactate dehydrogenase (LDH) E-box amplicon was used as positive control (58). The results are
expressed as enrichment of DNA in chromatin immunoprecipitated with anti-MYC (with respect the signal with anti-rabbit IgG) and normalized to the
amplicon A signal. The values are the means 6 S.E. of three determinations from two (TPA and imatinib) or three (plus control) independent ChIP experiments.
MYC-SKP2-p27 Axis in Human Leukemia Cells
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vation resulted in increased nuclear SKP2 and decreased
nuclear p27 levels in most cells. It is of note that some cells
showing higher nuclear SKP2 levels also showed lower p27
(Fig. 7A).
Theactual substrateof theSCFSKP2complex isp27phosphor-
ylated in threonine 187 (26). ForMYC-mediated degradation of
p27 via SKP2 up-regulation, it is thus necessary that a substan-
tial fraction of p27 be in the formofThr(P)-187-p27. In a kinetic
study to determine total p27 and Thr(P)-187-p27 in Kp27MER
cells treated with Zn21 and 4HT (4–24 h), MYC initially pro-
voked an increase in the phosphorylated p27 fraction (10-fold
after 8 h compared with control cells; Fig. 7B). At longer treat-
ment times, the phospho-p27 fraction and the total p27 levels
were reduced, as anticipated. We performed a dose-response
study to analyze total p27 and Thr(P)-187-p27 levels in cells
treated with 50 or 75 mM Zn21 and 4HT (12 h). The results
again showed that MYC activation resulted in a significant
increase in the Thr(P)-187-p27 fraction (Fig. 7C). This
increased p27 phosphorylation can be explained in part by the
MYC-induced up-regulation of CDK2 and cyclins in these cells
(40).
MYC Reduces p27 Protein Levels in K562—The previous
results indicated that SKP2 and p27 colocalize in the nucleus
and that a significant fraction of p27 is phosphorylated in Thr-
187, a prerequisite to acting as a SKP2 substrate.We assayed the
MYC effect on ectopic p27 levels after p27 induction with 50
mM ZnSO4. At this ZnSO4 concentration, p27 levels were not
high enough to titrate out the SCFSKP2 system, as occurs with
higher ZnSO4 doses (Fig. 7B and data not shown). Immunoblot
analysis showed that MYC activation with 4HT resulted in a
significant decrease in p27 levels when p27 was induced with
Zn21 (Fig. 8A, compare lanes 1 and 2 and lanes 3 and 4). Con-
sistent with the reduction in p27, the proliferation rate was
augmented by MYC in Kp27MER cells treated with 50 mM
ZnSO4 (data not shown and Ref. 40). In contrast, 4HT did not
reduce p27 levels in parental Kp27-5 cells, which bear a Zn21-
inducible p27 but not the MycER construct (Fig. 8B). We also
tested the MYC effect on the endogenous p27 that is up-regu-
lated when the KMER4 cells reach quiescence by culture satu-
ration (;1.5 3 106 cells/ml after 3 days of culture). Immuno-
blot results demonstrated that SKP2 levels were higher and p27
was lower in cells with activated MYC (Fig. 8C).
As a second approach to testing the MYC-SKP-p27 axis in
ourmodel, we infected KMER4 cells with retrovirus expressing
a short hairpin SKP2 (shSKP2) vector to generate the cell line
KMERshSKP2. Immunoblot results confirmed that SKP2 levels
were reduced by shSKP2 and that p27 levels were concomi-
tantly increased (Fig. 9A) compared with the KMERpSR cell
line expressing the empty vector. In agreement with the
increased p27 abundance, shSKP2-expressing cells grew at a
FIGURE 6. MYC and SKP2 expression in CML patients. A, RT-qPCR analysis of MYC and SKP2 mRNA expression in 31 samples from CML patients at diagnosis
in chronic phase (D), 8 patients in complete molecular response under imatinib treatment (T), and 4 healthy donors (H). The data are the means of three
determinations, arranged from low to high MYC expression. mRNA values were normalized to the levels of ribosomal protein small 14 in each case. B, corre-
lation between MYC and SKP2 levels in CML patients. The solid line indicates the linear prediction. The Pearson’s r, and p values are indicated. C, immunoblot
showing SKP2 and MYC expression in samples of CML patients at diagnosis. A picture of the gel stained with Coomassie (Coom.) Blue is shown to assess protein
loading.
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reduced rate (Fig. 9B) and showed cell accumulation in the G1
phase (not shown). This difference in growth rates was repro-
duced in vivo; whereas KMERpSR xenografts readily formed
tumors in nude mice, KMERshSKP2 cells did not form tumors,
or theyweremuch smaller (Fig. 9,C andD). Consistentwith the
lack of SKP2, p27 levels were not reduced by MYC in cells
expressing shSKP2 (not shown). Previous reports describe a
positive effect of SKP2 on MYC stability and transcriptional
activity (62, 63). Nonetheless, we found no significant changes
in MYC levels after SKP2 silencing in K562 cells (Fig. 9A). We
also testedMYC transcriptional activity after SKP2 silencing by
the shSKP2 expression vector. SKP2 silencing was confirmed
by immunoblot (Fig. 9E), but luciferase assays failed to show a
significant SKP2 effect on MYC-dependent transcriptional
activity (Fig. 9F). Collectively, our results show that MYC
induces SKP2 and that this induction is responsible, at least in
part, for p27 down-regulation.
DISCUSSION
MYC stimulates proliferation, and SKP2 expression is asso-
ciated with cell cycle progression (actually, SKP2 stands for S
phase kinase-associated protein 2). This has made it difficult to
date to distinguish whether SKP2 induction is a direct or an
indirect effect of MYC. Here we used four K562 cell-based
models in whichMYC can be induced or activated in cell cycle-
arrested cells. Proliferation arrest was achieved by several
approaches: ectopic p27 overexpression, p53 activation, TPA,
and imatinib treatments. In all cases, MYC induction resulted
in SKP2 up-regulation. In TM1 epithelial cells,MYC repression
similarly provoked SKP2 down-regulation although cells con-
tinued to proliferate. SKP2 regulation by MYC was therefore
not an indirect effect of MYC-induced cell cycle progression.
Moreover, our data strongly suggest that SKP2 is a direct MYC
target gene based on three additional observations: (i) MYC
up-regulates SKP2mRNA expressionwhen protein synthesis is
inhibited, (ii) MYC activates the SKP2 promoter in luciferase
reporter assays, and (iii) MYC binds to an E-box in the 59 reg-
ulatory region of human SKP2 in ChIP assays. Up-regulation of
SKP2 was also recently reported in MYC-induced murine lym-
FIGURE 7. SKP2 colocalizes with p27 in the cell nucleus and Myc induces
p27 phosphorylation. A, immunofluorescence of p27 and SKP2 proteins in
Kp27MER cells exposed for 24 h to ZnSO4 and 4HT. Most 4HT-treated cells
expressed nuclear SKP2, but two fields were selected to show cells with low
SKP2 and high p27 levels (arrows). Most cells exposed to ZnSO4 showed high
p27 levels and low SKP2 in the nuclei, but a field was selected showing a cell
with high SKP2 and low p27 (arrow). The nuclei were DAPI-stained.
B, Kp27MER cells were treated for 4 –24 h with 75 mM ZnSO4. Total p27, Thr(P)-
187-p27 (pT187-p27), and actin (as loading control) were assayed by immu-
noblotting. The third panel shows the signal of total p27 (red) and phospho-
p27 (green) to show the coexpression of both forms (yellow). Total p27 and
Thr(P)-187-p27 ratios as determined by densitometry are shown (bottom
panel). C, Kp27MER cells were treated for 12 h with 200 nM 4HT and 50 or 75
mM ZnSO4, as indicated. Total p27, Thr(P)-187-p27 (pT187-p27), and actin
(loading control) were assayed by immunoblot. Total p27:Thr(P)-187-p27 sig-
nal ratios, as determined by densitometry, are shown (bottom panel).
FIGURE 8. MYC-induced SKP2 correlates with p27 down-regulation.
A, expression of p27 in Kp27MER after MYC activation. The cells were treated
with 200 nM 4HT and 50 mM ZnSO4 for 24 and 48 h. p27, SKP2, and MYC protein
levels were determined by immunoblot. B, Kp27-5 cells were treated for 48 h
with ZnSO4 and 4HT, and protein levels of SKP2, MYC, p27 and actin (loading
control) were determined by immunoblot. C, KMER4 cells were cultured for
76 h to reach quiescence caused by cell density, alone or with 200 nM 4HT to
activate MYC. SKP2, p27, and MycER protein levels were determined by
immunoblot.
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phoma, although in contrast to our results, SKP2 was not
described as a direct target of MYC and had no effect on p27
degradation (34). The reason for this discrepancy could lie in
the different cell types and species involved, although MYC
binding to the SKP2 promoter of mouse embryonic stem cells
has recently been reported (64).
Our K562 cell model is derived fromCML, and in a cohort of
CML patient bone marrow samples, we found a correlation
between SKP2 andMYC expression. Expression of the tyrosine
kinase BCR-ABL is the hallmark of CML (65). SKP2 is reported
to be a mediator of BCR-ABL-induced myeloid leukemia in
mice (66), stressing the importance of MYC-mediated induc-
tion of SKP2 in CML cells. Cancer gene expression databases
such as Oncomine and GeneSapiens also show a MYC-SKP2
correlation in human lymphomas with activated MYC. Our data
are consistent with recent reports that SKP2 is among the MYC-
induced genes in transcriptional profiling analysis in murine
hematopoietic stem cells (67) and in genome-wide transcriptional
response toMYC silencing in human breast carcinoma cells (68).
SKP2 is nonetheless subject to complex regulation by several tran-
scription factors besides MYC, and SKP2 expression should thus
not be expected to correlate toMYC in all cell types or tumors.
However, our results show that MYC is required for serum-
dependent SKP2 expression in rat fibroblasts.
p27 can be degraded via SKP2-dependent and -independent
systems (61, 69). The phenotype of Skp22/2 mice and cells is
rescued by the concomitant knock-out of the p27 (Cdkn1B)
gene, however, indicating that the main transformation mech-
anismof SKP2 is linked to p27 degradation (70, 71). In ourK562
model, SKP2 induction by MYC also results in reduced p27
levels. Moreover, Thr-187 phosphorylation is a prerequisite for
SKP2 binding, and MYC promotes p27 phosphorylation at
Thr-187. Although other unknownmechanismsmay also oper-
ate, Thr-187 phosphorylation is likely related to the MYC-in-
duced up-regulation of CDK2 and cyclins A and E reported in
many systems (8, 11). A MYC-induced up-regulation of p27-
bound CDK2 has also been reported in K562 cells (40). Thus,
MYCwould drive p27 degradation by increasing both the levels
of SKP2 and of its substrate Thr(P)-187-p27. In other models,
MYC is reported to induce other SCF complex members such
as CKS1 (33) or CUL1 (32), reinforcing the idea that control of
p27 levels is an important MYC function.
SKP2 is reported to participate in MYC degradation and, at
the same time, to activateMYC transcriptional activity (62, 63).
However, in our model, the SKP2 effect on MYC levels was
marginal, in contrast to the decrease observed in p27. In addi-
tion, we detected no effect on MYC transcriptional activity as
measured with luciferase reporters. This discrepancy might be
due to the different cell types used in our study. A recent report
showed that MYC degradation in hematopoietic cells is only
dependent on FBW7 ubiquitin ligase and not on SKP2 (67).
Another possible explanation is exhaustion of the SKP2-depen-
dent degradation machinery for MYC in our system (63),
because the K562 cell line expresses high basal MYC levels
compared with other human leukemia cell lines (72).
The demonstration of SKP2 as a MYC target gene reveals a
previously unreported mechanism for the transforming activ-
ity, because SKP2 is itself an oncogenic protein. It is widely
accepted that abrogation of p27 activity is one of the MYC
transforming mechanisms. Here we propose another mecha-
nism, that of p27 degradation through SKP2 induction. Our
data strongly suggest that the MYC deregulation/SKP2 induc-
tion/p27 degradation axis contributes to the carcinogenic
mechanism of MYC.
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FIGURE 9. SKP2 silencing results in increased p27 without modifying MYC
levels or activity. A, KMERshSKP2 and KMERpSR cells were cultured for 2 and
4 days, and the protein levels of SKP2, p27, MYC, and a-tubulin (loading con-
trol) in cell lysates were assessed by immunoblot. B, proliferation rates of
KMERpSR and KMERshSKP2 cells were measured by counting viable cells in a
hemocytometer. The values are the means 6 S.E. of three independent exper-
iments. C, KMERpSR and KMERshSKP2 cells were injected into the left and
right flanks, respectively, of nude mice. Tumor weight was scored after 15–20
days and is shown in the box plot (covering from 25 to 75% percentiles). The
line represents the median. D, representative tumors induced in nude mice.
Bar, 1 cm. E, immunoblot analysis of transfected cell lysates to assess down-
regulation of SKP2 protein in cells expressing the shSKP2 vector (Vect.).
F, transactivation of a MYC-responsive reporter in cells with silenced SKP2.
K562 cells were cotransfected with the shSKP2 vector or the corresponding
empty vector and the 43Ebox-Luc or 4xE-boxMut-Luc luciferase reporters
(Mut). At 36 h post-transfection, the cell lysates were prepared, and luciferase
activity was determined. The data were normalized to Renilla luciferase activ-
ity for transfection efficiency. The data show the means 6 S.E. of three mea-
surements in two duplicate experiments.
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Myc Inhibits p27-Induced Erythroid Differentiation of Leukemia Cells
by Repressing Erythroid Master Genes without Reversing
p27-Mediated Cell Cycle Arrest£‡
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Inhibition of differentiation has been proposed as an important mechanism for Myc-induced tumorigenesis,
but the mechanisms involved are unclear. We have established a genetically defined differentiation model in
human leukemia K562 cells by conditional expression of the cyclin-dependent kinase (Cdk) inhibitor p27
(inducible by Zn21) and Myc (activatable by 4-hydroxy-tamoxifen). Induction of p27 resulted in erythroid
differentiation, accompanied by Cdk inhibition and G1 arrest. Interestingly, activation of Myc inhibited
p27-mediated erythroid differentiation without affecting p27-mediated proliferation arrest. Microarray-based
gene expression indicated that, in the presence of p27, Myc blocked the upregulation of several erythroid-cell-
specific genes, including NFE2, JUNB, and GATA1 (transcription factors with a pivotal role in erythropoiesis).
Moreover, Myc also blocked the upregulation of Mad1, a transcriptional antagonist of Myc that is able to
induce erythroid differentiation. Cotransfection experiments demonstrated that Myc-mediated inhibition of
differentiation is partly dependent on the repression of Mad1 and GATA1. In conclusion, this model demon-
strates that Myc-mediated inhibition of differentiation depends on the regulation of a specific gene program,
whereas it is independent of p27-mediated cell cycle arrest. Our results support the hypothesis that differen-
tiation inhibition is an important Myc tumorigenic mechanism that is independent of cell proliferation.
c-Myc (Myc herein after) is an oncogenic transcription fac-
tor of the helix-loop-helix/leucine zipper (HLH-LZ) protein
family that elicits a variety of biological responses related to
cell cycle control, genomic instability, immortalization, ener-
getic metabolism, ribosome biogenesis, apoptosis, intercellular
communication, and control of cell differentiation (for reviews,
see references 5, 17, 21, and 40). Myc forms heterodimers with
the protein Max and the Myc-Max dimers bind to E-boxes in
regulatory regions to transactivate genes. Also, an important
number of Myc target genes (30 to 50% across different stud-
ies) are repressed by Myc-Max in an E-box-independent man-
ner (18, 27, 39, 58; see also the Myc target gene database
[www.myccancergene.org]). The mechanism for Myc-mediated
transactivation involves chromatin acetylation, whereas the
mechanisms for Myc-mediated transrepression remain poorly
defined, with the exception of a few genes (1, 9, 11, 41). On the
other hand, Max form dimers with proteins of the Mad family.
Mad proteins are also HLH-LZ proteins that function as Myc
antagonists, since Mad-Max dimers repress transcription upon
binding to E-boxes (5, 21). Consistent with the Myc effects on
cultured cells and transgenic models, deregulated expression
of Myc is found in a wide array of human cancers, in many
cases associated with disease progression (30, 36).
Work in different mouse models has demonstrated that Myc
promotes differentiation in some tissues by expanding the stem
cell population (53, 56) or by promoting both proliferation and
differentiation of immature precursors (22). However, en-
forced Myc expression blocks differentiation of a wide variety
of cell types both in vitro and in vivo (for reviews, see refer-
ences 21 and 40). Actually, inhibition of differentiation was one
of the first biological effects described for Myc (8, 16, 44).
However, in contrast to the extensive research carried out on
the mechanisms by which Myc enhances proliferation, the
mechanisms for the Myc-mediated suppression of differentia-
tion are much less known. Since proliferation and differentia-
tion are usually mutually exclusive and Myc drives cells into
proliferation, it has been argued that Myc prevents terminal
differentiation by blocking the cell cycle exit (21, 40). Consis-
tently, Myc induces the expression of genes that promote cell
cycle progression (cyclins D2 and E1, Cdk4) and represses cell
cycle inhibitors as p21Waf1 and p27Kip1 (referred to as p27
hereafter) (30).
p27 was originally described as a negative regulator of cell-
cycle progression through the inhibition of cyclin-dependent
kinases (Cdks) (37, 46). However, p27 has also been involved
in biological functions unrelated to cell cycle, including the
differentiation of erythroid precursors (14, 48). Regarding he-
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matopoiesis, p27 is expressed in CD341 progenitor cells and in
the primitive erythroid precursors (48, 55), but p27-deficient
mice do not show gross abnormalities in the hematopoietic
lineages (reviewed in reference 34).
A functional antagonism between Myc and p27 in prolifer-
ation has been well established: Myc and p27 loss cooperates in
animal carcinogenesis models (31), and several reports dem-
onstrate the ability of Myc to abrogate p27 function (7, 43, 51,
54) and expression (54). However, in sharp contrast to the
information on the antagonism between Myc and p27 in pro-
liferation, the possible Myc-p27 cross talk in differentiation has
not been investigated.
The study of Myc effects on differentiation has been im-
paired by the complex array of pathways activated by cytokines
and chemicals used as differentiation inducers in most model
systems. We previously showed that induction of p27 results in
erythroid differentiation of K562 (35), and here we have investi-
gated the role of Myc in this genetically defined differentiation
model. We found that Myc blocks p27-mediated differentiation
but that it cannot rescue the p27-dependent proliferation arrest
and Cdk inhibition. We also report that Myc blocks the upregu-
lation of Mad1 and of a set of erythroid-differentiation-determin-
ing genes such as the transcription factor GATA1.
MATERIALS AND METHODS
Cell culture, differentiation assays, and transfections. K562 cells were grown
in RPMI 1640 medium supplemented with 8% fetal calf serum and antibiotics.
Kp27MER and KMER4 sublines were generated electroporating the pBABE-
MycER plasmid (28) into Kp27-5 and KMT sublines, which have been described
previously (35). The Kp27pBP and KMTpBP sublines were generated by elec-
troporating Kp27-5 and KMT with pBABE-puro vector. A total of 107 cells were
electroporated with 20 mg of DNA (260 V and 1 mFa in a Bio-Rad gene pulser)
and selected with 1 mg of puromycin (Sigma)/ml. Cells (2.5 3 105 cells/ml) were
treated with ZnSO4 to induce p27 expression, and 4-hydroxy-tamoxifen (4HT;
Sigma) to activate MycER. Unless otherwise stated, ZnSO4 and 4HT were used
at 75 mM and 100 nM, respectively. Transient transfection of Kp27MER (80,000
cells) was carried out with Lipofectamine 2000 (Invitrogen) with 1.2 mg of
pEF-GATA1 (50) and pEF-NFE2 (29) vectors or empty vector. Nucleofections
of K562 cells were performed in a Nucleofector (Amaxa) according to the
manufacturer’s indications with pCEFL-Myc (32), pCEFL-Mad1 (constructed by
inserting human Mad1cDNA into the pCEFL vector), pCEFL-p27 (35), pCEFL-
MycV394D, pME-MycD106-143 (49), CMV-MadMyc (6), pEF-GATA1, pEF-
NFE2, and 0.25 mg of a green fluorescent protein (GFP) vector (pmaxGFP;
Amaxa) to assess transfection efficiency.
Proliferation and cell cycle assays. Cell counting was performed in hemacy-
tometer. For DNA synthesis assay, cells were pulsed with 30 mM bromodeoxyuri-
dine (BrdU; Roche Applied Science) for 1 h, fixed in 90% ethanol, treated with
RNase and HCl, and incubated with fluorescein isothiocyanate-conjugated anti-
BrdU monoclonal antibody (Roche Applied Science) for 30 min as described
previously (34). Cells were analyzed by flow cytometry (Excalibur; BD Bio-
sciences). For cell cycle analysis, cells were resuspended in phosphate-buffered
saline (PBS)-sodium citrate buffer containing 10 mg of bovine serum albumin/ml,
200 mg of RNase/ml, and 50 mg of propidium iodide (Sigma Chemical Co.)/ml.
The cells were incubated at 37°C in darkness for 30 min and then analyzed by
flow cytometry using CellQuest software.
RNA analysis. Total RNA was isolated by using an RNeasy kit (Qiagen). For
reverse transcription-PCR (RT-PCR), first-strand cDNA was synthesized from 1
mg of total RNA by using SuperScript II RNase reverse transcriptase (Invitro-
gen) with random primers. Quantitative PCR (qPCR) was performed with a
QuantiTect Sybr green PCR kit (Qiagen). The sequences of the primers used and
amplicon sizes are shown in the Table S1 in the supplemental material. The data
were normalized to ribosomal protein S14 (RPS14) mRNA levels. RPS14 has not
been described as the Myc target gene (www.myccancergene.org).
Luciferase reporter assays. Three million of Kp27MER cells were electropo-
rated at 260 V and 1 mFa in a Bio-Rad electroporator with 3 mg of pGL2-M4-
Luc reporter (24) and 1 mg of pRL-TK (Promega). After 24 h of incubation,
cultures were split into aliquots and further incubated for 24 h with ZnSO4
and/or 4HT. Cells were lysed, and the luciferase activity was measured in dupli-
cate by a dual-luciferase reporter gene assay system (Promega). The data were
normalized against the Renilla luciferase activity.
Gene expression profiling. Biotinylated cRNA was obtained from total RNA
and hybridized to Affymetrix HG-U133A chip in the Genomic Facility of Centro
de Investigacio´n del Cancer (Salamanca, Spain). The data analysis and hierar-
chical tree clusters were generated by using the dChip software (26; see also
http://biosun1.harvard.edu/complab/dchip/). The expression data was filtered so
as to include genes with expression changes $2.3-fold and with a signal differ-
ence $50 between compared samples. The analysis was performed with data
from two independent experiments and RNA preparations of each treatment
(control, ZnSO4, 4HT, and ZnSO4 1 4HT) in Kp27MER and K562. The inter-
action network for differentially expressed genes was generated by using Inge-
nuity Pathways Analysis software.
Immunofluorescence and immunoblotting. For immunofluorescence, Kp27MER
cells were treated with ZnSO4 and/or 4HT for 12 and 24 h and immunostained
with the anti-Myc and anti-p27 antibodies, as well as with DAPI (49,69-di-
amidino-2-phenylindole) to stain nuclei. A total of 2 3 104 to 5 3 104 Kp27MER
cells were centrifuged at 1,500 rpm for 5 min, resuspended in 8 ml of PBS, and
dried on microslides. Cells were fixed for 15 min in 3.7% paraformaldehyde in
PBS at room temperature and permeabilized with 0.5% Triton X-100 for 30 min.
The cells were then incubated with primary (16 h at 4°C), washed, and incubated
with secondary antibodies (1 h at room temperature). The primary antibodies
used were anti-Myc rabbit polyclonal antibody and anti-p27 mouse monoclonal
antibody (both diluted 1:25). Secondary antibodies were conjugated with Texas
Red or FITC (Jackson Laboratories). Cells were mounted with antifading
mounting medium Vectashield (Vector Laboratories) with DAPI to visualize the
nuclei. Images were recorded by using a Bio-Rad MRC 1024 confocal laser
microscope. Immunoblots were performed as previously described (35). Blots
were revealed with an ECL system (Amersham). The antibodies used are de-
scribed in Table S2 in the supplemental material.
Immunoprecipitations and kinase activity assays. Protein extracts (500 mg per
assay) were immunoprecipitated with 1 mg of anti-cyclin D2, cyclin D3, and Cdk2
and p27 antibodies (see Table S2 in the supplemental material). Immunopre-
cipitation and kinase activity assays were performed as described previously (35).
Microarray data were deposited in the ArrayExpress database under accession
number E-MEXP-1772.
RESULTS
Generation of K562 sublines with conditional expression of
p27 and Myc. We previously reported that induction of p27 in
K562 human myeloid cells resulted in G1 arrest and erythroid
differentiation (35). We took advantage of this differentiation
system to ask whether Myc interferes with p27-mediated dif-
ferentiation and to study the possible mechanisms involved.
For this purpose, we first generated cells with conditional ex-
pression of both p27 and Myc. Kp27-5 cells (which carry a
Zn21-inducible p27 allele) were stably transfected with an ex-
pression vector for the fusion protein MycER, where Myc
activity is activated by 4HT (28). One of the transfectants,
termed Kp27MER, was selected, and immunoblot analysis
confirmed that the cells expressed MycER and retained p27
induction by Zn21. The activation of MycER by 4HT was
assessed, first, by the Myc downregulation of endogenous Myc
(Fig. 1A), an effect observed in many cell lines, including K562
(12, 42). We further confirmed the activation of MycER by
transactivation assays with a luciferase reporter carrying E-
boxes (Fig. 1B). Immunofluorescence studies demonstrated
that, in Kp27MER cells, ZnSO4 induced a dramatic accumu-
lation of p27 in cell nucleus and that the concomitant activa-
tion of Myc by 4HT did not modify this p27 localization (Fig.
1C). Altogether, the results demonstrated the activation of
MycER in response to 4HT in Kp27MER cells.
Myc inhibits p27-induced erythroid differentiation. We next
sought to determine whether Myc could antagonize the ery-
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throid differentiation mediated by p27. Kp27MER cells were
treated with ZnSO4 to induce p27 and 4HT to activate Myc,
and the erythroid differentiation was analyzed first by the frac-
tion of cells containing hemoglobin as determined by the ben-
zidine test. This fraction was reduced by 4HT in Kp27MER
cells but not in control Kp27pBP cells (Fig. 2A). Myc effect was
further confirmed by the expression of erythroid-cell-specific
genes as glycophorin A (GYPA), erythropoietin receptor
(EPOR), z-globin, and ε-globin. mRNA levels of these genes
were induced by p27, and this induction was blocked by 4HT
(Fig. 2B). Finally, Myc also reversed the morphological differ-
entiation into erythroid phenotype induced by p27, as shown by
the dramatic reduction in the number of basophilic erythro-
blast-like cells (Fig. 2C). Altogether, the results show that Myc
inhibited p27-induced differentiation.
Myc does not antagonize the proliferation arrest mediated
by p27. As proposed for other models, we explored the possi-
bility that Myc could inhibit erythroid differentiation by main-
taining the cells in a proliferative state. When p27 was induced
with 75 mM Zn21, Kp27MER cells underwent a rapid growth
arrest, similar to that induced by p27 in control cells
(Kp27pBP) (Fig. 3A). In agreement with the growth determi-
nations, p27 induction was accompanied by S-phase depletion
and G1-phase arrest (Fig. 3B). Surprisingly, the activation of
Myc by 4HT in these conditions did not reverse this arrest (Fig.
3A), and cell cycle analysis revealed the G1-phase arrest pro-
voked by p27 upon treatment with 75 mM Zn21 was not mod-
ified by Myc (i.e., by 4HT treatment) (Fig. 3B). Treatment with
lower Zn21concentrations (50 mM) resulted in moderate p27
levels (Fig. 3C) and a less severe proliferation arrest than with
higher p27 levels (i.e., with 75 mM Zn21) (Fig. 3A). Consis-
tently, moderate p27 levels (i.e., with 50 mM Zn21) induced a
weaker differentiation, which was also blunted by Myc (not
shown). In the presence of moderate p27 levels, however, Myc
provoked a slight but consistent increase in proliferation (Fig.
3A). This effect depended on Myc since 4HT did not modify
the proliferation rate of control Kp27pBP cells (Fig. 3A). Con-
sistently, Myc provoked an increase in the fraction of cells in S
phase when the cell cycle was analyzed (Fig. 3B). In agreement
with this result, Myc reversed the moderate repression of the
mitotic cyclin B1 in cells treated with 50 mM Zn21, as deter-
mined by immunoblot analysis (Fig. 3D). In contrast, the ex-
FIG. 1. Myc activation and p27 induction in Kp27MER cells.
(A) Kp27MER cells were incubated with 100 nM 4HT and/or 75 mM
ZnSO4 during 24 h, and protein extracts were analyzed by Western
blotting with antibodies to Myc, p27, and a-tubulin as a loading con-
trol. (B) Induction of Myc transactivation activity in Kp27MER in
response to 4HT. Cells were electroporated with a Myc-responsive
luciferase construct, and after 24 h the cultures were split into aliquots
and further incubated for 24 h with ZnSO4 and/or 4HT as indicated.
The data represent promoter activity normalized against the Renilla
luciferase activity. (C) Double immunofluorescence showing p27 and
Myc subcellular localization. Kp27MER cells were treated for 12 and
24 h with ZnSO4 and/or 4HT as indicated. Cytospin preparations were
subjected to immunofluorescence with anti-Myc and anti-p27 antibod-
ies and stained with DAPI to visualize the nuclei.
FIG. 2. Myc inhibits the erythroid differentiation induced by p27.
(A) Cells were treated for 72 h with ZnSO4 and 4HT, and the fraction
of hemoglobinized cells was assayed by the benzidine test. Values are
means 6 the standard deviations (SD) of three experiments.
(B) Downregulation of erythroid genes by Myc. Kp27MER as well as
control Kp27pBP cells were treated with ZnSO4 and 4HT as indicated.
The expression of the GYPA, EPOR, z-globin, and ε-globin expression
was determined by RT-qPCR. Cells were incubated with ZnSO4
and/or 4HT for 24 h except GYPA (72 h). Expression levels were
graphed relative to untreated Kp27MER cells. The data are means 6
the standard errors of the mean (SEM) of three independent experi-
ments. (C) Kp27MER cells were treated for 96 h with 75 mM ZnSO4
and 200 nM 4HT as indicated, and cytospin preparations were stained
by the May-Gru¨nwald-Giemsa method. Micrographs of representative
fields are shown. Arrows indicate cells with morphological features of
erythroid differentiation resembling basophilic erythroblasts.
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pression of the erythroid gene g-globin was similarly blunted
by Myc in the presence of 75 or 50 mM Zn21. The results were
confirmed by measurements of DNA synthesis by BrdU incor-
poration assays. As expected, DNA synthesis was halted in
Kp27MER cells treated with 75 mM Zn21 (i.e., high p27 lev-
els). Activation of Myc did not relieve this inhibition (Fig. 3E).
However, DNA synthesis was not totally inhibited in cells
treated with 50 mM Zn21 (moderate p27 levels), and Myc
induced a moderate increase in DNA synthesis (Fig. 3E). We
conclude that Myc inhibits p27-induced erythroid differentia-
tion without reversing the p27-mediated cell cycle arrest.
Myc does not reverse p27-mediated inhibition of Cdks. The
best-defined biochemical activity of p27 is the inhibition of Cdk
activity. Thus, we sought to determine whether Myc impaired
this activity in the K562 model in conditions where Myc is
blocking differentiation. We first compared the expression of
cyclins D and Cdk4, Cdk6, and Cdk2 in cells arrested and
differentiated by p27 (i.e., treated with ZnSO4) and in cells
with the differentiation blocked after Myc activation (i.e.,
treated with ZnSO4 and 4HT) (Fig. 4A). p27 induced the
accumulation of cyclins D, an effect likely due to protein sta-
bilization since there was no upregulation of cyclins D mRNA
(data not shown). Myc also induced a small increase in cyclin
A, cyclin D2, Cdk4, and Cdk2. No significant changes were
observed in parental K562 cells treated with ZnSO4 or 4HT
(results not shown).
In most models, the G1-phase arrest by p27 is associated
with retinoblastoma (RB) hypophosphorylation. Immunoblot
experiments show that this was also the case in Kp27MER
treated with ZnSO4. Interestingly, in the presence of p27, most
of the RB remained hypophosphorylated upon 4HT addition
(Fig. 4B). We next analyzed the levels of RB phosphorylated in
Ser780 and Thr821 using phospho-specific antibodies. Phos-
phorylation in Ser780 and Thr821 have been reported as spe-
cific for Cdk4/6 and Cdk2, respectively (25, 57). Immunoblot
results confirmed that p27 profoundly repressed RB phos-
phorylation and that Myc could reverse none of them.
We next studied the kinase activity in cyclin D2 and cyclin
D3 complexes, the most prevalent cyclin D forms in K562 (Fig.
4A and data not shown) using RB protein as substrate. In this
setting, the kinase activity assayed is mostly due to Cdk2, Cdk4,
and Cdk6. The kinase activity was dramatically inhibited by
p27, and Myc only slightly reversed this inhibition (Fig. 4C),
which is consistent with the small increase in phospho-RB
observed in 4HT-treated cells (Fig. 4B). K562 cells are defi-
cient in p15INK4B and p16INK4A (13), and thus these proteins
cannot contribute to Cdk4/6 inhibition in this system. Since RB
is also the substrate for Cdk2 kinase activity, we assayed the
kinase activity after immunoprecipitation with anti-Cdk2 anti-
body and in the presence or absence of Myc (i.e., with or
without 4HT treatment). The results showed a dramatic inhi-
bition of Cdk2 activity in p27-expressing cells, which was un-
changed by Myc (Fig. 4C). Thus, Myc cannot reverse the in-
hibition of Cdk4/6 and Cdk2 elicited by p27. The possibility still
FIG. 3. Myc induced proliferation in p27-arrested cells is p27 dose dependent. (A) Growth curves of Kp27MER and Kp27pBP cells treated with
(E) or without (F) 4HT and 75 or 50 mM ZnSO4. Values are means 6 the SD of three experiments. (B) Cell cycle analysis of Kp27MER treated
for 24 h with 100 nM 4HT and 50 or 75 mM ZnSO4 as indicated. The percentages of the cells in each cell cycle phase are indicated.
(C) Dose-dependent expression of p27. Kp27MER cells were treated with 50 and 75 mM ZnSO4 and 4HT for 24 h, and the expression of p27 and
a-tubulin (as loading control) was assayed by immunoblotting. (D) Kp27MER cells were treated with the indicated concentrations of ZnSO4 and
4HT, and the expression of cyclin B1 (to assay proliferation), g-globin (to assay differentiation), and actin (as loading control) was assayed by
immunoblotting. (E) DNA synthesis in Kp27MER cells assayed by BrdU incorporation. Cells were incubated during 24 h with or without 4HT and
75 or 50 mM ZnSO4 and pulsed for 1 h with BrdU, and the incorporation of the nucleoside was determined by flow cytometry. The graph shows
the percentages of BrdU-positive cells. The data are means 6 the SD from three independent experiments.
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existed that Cdk inhibition was a secondary effect of the p27-
induced differentiation rather than the inhibitory interaction of
p27 with cyclin-Cdk complexes. Thus, we studied the proteins
associated with p27 by immunoprecipitation experiments.
Cdk2, Cdk4, and Cdk6 were found in p27 immunoprecipitates,
and Myc did not modify their levels (Fig. 4D). However, Myc
activation also resulted in greater amounts of cyclins D. Thus,
we also tested the possibility that Myc modified the affinity of
p27 for cyclin D-Cdk4/6 complexes. However, Myc activation
did not change the relative amounts of p27, Cdk4, and Cdk6
present in cyclin D2 and D3 immunoprecipitates (Fig. 4E) and
correlated to the amounts present in total extracts (Fig. 4A and
data not shown). The results are again consistent with the lack
of recovery in Cdk activity (Fig. 4C). Taken together, the data
demonstrate that Myc inhibited p27-induced erythroid differ-
entiation without reversing the p27-dependent inhibition of
Cdks, a result that is consistent with the inability of Myc to
reverse p27-mediated proliferation arrest.
Myc antagonizes the upregulation of erythroid-cell-specific
genes mediated by p27. Since Myc inhibited Kp27MER differ-
entiation without rescuing the cells from the G1 arrest imposed
by p27, this model provided an ideal opportunity to identify
proliferation-independent targets of Myc that may explain its
activity as a differentiation inhibitor. We therefore carried out
microarray analysis with the Affymetrix platform testing RNA
from Kp27MER cells either untreated or treated for 12 h with
ZnSO4, 4HT, or both. The experimental conditions and asso-
ciated phenotypes, as well as the number of regulated genes,
are schematized in Fig. 5A. We focused in the genes regulated
by Myc in the presence of p27, comparing the transcriptomes
of Kp27MER treated with ZnSO4 with cells treated with
ZnSO4 plus 4HT. After subtracting the genes changed in con-
trol samples, filtering, and statistical analysis, we found that
Myc regulated 200 genes with $2.3-fold change, being 121
genes downregulated (see Table S3 in the supplemental mate-
rial). The clustering analysis of these genes showed that all
Myc-expressing cells cluster together (Fig. 5B). This data set
was further analyzed with the Ingenuity Pathways software to
reveal the network of interactions between differentially regu-
lated genes in the Kp27MER cells after induction of Myc and
thus assaying the possible relevance of Myc activation in this
model. The results revealed that the top-ranked network had
Myc at the most significant node of interactions among pro-
teins whose expression levels (at the mRNA level) changed
between cells treated with ZnSO4 and cells treated with ZnSO4
plus 4HT (Fig. 5C). This result argues that Myc is responsible
for the phenotypic change of Kp27MER cells upon addition
of 4HT.
Myc downregulates erythroid genes. Microarray analysis re-
vealed that a significant fraction of the genes downregulated by
Myc in the presence of p27 were erythroid cell related (see
Table S4 in the supplemental material), and the same result
was observed for other erythroid genes (e.g., ε-globin and
z-globin). Interestingly, some of these genes downregulated by
Myc encode transcription factors able to drive erythroid dif-
ferentiation in cell culture, as well as in in vivo models, such as
GATA1, NFE2, STAT5A, STAT3, LMO2, LYL1, and JUNB.
Moreover, Myc upregulated genes that block erythroid differ-
entiation, such as the NOTCH ligand JAG2 and the transcrip-
tion factor MAFK. Myc-mediated regulation of GATA1,
NFE2, JUNB, and MAFK mRNA levels was confirmed by
RT-qPCR (Fig. 6A). In contrast, Myc did not antagonize the
p27-mediated downregulation of genes involved in DNA rep-
lication and mitosis, in agreement with the inability of Myc to
FIG. 4. Myc does not reverse Cdk inhibition by p27. (A) Expression
of G1-phase cyclins and Cdks. Protein extracts of Kp27MER cells
treated for 24 h with or without 4HT and ZnSO4 were assayed by
immunoblotting for the indicated cyclins and Cdks. (B) Myc does not
reverse RB hypohosphorylation. Total RB levels and phospho-specific
RB levels were determined by immunoblotting in Kp27MER cells. See
Table S2 in the supplemental material for antibody details. The posi-
tion of hypophosphorylated RB and hyperphosphorylated RB (pRB)
are marked by arrowheads. (C) Cdk activity determination. Lysates
were immunoprecipitated with antibodies to cyclin D2, cyclin D3, and
Cdk2 and assayed for kinase activity using RB (for cyclins) or histone
H1 (For Cdk2) as a substrate. The kinase activity was normalized
against the amounts of cyclin D2, D3, and Cdk2 pulled down in the
immunoprecipitates. (D) Composition of p27 complexes. Lysates from
Kp27MER cells treated with ZnSO4 and/or 4HT were immunoprecipi-
tated with anti-p27 antibodies, and the levels of p27, cyclin D1, D2, D3,
Cdk6, Cdk4, and Cdk2 in the immunoprecipitates were assayed by im-
munoblotting. The corresponding nonimmunoprecipitated samples are
shown in panel A. (E) Cyclin D2 and D3 immunoprecipitations. Cells
were treated with ZnSO4 and/or 4HT, lysates were immunoprecipitated
with cyclin D2 or cyclin D3 antibodies, and the levels of p27, Cdk4, and
Cdk6 in the immunoprecipitates were assayed by immunoblotting.
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reverse p27-mediated growth arrest as cyclins E, Cdk1, Cdc6,
Cdc25A, PCNA, RFCs, and MCMs (results not shown). We
sought to confirm the effect of Myc on p27-induced differen-
tiation observed in the Kp27MER cell line in the parental
K562 cells. For this, K562 cells were transiently transfected
by nucleofection with expression vectors for p27 and Myc.
In agreement with the results obtained with the Kp27MER
line, p27-transfected K562 cells overexpressed erythroid-cell-
specific genes such as GYPA and EPOR, and transfection of
Myc vector inhibited this effect (Fig. 6B). It has been described
that Myc represses genes through the interaction with the zinc
finger protein Miz1, forming a complex that binds to the region
of the transcription initiation site (reviewed in reference 52).
To test the possibility that Miz1 could be involved in the
repression of erythroid genes and to confirm the effects of Myc
on p27-induced differentiation, we transiently transfected K562
cells with expression vectors for p27, Myc, and MycV394D, a
mutant unable to bind Miz1 (23). MycV394D was as efficient as
wild-type Myc in antagonizing the upregulation of GATA1 and
NFE2 induced by p27 (Fig. 6B). Consistently, we did not detect
binding of Myc to the region of GATA1 gene that contains the
transcription initiation site by chromatin immunoprecipitation
(data not shown). This result suggests that Myc repress
GATA1 and NFE2 through a Miz1-independent mechanism.
We also sought to determine whether the Myc effect is depen-
dent on Myc box II. This region is required for transactivation,
for transformation, and also for gene repression activities of
Myc (reviewed in references 21 and 40). The results showed
that MycD106-143 (carrying a deletion that encompasses Myc
box II) was much less efficient at antagonizing p27-mediated
upregulation of GATA1 and NFE2 (Fig. 6B) and other ery-
throid markers as ε-globin and EPOR (data not shown).
GATA1 antagonizes the effect of Myc as an inhibitor of
erythroid differentiation. Of the genes regulated by Myc, we
focused on GATA1 and NFE2, two transcription factors es-
sential for erythroid lineage commitment (19). In erythroid
differentiation, GATA1 nucleates the subsequent binding (2).
Thus, we sought to determine whether GATA1 and NFE2
were partly responsible for the p27-induced differentiation by
transiently transfecting Kp27MER cells. We first confirmed by
immunoblot analysis that GATA1 transfection and overexpres-
sion did not modify the induction of p27 by ZnSO4 (Fig. 6C).
Activation of Myc (i.e., by 4HT treatment) impaired erythroid
differentiation, as assessed by the diminished upregulation of
GYPA (Fig. 6D), ε-globin (Fig. 6E), and the fraction of he-
moglobinized cells (data not shown). However, differentiation
was increased to some extent by GATA1 coexpression (Fig.
6D,E). We also transfected Kp27MER cells with NFE2 expres-
sion vector (Fig. 6F). In contrast to GATA1, NFE2, at the
levels achieved in the transfections, did not rescue the differ-
entiation inhibitory effect of Myc as assayed by ε-globin ex-
pression (Fig. 6G) and benzidine staining (not shown). When
both GATA1 and NFE2 were cotransfected, the effect was
similar to that achieved by GATA1 alone (data not shown).
Thus, downregulation of GATA1 is involved in the differenti-
ation inhibition by Myc, but other additional mechanisms seem
to be operative.
Myc antagonizes Mad1 upregulation mediated by p27. It has
been shown that Mad1, which forms dimers with Max that
repress transcription, antagonizes Myc functions. In addition,
FIG. 5. Myc-regulated genes in the Kp27MER system. (A) Scheme
of the Kp27MER samples subjected to microarray analysis and the
resulting phenotypes. Cells were treated for 12 h with ZnSO4 and
4HT. The numbers of genes regulated ($2.3-fold) are indicated in
red. Gene expression changes between samples separated by the red
line are subjected to clustering analysis in panel B. (B) Heat map of
clustered samples and genes of expression data of duplicated sam-
ples of Kp27MER treated with ZnSO4 (i.e., p27) in the presence or
absence of 4HT (i.e., Myc). The hierarchical clustering was per-
formed for genes with expression variation $2.3-fold between cells
expressing p27 and cells expressing p27 and Myc (P , 0.005), after
subtraction of the corresponding controls in parental K562 cells.
The genes are listed in the Table S3 in the supplemental material.
The scale at the bottom shows the relationship between color sat-
uration and the expression ratios. (C) Interaction network for dif-
ferentially expressed genes in the presence of Myc and p27. A
knowledge-based database (Ingenuity Pathways Analysis) was
seeded with the differentially expressed genes between cells ex-
pressing p27 and cells expressing p271Myc shown in panel B.
Genes in red were upregulated and those in gray were downregu-
lated in the samples treated with 4HT (i.e., Myc). The figure rep-
resents the network with the highest score identified by the program
and shows Myc (in blue) at a central node of the network. The
meanings of node shape and lines are indicated at the bottom.
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it has been reported that Mad1 induces erythroid differentia-
tion in Friend murine erythroleukemia cells (10). Thus, we
sought to determine whether the functional antagonism be-
tween Myc and Mad1 could also contribute to explain the
Myc-mediated inhibition of differentiation in the K562 system.
We assayed the expression of Mad proteins in the Kp27MER
system and found that Mad1 protein (Fig. 7A) and mRNA
(Fig. 7B) was upregulated upon p27-induced differentiation.
Interestingly, Mad1 upregulation was reduced when Myc was
activated by 4HT (Fig. 7A and B). In contrast, other members
of the Mad family such as Mnt and Mxi1 were not upregulated
by p27 (Fig. 7A). Moreover, transient transfection of p27 in
K562 resulted in an increase in Mad1 mRNA (not shown). We
next sought to determine whether Mad1 could contribute to
p27-induced differentiation in this model. Cells were tran-
siently transfected with expression vectors for Mad1 and Myc,
and the erythroid differentiation was assayed by the benzidine
test and the expression of ε-globin and EPOR. The results
showed that Mad1 increased the expression of differentiation
markers (Fig. 7D and E). We also transfected the MadMyc
construct, which carries the transrepression domain of Mad1
linked to the HLH-LZ domain of Myc and acts as a strong
repressor of Myc-responsive transcription (6). MadMyc was
transfected into K562, and its expression demonstrated by im-
munoblotting (Fig. 7C). We found that MadMyc efficiently
induced differentiation as assessed by the upregulation of
EPOR and ε-globin genes (Fig. 7E). Finally, coexpression of
Myc blunted the differentiation induced by Mad1 and by Mad-
Myc in transient-transfection experiments (Fig. 7C and D). We
conclude that Mad1 upregulation is part of the differentiation
response and that Myc also functions as a Mad1 antagonist in
this system.
DISCUSSION
One of the first biological activities described for Myc was
differentiation inhibition, namely, the chemically induced ery-
throid differentiation of FMEL cells (8, 16, 44). This effect is
consistent with the erythroleukemia induced in transgenic mice
with enforced Myc expression in erythroid precursors (47).
However, the mechanisms by which Myc blocks differentiation
are poorly understood. Proliferation stimulation can certainly
contribute to Myc-mediated inhibition of differentiation, but
the hypothesis that Myc exerts proliferation-independent
mechanisms to block differentiation has received little atten-
tion. Several studies have shown that Myc antagonizes the cell
cycle arrest effect of p27, and the prevalent mechanism pro-
posed is the sequestration of p27 in type D cyclins complexes
(7, 43, 51). In contrast, there is little information on whether
and how Myc impairs p27-induced differentiation. In this con-
text, it has been shown that the monocytic differentiation in-
duced by retinoic acid in U937 myeloid cells is mediated by p27
and inhibited by Myc (15) and that inactivation of p27 gene
rescues the cerebellar development otherwise impaired in N-
Myc-deficient mice (59).
We have established a genetically defined model system
where differentiation can be induced in K562 human myeloid
leukemia cells by p27 induction and Myc can be conditionally
activated. The molecular mechanisms by which p27 induces
differentiation in this model are unknown. However, they do
FIG. 6. Erythroid genes downregulated by Myc. (A) Kp27MER
and K562 cells were incubated for 12 h with ZnSO4 and/or 4HT, and
mRNA levels of the indicated erythroid transcription factor genes
were determined by RT-qPCR. Values represent means6 the SEM of
three independent experiments. (B) Expression of erythroid genes in
K562 cells after transient transfection of vectors for p27, Myc, Myc-
V394D (MycVD), and Myc D106-143 (MycD106). The plasmids were
nucleofected, and the mRNA levels of GYPA, EPOR (24 h after
transfection), or GATA1 and NFE2 (48 h after transfection) were
determined by RT-qPCR. An expression vector for GFP was cotrans-
fected in each case, and the data were normalized to the expression of
GFP. Values are means 6 the SEM from four independent experi-
ments. (C) Enforced expression of GATA1 in Kp27MER. Cells were
transfected by lipofection with GATA1 or empty vector. At 12 h after
transfection, cells were treated with ZnSO4 and/or 4HT. After 24 h of
incubation, the expression of GATA1, p27, and Myc was analyzed by
immunoblotting. The anti-GATA1 antibody used recognizes the N-
terminal domain of mouse protein. (D) GYPA mRNA levels assayed
by RT-qPCR in Kp27MER cells transiently transfected with GATA1.
At 12 h after transfection the cells were treated for 72 h with ZnSO4
and 4HT, and the mRNA level was determined by RT-qPCR. Values
are means 6 the SEM of two independent experiments. (E) ε-Globin
mRNA levels of Kp27MER transfected with GATA1, assayed as in
panel D. (F) Enforced expression of NFE2 in Kp27MER. Cells were
transfected with an NFE2 expression vector or empty vector and an-
alyzed by immunoblotting as in panel C. (G) ε-Globin mRNA levels of
Kp27MER transfected with NFE2, assayed as in panel D. The data are
means 6 the SEM of two independent experiments.
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not entirely depend on cell cycle arrest since p21 also arrests
proliferation of K562 while inducing a different type of differ-
entiation (34). In the present study we show that Myc impairs
the erythroid differentiation through a mechanism that is in-
dependent of the proliferation arrest and Cdk inhibition im-
posed by p27. Thus, the Myc effect on differentiation inhibition
is uncoupled from its effects on proliferation. Microarray anal-
ysis showed that Myc antagonizes the p27-mediated upregula-
tion of genes of transcription factors that direct erythroid dif-
ferentiation (GATA1, NFE2, JUNB, LMO2, and STAT5A).
Myc also antagonizes the p27-mediated downregulation of
genes that oppose erythroid differentiation (MAFK and
JAG2). Moreover, enforced expression of GATA1, a “master
gene” of erythropoiesis (19), partially rescues the differentia-
tion inhibition induced by Myc, indicating that Myc effect is
mediated, in part, by antagonizing GATA1 induction. How-
ever, GATA1 is only partly rescuing the anti-differentiation
effect of Myc, since Myc is likely impairing differentiation by
repressing several erythroid-determining genes.
The molecular mechanism by which Myc represses GATA1
is unclear. Actually, about half of Myc target genes are re-
pressed, but the mechanism of repression is unknown for the
vast majority of the genes. In a small subset of genes, Myc-
mediated repression depends on the interaction with Miz1
(52). In the case of GATA1 in the K562 model, this effect
seems to be Miz1 independent, since a Myc mutant unable to
bind Miz1 antagonized the upregulation of GATA1 and ery-
throid differentiation as efficiently as did wild-type Myc. In
contrast, a Myc mutant lacking Myc box II (a conserved region
required for transformation, transactivation, and repression
activities of Myc) cannot efficiently antagonize p27-induced
differentiation in our model. This result has also been observed
for other differentiation models (4, 20) and suggests that Myc
is using a common molecular mechanism to transform and to
abrogate differentiation. On the other hand, it has been re-
ported that GATA1 represses Myc and induces p27 in murine
embryonic cells (45), suggesting the possibility of a regulatory
p27-GATA1 loop. However, GATA1 does not repress Myc in
our K562 model (data not shown).
Myc and Mad1 have antagonist activities in transcription
upon binding to the same E-boxes and in cell proliferation (5,
21). We found that p27-induced differentiation of K562 is
accompanied by Mad1 upregulation and that Mad1 is able to
promote K562 erythroid differentiation, although less effi-
ciently than p27. Moreover, MadMyc, a chimeric protein that
represses gene expression upon binding to Myc-binding sites
(6), is a potent differentiation inducer. Thus, Myc would an-
tagonize this Mad1 effect at the transcriptional level. Further-
more, Myc activation in our model provokes Mad1 downregu-
lation in K562 cells and Myc coexpression impairs Mad1 and
MadMyc-induced differentiation. This suggests that the im-
pairment of Mad1 function by Myc is contributing to differen-
tiation inhibition in the K562p27MER model. These results
are consistent with Mad1 inducing erythroid differentiation of
murine erythroleukemia cells (10). Moreover, it has been
shown that Mad1 and p27 cooperate for a correct development
of the myeloid compartment in vivo (33). Similar scenery
seems to operate in K562 differentiation, and our data suggest
that Myc might impair the Mad1-p27 functional interaction.
In summary, the results in the K562 model demonstrate that
the differentiation-inhibitory effect of Myc depends on its gene
regulatory activity and is uncoupled from its effect as prolifer-
ation stimulator. Importantly, tumor cell redifferentiation is
the mechanism for the tumor regression after Myc deactivation
in some transgenic mice models (reviewed in reference 3).
FIG. 7. Mad1 induction by p27 and repression by Myc. (A) Immu-
noblot showing Mad1 expression in Kp27MER cells treated with 200
nM 4HT and the indicated concentrations of ZnSO4. The expression
of p27, Mnt, and Mxi1 (members of the Mad family) was also deter-
mined. The levels of p21 and endogenous Myc are also shown to
confirm the activation of Myc by 4HT. (B) Expression of Mad1 mRNA
in Kp27MER and K562 cells. Cells were treated for 12 h with 4HT and
ZnSO4, and mRNA expression was determined by RT-qPCR. The
data are means 6 the SEM of three experiments. (C) Mad1 induces
the expression of erythroid markers in K562, and Myc impairs the
Mad1-induced differentiation. K562 cells were nucleofected with ex-
pression vectors for Mad1, Myc, the MadMyc hybrid construct, and a
mixture of Mad11Myc and MadMyc1Myc vectors. At 24 h after
transfection, the expression of the ectopic proteins was analyzed by
immunoblotting. (D) K562 cells were transfected as in panel C, and the
benzidine-positive cells were scored 72 h after transfection to assess
erythroid differentiation. The data are means 6 the SEM of two
independent experiments. (E) EPOR and ε-globin mRNA levels were
assayed by RT-qPCR in K562 cells transiently transfected as described
in panel C. The data are means 6 the SEM of two independent
experiments.
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Moreover, Myc is one of the four transcription factor set ca-
pable of conferring pluripotent stem cell properties to differ-
entiated adult cells, and Myc is reactivated in the tumors aris-
ing in the chimeric mice derived from such cells (38). Thus, it
is conceivable that Myc displays common pathways as a “stem
cell-ness” keeper and as an oncogene, preventing differentia-
tion in both cases. Our results in the K562 model support the
hypothesis that inhibition of cell differentiation is a Myc tu-
morigenic mechanism independent of Myc effects in cell pro-
liferation.
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SHORT COMMUNICATION
MYC antagonizes the differentiation induced by imatinib
in chronic myeloid leukemia cells through downregulation
of p27KIP1
MT Go´mez-Casares1, E Garcı´a-Alegria2, CE Lo´pez-Jorge1, N Ferra´ndiz2,5, R Blanco2, S Alvarez3, JP Vaque´2,6, G Bretones2,
JM Caraballo2, P Sa´nchez-Bailo´n4, MD Delgado2, J Martı´n-Perez4, JC Cigudosa3 and J Leo´n2
Chronic myeloid leukemia (CML) progresses from a chronic to a blastic phase where the leukemic cells are proliferative and
undifferentiated. The CML is nowadays successfully treated with BCR-ABL kinase inhibitors as imatinib and dasatinib. In the
CML-derived K562 cell line, low concentrations of imatinib induce proliferative arrest and erythroid differentiation. We found that
imatinib upregulated the cell cycle inhibitor p27KIP1 (p27) in a time- and -concentration dependent manner, and that the extent of
imatinib-mediated differentiation was severely decreased in cells with depleted p27. MYC (c-Myc) is a transcription factor frequently
deregulated in human cancer. MYC is overexpressed in untreated CML and is associated to poor response to imatinib. Using K562
sublines with conditional MYC expression (induced by Zn2þ or activated by 4-hydroxy-tamoxifen) we show that MYC prevented
the erythroid differentiation induced by imatinib and dasatinib. The differentiation inhibition is not due to increased proliferation
of MYC-expressing clones or enhanced apoptosis of differentiated cells. As p27 overexpression is reported to induce erythroid
differentiation in K562, we explored the effect of MYC on imatinib-dependent induction of p27. We show that MYC abrogated the
imatinib-induced upregulation of p27 concomitantly with the differentiation inhibition, suggesting that MYC inhibits differentiation
by antagonizing the imatinib-mediated upregulation of p27. This effect occurs mainly by p27 protein destabilization. This was in
part due to MYC-dependent induction of SKP2, a component of the ubiquitin ligase complex that targets p27 for degradation. The
results suggest that, although MYC deregulation does not directly confer resistance to imatinib, it might be a factor that contributes
to progression of CML through the inhibition of differentiation.
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INTRODUCTION
c-Myc (MYC herein after) is an oncogenic transcription factor of the
helix–loop–helix/leucine zipper protein family. MYC is a widespread
regulator of transcription that regulates about one thousand
genes.1,2 MYC is found deregulated in around half of human
tumors and appears frequently associated with tumor progression
in solid tumors and leukemia.3,4 MYC activities include increased
proliferative potential, enhanced protein synthesis and energetic
metabolism and genomic instability.2,5 One of the most relevant
activities of MYC in carcinogenesis is the impairment of cell
differentiation6.
p27 was originally described as a cyclin-dependent kinases
inhibitor, with cyclin E-cyclin-dependent kinases 2 complexes
as its primary targets.7,8 p27 is regulated mainly at the
protein stability level and low p27 levels are associated with a
poor prognosis in most tumors.9,10 The degradation of p27 in
proteasoma is preceded by ubiquitylation by the SCFSKP2 complex,
where SKP2 is the p27-recognizing subunit.11–13 Recently it has
been shown that SKP2 is a MYC target gene, which may explain
the inverse correlation between MYC and p27 levels found in
many systems.14
Chronic myeloid leukemia (CML) is a myeloproliferative
malignancy that progresses from a relatively benign chronic
phase to a blastic crisis phase.15 The molecular hallmark of all CML
phases is the expression of the BCR-ABL kinase. CML is a
hematopoietic stem cell malignancy where BCR-ABL would lead
to a progressive block of differentiation and increased genetic
instability.16–18 However, the molecular mechanisms underlying
CML progression into the blastic phase are still uncertain. We
recently showed that MYC expression was higher in CML patients
at diagnosis and that correlated with a poor response to
imatinib.19 Moreover MYC antagonizes the erythroid
differentiation of the CML-derived cell line K562 induced by
cytosine arabinoside20 and by p27.21 Imatinib, a BCR-ABL inhibitor,
is the frontline drug in CML therapy.22–24 Given that differentiation
inhibition is a hallmark of the CML progression we explored a
possible effect of MYC on imatinib-dependent differentiation. We
show here that MYC impairs the imatinib-induced erythroid
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differentiation of CML-derived cells. This inhibition is mediated by
destabilization of p27, which is achieved in part by the induction
of SKP2. Our data suggests that the block in differentiation is a
mechanism by which MYC contributes to CML progression.
RESULTS AND DISCUSSION
Treatment of K562 cells with low imatinib concentrations (0.5 mM)
abolished cell proliferation as shown by cell counting (Figure 1a)
and by [3H]thymidine incorporation (Figure 1b). We examined the
imatinib-induced erythroid differentiation in cells treated with
0.5 mM imatinib. The fraction of benzidine-positive (assessed by
benzidine cytochemical assay, which detects cells containing
hemoglobin) augmented in a dose and time-dependent manner
(Figure 1c). The erythroid differentiation was also confirmed by
the increased mRNA levels of e-globin, transferring receptor 2 and
erythropoietin receptor (Figure 1d) and glycophorin A as
measured by flow cytometry (not shown). Higher imatinib
concentrations (2.5mM) also induced erythroid differentiation but
provoked significant apoptosis (Shah et al.,25 Albajar et al.26 and
data not shown).
We next investigated the mechanism for imatinib-induced
erythroid differentiation. It was reported that p27 induces
erythroid differentiation in K562 cells27 and that BCR-ABL activity
decreases p27 levels.28,29 Thus, we tested the hypothesis that
differentiation depended on imatinib-mediated upregulation of
p27. Imatinib induced the expression of p27 protein in K562
cells in a time- and concentration-dependent manner (Figure 1e).
Importantly, there was a correlation between p27 levels and
erythroid differentiation as assessed by the expression of g-globin
(Figure 1e). To confirm p27 involvement we analyzed the imatinib
effect in p27 depleted cells. A short-hairpin vector for p27 was
transiently transfected into K562, resulting in lower p27 levels in
cells treated with imatinib, as compared with empty vector-
transfected cells (Figure 1f). Consistently, these cells showed a
lower level of differentiation in response to imatinib as assessed
by the elevated g-globin expression (Figure 1f, compare lanes 2
versus 4) and by the increase in the fraction of benzidine-positive
cells (Figure 1f, bottom panel).
To investigate whether the imatinib-induced p27 was sufficient
to differentiate the cells, we compared the levels of p27 and
differentiation obtained by imatinib in K562 with those achieved
by Zn2þ in Kp27-5 cells. These are K562 cells carrying a zinc-
inducible p27 gene that undergoes erythroid differentiation upon
p27 induction.27 The proliferative arrest induced by p27 in Kp27-5
cells was similar to that achieved by imatinib and the
antiproliferative effects of p27 and imatinib were not additive
(Figure 1g). Also, p27 did not potentiate the imatinib-induced
apoptosis (not shown). The levels of p27 achieved after 24 h of
imatinib treatment were similar to those of Kp27-5 treated with
Zn2þ for the same period of time (Figure 1h) and the concomitant
treatment with Zn2þ and imatinib did not significantly increase
the levels of p27 (Figure 1h, upper panel). Consistently, the extent
of differentiation was similar to the differentiation achieved with
Zn2þ or imatinib alone (Figure 1h, lower panel). In a second
approach to elevate p27 levels we used the proteasome inhibitor
bortezomib. Bortezomib provoked the accumulation of p27 in a
concentration- and time-dependent manner (Supplementary
Figure 1a) and induced erythroid differentiation of K562, as
shown by the accumulation of hemoglobinized cells and e-globin
expression (Supplementary Figures 1b and c). We conclude that
the upregulation of p27 is, at least in part, responsible of the
differentiation elicited by imatinib.
As p27 is described as a cyclin-dependent kinases inhibitor, we
asked whether differentiation was linked to proliferation arrest
using K562-R cell line, a K562 derivative resistant to imatinib
mainly due to LYN kinase overexpression.30 In K562-R imatinib did
not provoke growth arrest (Figure 2a) and erythroid differentiation
(Figures 2b and c). Consistently, p27 expression was not induced
in K562-R cells treated with imatinib concentrations high enough
(2.5mM) to inhibit BCR-ABL, as assessed by CRK-L phosphorylation
(Figure 2c). Similar results were observed in KmycBT315I, a
imatinib-resistant cell line expressing the BCR-ABL-T315I mutant19
(not shown). However, imatinib-induced erythroid differentiation
is not a mere consequence of the growth arrest because other
drugs that provoke growth arrest of K562 (interferon-a, busulfan,
TPA, staurosporin) do not induce erythroid differentiation.20,31,32
It has been reported that MYC is involved in CML progression.19
Thus, we investigated whether MYC also impaired the imatinib-
induced differentiation. We first showed that the low
concentrations of imatinib capable of inducing differentiation also
caused MYC downregulation in K562 after 24–72 h of treatment
(Figure 2d). This downregulation was also demonstrated at the
mRNA level, as shown by northern analysis (Figure 2e). It was
noteworthy the correlation between the imatinib-mediated MYC
repression and erythroid differentiation, as assessed by globin
expression (Figures 2d and e). The decrease in MYC mRNA
suggested that imatinib repressed MYC at the transcriptional level.
This was confirmed by luciferase assays using a luciferase reporter
harboring the human MYC promoter which was inactivated by
imatinib (Figure 2f).
The former results prompted us to study whether MYC impaired
the differentiation triggered by imatinib. To explore this we used
two K562 sublines with conditional MYC expression. KMER4 cells
expresses the MycER fusion protein,19 which is activated by
4-hydroxy-tamoxifen (4HT).33 The expression of MycER in KMER4
cells treated with imatinib was confirmed by immunoblot
(Figure 3a). The benzidine assay indicated that MYC antagonized
the imatinib-dependent differentiation in KMER4 cells (Figure 3b).
We also demonstrated that the imatinib-mediated induction of
e-globin and transferring receptor 2 mRNA was blunted by MYC
(Figure 3c). We sought to confirm the former results in a different
system of conditional MYC expression. KmycB cells carry a Zn2þ -
inducible MYC.20 KmycB treated with Zn2þ in the presence of
imatinib expressed significant levels of MYC (Figure 3d). Impor-
tantly, the addition of ZnSO4 did not result in supra-physiological
levels of MYC but rather restores the levels of control cells. MYC
expression in KmycB resulted in a dramatic decrease in the
fraction of hemoglobin-containing cells (Figure 3e). We also found
that MYC decreased the levels of erythroid markers as e-globin
and transferring receptor 2 mRNA which were induced by imatinib
(Figure 3f). Treatment with 4HT or Zn2þ did not modify the
differentiation of parental K562 (not shown). To further confirm
the effect of MYC on imatinib-dependent differentiation we
hybridized complementary DNA microarrays containing probes of
4466 genes with labeled complementary DNA from KmycB cells
treated with imatinib in the presence or absence of MYC. Out of 30
genes that were downregulated by MYC in imatinib-treated cells,
15 genes are associated to erythroid lineage or erythrocyte
markers, including embryonic globins, heme synthesis genes,
erythrocyte membrane proteins and erythroid-specific enzyme
isoforms (Supplementary Table 1). Altogether, the results demon-
strate that MYC impairs the erythroid differentiation mediated by
imatinib in K562 cells.
We also tested the effect of dasatinib, a more potent BCR-ABL
inhibitor also active against SRC kinase and recently introduced in
CML therapy.34,35 Dasatinib induced differentiation of K562
(Figure 3g), as well as downregulation of MYC and upregulation
of p27 (Figure 3h). Next, we asked whether MYC impaired the
dasatinib-mediated differentiation. For this purpose we used
KMER4 cells, which expressed the MycER protein in the presence
of dasatinib and 4HT (Figure 3i). We found that the activation of
MYC impaired the dasatinib-induced differentiation of KMER4, as
shown by the benzidine test (Figure 3j) and the expression of
g-globin (Figure 3k). We conclude that MYC impairs the differentia-
tion induced by the anti-CML drugs imatinib and dasatinib.
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Figure 1. Erythroid differentiation induced by imatinib in K562 cells. (a) Inhibition of proliferation mediated by imatinib. Cells were treated
with the indicated concentrations of imatinib and proliferation was determined by cell counting, using a hemocytometer. (b) DNA synthesis
arrest mediated by imatinib. Cells were treated for 24–72 h with imatinib and DNA synthesis was determined by 3H-thymidine incorporation as
described.19 Data are mean values of 3H-thymidine incorporation from three experiments, relative to the thymidine incorporation in untreated
cells at each time point; bars, s.e.m. (c) Erythroid differentiation induced by imatinib. The fraction of hemoglobinized (benzidine-positive) cells
was determined after treatment with 0.5 mM and 2.5 mM imatinib for 24 and 48 h. Benzidine assays were performed essentially as described.44
At least 300 cells were counted in each determination. Data are mean values from three independent experiments; bars, s.e.m. (d) Expression
of e-globin, transferring receptor 2 (TFR2) and erythropoietin receptor (EPOR) mRNA measured by reverse transcription-quantitative PCR
(RT–qPCR) in K562 cells treated with 0.5 mM imatinib for 48 h. Expression of the housekeeping genes GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) and GUSB (b-glucuronidase) were also measured as controls of non-erythroid genes. Total RNA extraction was carried out
with the Trizol reagent (Life Technologies, Carlsbad, CA, USA). For RT–qPCR, the first-strand complementary DNA was synthesized from 1 mg of
total RNA using SuperScript II RNase reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and random primers as described.26 The data were
normalized against the levels of ribosomal protein small 14 (RPS14) mRNA. qPCR were carried out in a MyCycler apparatus (BioRad, Hercules,
CA, USA). Primer sequences are available upon request. Data are mean values from three mRNA determinations from two independent
experiments; bars, s.e.m. (e) Induction of p27 by imatinib in K562. Cells were treated with 1 mM imatinib for 0–48 h (left panel), and for 48 h with
0–1.5 mM imatinib (right panel). The levels of p27 and g-globin were determined by immunoblot. Tubulin expression was determined to assess
protein loading. Cell lysis and protein immunoblotting were performed as described.21 The antibodies used were: anti-a-tubulin (H-300, rabbit
polyclonal), g-globin (51-7, mouse monoclonal) and p27 (C19, rabbit polyclonal). All antibodies were from Santa Cruz Biotech (Santa Cruz, CA,
USA). (f ) Upper panel: siRNA-mediated depletion of p27 impairs the imatinib-dependent differentiation. A p27 short-hairpin vector45 was
transiently transfected by nucleofection (kit V, Amaxa, Koln, Germany) into K562 cells and 12 h later imatinib (1 mM) was added. After 48 h of
imatinib treatment the cells were lysed and the protein levels of p27, g-globin and actin (as loading control) were determined by immunoblot
(upper panel). Anti-actin antibody was I-19, goat polyclonal from Santa Cruz Biotech. The transfection was repeated three times with
essentially the same result. Lower panel: fraction of hemoglobinized (benzidine-positive) cells determined after 48 h treatment with 1 mM
imatinib and 60 h post-transfection. Data are mean values from two independent experiments; bars, s.e.m. (g) Imatinib and p27 do not
cooperate in the proliferation arrest of K562 cells. Kp27-5 cells were treated for 72 h with 0.5 mM imatinib or/and 75mM ZnSO4 as indicated and
proliferation was determined by cell counting. (h) Upper panel, Kp27-5 cells were treated for 24 h with 75 mM ZnSO4 or 1 mM imatinib and the
levels of actin and p27 were determined by immunoblot. Lower panel, the fraction of benzidine-positive cells was also determined in the
same samples and data (mean±s.e.m.) is indicated at the bottom of each lane.
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So far we showed that (a) imatinib-mediated differentiation
depends on the upregulation of p27 and, (b) MYC inhibits this
differentiation. As MYC impairs p27-mediated differentiation of
K56221 we determined p27 expression in KMER4 cells treated
with 4HT and 0.5 mM imatinib, that is, under conditions where
erythroid differentiation was inhibited by MYC. The results of
the immunoblot showed that MYC activation blunted the
upregulation of p27 by imatinib after 24h and 48 h of treatment
(Figure 4a). To assess the erythroid differentiation we determined
g-globin expression levels which correlated with those of p27
(Figure 4a). We confirmed this effect of MYC using the KmycB cells.
The induction of MYC antagonized the upregulation of p27 and
g-globin by imatinib in KmycB (Figure 4b). Although MYC
decreased p27 protein levels, MYC did not significantly reduced
p27 mRNA levels in the presence of imatinib (not shown).
Therefore, we concluded that MYC should control p27 stability.
To test this hypothesis, we first ruled out that MYC interferes with
the inhibition of BCR-ABL activity by imatinib (Supplementary
Figure 2a). As BCR-ABL activates SRC kinase36 and SRC stimulates
p27 degradation37 we asked whether MYC impaired SRC
inactivation by imatinib. Imatinib partially inhibited the activity
of SRC, as expected (Supplementary Figure 2c) and the specific
SRC inhibitor SU6656 induced erythroid differentiation at non-
cytotoxic concentrations (Supplementary Figure 2b). Interestingly,
MYC activation antagonized the differentiation provoked by
SU6656 (Supplementary Figure 2b), in agreement with the
inhibition of dasatinib-mediated differentiation shown above.
However, MYC did not revert SRC inactivation, either in KmycB
cells upon induction of MYC by Zn2þ or in KMER4 cells upon
activation of MYC by 4HT (Supplementary Figures 2c and d
Figure 2. Imatinib-dependent differentiation is associated to proliferative arrest and MYC downregulation. (a) K562 and K562-R cells were
seeded at a density of 2 105 cells/ml and treated for 48 h with the indicated imatinib concentrations and the cells were counted after 72 h.
(b) K562 and K562-R cells were treated for 48 h with the indicated imatinib concentrations and subjected to the benzidine cytochemical test to
count hemoglobin-producing cells. Data are mean values±s.e.m. of three independent experiments. (c) K562-R cells and parental K562 cells
were treated for 48 h with the indicated imatinib concentrations and the levels of p27, g-globin (to assess erythroid differentiation) and
phospho-CRK-L (to assess BCR-ABL activity) (anti-phosho-Tyr207-Crk-L, from Cell Signalling, Danvers, MA, USA) determined by immunoblot.
a-tubulin levels were also measured to assess the protein loading. (d) Concomitant MYC downregulation and g-globin upregulation induced
by imatinib. K562 cells were treated with 0.5mM imatinib for the indicated periods of time and the MYC and g-globin protein levels were
determined by immunoblot. Levels of actin were determined as a control of protein loading. MYC antibody (N-262, rabbit polyclonal from
Santa Cruz Biotech). (e) Downregulation of MYC mRNA by imatinib in K562. Cells were treated with the indicated concentrations of imatinib
for 48 h and the MYC and e-globin mRNA levels were determined by Northern analysis. Probe labeling with (a-32P)dCTP and filter hybridization
were carried out according to standard procedures. Probes for human MYC and e-globin were as described.46 A picture of the filter after
transfer showing the ribosomal RNAs stained with ethidium bromide is shown in each case to assess the loading and integrity of the RNAs.
(f ) Imatinib represses the MYC promoter in K562 cells. The activity of a MYC luciferase construct carrying 2.4 kb of human MYC promoter47 was
assayed after 24 h of treatment with 0.5mM imatinib (‘Imat.’), washed and further incubated 24 h without drug (‘ImatþW’). Transfections
(2 106 cells per transfection) were performed at 260 v and 1mFa in a Bio-Rad electroporator (BioRad). As an internal control, cells were co-
transfected with pRL-null plasmid encoding for Renilla luciferase (Promega) and the luciferase activity was normalized to Renilla luciferase.
Data are mean values of three independent experiments; bars, s.e.m.; *Po0.05 versus control and washed cells.
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Figure 3. MYC impairs the erythroid differentiation induced by imatinib. (a) Immunoblot showing MYC protein levels in KMER4 cells treated
for 48 h with 0.5mM imatinib and 200 nM 4HT. The upper and lower band corresponds to the ectopic MycER and endogenous MYC protein,
respectively. Alpha-tubulin levels are shown to assess the protein loading. (b) KMER4 cells were treated with 0.5 mM imatinib and 200 nM 4HT
for 48–72 h and subjected to the benzidine test to score hemoglobin-producing cells. Data are mean values±s.e.m. of three independent
experiments. *Po0.05 versus imatinib. (c) KMER4 cells treated for 48 h with 0.5mM imatinib and/or 200 nM 4HT. The erythroid differentiation
was assessed by e-globin and transferring receptor 2 (TFR2) mRNA expression. Data are mean values±s.e.m. of two independent experiments.
*Po0.05 versus imatinib treatment. (d) Immunoblot showing the MYC protein levels in KmycB cells treated with 0.5 mM imatinib and 75 mM
ZnSO4 (to induce MYC) for the indicated periods of time. a-tubulin levels were also determined to assess the protein loading. (e) KmycB were
treated as in (b) and subjected to the benzidine test to score hemoglobin-producing cells. Data are mean values±s.e.m. of three independent
experiments. *Po0.05 versus imatinib. (f ) KmycB cells were for 48 h with 0.5 mM imatinib and 75mM ZnSO4 and the erythroid differentiation
was assessed by e-globin and TFR2 mRNA expression. Data are mean values±s.e.m. of three independent experiments. *Po0.05 versus
imatinib treatment. (g) Erythroid differentiation induced by dasatinib (purchased from LC Laboratories, Woburn, MA, USA) in K562 cells. The
fraction of benzidine-positive cells was determined after treatment with the indicated dasatinib concentrations for 48 h. Data are mean
values±s.e.m. from three independent experiments. (h) Immunoblot showing the downregulation of MYC and upregulation of p27 in
response to dasatinib. K562 cells were treated for 48 h with the indicated concentrations of dasatinib and the levels of the proteins shown at
the right were determined by immunoblot. Globin was determined to assess erythroid differentiation, p-CRK-L to assess the inhibition of BCR-
ABL by dasatinib and a-tubulin to assess protein loading. (i) Immunoblot showing the levels of MYC protein in KMER4 cells treated for 48 h
with 100 nM dasatinib and 200 nM 4HT. The upper and lower band corresponds to the ectopic MycER and endogenous MYC protein,
respectively. Alpha-tubulin levels are shown to assess the protein loading. (j) KMER4 cells were treated with 50 or 100 nM dasatinib and 200 nM
4HT for 48 h and subjected to the benzidine test to score hemoglobin-producing cells. One representative experiment is shown. (k) KMER4
cells were treated for 24 h with 100 nM dasatinib and the erythroid differentiation was assessed by e-globin mRNA expression. Data are mean
values±s.e.m. of two independent experiments.
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respectively). Therefore we ruled out SRC activity as a major
mechanism for p27 degradation in response to MYC.
SKP2 is the p27-recognizing component of the SCFSKP2
ubiquitilation complex and the main regulator of p27 levels
in vivo.38,39 In addition, SKP2 is upregulated by BCR-ABL40,41 and
SKP2 is a MYC target gene.14 Therefore, we tested the hypothesis
that, in the presence of imatinib, MYC downregulates p27 through
the induction of SKP2. We first confirmed that the zinc-mediated
induction of MYC in the presence of imatinib results in SKP2
mRNA increase in KmycB cells (Figure 4c). The immunoblot of
Figure 4d shows that p27 protein levels are decreased upon MYC
and SKP2 upregulation. To confirm the SKP2 involvement we next
used KMERshSKP2 cells, which are a K562 derivative carrying the
MycER construct and in which SKP2 has been partially silenced.14
The expression of MycER and the reduced levels of SKP2 in
KMERshSKP2 were confirmed by immunoblot (Figure 4e). The
Figure 4. Myc antagonizes the upregulation of p27 induced by imatinib. (a) KMER4 cells were treated for 24–48 h with 0.5 mM imatinib and 4HT
as indicated. The levels of p27 and g-globin (as a marker of erythroid differentiation) were determined by immunoblot. Levels of actin were
determined as a control of protein loading. (b) KmycB cells were treated for 24–48 h with 0.5mM imatinib and 75 mM ZnSO4 as indicated. The
levels of the proteins indicated at the right were determined by immunoblot. (c) KmycB cells were treated for 48 h with 0.5mM imatinib and
75mM ZnSO4 as indicated and mRNA expression of MYC and SKP2 determined by RT–qPCR. Data are mean values±s.e.m. of three
independent experiments. (d) MYC-mediated induction of SKP2 in the presence of imatinib correlates with decreased p27 levels. KmycB cells
were treated for 24–48 h with 75 mM ZnSO4 and 0.5 mM imatinib as indicated, and the levels of MYC, SKP2, p27 and a-tubulin (as protein loading
control) were assayed by immunoblot. (e) KMERshSKP2 and the control cells (KMERpSR) were treated with 1 mM imatinib and 200 nM 4HT for
24 h as indicated, and the levels of SKP2, MycER and p27 were determined by immunoblot, using a-tubulin as protein loading control.
(f ) Enhanced erythroid differentiation in cells with silenced SKP2. KMERshSKP2 cells and control cells (KMERpSR) were treated with 1 mM
imatinib and 200 nM 4HT for 72 h and the fraction of differentiated cells was determined by the benzidine assay. Data are mean values from
three independent experiments; bars, s.e.m. (upper graph). The levels of g-globin were determined by immunoblot, using actin as protein
loading control (lower panel). (g) Model for MYC-mediated inhibition of the differentiation induced by imatinib in CML cells. The model
proposes that, in the presence of imatinib, MYC can provoke the downregulation of p27 through the induction of SKP2. Other alternative
pathways leading to the downregulation of p27 or the cell differentiation by BCR-ABL cannot be ruled out and are shown in dotted lines.
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extent of differentiation was significantly higher in shSKP2-
expressing cells, as assessed by the benzidine assay and the
expression of g-globin (Figure 4f), as well as by the increased
e-globin and erythropoietin receptor mRNA (not shown). As
expected, the anti-differentiation effect of MYC was also reduced
in SKP2-depleted cells, as compared with control cells (Figure 4f).
Therefore, it is likely that the reported induction of SKP2
expression by BCR-ABL is indeed mediated by MYC. Altogether,
these results suggest that the induction of SKP2 is at least one
mechanism by which MYC antagonizes the differentiation
mediated by imatinib.
In summary, we have demonstrated that MYC impairs the
differentiation of K562 induced by anti-CML drugs as imatinib and
dasatinib. The relevance of our work is based in that (a) the loss of
myeloid differentiation is a critical hallmark of CML progression
into blastic phase and (b) that MYC has been involved in CML
progression. The inhibition of differentiation is not due to
overgrowth of MYC-expressing undifferentiated clones or to
apoptosis of differentiated clones, as we previously showed that
MYC induction does not stimulate cell proliferation and does not
enhance the apoptosis due to imatinib (19 and data not shown). In
contrast, our data show that MYC impairs differentiation by
blocking p27 upregulation induced by imatinib. We cannot rule out
additional mechanisms by which BCR-ABL downregulate p27 (for
example, PI3 kinase activation,28) or that MYC blocks differentiation
through SKP2-independent mechanisms, but the results suggest
that MYC opposes imatinib-dependent differentiation through the
MYC-SKP2-p27 axis. The model is depicted in Figure 4g. It is
reasonable to speculate that p27 upregulation is one of the
mechanisms by which imatinib contributes not only to limit the
proliferation of leukemic cells but also to prevent the loss of
differentiation control. Interestingly, ablation of SKP2 in hemato-
poietic progenitors attenuates BCR-ABL-induced myeloproliferative
disease42 and erythroid differentiation in bone marrow is
associated with accumulation of p27.43 In conclusion, MYC
deregulation may contribute to CML progression through
different mechanisms including inhibition of cell differentiation.
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MYC Accelerates p21CIP-Induced
Megakaryocytic Differentiation
Involving Early Mitosis Arrest in
Leukemia Cells
MARI´A J. MUN˜OZ-ALONSO,1,2 LAURA CEBALLOS,1,3 GABRIEL BRETONES,1,4 PILAR FRADE,1
JAVIER LEO´N,1,4* AND ALBERTO GANDARILLAS1,3,5*
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p21CIP is a potent cell cycle inhibitor often up-regulated in differentiation. Protooncogene MYC induces cell growth and proliferation,
inhibits differentiation and represses p21CIP. However, both molecules are involved in processes of polyploidisation, cell size increase,
differentiation and senescence. It is unclear why MYC has a dual role in differentiation.We have previously shown that overexpression of
p21CIP in K562 myeloid cells induces megakaryocytic differentiation with polyploidy. We have now investigated the requirements for
p21CIP to block mitosis and induce differentiation in the presence of overactivated MYC. Silencing and over-expression studies showed
that p21CIP is required to induce differentiation. However, the expression of p21CIP needs to be transient to irreversibly inhibit mitosis but
not DNA replication, what leads to polyploidy. Transient overexpression of p21CIP caused early down-regulation of mitotic Cyclins and
up-regulation of G1/S Cyclins D and E, changes typical of endoreplication. Interestingly, over-activation of MYC did not release the
proliferative block imposed by p21CIP and instead, accelerated cell size increase, megakaryocytic differentiation and polyploidisation. Our
data suggests that in some systems p21CIP takes part in a mitosis control driving MYC-induced cellular growth into differentiation.
J. Cell. Physiol. 227: 2069–2078, 2012.  2011 Wiley Periodicals, Inc.
Transcription factor MYC is a central regulator of cellular
growth, with wide implications in cellular processes from
proliferation to apoptosis (Eilers and Eisenman, 2008; Meyer
and Penn, 2008). MYC is amplified in a variety of malignancies
and it often inhibits cell differentiation (Nesbit et al., 1999; Vita
and Henriksson, 2006; Leon et al., 2009). However, MYC has
been found to stimulate differentiation in systems where it is
closely associated with cell growth (Eilers and Eisenman, 2008).
It is unclear why MYC has this dual effect on differentiation and
it has been proposed that it might depend on the cell context
and whether it has or not a direct effect on mitosis (Johnston
et al., 1999; Gandarillas et al., 2000; Beer et al., 2004). In some
systems, overactivation of MYC causes cell hypertrophy with
polyploidy due to a mitosis block (e.g., Schmidt, 1999; Felsher
et al., 2000; Gandarillas et al., 2000; Maines et al., 2004; Pierce
et al., 2004; Zanet et al., 2005). The capacity ofMYC to drive the
cell cycle is in part due to its ability to repress cell cycle
inhibitors (Lutz et al., 2002; Wu et al., 2003).
Small cell cycle inhibitors of theCIP andKIP families are often
induced during cellular differentiation or apoptosis and lost in
human cancer (Besson et al., 2008). In particular, p21CIP
(hereafter p21) is involved in a variety of differentiation systems
(Weiss, 2003; Abbas and Dutta, 2009). p21 binds and inhibits
the Cyclin dependent kinases (CDKs) that control the different
cell cycle phases. The initially established function of p21 was
cell cycle arrest in G1 by inhibiting the DNA replication phase
CDK2. Consistently, p21 is repressed by the cell cycle inducer
MYC (reviewed in Jung andHermeking, 2009; Leon et al., 2009).
However, a growing body of data has shown that p21 is also able
to block mitosis through binding CDK1 and yet allow DNA
replication and cellular growth (e.g., Bates et al., 1998; Medema
et al., 1998; reviewed in Ullah et al., 2009). Re-replication and
polyploidy are often found in cancer but also in normal cells
undergoing terminal differentiation and cellular growth
(referred to as endoreplication; reviewed in Edgar and
Orr-Weaver, 2001; Ullah et al., 2009). One of such systems is
the megakaryocyte, which grows in size and ploidy prior to
fragment into platelets (Ravid et al., 2002a). Megakaryocytic
differentiation associates with p21 induction (Kikuchi et al.,
1997; Matsumura et al., 1997; Baccini et al., 2001). Interestingly,
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we have shown that over-expression of p21 in human K562
myeloid leukemia cells, induces megakaryocytic differentiation
with polyploidy. In contrast, over-expression of another CDK2
inhibitor, p27KIP, induced erythroid differentiation without
polyploidy (Mun˜oz-Alonso et al., 2005) and this process is
inhibited by MYC (Acosta et al., 2008). The mechanisms by
which p21 blocks mitosis and triggers megakaryocytic
differentiation, as well as the role of MYC in this process, are
unclear.
We have taken advantage of a p21-inducible expression
system due to a Zinc-regulatable promotor, to investigate the
crosstalk between MYC overactivation and a mitosis block in
K562 cells. We have made use of various DNA constructs to
(i) to knock-down endogenous p21 by antisense sequences or
(ii) to express p21 or MYC constitutively or conditionally. The
results show that a transient expression of p21 is necessary and
sufficient to early and irreversibly block mitosis in the
concurrence of DNA replication, leading to polyploidy.
Remarkably, overactivation of MYC not only was unable to
abrogate the mitosis arrest caused by p21, but it amplified and
accelerated megakaryocytic differentiation. The evidence
provides novel clues into themechanisms bywhich p21 in some
instances provokes increased cell volume and polyploidy and
into the dual role of MYC in mitosis control and differentiation.
Material and Methods
DNA constructs and antibodies
The entire coding sequence of human p21 was subcloned in the
sense orientation into pLPCX to generate pLPCXp21 and in the
antisense orientation into pCEFL to construct pCEFLASp21. In
the pCEFL vector the expression of the cloned genes is directed
by the translation EF-1a promoter. The pMTp21 vector that
contains the sheep metallothionein promoter for Zn2þ-
inducible expression was described previously (Mun˜oz-Alonso
et al., 2005). This promoter, due to its regulatory features,
achieves a transient expression of the genes it controls upon
addition of Zn2þ likely due to promoter transcriptional
deactivation (Delgado et al., 1995; Mun˜oz-Alonso et al., 2005).
pBabe and pBabeMycER are described in Littlewood et al.
(1995). The following primary antibodies were used in this
study from Santa Cruz Biotech (Santa Cruz, CA): anti- p21
(C-19), CDK2 (M2), CDK4 (C-22), CDK6 (C-21; M2), total-Rb
(C-15), Cyclin E (HE12), Cyclin A (BF683), Cyclin B1 (GNS1),
p(Y15)-CDK1, MYC (N-262), Actin (I-19), Cyclin D2, Cyclin
D3 and phospho-histone H3 (p-Ser10, sc-8656-R). pRb-Ser780
(phospho-Rb; P-Rb) was from Cell Signaling (Beverly, MA);
a-tubulin (a gift from N. Cowan, New York University, New
York); p21 (P1484) and cdk1 (p34cdc2) from Sigma Chemical
Co. (St. Louis, MO) CD61 (VI-PL2) from BD Pharmingen (San
Diego, CA).
Cell culture, transfections and retroviral infections
K562 cell line was derived from a human chronic myeloid
leukemia in blast crisis (Klein et al., 1976). K562 cells retain the
capacity to undergo erythroid or megakaryocytic
differentiation depending on the stimulus (Delgado et al., 1995;
Lerga et al., 1999). Treatment of K562 cells by staurosporin
(STA) induces polyploidisation, large cell size and markers
specific of megaryocytes and platelets (Lerga et al., 1999).
Kp21-3 andKp21-4 lines (hereafter, Kp21) are K562 cells stably
containing a Zn2þ-inducible p21 expression construct (Mun˜oz-
Alonso et al., 2005); Kas21A, Kas21B and Kas21C K562 stably
expressing a p21 anti-sense construct (pCEFL-AS-p21) and
Kpc1 and Kpc2 are K562 stably containing the empty vector
(pCEFL) as controls. K21A, K21B ad Kp21C are K562 stably
transfected with a vector for p21 (pLPCX-p21) and Kplx are
K562 transfected with the empty vector (pLPCX). All lines
were generated by electroporation (260 V and 1mFa in a
Bio-Rad electroporator, Hercules, CA), subsequently selected
by 0.5mg/ml G418 (Invitrogen, Carlsbad, CA) and cloned by
limiting dilution. To generate K562 cells expressing conditional
p21 and pBabe-MycER (Littlewood et al., 1995), Kp21 cells
were infected with pBabeMycER-carrying retrovirus produced
by AM12 amphotrophic cells and selected with 1mg/ml
puromycin as previously described (Morgenstern and Land,
1991). pBabe-puro empty vector was used to make control
cells. To generate K562 expressing conditional p21 and
constitutiveMYC,K562were nucleofected (Kit V, Amaxa)with
pMTp21 and pBabe-Myc. Empty vectors were transfected in
parallel samples as controls to generate the Kp21pb cell line. To
make stable pools, cells were selected from 48 h after the
transfection with 0.5mg/ml G418 and 1mg/ml puromycin
(pBabe-puro). Cells were grown in RPMI 1640 medium (Lonza,
Cologne, Germany) supplemented with 10% fetal calf serum
and antibiotics in a 378C incubator with 5% CO2. All
experiments were performed on exponentially growing
cultures and repeated at least twice with duplicate samples with
similar results. Cells were plated at 2.5 105 cells/ml in fresh
medium and 6 h later treated with 100 nM STA (Sigma) to
induce megakaryocytic differentiation, 50–75mM ZnSO4 to
induce p21 or 200 nM 4-hydroxy-tamoxifen (OHT) to activate
MycER. For 3 days treatments, the culture medium was
replaced by fresh medium after 48 h by centrifugation.
Flow-cytometry
Cells treated or untreated with STA, ZnSO4 and/or 4-hydroxy-
tamoxifen for the indicated periods of time were stained with
propidium iodide as described previously (Zanet et al., 2005) and
analysed by flow cytometry on FACScanTM or a BD
FACSCantoTM (BD Biosciences, San Diego, CA). One million
cells were stained per sample. Ten thousand events were gated
and acquired in list mode for every sample and analysed using
CellQuest or BDFACSDiva software (BD Biosciences). For
double staining for the megakaryocytic marker CD61 and DNA,
1million cells were fixed in 70% ethanol and stained as described
in Zanet et al. (2005). Double and single blank cell samples were
always included for cross-filters fluorescence compensation
Negative isotope control immunoglobulins were always used to
control the staining on parallel samples (mouse IgGs; Sigma). The
secondary antibody was goat anti mouse-Dylight (Jackson
ImmunoResearch Inc.WestGrove, PA). Large cellsweredefined
as those with a size bigger than 90% of the control cells in each
analysis (see Supplementary Figs. 2, 3 and 5).
mRNA expression
Total RNA was isolated using RNeasy Kit (Qiagen, Valencia,
CA) according to themanufacturer’s instructions, separated by
electrophoresis through agarosa-formaldehyde gel and
transferred to nitrocellulose. Northern blots were hybridised
to 32P-labelled probes as described (Mun˜oz-Alonso et al.,
2005). Probes were fragments of human integrin b3, vimentin,
Cdc25A and Cdc25B cDNAs (provided by A. Corbı´, C.I.B,
Madrid, Spain).
Western blotting
Cell pellets were lysed in a buffer containing 50mM Tris (pH
8.0), 150mM NaCl, 1% Nonidet P-40, phosphatase inhibitors
and protease inhibitors. Insoluble debris was removed by
centrifugation at 12,000 rpm for 30min at 48C. Protein
concentration was determined using a Bio-Rad protein assay.
Equal amounts (40–80mg) of extracts were resolved on 12–7%
by SDS-PAGE and transferred to nitrocellulose membranes
using standard techniques. The membranes were blocked with
5% dry milk in 0.05% Tween-Tris buffered saline (TTBS),
probed with primary antibodies followed by incubation with
horseradish peroxidase-conjugated secondary antibodies
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(Bio-Rad) and analysed by ECL (GE Healthcare Biosciences,
Piscataway, NJ), or with IRdye800 secondary antibody (Lincoln,
NE) and analysed with an Odyssey scanner (Li-Cor).
Densitometric analyses were performed with a ChemiDoc
(Bio-Rad).
Immunoprecipitation and kinase activity assays
CDK2- or Cyclin B1-associated kinase activities assay were
performed as described previously (Mateyak et al., 1999).
Briefly, cells were washed with PBS and lysed at 48C in a
buffer containing 50 mM Hepes (pH 7.5), 150 mM NaCl,
2.5 mM EGTA, 1 mM EDTA, 1 mM dithriothreitol (DTT), 10%
glycerol, 0.25% tween20, 10 mM b-gycerophosphate and
phosphatase and protease inhibitors. Five hundred micrograms
of cellular protein extract were immunoprecipitated with 1mg
of anti-CDK2 (M2; Santa Cruz) or anti-Cyclin B antibodies
(GNSI; Santa Cruz), and collected on Gammabind Sepharose
(Pharmacia) beads. After extensive washed, kinase activity was
assayed by transfer 32P to Histone H1 as substrate at 308C for
Fig. 1. Transient expression of p21 is required to induce megakaryocytic differentiation. A: left panel: K562 clones expressing antisense p21
(Kas21A, Kas21B, Kas21C) or control clones (Kpc1, Kpc2) were treated with STA to induce megakaryocytic differentiation. mRNA expression of
p21 (after 3 h of treatment) and differentiation markers b3 integrin, and vimentin (after 72 h of treatment) were analysed by northen blotting.
rRNA(stainedwith ethidiumbromide) is shownas loading control. Rightpanel:DNAcontent as analysedbyflow-cytometryof the cells indicated,
untreated, or treated with STA for the lengths of time indicated. B: upper panel: Western blotting showing protein levels of p21 anda-tubulin (as
loading control) in K562 and clones constitutively expressing p21 (K21A, K21B, K21C) or the empty vector (Kplx). Lower panel: DNA content of
K562andKp21Bcellsanalysedbypropidiumiodide stainingandflow-cytometryafter treatmentwithSTAas indicated.Dataarerepresentativeof
three independent experiments.
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30min with 10mCi [g-32P] ATP (6,000Ci/mmol;
Amersham Pharmacia) and 5mg of histone H1 (Roche,
Mannheim, Germany). The reaction products were separated
by SDS-PAGE, transferred to immobilon P membranes
(Millipore), exposed to X-ray film and quantified with a
PhosphorImager (Bio-Rad). To detect the immunoprecipitated
proteins, the complexes were subject to western blotting as
above.
Results
Transient expression of p21 is required to induce
megakaryocytic differentiation
K562 human myeloid leukaemia cells retain the capacity to
undergo erythroid ormegakaryocytic differentiation depending
on the stimulus (Delgado et al., 1995; Lerga et al., 1999).
Treatment of K562 cells by STA induces polyploidisation, large
Fig. 2. Transientexpressionofp21blocksmitosisandslowsdowncellcycleprogressionbutnotcellulargrowth.A:upperpanel: schemeofthep21
and differentiation induction in the Kp21 cell line. Lower panel: DNA content of Kp21 cells as determined by propidium iodide staining and flow-
cytometryafteradditionofZn2R forthelengthsoftimeindicated;peaksofcellswith2,4or8DNAcontents(C)areindicated.B:Flow-cytometrydot
plot representing cell size (forward light scatter, Y-axis) andDNAcontent (X-axis) ofKp21 cells untreated, or after addition of stauroporin (STA)
or Zn2R for 4 days; note that p21 provokes a higher size increase than STA for the same level of ploidy (e.g., 4C). Data are representative of two
independentexperiments.C: leftpanel:kinaseassays(onhistoneH1assubstrate)afterimmunoprecipitation(IP)withanti-CDK2andanti-cyclinB.
The levelsofCDK1,CDK2andp21 inthe immunoprecipitatesweredeterminedbywestern.Rightpanel:Barhistogramsshowthequantificationof
the kinase assays indicated in (C), relative to the activity of the untreated control cells (100%); small bars are s.e.m.
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cell size and markers specific of megaryocytes and platelets
(Lerga et al., 1999). Therefore STA induces mechanisms of
megakaryocytic differentiation in these malignant cells. In
addition, the megakaryocytic programme induced by STA is
associated by an early and transient induction of endogenous
p21 (Mun˜oz-Alonso et al., 2005) and this also mimics natural
megakaryocytic differentiation (Taniguchi et al., 1999;
Yaroslavskiy et al., 1999). Consistently, when transient
expression of p21 is achieved by a Zn2þ-conditional transgene
in K562 cells, they undergo a similar megakaryocytic
programme (Mun˜oz-Alonso et al., 2005). The metallothionein
promoter utilised, due to its regulatory features, achieves a
transient expression of the genes it controls upon addition
of Zn2þ as described previously (see Materials and Methods
section, Delgado et al., 1995; Mun˜oz-Alonso et al., 2005). The
transient expression of p21 induced by Zn2þ mimics the
induction of the endogenous gene by STA (Mun˜oz-Alonso et al.,
2005) and during normal megakaryocytic differentiation
(Taniguchi et al., 1999; Yaroslavskiy et al., 1999). In order to
investigate whether endogenous p21 is involved in the signal to
differentiation of K562 upon Zn2þ, we generated K562 sublines
constitutively overexpressing antisense mRNA (Kas21A,
Kas21B and Kas21C). Antisense p21 blunted the up-regulation
of endogenous p21 and the capacity of the cells to differentiate
towards megakaryocytes in response to STA, as measured by
the expression of b3-integrin and vimentin and polyploidy
(Fig. 1A). We next investigated the effect of constitutive p21
expression on STA-induced differentiation. In addition, we
generated K562 cell lines with constitutive overexpression of
p21 (K21A, K21B, K21C; Fig. 1B). As expected, these cells
proliferated more slowly as compared to the parental K562
(Supplementary Fig. 1A–C). As shown in Figure 1B, high
constitutive expression of p21 also inhibited the acquisition of
polyploidy characteristic of megakaryocytic differentiation
induced by STA.
Transient p21 causes early mitosis arrest
Forced transient induction of p21 provoked K562 cells to
accumulate in G2/M, re-replicate and become polyploid
(Fig. 2A; Mun˜oz-Alonso et al., 2005). In addition, p21 induction
produced a dramatic increase in cell size (forward light scatter,
FSC; Fig. 2B). This increase was even stronger than that
observed in cells undergoing megakaryocytic differentiation in
response to STA for the same level of ploidy (for e.g., 4C in
Fig. 2B). The smaller increase in ploidy produced by p21 as
compared with the increase produced by STA might be due to
the transient inhibition of the DNA replication kinase CDK2.
Consistently, p21 bound to CDK2 as well as to the mitosis
complex Cyclin B/CDK1 (Fig. 2C). This inhibited the kinase
activity of the different forms of both CDKs, whose expression
subsequently decreased. However, their associated activities
started to recover by 48 h, as p21 became undetectable
(Figs. 2C).
In order to explore how transient over-expression of p21
affected the cell cycle regulation in the onset of megakaryocytic
differentiation, we examined the dynamics of Cyclins and
CDKs, key regulators of the different phases of the cell cycle
(Murray, 2004). As shown in Figure 3, the induction of p21
provoked an up-regulation of Cyclins D2, D3 and E that peaked
by 2 days, whereas they decreased in control cells due to
culture saturation (see also Supplementary Fig. 2). Cyclins D
and E have both been involved in the endoreplication that
accompanies megakaryocytic differentiation and
polyploidisation (Wang et al., 1995; Garcia et al., 2000; Geng
et al., 2003). In contrast, CDK1, Cyclins A and B, which are
required for completion of mitosis, were transiently
suppressed by 24 h (Figs. 2C and 3 and Supplementary Fig. 2).
The detection of p21 in the immunoprecipitates of mitotic
Cyclins decreased by 24 h as the Cyclins did, anticipating the
decline of total p21 (Figs. 2C and 3). CDC25A and B,
phosphatases involved in CDK2 and CDK1 activation, were
also down-regulated concomitantly with the induction of p21
(not shown). No significant changes were observed in the
expression of CDK6 or CDK2 (Fig. 3) and CDK4 (not shown).
Although the effects exerted by transient p21 over the cell cycle
regulatorswere also transient, they caused an irreversibly block
of mitosis exit (Fig. 2A,B). Therefore, p21 provoked a transient
S phase arrest but an irreversible mitosis block. In fact, a
6h Zn2þ treatment of Kp21 cells to induce p21 was sufficient to
irreversibly trigger megakaryocyte differentiation and
polyploidy (Mun˜oz-Alonso et al., 2005; Leo´n et al.,
unpublished).
Fig. 3. Transient p21 causes early inhibition of mitotic regulators.
Expression of the cell cycle regulators indicated on the right, analysed
by western blotting after induction of p21 by addition of Zn2R for the
lengths of time indicated. Cyc: Cyclin; a-tubulin (a-tub.) as a loading
control. Note that Cyclins A and B and CDK1 are down-regulated
whereas Cyclins D and E accumulate, after the addition of Zn2R
(arrows). Bar histograms: densitometry of signals for Cyclins D3,
E and A, normalised to the levels of a-tubulin.
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MYC enhances p21 effects in differentiation and
polyploidisation
Proto-oncogeneMYC is a potent cell cycle activator and has the
ability to repress p21 but also to cause increased cell size and
ploidy (see Introduction section). Moreover, MYC has been
involved in mouse megakaryocytic differentiation in vivo (Guo
et al., 2009), but had no effect per se on the differentiation
capacity of K562 cells. We first examined the expression of
endogenousMYC after the induction of p21 by Zn2þ. Transient
induction of p21 in K562 caused down-regulation of MYC by
6 h, which recovered by 12 h and was sustained during
differentiation whereas it became undetectable in control cells
due to culture saturation (Fig. 4A). We questioned whether
constitutive overactivation of the cell cycle by MYC would
release the early cell cycle block imposed by p21 in K562 and
affect megakaryocyte differentiation.
We generated Kp21 cells stably expressing wild type MYC,
termed Kp21Myc. These cells constitutively express ectopic
MYC to levels threefold above those of endogenous MYC
(Fig. 4B). Overexpression of MYC by itself in Kp21cells did not
cause detectable effects on polyploidy and differentiation
(Fig. 4B and Supplementary Fig. 3). However, when p21was also
induced by addition of Zn2þ in Kp21Myc cells, there was a
significant increase of cell size and polyploidy and a slight
increase in apoptosis with respect to Kp21 cells (on basis of the
proportion of large, polyploid or apoptotic cells; Fig. 4B and
Supplementary Fig. 3). More strikingly, ectopic MYC in cells
overexpressing p21 led to an increase of CD61 expression, a
specific marker of megakaryocytes and platelets, that was by
3 days markedly higher than the effect caused by the mere
induction of p21 (Fig. 4B and Supplementary Fig. 3).
Tomonitor the effects of MYCoveractivation, we generated
Kp21 cells expressing OHT-activatable MycER (Kp21MER;
Fig. 4C–D). The use of conditional MycER (activatable by
4-hydroxytamoxifen (OHT); Littlewood et al., 1995) allows an
acute activation of MYC, avoiding cell culture selection effects.
Activation of MycER by OHT in Kp21 cells down-regulated
endogenous MYC and p21 as previously described (Fig. 4C and
Supplementary Fig. 5; Facchini et al., 1997). Themere activation
of MycER had no significant effect on polyploidy or
differentiation (Fig. 4C and S4). Interestingly, concomitant
induction of p21 (by Zn2þ) and MycER (by OHT) for 3 days led
to a striking increase of cell size and polyploidy (Fig. 4C–D and
Supplementary Fig. 4). The ectopic overactivation of MycER
also resulted in a significant fraction of apoptosis (Fig. 4C), as
described in other systems (reviewed in Hoffman and
Liebermann, 1998). After 5 days a fraction of cells underwent
mitotic catastrophe and fragmented and the remaining cells
culminated terminal differentiation (Supplementary Fig. 4B).
Altogether the results show thatMYCwas unable to release the
mitotic block imposed by p21. Consistently, the combination of
p21 induction and MYC overactivation produced frequent
aberrant giant cell structures typical of mitosis failure
(Supplementary Fig. 4B, arrows).
Analyses of cell cycle regulators showed that overexpression
of MYC accelerated by 24h the up-regulation of Cyclin E
observed in Kp21þZn2þ (compare Figs. 3 and 5). MYC also
potentiated the inactivation of tumour suppressor Rb by
phosphorylation (P-Rb; Fig. 5). In addition, the activation of
MycER in Kp21 cells enhanced the up-regulation of Cyclin D2
(Supplementary Fig. 5). Altogether, MYC attenuated the early
inhibition of cell cycle entry imposed by the transient
expression of p21 but permitted and accelerated the down-
regulation of mitotic Cyclins A and B caused by p21 (compare
Figs. 5 and 3). Phosphorylation of histone H3, a marker of
chromosome condensation, indicated a slight accumulation of
Fig. 4. MYC enhances p21-induced megakaryocytic differentiation. A: Expression of MYC in Kp21 cells as analysed by western blotting after
additionofZn2R for the lengthsof time indicated;a-tubulinwasusedasprotein loadingcontrol;KMTarecontrolcellsexpressingtheemptyvector.
B: left panel: MYC protein expression in Kp21Myc cells as compared with parental Kp21 cells. Actin was a loading control. The histogram below
shows the densitometric quantification of MYC signal normalised to the actin levels. Right panel: Bar histogram showing quantitations of the
flow-cytometry analyses of Kp21Myc and Kp21pb (empty vector control cells) 3 days after addition of Zn2R. Cell size, polyploidy, apoptosis and
expressionofCD61markerweredeterminedbythegatesshowninSupplementaryFig.3(M1,M2).SmallbarsareSD.MP<0.05;n.s.,non-significant
difference (P>0.05) C, left panel: Expression ofMycER, endogenousMYCand p21 in Kp21MER cells untreated or after the treatments indicated.
Protein levels were determined by western blotting; the histogram shows the densitometric analysis of the signal for endogenous MYC (endo.,
arrowhead) orMycER (arrow), normalised to the actin levels. Right panel: cell size, polyploidy and apoptosis inKp21MER cells untreated, or upon
activation of MycERwithOHT and/or induction of p21 for 3 days as indicated; quantitations by flow-cytometry as in B and Supplementary Fig. 3.
M
P<0.05 D: Representativemicrophotographs of Kp21 and Kp21MER cells after the treatments indicated from experiments in (E). Bar: 150mm.
Arrows mark big cells in cultures after induction of p21 and activation of MYC. Small apoptotic-like cells are also observed in these cultures
(arrowheads).
Fig. 5. MYC accelerates the changes in the cell cycle regulation
caused by p21. Expression of the cell cycle regulators indicated on the
right, analysed by western blotting after induction of p21 untreated,
or after for the indicated periods of time after addition of Zn2R in the
presence of constitutive MYC. Actin was used as a protein loading
control. Cyc: Cyclin. Data are representative of two independent
experiments. Note that Cyclin A is down-regulated already by 12 h
and Cyclin E accumulates by 24 h after addition of Zn2R (arrows).
Histograms: densitometric analysis of signals for Cyclins E and A,
normalised to the levels of actin.
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mitotic nuclei concomitant with p21 induction (Supplementary
Fig. 6).
Altogether the results indicate that MYC stimulated S phase
progression independently on the mitosis block produced by
p21 and augmented the polyploidisation induced by p21. We
therefore questioned whether overactivation of MYC would
rescue these cells from the block imposed by p21 to the
polyploidisation induced by STA (Fig. 1B). As expected,
endogenous MYC was markedly down-regulated by 6 h after
addition of STA (Fig. 6A). In these conditions p21 expression is
sustained by Zn2þ and STA along the assay (Figs. 3 and 1A).
Sustained expression of p21 blocked STA-induced
polyploidisation (Fig. 6B and Supplementary Fig. 7). Interestingly
however, p21 did not inhibit the expression of the
megakaryocytic marker CD61 induced by STA (Fig. 6B and
Supplementary Fig. 6), indicating that polyploidisation and
differentiation are uncoupled megakaryocytic features (see
also, Kikuchi et al., 1997). Overexpression of wild type MYC
was unable to release the block imposed by p21 to STA-induced
polyploidisation, or to suppress the induction of the
megakaryocytic marker CD61 (Fig. 6B and Supplementary
Fig. 7).
Discussion
Proto-oncogene MYC induces cell cycle progression and
inhibits differentiation in part by repressing cell cycle
inhibitors such as p21 (reviewed in Jung and Hermeking,
2009; Leon et al., 2009). We have here provided evidence
that both molecules synergise to drive post-mitotic
megakaryocytic differentiation and polyploidy. The studies
show that transient p21 caused an irreversible mitosis block
that was independent on and dominant over, MYC potential to
induce proliferation.
K562 myeloid leukemia cells can be induced to undergo
erythroid or megakaryocytic differentiation depending on the
stimulus (Leon et al., 2009). Both treatment with STA or
ectopic transient expression of p21 in these cells induces
megakaryocytic features that mimic the natural differentiation
process (Lerga et al., 1999; Mun˜oz-Alonso et al., 2005). Natural
megakaryocytic differentiation also involves induction of p21
(Yaroslavskiy et al., 1999; Taniguchi et al., 1999). The role of p21
in this process is however unclear, since constitutive
overexpression of the inhibitor in cultured megakaryocytes
inhibited polyploidisation (Baccini et al., 2001). p21 is capable to
Fig. 6. MYC is unable to inhibit the block imposed by sustained p21 to polyploidisation. A:Western blotting of MYC in K562 cells untreated or
treated with STA for the periods of time indicated. Bar histogram: densitometry of signal forMYC, normalised to the levels ofa-tubulin (a-tub).
B: Kp21Myc and Kp21pb were untreated or treated for 72h with STA, or STA and Zn2R as indicated and the cell size, polyploidy, apoptosis and
expressionofCD61weredeterminedbyflow-cytometryasinFig.4.DataaremeanofthreeindependentexperimentswithduplicatesamplesWSD.
M
P<0.05;n.s., non-significantdifference (P>0.05).C:Representativemicrophotographsof cells treatedas indicated fromexperiments in (B).Bar:
150mm.
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block either cell cycle entry and DNA replication by inhibiting
CDK2, or the execution of mitosis by inhibiting mitotic CDK1.
In the latter case the cell cycle block allows DNA replication
(reviewed in Ullah et al., 2009). Our p21 knock-down studies
showed that the endogenous protein is required to drive K562
cells towards megakaryocytic differentiation. However,
sustained expression of p21 rendered these cells resistant to
undergo megakaryocytic differentiation.
There is a good rationale for the need of p21 expression to
be transient to induce megakaryocytic polyploidy. In our
experiments, p21 induction sequentially inhibited mitotic
CDK1 and S phase kinase CDK2. Subsequently, p21 must be
down regulated to allow cell cycle progression, since
constitutive inhibition of CDK2 by p21 did not allow cell cycle
progression and DNA re-replication. After the initial inhibition
of CDKs their activities recovered and Cyclins D2, D3 and E
accumulated. D-type Cyclins have been associated with
endoreplication (see Wang et al., 1995; Datar et al., 2000).
Elevated Cyclin E accompanies endoreplication in a variety of
biological systems (Edgar and Orr-Weaver, 2001; Larkins et al.,
2001; Ravid et al., 2002b; Guidotti et al., 2003; Zanet et al.,
2010). More specifically, ectopic Cyclin E is able to drive
endoreplication in K562 cells (Garcia et al., 2000) and it is
required in vivo for polyploidisation of mouse megakaryocytes
(Geng et al., 2003). Therefore the inhibition of the S phase of
DNA replication by transient induction of p21 in K562 was also
transient, whereas the block of mitosis was irreversible.
Consistently, cumulative evidence shows that the levels of
CDK2 activity required to drive DNA replication are lower
than the levels of CDK1 activity required to drive mitosis
(Krasinska et al., 2008; Coudreuse and Nurse, 2010). In
addition, recent evidence indicates that deregulated Cyclin E
impairs mitosis through CDC25 (Bagheri-Yarmand et al., 2010)
and we detected accumulation of Cyclin E and down-regulation
of CDC25A and B in our experiments after induction of p21.
Finally, p21 might block mitosis in K562 cells by mechanisms
added to CDK1 inhibition, since it down-regulates the
transcription of other mitotic regulators (Chang et al., 2000;
Leo´n et al., unpublished).
The mitotic block imposed by transient expression of p21
was irreversible even in the presence of overactivated MYC.
This is intriguing because MYC has been shown to repress p21
expression (Seoane et al., 2002; Wu et al., 2003). However in
some casesMYCand p21 coexist. For instance,MYC stimulates
epidermal differentiation involving cellular growth (Gandarillas
and Watt, 1997; Gandarillas et al., 2000) and induction of p21
(Harvat et al., 1998; Dazard et al., 2000; Dotto, 2000;
Gandarillas et al., 2000). Recently, up-regulation of p21 has also
been found in MYC-induced senescence in the absence of
CDK2 (Campaner et al., 2010). Although MYC has more often
been shown to promote proliferation, it drives post-mitotic
differentiation in some cell systems (Leon et al., 2009). It is
unclear why MYC has a dual effect on cell differentiation,
but two lines of argument might provide clues to this issue:
(i) MYC promotes differentiation in systems where
differentiation is closely associated to cell growth (Zanet et al.,
2005; Eilers and Eisenman, 2008). (ii) MYC might promote
mitosis or not depending on the cellular context and other
activated molecular pathways (Gandarillas, 2000; Beer et al.,
2004).
The cooperation between MYC and p21 in megakaryocytic
differentiation here shown is in contrast with the inhibition of
p27-induced erythroid differentiation in the same cells (Acosta
et al., 2008). p27KIP is another CDK inhibitor of the CIP/KIP
family (Besson et al., 2008). However and unlike p21, it has not
been clearly shown to bind mitotic CDK1 and it might thus be
more specific of CDK2 (Besson et al., 2008; Abbas and Dutta,
2009; Ullah et al., 2009). Interestingly, p27 induced erythroid
differentiation and arrested K562 cells in G1. In contrast, p21
provoked polyploidisation and increased cell volume.
Polyploidisation or endoreplication significantly simulates cell
size increase (e.g., Edgar andOrr-Weaver, 2001). Consistently,
inactivation of MYC inmouse bonemarrow progenitors in vivo
led to a lesser level of ploidy and smaller megakaryocytes and
platelets (Guo et al., 2009). Similar observations have been
made in MYC-deficient flies and MYC-deficient mouse
epidermis (Maines et al., 2004; Pierce et al., 2004; Zanet et al.,
2005; Steiger et al., 2008). Therefore, MYC might promote
differentiation processes that are associated with cellular
growth and inhibit differentiation processes that are associated
with cell cycle arrest.
In our studies MYC function was independent of mitosis
control. The effect of p21 in blockingmitosiswas dominant over
MYC-activation of the cell cycle. MYC is not required for
megakaryocytic differentiation (Guo et al., 2009) and in our
studies it had no effect per se on the megakaryocytic
differentiation capacity (Lerga et al., 1999). However, by
establishing an irreversible block on mitosis via p21, the
stimulation of cell cycle progression and cellular growth by
MYC in our experiments accelerated and enhanced cell size
increase and poliploidisation (see Fig. 7). Therefore, the
p21-block of mitosis drove MYC cell cycle activation into
cellular growth and differentiation.
Apoptosis often acts to limit MYC oncogenic potential. For
instance, overexpression of MYC in mouse bone marrow
progenitors provoked acute myeloid leukemia due to their
intrinsic resistance to apoptosis (Luo et al., 2005). MYC also
contributes to progression of human leukemia (Delgado and
Leon, 2010). The mitosis control by p21 leading to
differentiation in the presence of overactivated MYC might
constitute an anti-oncogenic mechanism alternative to
apoptosis.
Fig. 7. ModelforthecombinedactionofMYCandp21inK562cells.A:
Constitutivep21 inhibits S phase andmitoticCDKs thus inhibiting cell
cycle progression. B: Transient p21 blocks mitosis but allows cell size
increase and DNA polyploidisation, resulting in megakaryocytic
differentiation (Mega. Diff.). C: Overactivation of MYC drives cellular
growthandproliferation.D:Thecombinedactionof transientp21and
overactivationofMYCon theonehand irreversibly blocksmitosis and
on the other hand it stimulates the S phase of the cell cycle and
enhances cell size increase and polyploidy, resulting in accelerated
megakaryocytic differentiation.
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Abstract
Although mutant Ras proteins were originally described
as transforming oncoproteins, they induce growth
arrest, senescence, and/or differentiation in many cell
types. c-Myc is an oncogenic transcription factor
that cooperates with Ras in cellular transformation
and oncogenesis. However, the Myc-Ras relationship in
cellular differentiation is largely unknown. Here, we have
analyzed the effects of c-Myc on PC12-derived cells
(UR61 cell line), harboring an inducible N-Ras oncogene.
In these cells, Ras activation induces neuronal-like
differentiation by a process involving c-Jun activation.
We found that c-Myc inhibited Ras-mediated
differentiation by a mechanism that involves the
blockade of c-Jun induction in response to Ras signal.
Accordingly, ectopically expressed c-Jun could bypass
c-Myc impediment of Ras-induced differentiation and
activator protein 1 activation. Interestingly, it did not
rescue the proliferative arrest elicited by Ras and did not
enhance the differentiation-associated apoptosis. The
blockade of Ras-mediated induction of c-Jun takes place
at the level of c-Jun proximal promoter. Mutational
analysis revealed that c-Myc regions involved in DNA
binding and transactivation are required to block
differentiation and c-Jun induction. c-Myc does not
seem to require Miz-1 to inhibit differentiation and block
c-Jun induction. Furthermore, Max is not required for
c-Myc activity, as UR61 cells lack a functional Max gene.
c-Myc–inhibitory effect on the Ras/c-Jun connection is
not restricted to UR61 cells as it can occur in other
cell types as K562 or HEK293. In conclusion, we
describe a novel interplay between c-Myc and c-Jun
that controls the ability of Ras to trigger the
differentiation program of pheochromocytoma cells.
(Mol Cancer Res 2008;6(2):325–39)
Introduction
c-Myc (Myc hereafter) is an oncogenic transcription factor
of the basic-helix-loop-helix protein family. Myc forms hetero-
dimers with the protein Max. Myc-Max dimers bind to specific
DNA sequences (E-boxes) in the regulatory regions of target
genes. Genes up-regulated by Myc include genes involved in
carbohydrate metabolism, protein biosynthesis, cell cycle regu-
lation, and other less represented functions. Also, an important
fraction of the genes targeted by Myc (30-50% in different
studies) are repressed by it (reviewed in refs. 1-3; a list of
regulated genes can be found online4). Consistent with its
effects on cultured cells and transgenic in vivo models, dere-
gulated expression of Myc is found in a wide array of human
cancers, in many cases associated to disease progression (4, 5).
Myc activity on its genomic targets translates into multiple
biological effects. Importantly, Myc activity drives cells into
proliferation by mechanisms impinging on G1 cell cycle phase
control (6, 7). Myc is also known to block differentiation in a
number of model systems (5, 8). The mechanism(s) whereby
Myc inhibits differentiation are unclear, but, as terminal dif-
ferentiation is usually associated with cell cycle arrest, it has
been proposed that Myc inhibits differentiation by stimulating
cell cycle progression. Indeed, a significant number of Myc-
induced genes encode positive regulators of the cell cycle
(e.g., cyclin D2, cyclin E1, and CDK4), whereas cell cycle inhi-
bitors such as p15INK4B, p21WAF1, and p27KIP1 are repressed by
Myc (7).
The Ras family of small GTPases includes three closely
related proteins in mammals (H-, K-, and N-Ras). Ras proteins
are activated by signals originated in surface receptors, acting
as key components of signaling pathways by relaying signals
downstream through diverse routes. Activated Ras interacts
with diverse signaling effectors. One of the most relevant is the
Raf kinase that signals through activation of mitogen-activated
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protein/extracellular signal-regulated kinase (ERK) kinase and
ERK kinases (9, 10). Ras has been classically regarded as a
transforming oncogene. In fact, activating point mutations
in Ras genes that render a constitutively active protein have
been found in 30% of all human cancers (11). However, the
proliferative and transforming activity of Ras is cell context
dependent. Thus, Ras exerts proliferation arrest and senescence
in primary fibroblasts (12) and also exerts antiproliferative
effects in some tumor cell lines as leukemia-derived K562
(13, 14). Also, Ras can induce differentiation of pheochromo-
cytoma cells (15-17) and adipocytic precursors (18). Moreover,
a systematic survey of the literature reveals that the most
common response to Ras ectopic expression in cell lines
derived from distinct tissues with differentiation potential is
differentiation (19).
One of the earliest examples of oncogene cooperation was
described for Myc and Ras in the transformation of rodent
primary fibroblasts (20). However, to date, all the studies on
Myc and Ras cross-talk have been undertaken in murine or
human fibroblasts (21, 22) and in murine models (23-25),
where Myc-Ras cooperation results in cellular transformation
and oncogenesis (23-25). In sharp contrast, the Myc-Ras cross-
talk in differentiation models has not been studied.
PC12 cells is a rat pheochromocytoma-derived cell line that,
in response to nerve growth factor (NGF), differentiates into a
sympathetic neuron-like phenotype, characterized by neurite
outgrowth and induction of neuronal specific genes (26). NGF
activates Ras and NGF-induced differentiation is dependent
on Ras-ERK activation (27, 28). Consistently, H-Ras (15, 17),
K-Ras (17), and N-Ras (16) oncogenes induce neuronal-like
differentiation in PC12 cells.
c-Jun is a transcription factor of the leucine zipper family
that dimerizes with another leucine zipper partner protein (c-Jun
itself, ATF2 and members of the Fos and Fra families) to form
active activator protein 1 (AP-1) complexes (29, 30). c-Jun
expression is subjected to positive autoregulation, which
depends on two AP-1 sites in the proximal promoter (30). In
PC12, it has been shown that NGF induces c-Jun expres-
sion (31, 32) and that the concerted signaling through ERK and
Jun NH2-terminal kinase converge at the expression and
phosphorylation of c-Jun, an essential event for NGF-induced
differentiation (33-35). Consistently, ectopic expression of
constitutively active c-Jun is sufficient to induce neuronal-like
differentiation of these cells (33).
Here, we investigated the effect of Myc constitutive expres-
sion in Ras-mediated differentiation. For this purpose, we used
the UR61 cell line, a PC12-derived cell line with inducible
expression of the N-Ras oncogene. Surprisingly, we found
that Myc impairs the neuronal-like differentiation induced by
Ras through a mechanism involving the repression of c-Jun
up-regulation.
Results
Myc Inhibits Ras-Mediated Differentiation of UR61 Cells
Treatment of UR61 cells with dexamethasone led to a prog-
ressive increase in N-Ras mRNA (Fig. 1A) and protein expres-
sion (Fig. 1B). This resulted in neuronal-like differentiation,
as shown by morphologic changes, including the extension of
neurites (Fig. 1C, bottom) as well as nuclear reorganization and
expression of neuronal markers (not shown). Differentiation of
UR61cells was maximal and irreversible after 24 h of exposure
to dexamethasone (Fig. 1C).
To study Ras-Myc interaction in UR61 differentiation, we
generated by retroviral infection a polyclonal cell line (termed
UR61Myc) with constitutive expression of human Myc protein.
As a control for potential Ras-independent effects of Myc, we
also infected U7 cells (UR61 parental cells) with Myc viruses
and obtained the cell line U7Myc. To assess the activity of Myc
in these cells, we determined the transactivation of a reporter
containing four Myc-responsive E-boxes directing the expres-
sion of the luciferase gene. The results (Fig. 2A) showed the
transactivation of the E-box–containing promoter in UR61Myc.
We also tested the expression of PDK2 (pyruvate dehydroge-
nase kinase 2) and LDHB (lactate dehydrogenase B), two genes
previously described as Myc target genes.4 We chose these
genes because they appeared up-regulated in UR61Myc cells
in our preliminary microarray analysis. The mRNA levels was
determined by quantitative reverse transcription-PCR (RT-PCR),
and the results showed that both genes were up-regulated in
UR61Myc cells compared with control cells in the absence or
presence of Ras (i.e., dexamethasone; Fig. 2B).
We next asked whether constitutive expression of Myc
modified the Ras-induced neuronal differentiation in these cells.
Most of the UR61V cells (75-85% in our culture conditions)
extended neurites upon Ras induction. In sharp contrast, the
majority of UR61Myc cells (around 90%) either lacked neurites
or these were much shorter (Fig. 2C), suggesting that Myc can
inhibit the activation of the differentiation program activated
by Ras in these cells. We sought to confirm the inhibition of
differentiation by analyzing the expression of two neuronal
differentiation markers known to be up-regulated by NGF in
PC12 cells, namely GAP43 (neuromodulin, a neuronal
plasticity-related protein; refs. 36, 37) and SNAP25 (synapto-
somal-associated protein 25 kDa, a protein involved in synaptic
exocytosis; ref. 38). Real-time RT-PCR revealed that Myc
inhibited Ras mediated up-regulation of both markers (Fig. 2D).
In contrast, treatment of U7V or U7Myc cells with dexameth-
asone did not result in morphologic differentiation (not shown)
and did not induce the expression of these genes (Fig. 2D). The
absence of up-regulation of GAP43 protein in UR61Myc cells
by Ras was also confirmed by immunoblot (Fig. 2E).
To confirm that Myc overexpression was the cause for the
block in differentiation of UR61Myc cells, we asked whether
the suppression of Myc expression restored the differentiation-
competent phenotype. To this purpose, we used a vector expres-
sing a short hairpin RNA for human Myc (shMyc) previously
shown to suppress human Myc expression (39). The ability of
this vector to reduce Myc levels in UR61Myc cells was
confirmed by immunoblot analysis (Fig. 3A). To test shMyc
effect on differentiation, UR61 cells were cotransfected with a
green fluorescent protein (GFP) vector together with the shMyc
vector or the empty vector and the fraction of GFP-expressing
differentiated cells was then scored. The result indicated that
shMyc transfection significantly increased the fraction of
differentiated cells upon treatment with dexamethasone
(Fig. 3B). These data show that Myc antagonizes Ras-mediated
differentiation.
Vaque´ et al.
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Myc Does Not Inhibit Ras Induction and Activation
We next explored possible mechanisms by which Myc could
impair Ras-induced differentiation. First, we wanted to rule out
the possibility that Myc could hinder directly or indirectly the
activity of mouse mammary tumor virus promoter, so as to
inhibit the induction of Ras expression by dexamethasone.
Northern blot analysis showed that N-Ras mRNA induction
was similar in the parental UR61, UR61V, and the Myc-
expressing UR61Myc cells (Fig. 4A). We also confirmed by
immunoblot that N-Ras protein induction was similar in
UR61V and in UR61Myc cells (Fig. 4B). In the immunoblot
shown in Fig. 4B, as well in others described below (Figs. 5E
and 7A), it is apparent that Myc protein levels were dra-
matically elevated in response to Ras. This effect is dependent
on Ras, and not on the hormone, as shown by Myc immunoblot
analysis of the U7Myc cells (which lack Ras ectopic expres-
sion; Fig. 4B). The Ras-dependent increase in protein levels is
likely due to Myc stabilization, an effect previously reported in
other systems (40), although concomitant increase in mRNA
levels cannot be ruled out. Next, we tested the possibility that
Myc impaired not the expression, but the activation of N-Ras
oncoprotein in this system. Activation of Ras was analyzed
by a Ras-GTP pull-down assay with the Ras-binding domain
of Raf, which only binds GTP-bound Ras. The results showed
that the fraction of active N-Ras was unchanged in UR61Myc
cells compared with UR61V cells (Fig. 4C). We concluded that
Ras activation was not impaired by Myc expression in this
model, and thus Myc is acting at a level downstream of Ras
activation.
Myc Does Not Inhibit Proliferation Arrest of UR61 Cells
Induced by Ras
In view of the well-known effects of Myc as a stimulator of
cell cycle progression and the growth arrest associated to Ras-
mediated differentiation in UR61 cells, it was conceivable that
Myc would inhibit differentiation by maintaining the cells in a
proliferative state. As such, we asked whether Myc-expressing
cells continued proliferating despite the induction of Ras. To
test this, we seeded similar numbers of UR61V and UR61Myc
cells, and after 48 and 72 h the attached cells were counted. The
results (Fig. 5A) showed that cells expressing Myc, despite
their undifferentiated phenotype, remained growth arrested,
similarly to differentiating UR61. To analyze the cell cycle dis-
tribution, DNA content was determined by flow cytometry. Ras
induction resulted in a depletion of S-phase cells in both
differentiating UR61V and nondifferentiated UR61Myc cells
(Fig. 5B). In conclusion, Myc impaired Ras-mediated differen-
tiation but did not reverse the proliferation arrest elicited by
Ras. It has been previously reported that Myc sensitizes
different cell types in response to growth factor deprivation and
other stress stimuli (41). Myc-dependent apoptosis have also
been reported in serum-deprived PC12 cells (42). Thus, we
analyzed the effect of Myc on apoptosis of UR61 cells.
Similarly to parental PC12 cells, serum deprivation resulted
in higher rate of cell death in UR61Myc than UR61 cells
(Fig. 5C). The results also confirmed the previous results
(Fig. 5A and B) that Myc expression does not induce cell
proliferation in Ras-induced cells.
It was conceivable that proliferation of UR61Myc cells
in the presence of dexamethasone was limited by concomitant
enhanced apoptosis mediated by Myc. We studied the
apoptosis in response to Ras induction in both cell lines.
The results showed that differentiation was accompanied with
apoptosis, which increased after 24 h (i.e., once morpho-
logic differentiation was already at its maximum levels).
However, the extent of apoptosis was similar in UR61Myc
cells and in control UR61V cells. This result was assessed
by measuring apoptosis through the binding of Annexin V
FIGURE 1. Ras induces differentiation in UR61 cells. A. Northern analysis showing the induction of N-Ras in UR61 cells upon treatment with 200 nmol/L
dexamethasone (Dex ). Arrows, the three transcripts of the murine transgene. A picture of the filter stained with ethidium bromide is shown to assess RNA
loading and integrity. B. N-Ras protein induction in UR61 cells. Cells were treated with 200 nmol/L dexamethasone for 12 to 36 h as indicated and whole-cell
extracts were subjected to immunoblotting for N-Ras and (as protein loading control) MEK. C. Irreversibility of Ras-induced differentiation. UR61 cells were
treated with 200 nmol/L dexamethasone for the indicated periods, washed twice with PBS, and the morphologically differentiated cells were scored after 48 h.
Columns, mean of two independent experiments; bars, SE. Bottom, representative micrographs of cells corresponding to the indicated time points stained
with crystal violet.
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(Fig. 5D) and the fraction of cells with sub-G1 content of
DNA (Fig. 5E). In aggregate, the results indicate that in this
model Myc is impairing differentiation without inducing cell
proliferation.
Myc Inhibits Ras-Mediated AP-1 Activity and c-Jun
Expression in UR61 Cells
It is well established that in PC12 cells, sustained Ras-ERK
activity induces c-Jun expression and that c-Jun up-regulation is
critical for NGF-mediated differentiation (33). Thus, we asked
whether this was also the case in the UR61 model. Similarly to
PC12, the expression of c-Jun mRNA and protein increased
upon Ras activation in UR61 cells (Fig. 6A and C). To assess
the relevance of c-Jun in UR61 differentiation, we used a
constitutively activated form of c-Jun (v-Jun). Cells were co-
transfected with v-Jun expression vector (or the empty vector)
and a GFP expression vector in a 10:1 ratio. The cells were
treated with dexamethasone and the fraction of morphologically
differentiated GFP-positive cells was scored 24 h later. It was
found that f55% of the v-Jun transfected cells appeared
differentiated 24 h after transfection, versus <5% in cells
transfected with the empty vector. Thus, v-Jun was sufficient to
induce differentiation in UR61 cells in the absence of Ras
induction (Fig. 6B). The above results suggested that the Ras-
Jun signal was sufficient for the differentiation of UR61 cells,
similarly to what is described for NGF-induced differentiation
in PC12 cells (33, 43, 44).
Given this relationship between c-Jun and differentiation in
UR61 cells, we next sought to investigate whether Myc could
affect the Ras-mediated up-regulation of c-Jun gene expression.
To address this, we first analyzed c-Jun expression in UR61V
and UR61Myc cells after Ras induction. In UR61V cells, c-Jun
levels dramatically increased upon dexamethasone addition but
this induction was abrogated in UR61Myc cells after 24 h of
treatment, when differentiation is irreversible (Fig. 6C, left). It
has been described that the protein ATF2 dimerizes with c-Jun
to form the AP-1 factor that binds the c-Jun promoter (45) and
that ATF2 is also activated during differentiation of PC12 cells
(43). Thus, we studied ATF2 levels and phosphorylation in the
UR61 model. We observed ATF2 phosphorylation in UR61
after Ras induction, but Myc did not modify the levels of
phospho-ATF2 (Fig. 6C, right).
FIGURE 2. Myc inhibits Ras-induced differentiation of UR61 cells. A. Transactivation of a Myc-responsive promoter by UR61V and UR61Myc cells. Cells
were transiently transfected with a luciferase reporter containing four E-boxes or four mutated E-boxes (E-boxMut ). Data are relative to the activity in cells
transfected with the mutated E-box. Columns, mean of two independent experiments; bars, SE. B.mRNA expression of PDK2 and LDHB . Cells were treated
for 24 h with 200 nmol/L dexamethasone as indicated, total RNA was prepared, and relative mRNA levels were determined by quantitative RT-PCR with
normalization against levels of RPS14 mRNA. C. Right graph, fraction of cells with neurites of the indicated cell lines was measured after 24 and 48 h of
treatment with 200 nmol/L dexamethasone. Columns, mean of three independent experiments; bars, SE. Left, representative images from UR61V or
UR61Myc cells treated for 24 h with 200 nmol/L dexamethasone. D. mRNA expression of the neuronal-specific genes GAP43 and SNAP25 . Cells were
treated with 200 nmol/L dexamethasone as indicated and total RNA was prepared. Relative levels of GAP43 and SNAP25 transcripts were measured as in
A. Inset, SNAP25 expression in U7V and U7Myc cells. Data are relative to the mRNA levels of untreated U7V cells. Columns, mean of two measurements;
bars, SE. E. UR61V and UR61Myc cells were treated with 200 nmol/L dexamethasone for 36 h as indicated and whole-cell extracts were subjected to
immunoblotting for GAP43 and (as protein loading control) a-tubulin.
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We next analyzed whether Myc overexpression also
antagonized c-Jun binding to DNA in the UR61 model. We
did electrophoretic mobility shift assays using as the probe an
oligonucleotide encompassing the AP-1 (jun1) site of the rat
c-Jun promoter mapping at 133/126, conserved in human,
mouse, and rat genes (46, 47). We tested nuclear extracts
from UR61V and UR61Myc cells untreated or treated for
24 h with dexamethasone to induce Ras. The results (Fig. 6D)
showed that Ras activation resulted in a dramatic retardation
in control cells, but Myc completely inhibited this effect. We
sought to confirm this result by testing the binding of c-Jun
to its own promoter by chromatin immunoprecipitation
(ChIP). c-Jun autoregulates its transcription via two conserved
AP-1 binding sites (termed jun1 and jun2 , mapping at 124
and 243 from transcription start site), conserved in rat,
mouse, and human promoters (46, 47). These sites are also
critical for c-Jun induction during PC12 differentiation (48).
The results of ChIP analysis (Fig. 6E) showed a dramatic
increase in the amount of c-Jun bound to a promoter fragment
containing jun1 and jun2 sites after Ras induction in control
UR61V cells. In contrast, such binding was not observed in
UR61Myc cells.
Although UR61Myc is a polyclonal cell line generated by
viral transduction, to rule out the possibility that the inhibition of
c-Jun expression was due to an artifact during the selection of the
cell line, we followed two experimental approaches. First, we
generated a UR61-derived cell line with conditional Myc
activation. UR61 cells were infected with a retrovirus expressing
the MycER fusion protein, which can be activated by 4-
hydroxytamoxifen. The resultant polyclonal cell line was termed
UR61MER. The functionality of the MycER chimera was
confirmed by the transactivation assays using a luciferase
reporter carrying four Myc-responsive E-boxes in the promoter.
The results show that the treatment with 4-hydroxytamoxifen
resulted in increased transactivation of the promoter (Fig. 7A).
As expected, treatment with 4-hydroxytamoxifen partially
inhibited the morphologic differentiation induced with dexa-
methasone (not shown). Immunoblot analysis revealed that Ras-
mediated up-regulation of c-Jun decreased upon addition of
4-hydroxytamoxifen in a dose-dependent manner (Fig. 7B). The
immunoblot also showed that Ras also dramatically stabilized
the MycER protein, as already observed for Myc protein in
UR61Myc cells (Fig. 4B). Overall, the results obtained with both
cell lines (UR61Myc and UR61MER) show that Myc ablates
Ras-mediated up-regulation of c-Jun.
The second approach to elucidate the effect of Myc on c-Jun
regulation was to transiently express Myc in UR61 and analyze
the expression of c-Jun, after Ras induction, in the transfected
(GFP expressing) cells. The results indicated that in almost
every Myc-expressing cell under observation, c-Jun was
FIGURE 3. Silencing of Myc expression in UR61Myc cells restores the
differentiation response to Ras. A. Reduction of Myc protein levels in
UR61Myc transfected with a shMyc expression vector (pRS/myc). Cells
were transfected with 8 Ag of vector and 4 and 8 Ag of pRS/myc. Twenty-
four hours after transfection, Myc levels were determined by immunoblot.
Levels of a-tubulin were also determined as protein loading control. B.
Cells were cotransfected with vectors for GFP and shMyc (or the empty
vector) in a 1:10 proportion (GFP/Myc) and incubated for 12 h.
Dexamethasone was then added (200 nmol/L) and after 24 h the fraction
of differentiated cells among those expressing GFP were counted.
Columns, mean of two independent experiments; bars, SE. *, P < 0.01,
statistically significant difference from control. Right, three representative
images of cells expressing Myc/GFP.
FIGURE 4. Myc does not impair N-Ras induction and activity in
UR61Myc cells. A. Northern blot demonstrating N-Ras mRNA induction in
the indicated cell lines untreated or treated for 24 h with 200 nmol/L
dexamethasone. A picture of the filter stained with ethidium bromide is
shown to assess RNA loading and integrity. B. Immunoblots showing the
induction of N-Ras protein by 200 nmol/L dexamethasone. The same blot
was successively incubated with antibodies against N-Ras, Myc, and (as
loading control) ERK2. C. Rasf-RBD pull-down analysis showing the
fraction of active Ras (Ras-GTP) in UR61V and UR61Myc cells. Pulled-
down material was subjected to immunoblot incubated with anti –N-Ras
and (as protein loading control) anti –a-tubulin antibodies.
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undetectable or very low when compared with neighboring
untransfected cells (Fig. 7C). In turn, if the mechanism
responsible for the inhibition of differentiation elicited by
Myc was the down-regulation of c-Jun expression, it would be
expected that c-Jun overexpression should counteract the Myc
effect. We addressed this point by transfecting a c-Jun expres-
sion vector into UR61Myc cells and quantifying the morpho-
logically differentiated cells upon Ras induction. The results
showed that c-Jun expression resulted in a 3-fold increase on
UR61Myc cells undergoing differentiation compared with cells
transfected with the empty vector (Fig. 7D). Altogether, these
data argue that Myc inhibits differentiation of UR61 via the
down-regulation of c-Jun expression and activity.
Myc Inhibits Ras-Mediated Transcriptional Activation of
c-Jun Promoter
The aforementioned results indicated that Myc blocked the
up-regulation of c-Jun expression induced by Ras.We next asked
whether Myc exerted this effect at a transcriptional level. To this
end, we first analyzed c-Jun mRNA levels by quantitative RT-
PCR. The results showed that 24 h after the induction of Ras by
dexamethasone addition, c-Jun mRNA dramatically increased in
control UR61V cells but not in UR61Myc cells (Fig. 8A). This
result suggested that, in the UR61 system, Myc was impairing
c-Jun expression at the transcriptional level. Thus, we next tested
whether Myc inhibited the activity of the Jun promoter. We
carried out luciferase reporter assays in UR61 cells with a
luciferase reporter carrying the murine c-Jun proximal promoter.
We found that Myc partially inhibited Ras-mediated activation
of c-Jun promoter (Fig. 8B). However, Myc had no effect
on the transactivation exerted by an activated c-Jun isoform (i.e.,
v-Jun), suggesting that Myc did not affect the transcriptional
activity of c-Jun and its effect is likely limited to inhibit its
induction in response to Ras.
As noted above, two AP-1 response elements (jun1 and
jun2) in c-Jun promoter are critical for c-Jun autoregulation
FIGURE 5. Myc does not
rescue Ras-mediated prolifer-
ation arrest of UR61 cells. A.
Growth curves of UR61Myc
and UR61V (control cells) treat-
ed with 200 nmol/L dexametha-
sone to induce Ras. At the
indicated times, the number of
viable cells was determined by
trypan blue method. Points,
mean of four independent
experiments; bars, SE. B. Cell
cycle distribution of UR61Myc
and UR61V cells after 48 h of
Ras induction. Cell nuclei were
stained with propidium iodide
and the cell cycle distribution
was analyzed by flow cyto-
metry. The fraction of cells in
S phase is indicated in each
case. C. Cells were seeded in
six-well plates at a density of
150,000 per well. Twenty-four
hours later, the medium was
replaced with fresh medium
containing 0%, 2%, and 10%
FCS and 100 nmol/L dexa-
methasone and further incu-
bated for up to 72 h. Cells
were stained with crystal violet
and the cell amount was mea-
sured as indicated in Materials
and Methods. Columns, mean
from two independent experi-
ments; bars, SE. D. Apoptosis
of UR61V and UR61Myc cells
assessed by Annexin V bind-
ing. Cells were treated with
200 nmol/L dexamethasone
for the indicated periods and
the fraction of cells bound to
Annexin V was analyzed by
flow cytometry. Columns,
mean of two independent
experiments; bars, SE. E.
Apoptosis of UR61V and
UR61Myc cells analyzed by
the fraction of subdiploid cells.
Cells were stained with bro-
modeoxyuridine and analyzed
by flow cytometry. Columns,
mean of two independent
experiments; bars, SE.
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and bound by c-Jun in UR61 cells (Fig. 6E). To investigate
whether Myc effects on c-Jun transcription depended on these
AP-1 sites, we analyzed the effect of the transient coex-
pression of H-RasG12V and Myc on the transcriptional
activity of AP-1 using a luciferase reporter containing four
AP-1 response elements (4AP-1-Luc). The results (Fig. 8C)
showed that Ras activated this promoter, but the coexpression
of Myc inhibited the activation of AP-1. In contrast, a Myc
mutant carrying a deletion of a conserved region required for
transactivation and transformation (MycD106-143) was unable
to block Ras-mediated activation of c-Jun promoter (Fig. 8B)
and to antagonize c-Jun transcriptional activity in UR61 cells
using the 4AP-Luc reporter (Fig. 8C). Similarly, a Myc
mutant carrying and insertion in the basic region and unable to
bind DNA (MycIn373; ref. 49) did not repress the Ras-
induced activation of the AP-1 reporter (Fig. 8C). However,
Myc did not impair the activation of the AP-1-Luc reporter
induced by a constitutively activated c-Jun form as v-Jun
FIGURE 6. Myc impairs Ras-induced up-regulation of c-Jun. A. Expression of c-Jun mRNA during Ras-induced differentiation of UR61 cells. Cells were
treated with 200 nmol/L dexamethasone for the indicated periods, and total RNA was analyzed by Northern blot. B. v-Jun induces differentiation of UR61
cells. Cells were transiently cotransfected with expression vectors for v-Jun and GFP in a proportion 1:10 (GFP/Jun). Twenty-four hours after the transfection,
the fraction of morphologically differentiated cells was determined. The graph shows the results from 300 GFP-expressing cells. A representative image with
a GFP/Jun–expressing differentiated cell is shown at the right. C. c-Jun up-regulation induced by Ras is impaired in UR61Myc cells. Cells were treated with
dexamethasone for the indicated periods and whole-cell extracts were subjected to immunoblotting for c-Jun (left), ATF2, and phosphorylated ATF2 (P-
ATF2 ; right ). a-Tubulin levels were also determined as loading control. D. Electrophoretic mobility shift assay showing the inhibition of protein bound to a
Jun/ATF2-binding site in UR61Myc cells in response to Ras-mediated differentiation. UR61V extracts were incubated with the labeled probe plus a 100-fold
excess of unlabeled probe or unlabeled mutated probe as specificity controls. E. ChIP of c-Jun on the promoter of rat c-Jun, showing that Myc inhibits binding
of c-Jun to its promoter in UR61Myc cells upon induction of Ras. Cells were treated with 200 nmol/L dexamethasone for 24 h to induce Ras and the chromatin
was immunoprecipitated with anti –c-Jun and (as a specificity control) anti –h-hemoglobin antibodies. The immunoprecipitated DNA was analyzed by
quantitative PCR was carried out with primers encompassing the jun1 and jun2 sites of rat c-Jun promoter (AP-1 amplicon) and other three control amplicons
as indicated. Data are normalized to the corresponding inputs of chromatin before immunoprecipitation and are expressed as relative to the value of the
downstream control amplicon. Columns, mean of two independent ChIP experiments; bars, SE.
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(Fig. 8C). Thus, although Myc antagonizes Ras-mediated
induction of c-Jun, it did not impair c-Jun transcriptional
activity once it is activated.
Myc represses some promoters through the interaction with
the zinc finger protein Miz-1 (reviewed in ref. 50). We explored
the possibility of Miz-1 involvement in the UR61 model by
using the MycV394D mutant, which is unable to bind Miz-1
(51). The results showed that MycV394D abolished Ras-
mediated activation of the AP-1 reporter as efficiently as wild-
type Myc (Fig. 8C), suggesting that the repression that Myc
exerts on c-Jun promoter does not depend on its interaction with
Miz-1. We also addressed the possible involvement of Miz-1 by
ectopically expressing Miz-1 in UR61V and UR61Myc and
asking whether the differentiation and/or c-Jun expression were
affected in UR61Myc cells. Cells were transiently transfected
by nucleofection with a Miz-1 expression vector, resulting in
z40% efficiency of transfection. Morphologic differentiation,
expression of the differentiation marker GAP43/Neuromodulin,
and expression of c-Jun protein were determined in the
transfected cells. The results indicated that Miz-1 overexpres-
sion did not modify the block in c-Jun expression of UR61Myc
cells (Fig. 8D, top) and in morphologic differentiation (Fig. 8D,
bottom). Finally, we asked whether the repression of Miz-1
blunted the effect of Myc on c-Jun regulation. For this purpose,
we infected the UR61Myc cells with a retrovirus expressing
a short-hairpin RNA for rat Miz-1 gene (shMiz-1). This
retroviral construct has been previously validated in rat cells
(52). As we could not detect endogenous Miz-1 protein, we
confirmed the repression of Miz-1 at the mRNA level,
comparing the UR61Myc-shMiz1 with the cells transduced
with the empty vector (UR61Myc-pRS). The results showed
40% to 50% reduction in Miz-1 expression (Fig. 8E). The
results also show a down-regulation of Miz-1 by dexametha-
sone, a result also observed in parental UR61V and UR61Myc
cells (not shown). We next asked whether the reduction in
Miz-1 affected the block in Ras-mediated induction of c-Jun.
The results showed that c-Jun was not induced by Ras in cells
expressing shMiz-1. On the contrary, a modest decrease in
c-Jun mRNA levels was detected, which was similar in control
cells and shMiz-1 cells (Fig. 8E). Also, no induction of the
FIGURE 7. Myc-dependent inhibition of c-Jun up-regulation by Ras. A. Transactivation of a Myc-responsive promoter in UR61MER cells. Cells were
transiently transfected with a luciferase reporter containing four E-boxes or four mutated E-boxes (E-boxMut ). Following 24 h of transfection, 4-
hydroxytamoxifen (4HT ) was added to 500 nmol/L, and 1 h later dexamethasone was added to 200 nmol/L. The cells were further incubated for 24 h and the
luciferase activity was measured in duplicates. Luciferase activity is expressed relative to the activity in cells transfected with the mutated E-box. Columns,
mean of two independent transfection experiments; bars, SE. B. Myc down-regulated c-Jun in UR61MER cells. 4-Hydroxytamoxifen was added to the
indicated concentrations 1 h before dexamethasone (final concentration, 100 nmol/L). Lysates were prepared 12 h later and analyzed by immunoblot with
antibodies against c-Jun, Myc (detecting the MycER protein), N-Ras, and a-tubulin. C. UR61 cells were cotransfected with an expression vector for human
Myc and GFP in a 10:1 proportion. Twelve hours after transfection, the cells were treated with dexamethasone and 24 h later the expression of c-Jun was
assayed by immunofluorescence. The results from 500 GFP-expressing cells are shown in the graph and a representative field is shown at the right.
Arrowheads, two cells expressing Myc/GFP and lacking c-Jun. D. Ectopic c-Jun rescues the Myc-mediated inhibition of differentiation. Left graph, UR61V
and UR61Myc were cotransfected with mixtures of expression vectors for GFP and c-Jun (or its empty vector) in a 1:10 proportion. Twelve hours after
transfection, the cells were treated with dexamethasone, and 24 h later the fraction of differentiated cells was determined. The results from 400 GFP-
expressing cells are shown in the graph. Columns, mean of three independent transfections; bars, SE. The difference between UR61Myc cells transfected
with the empty vector and the c-Jun vector was significant (*, P < 0.01). Right, images of UR61Myc cells transfected with c-Jun and GFP and treated with
dexamethasone showing two differentiating cells.
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FIGURE 8. Myc impairs Ras-mediated activation of c-Jun promoter in UR61 cells. A. Inhibition of c-Jun mRNA up-regulation in UR61Myc cells after
24 h of treatment with dexamethasone. Levels of c-Jun transcripts in UR61Myc and UR61V cells were determined by quantitative RT-PCR. Columns, mean
of four independent experiments (six measurements); bars, SE. B. Activity of murine c-Jun promoter. UR61 cells were cotransfected with the c-Jun-luc
reporter and H-Ras-G12V or v-Jun (2 Ag) and the Myc or its vector (4 Ag) as indicated. Luciferase activity was measured 24 h after transfection and
normalized against the activity detected with RasG12V. Columns, mean of three independent transfections; bars, SE. The difference between values of cells
transfected with wild-type Myc and vector were statistically significant (P < 0.01). C. Activity of the 4AP-1-luciferase reporter. UR61 cells were
cotransfected with the reporter and expression vectors for Ras-G12V or v-Jun (5 Ag) and Myc wild-type or mutants (5 Ag) as indicated at the right of the graph.
Luciferase activity was measured 24 h after transfection and normalized against the RasG12V+vector value. Columns, mean of three independent
transfections; bars, SE. Differences in luciferase activity between samples transfected with wild-type Myc, MycV394D, and vector were statistically significant
(*, P < 0.05; **, P < 0.01), whereas the difference between MycIn373 and vector was not significant. D. Top, cells were nucleofected with an expression
vector for Miz-1 or the corresponding empty vector. Following 12 h of transfection, dexamethasone was added to 200 nmol/L, and 24 h later whole-cell
extracts were subjected to immunoblotting for Miz-1, c-Jun, GAP-43 (as a control for differentiation), and a-tubulin (as protein loading control). Bottom,
fraction of morphologically differentiated cells from the above described transfections. Columns, mean of two independent transfections; bars, SE. E.
Expression of Miz-1 and c-Jun mRNA in UR61Myc-shMiz1 and the control cell line UR61Myc-pRS (transduced with the empty vector). Cells were treated for
24 h with 200 nmol/L dexamethasone as indicated and RNA was prepared and analyzed by quantitative RT-PCR using RPS14 mRNA levels as internal
control. The expression in untreated UR61Myc-pRS cells was defined as 100% for each gene and the other values were normalized accordingly.
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neuronal marker SNAP25 and no morphologic differentiation
was detected in cells expressing shMiz-1 treated with
dexamethasone (not shown). Taken together, the results suggest
that Myc blocks c-Jun induction by a mechanism independent
from Miz-1.
As UR61 are deficient in Max, we considered the possibility
that Myc impairs c-Jun induction through mechanisms
unrelated to DNA binding activity of Myc. We first showed
that a Myc mutant defective for DNA binding, MycIn373,
failed to block Ras-mediated activation of c-Jun promoter-
luciferase reporter (Fig. 8B) and the 4AP-1-Luc reporter
(Fig. 8C). Thus, we assayed the ability of MycIn373 to inhibit
differentiation in transient transfection experiments. The results
showed that MycIn373 was not able to inhibit Ras-mediated
differentiation compared with wild-type Myc (Fig. 9A). These
results suggest that Myc must bind to DNA targets to exert its
effect as differentiation inhibitor in this model. Thus, we asked
whether Myc could bind the promoter of rat c-Jun. Bioin-
formatic analysis revealed the presence of a noncanonical
E-box (CATGCG) in the 5¶ region of rat c-Jun gene, mapping
at –805/–799. ChIP analysis showed that Myc bound this
E-box, and some binding was also detected to the amplicon
containing the AP-1 sites. This could mean a low-affinity
binding or, more likely, a residual binding to the proximity of
the E-box–containing amplicon.
Myc Inhibits Ras-Mediated Transcriptional Activation of
c-Jun Promoter in Different Cell Types
Finally, to address whether Myc repression of the Ras-
mediated c-Jun induction is unique to the UR61 model, either
because of its species or neuronal origin or its deficiency in
Max (ref. 53; and data not shown), we analyzed four human cell
lines derived from different tissues: HEK293T (kidney embryo
cells), HeLa (cervical carcinoma cells), MEG05, and K562
(both myeloid leukemia cells). In these cell lines, Ras did not
induce differentiation; however, in K562 and HeLa, Ras pro-
vokes proliferation arrest (14). Expression vectors for onco-
genic H-Ras and Myc were cotransfected in these cell lines
along with the 4AP-1-Luc reporter. The results showed that
Ras activated this promoter and Myc antagonized this effect in
all the cell types (Fig. 10A), confirming our previous results in
UR61 cells. In K562 cells, similar results were obtained using a
luciferase reporter for the proximal promoter of collagenase II,
a typical AP-1–responsive promoter (not shown). We also
tested the MycIn373 and MycD106-143 mutants in the K562
and we found that both were incapable of inhibiting AP-1
reporter (Fig. 10A), thus reproducing the results observed in
UR61. Finally, we asked whether this effect correlated with
down-regulation of c-Jun protein in HEK293T cells (which
shows higher transfection efficiency). The immunoblot results
revealed that Myc antagonized the up-regulation of c-Jun
brought about by oncogenic Ras (Fig. 10B), thus confirming
that impairment of c-Jun up-regulation by Myc was not unique
to the UR61 model.
Discussion
Whereas the cooperation between Myc and Ras in trans-
formation has been explored in numerous studies, their func-
tional interaction during cellular differentiation has been poorly
investigated. This is surprising considering that the induction of
differentiation is one of the most prominent effects of Ras (19)
and that differentiation inhibition is one of the main and first
biological effects described for Myc (reviewed in refs. 5, 8). In
the present study, we show that Myc abrogates Ras-mediated
neuronal differentiation of pheochromocytoma UR61 cells
without reversing the proliferation arrest, and that the dif-
ferentiation inhibition is mediated, at least in part, by blocking
c-Jun up-regulation.
FIGURE 9. A. DNA binding domain of Myc is required for differentiation inhibition. UR61 cells were transiently transfected with expression vectors for
GFP and wild-type Myc, MycIn373, and the empty vector (pMLV). Twelve hours after transfection, dexamethasone was added and the fraction of
differentiated cells was determined after 48 h. Columns, means from two independent experiments; bars, SD. B. ChIP of Myc on the promoter of rat
c-Jun. Cells were treated with 200 nmol/L dexamethasone for 24 h to induce Ras and the chromatin was immunoprecipitated with anti – c-Myc and (as a
specificity control) anti –h-hemoglobin antibodies. The immunoprecipitated DNA was analyzed by quantitative PCR, which was carried out with primers
encompassing the three amplicons of the rat c-Jun promoter and, as a control for Myc binding, the first intron of rat nucleolin. Data are normalized to the
corresponding inputs of chromatin before immunoprecipitation and are expressed as relative to the value of the c-Jun gene upstream amplicon. Columns,
mean of two independent ChIP experiments; bars, SE.
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In the classic experiments on Ras and Myc cooperation
in transformation of primary fibroblasts (20), Myc seems to
antagonize Ras-mediated growth arrest and senescence, switch-
ing Ras into a growth-promoting protein (12). In contrast, in the
UR61 model, Myc inhibits Ras-induced differentiation without
affecting the growth inhibition associated to differentiation.
Apoptosis ensues once the cells have achieved differentiation,
but Myc does not enhance this apoptosis. Thus, the observed
growth arrest is not due to apoptosis concomitant with
increased-Myc induced proliferation. Inhibition of cell differ-
entiation by Myc has been explained in some models as the
result of the stimulation of cellular proliferation, thus
antagonizing the cell cycle arrest associated to terminal
differentiation (5, 6). However, our results in the UR61 system
argue that unabated proliferation is not the only mechanism by
which Myc can inhibit differentiation.
One of the first identified biochemical effects of Ras was the
up-regulation of c-Jun, not only in fibroblasts (54, 55) but also
in PC12 cells (31). However, the effect of Myc on the Ras-Jun
interaction had not been explored thus far. This is probably
because Ras cooperates with either c-Jun or Myc to induce
transformation of fibroblasts, and therefore a major effect of
Myc on the Ras-Jun pathway during transformation was not to
be expected. However, in those models where the Ras-Jun
signal results in cell differentiation, Myc could block the Ras-
Jun effect. In UR61 cells, we found that Ras up-regulates c-Jun
and that constitutively active c-Jun (i.e., v-Jun) is sufficient to
induce differentiation, as previously described in parental PC12
cells (33, 56). Interestingly, Myc impairs this Ras-induced up-
regulation of c-Jun in UR61 cells, and coexpression of Myc
with c-Jun decreases the antagonistic effect of Myc on Ras-
induced differentiation. Although alternative mechanisms could
also contribute to Myc-mediated inhibition of differentiation
(e.g., regulation of genes other than c-Jun), our results indicate
that c-Jun suppression mediated by Myc plays an essential role
for the inhibition of Ras-induced differentiation.
The data suggest that Myc antagonizes c-Jun up-regulation
at the transcriptional level, as shown by the drop of c-Jun
mRNA and the diminished c-Jun promoter activity. However,
Myc could not reverse the transactivation activity of the
constitutively activated v-Jun and did not impair Jun NH2-
terminal kinase activity as assessed by Jun NH2-terminal kinase
phosphorylation.5 These findings are consistent with a model in
which Myc blunts Ras-mediated transcriptional activation of
c-Jun by interfering with its positive autoregulation, but does
not impair the transactivation activity of c-Jun once it is
expressed and active.
The mechanism underlying this unexpected activity of Myc
is unclear, but Myc impairment of Ras-mediated activation of
c-Jun is not exclusive of PC12-derived cells, as it is also
observed in other cell lines derived from different tissues. The
mechanism seems to be independent of Miz-1, as (a) it is
reproduced by a Myc mutant (MycV394D) unable to bind
Miz-1, and (b) enforced Miz-1 expression and partial Miz-1
silencing do not modify the Myc-mediated inhibition of dif-
ferentiation and the block in c-Jun up-regulation. Our
observations are consistent with a recent report in human
lymphoid cells that identifies c-Jun as a gene down-regulated
by Myc (57). Interestingly, UR61 cells are deficient for Max,5
like their parental cell line, PC12 (53). Max independence for
Myc-mediated apoptosis of PC12 (upon serum deprivation)
has already been described (42). We now show that Myc blocks
c-Jun induction and neuronal differentiation in a Max-
independent manner. However, Max deficiency is not required
for inhibition of AP-1–dependent transcription by Myc,
because such inhibition is not unique to UR61 but also occurs
in Max-expressing cells (e.g., HeLa, HEK293T, and K562).
Interestingly, a DNA-binding defective Myc mutant is
unable to block differentiation and to inhibit c-Jun induction,
suggesting that DNA binding is required for Myc activity in this
system. Also, Myc mutant lacking the conserved Myc box II
region (amino acids 106-143, required for transactivation and
transformation) failed to inhibit c-Jun promoter activity. ChIP
assays show that Myc binds an E-box in the rat c-Jun promoter
in UR61Myc cells, although further work is required to
elucidate whether Myc binding is directly involved in the
FIGURE 10. Myc impairs Ras-mediated activation of c-Jun in different cell lines.A. Luciferase assays with 4AP-1-luciferase reporter in the indicated cell
lines. Cells were electroporated with the reporter (2 Ag), Ras expression vector (pCEFL-H-RasG12V, 2 Ag), and Myc (pMLV-Myc wild-type, pMLV-MycIn373,
and pMLV-MycD106-143, 5 Ag). Luciferase activity was measured 36 h after transfection and normalized against the H-RasG12V value. Columns, mean of
three independent transfections; bars, SE. B. Myc-mediated inhibition of c-Jun up-regulation in HEK293T cells. Cells were grown for 5 h in medium with 1%
FCS and transfected with 1.5 Ag of H-RasG12V expression vector and 4.5 Ag of Myc expression vector (or 6 Ag of empty vector) and 36 h later protein
extracts were prepared and analyzed by immunoblot for the indicated proteins.
5 Unpublished results.
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block of the promoter activation and which are the dimerization
partners of Myc, if any, when bound to the E-box. Thus, the
mechanism for the Myc effect may be indirect, that is, mediated
through the up-regulation or repression of other Myc target
genes. Further work in our laboratories is aimed to dissect the
mechanism(s) by which Myc interferes with c-Jun autoregula-
tion in UR61 without Max intervention.
Regardless of the molecular mechanisms involved, our
results support the hypothesis that inhibition of differentiation
by Myc occurs independently of its effects on proliferation
and this may represent an important mechanism by which
Myc exerts its oncogenic function. It is noteworthy that recent
observations in conditional Myc-expressing mice indicate
that redifferentiation upon discontinued expression of Myc
is the mechanism responsible for tumor regression in some
models (58).
In summary, our findings identified a novel activity of Myc,
which is its ability to prevent cell differentiation provoked
by Ras by inhibiting the expression of c-Jun. In turn, these
observations suggest that the proproliferative and the differen-
tiation inhibitory activities of Myc can both contribute to
promote the unregulated growth of Myc-induced neoplasias.
Materials and Methods
Cell Culture and Retroviral Infections
U7 cell line is a derivative of PC12 characterized by faster
growth and a diminished differentiation capacity (16, 59).
TheUR61 cell line was generated by the stable transfection of U7
cells with an N-ras oncogene (N-rasQ61K) under the control
of the dexamethasone-inducible mouse mammary tumor virus
promoter (60). Ecotropic retroviruses were generated in Phoenix-
E cells. To generated U7 and UR61 cells with constitutive
expression of Myc, cells were infected with pBSH2-h-Myc and
pBSH2 retrovirus, in the presence of polybrene (4 Ag/mL).
Retroviral pBSH2 and pBSH2-h-c-Myc vectors have been
described (61). Infected cells were selected with 100 Ag/mL
hygromycin-B (Roche Applied Science). To generate U7 and
UR61 cells expressing the Myc-ER fusion protein, cells were
infected with the pBabePuro and pBabePuro-MycER retrovi-
ruses (62) and selected with puromycin (1 Ag/mL). To generate
UR61Myc-pRS and UR61Myc-shMiz1, UR61Myc cells were
infected with pRetroSuper and pRetroSuper-shMiz1 retroviruses
(52) and selected with puromycin (1 Ag/mL).
U7 and UR61 and their derivatives were grown in DMEM
supplemented with 8% FCS, gentamicin (80 Ag/mL), and
ciprofloxacin (2 Ag/mL). The media for UR61 and its
derivatives were also supplemented with G418 (250 Ag/mL).
HeLa and HEK293T cells were grown in DMEM with 8%
FCS; K562 and MEG01 (both derived from human chronic
myeloid leukemia) were grown in RPMI 1640 with 8% FCS.
Unless otherwise stated, Ras was induced with 200 nmol/L
dexamethasone (Sigma Chemical Co.) and MycER was
activated with 200 or 500 nmol/L 4-hydroxytamoxifen (Sigma
Chemical).
Cell Growth, Apoptosis, and Differentiation
Cell proliferation was assessed by counting trypsinized cell
suspensions in hemocytometer and by crystal violet stain-
ing. For this, cells were washed with PBS, stained with 1%
crystal violet in methanol for 15 min, dry, destained with 10%
acetic acid for 2 h, and the color was measured in a colorimeter
at A590 nm. For apoptosis determination by Annexin V binding,
cells were trypsinized, washed with PBS, and the Annexin V
binding was determined by flow cytometry and Annexin V-
phycoerythrin (BD PharMingen) following the manufacturer’s
instructions. For determination of subdiploid cells, the cells
were stained with propidium iodide and analyzed as described
below. Cell morphology was assessed by phase-contrast
microscopy. Cells forming at least one neurite as long as the
diameter of the cell soma was scored as differentiated. At least
300 cells were scored in each differentiation experiment.
Cell Cycle Analysis
Cells (1  106) were collected and suspended in PBS, then
fixed in ethanol 90% 4jC for 30 min. Cells were resuspended in
PBS-sodium citrate buffer containing 10 Ag/mL bovine serum
albumin, 200 Ag/mL RNase, 50 Ag/mL propidium iodide
(Sigma Chemical); incubated at 37jC in the darkness for
30 min; and analyzed by flow cytometry in an Excalibur
cytometer (Becton Dickinson) and with the CellQuest software.
Expression Vectors and Transient Transfections
The vectors used in transient transfections were as follows:
pCEFL-H-RasG12V (14), pRS/myc (expressing short-hairpin
RNA for human Myc; ref. 39), pMLV-Myc, pMLV-MycIn373
(49, 63), pCEFL-Myc (64), pCEFL-MycV394D (65), pRSV-
v-Jun and pRSV-c-Jun (66), pcDNA3-Miz1 (provided by
Martin Eilers, Marburg University, Marburg, Germany),
pEGFP-N2 (expressing GFP; Clontech Laboratories), and the
corresponding empty vectors (pCEFL, pMLV, pcDNA3, and
pRetroSuper). For transient transfections for immunofluores-
cence or protein expression analysis, plasmids were trans-
fected into UR61 and HEK293T cells with FuGene-6
transfection reagent (Roche Applied Science). Nucleofection
was carried out in an Amaxa nucleofector using the kit V
(Amaxa AG). Two million cells were transfected with 2.5 Ag
of the Miz-1 expression vector or the corresponding empty
vector and 0.5 Ag of the GFP-encoding vector pmaxGFP
(Amaxa). At least 40% of the cells expressed GFP 24 h after
each nucleofection.
Immunoblots
Cells were lysed in cold NP40 buffer and 50 Ag of protein
per lane were electrophoresed on SDS-10% polyacrylamide
gels and transferred onto nitrocellulose membranes by standard
procedures. The primary antibodies used were anti–c-Jun
(Santa Cruz Biotechnology), anti–c-Myc (Santa Cruz Biotech-
nology), anti-MEK1/2 (Cell Signalling), anti–N-Ras (Santa
Cruz Biotechnology), anti-ATF2 (Cell Signalling), anti –
phospho-Thr69/71-ATF2 (Cell Signalling), anti-ERK2 (Santa
Cruz Biotechnology), anti-GAP43 (BD Transduction Labora-
tories), anti–Miz-1 (Santa Cruz Biotechnology), anti-actin
(Santa Cruz Biotechnology), and anti–a-tubulin (provided by
Nicholas Cowan, New York University, New York, NY).
Immunoblots were revealed with the enhanced chemilumines-
cence system (Amersham Pharmacia Biotech).
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Immunofluorescence
Cells (grown at 50% of confluence on coverslips) were
transfected with a mixture of the GFP vector pEGFP-N2
(Clontech) and the indicated expression vector (Myc, shMyc,
v-Jun, c-Jun) in a 1:10 proportion and 2 Ag of total DNA. After
transfection, cells were incubated for 12 h, treated with
200 nmol/L dexamethasone for 24 h, and then fixed in 3.7%
paraformaldehyde-PBS. Immunofluorescence was done as
described (13) using the anti–c-Jun antibody and Texas red–
conjugated goat anti-rabbit IgG (The Jackson Laboratory). The
statistical significance was determined using Student’s t test.
Electrophoretic Mobility Shift Assays
Nuclear extracts from UR61 cells were prepared as
described (67). Gel retardation assays were done at room
temperature in 20 AL reactions containing 15 Ag of protein of
nuclear extract and annealed oligonucleotides previously
labeled with [a-32P]dCTP using Klenow fragment. DNA-
protein and free complexes were resolved in 4% nondenaturat-
ing polyacrylamide gels. The oligonucleotides were 5¶-GGA-
AGGCCTTGGGGTGACATCATGGGCTATTTTTAG-3¶ and
its complementary 5¶-CTTCCGGAACCCCACTGTAGTAC-
CCGATAAAAATGGG-3¶. The AP-1 site at 133 of rat
promoter (Genbank accession no. NM021835) is underlined
(46, 47). As specificity controls, we incubated extracts with the
labeled probe and a 100-fold excess of cold probe and of a
mutated probe with the underlined nucleotides (AP-1 binding
site) mutated to ATCAGCAT.
Chromatin Immunoprecipitation
Cells (5  107) were used for each ChIP assay. Cells were
fixed in 1% formaldehyde, lysed, and sonicated essentially as
described (68). The ChIP was done by using Dynabeads-
Protein G (Dynal Biotech) coupled to anti–c-Myc, anti–c-Jun,
and (as specificity control) anti–h-hemoglobin antibodies (all
rabbit polyclonal antibodies were from Santa Cruz Biotechnol-
ogy). Dynabeads were incubated with lysates for 12 h at 4jC
and washed several times with 50 mmol/L HEPES (pH 7.6),
1 mmol/L EDTA, 0.7% sodium deoxycholate, 1% NP40, and
0.5 mol/L LiCl. Chromatin was eluted with 500 AL elution
buffer [50 mmol/L Tris (pH 8), 10 mmol/L EDTA, 1% SDS],
decrosslinked (8h at 65jC), and purified through Qiaquick
columns (Qiagen). Real-time PCRs of the eluted DNA were
done at 56jC as annealing temperature in a Bio-Rad iCycler
apparatus. The PCR primers (in 5¶-3¶ sense) are listed below.
The sites of the rat c-Jun gene where the corresponding
amplicons map (with respect to the transcription start site as in
the NM021835 sequence) are indicated. For the distal upstream
sequence (negative control), TTGGAAGACTGAGGG-
CAAAC and TGAAAGCTCGGTTGGTAAGG, which amplify
between 2725 and 2579; for the proximal upstream
sequence (negative control), CAAGCTCGCCACCTC-
TTTAG and CTGGGAAAACAAGCCTTGAG, which amplify
between 879 and 649; for E-box (879/799 from rat c-
Jun transcription start site), ATTCCGAGCACAGCAAATCT
and AATGATCTGGGCGATTGAAG, amplifying between
879 and 648; for the AP-1 sites (jun1 and jun2),
CATTACCTCATCCCGTGAGC and AGGCAGTCTCTGCA-
CACTCA, amplifying between 136 and +8; for the c-jun
exon (negative control), CGCACGCTCCTAAACAAACT and
CGTTTCCATCTTTGCAGTCA, amplifying between +725
and +3845; for the downstream sequence (negative control),
GAGCCTGTGGTGGTAAATCC and GTGCCTCCACTCC-
CAGTAAC, amplifying between +3706 and +3845; for
nucleolin first intron (positive control for Myc binding;
ref. 69), CGCGTCCGAGGCA GTG and TCCATCTACCGT-
CACGGTCAG.
RNA Analysis
Total RNA was isolated using Tri Reagent (Ambion, Inc.).
For Northern blot analysis, total RNA (15 Ag per lane) was
separated by electrophoresis through agarose-formaldehyde
gel and transferred to nitrocellulose. Probe labeling with
[a-32P]dCTP and filter hybridization were carried out accord-
ing to standard procedures. Probe for mouse N-Ras and
c-Jun have been described (70, 71). The amount and integrity
of the rRNAs were assessed by staining of the filter
with ethidium bromide. cDNAs were obtained by reverse
transcription using ScriptTM Kit (Bio-Rad Laboratories).
For quantitative RT-PCR, cDNAs were amplified with
SYBR-fluorescein PCR mix (ABgene) using an iCycler
Bio-Rad apparatus. The primers for the indicated rat
genes, written in the 5¶ to 3¶ sense, were as follows:
for c-Jun , CGCACGCTCCTAAACAAACT and CGTTT-
CCATCTTTGCAGTCA; for GAP43 , GTCAAACCGGAG-
GATAAGG and CTTCTCCACACCA-TCAGCAA; for
SNAP25 , GAATCGCCAGATTGACAGG and CCATGAGA-
GAAGCATGAAGGA; for Miz-1 , ACCATCTCCTCCCA-
TTCCTC and CCGCTGAATACTGCTTTGAAC-3¶; for
LDHB , TCTGGATTCTGCTCGGTTTC and GACTCCTGC-
CACATTCACC; for PDK2 , AGGAAGTCAATGCCAC-
CAAC and TTGATGGGAGGGAGAGTGAG; for ribosomal
protein 14 (RPS14), 5¶-CAAGGGGAAGGAA-AAGAAGG-3¶
and 5¶-GAGGACTCATCTCG-GTCAGc-3¶. The expression
of the different genes was normalized against levels of
RPS14 mRNA.
Luciferase Assays
The luciferase reporters used were as follows: 4 AP-1-Luc,
carrying four concatamers of a consensus AP-1–binding site
(72); pJun-luc, carrying the mouse proximal promoter and part
of the first exon (73); pGL3-E-box, carrying four E-box
elements in the pGL3 vector; and pGL3-E-BoxMut, carrying
four mutated E-boxes (74). For the assays with 4 AP-1-Luc
and pJun-Luc, cells (2  106) were electroporated at 260 V and
1 mFa (Bio-Rad Gene pulser). Luciferase assays were done
using 2 Ag of the firefly luciferase reporter and 1 Ag of the
plasmid for Renilla luciferase (pRL-Null, Promega), and, when
indicated, 5 Ag of the expression vectors. Thirty-six hours after
electroporation, the cells were lysed and luciferase activity was
measured with the Dual Luciferase Assay kit (Promega). For
the assays with pGL3-E-box and pGL3-E-boxMut, the cells
were incubated for 24 h after transfection and further incubated
for other 24 h in the presence or absence of 200 nmol/L
dexamethasone and/or 500 nmol/L 4-hydroxytamoxifen. The
cells were lysed and luciferase activity was measured as above.
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The activity of firefly luciferase was normalized to that of
Renilla luciferase used as internal control. Statistical signifi-
cance of the differences between luciferase values was based on
P values calculated using the Student’s t test.
Ras Activation Assay
Ras-GTP was determined by the glutathione S-transferase-
Ras–binding domain of Raf (amino acids 1-149) pull-down
assay as described previously (75). Total and pulled-down
proteins were analyzed by immunoblot antibodies.
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